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Introduction and outline of the thesis
General introduction
The host immune system has evolved as the central guardian to maintain homeostasis of the 
human body. This multifaceted machinery enables to detect and adequately respond to invasion 
of potentially harmful microorganisms, to provide tolerance to self-antigens, and to prevent tumor 
development by eradicating cancer cells in an early stage. For each of these purposes tailored 
immune responses are to be initiated, since different effector mechanisms should be activated 
depending on the desired effect. This also concerns appropriate handling of the wide variety 
of microorganisms that can be encountered and may cause infection, ranging from viruses and 
bacteria, to fungi and protozoa. Again, specific immune responses are to be elicited, since different 
host defense strategies are required for controlling the invaders. After initial activation of innate 
immunity, cells of the adaptive immune system are recruited to further tailor and augment the 
power of innate immunity mechanisms. Adaptive immunity consists of humoral (B lymphocytes) 
and cellular (T lymphocytes) responses. Communication between the different types of immune 
cells critically depends on production of soluble mediators termed cytokines and chemokines, of 
which a large number has been identified, providing an additional layer of complexity to the system 
(Figure 1).  
One can envision that, in a continuously changing environment, innate immunity is triggered 
by different microbial challenges depending on e.g. climate and geographical location, thereby 
exerting evolutionary pressures that shape the genome of the population. The platform required 
for evolutionary pressures to lead to either positive or negative selection is the genetic variation 
between individuals within a population. Only when a beneficial genetic variant is present at the 
right time and space, the genetic make-up of the population can change by selecting carriers 
(survivors) from non-carriers (non-survivors). Consequently, our genome is the result of millions 
of years of evolutionary processes that selected the most beneficial and fittest genetic variants 
at every single time point our ancestors were faced with an environmental challenge. However, 
the most optimal genetic make-up for a certain habitat, if it exists, is no more than a snapshot 
in a continuously changing environment. Therefore, genetic variants previously selected for their 
beneficial effect in a certain circumstance can turn into important determinants of disease after a 
number of generations when environmental factors have changed. 
Studies have demonstrated that the most extensively adapted gene cluster throughout human 
evolution is the cluster of immune genes, suggesting that these genes were exposed to the most 
powerful evolutionary pressures in human history (1). Consequently, a large number of immune gene 
variants are embedded in the human population at present, which, upon changing environmental 
factors, could potentially have detrimental effects in the present time and space and predispose 
to immunopathology. Thus, evolutionary processes that occurred long ago during the evolutionary 
history of Homo sapiens could influence the susceptibility to disease in modern human populations. 
The aim of the present thesis is to identify and characterize genetic determinants of infectious and 
autoimmune diseases in order to provide insights in disease pathogenesis, progression and clinical 
outcome, to identify novel therapeutic targets for personalized treatment and thereby improve 
patient management strategies.     
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Figure 1. Pattern recognition receptors regulate innate and adaptive immune responses. Dendritic cells and 
macrophages abundantly express pattern recognition receptors (PRRs). When microbial triggers (viruses, bac-
teria, fungi) bind to PRRs, signal pathways are activated and cytokines are secreted. After phagocytosis, the 
microbes are degraded by the autophagy pathway through formation of the phagolysosome and presented on 
MHC class II. The combination of the antigen – MHC-II complex that binds the T-cell receptor, the membrane 
expression of costimulatory molecules involved in the immunological synapse and especially the secreted cyto-
kines determines the direction of differentiation of the activated naive T-cell.
 
Outline of the thesis
The first section of the thesis is entitled “Modulation of the inflammatory reaction” and comprises 
Chapters 2 to 8. In this first set of studies, we addressed the question which mechanisms are 
responsible for the modulation of inflammation, including the role of processes such as autophagy 
or probiotic challenge, as well as genetic variants with effects on the extent of the inflammatory 
reaction.
Autophagy, the cellular machinery for targeting intracellular components for lysosomal 
degradation, is critically involved in the host defense to pathogenic microorganisms. Autophagy 
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facilitates antigen presentation, T-cell activation and modulates production of pro-inflammatory 
cytokines. Autophagy defects have been associated with elevated interleukin (IL)-1β responses 
and susceptibility to Crohn’s disease (2;3). In Chapter 2, the potential modulatory effect of 
autophagy on cytokine responses, production of IL-1β and TNFα, is studied in ex vivo human 
primary cells. Effects of the autophagy pathway are assessed by both activating and inhibiting 
stimuli and the molecular mechanisms are investigated. In Chapter 3 we aimed to elucidate the 
functional consequences of the Thr300Ala polymorphism in the human autophagy gene ATG16L1. 
This gene was previously associated with susceptibility to Crohn’s disease (3) and appeared to be 
mechanistically linked to the Nod-like receptor NOD2 that initiates innate immune responses upon 
recognition of peptidoglycans (4;5). Primary cells obtained from individuals with different ATG16L1 
Thr300Ala genotypes are compared for their capacity to evoke cytokine responses and pattern-
recognition receptor (PRR) induced autophagy. In Chapter 4 we provide a general overview of the 
role of autophagy pathways in innate and adaptive host defense in health and disease with special 
emphasis on the role of autophagy and genetic variants of autophagy genes on susceptibility to 
infections with intracellular bacteria and to Crohn’s disease. Although autophagy was originally 
regarded as a non-specific protein degradation pathway, evidence has accumulated that autophagy 
processes are heavily intertwined with innate host defense pathways comprising phagocytosis, 
antigen presentation to activate adaptive immunity and modulation of cytokine production, 
especially interleukin (IL-) 1β (2;6). 
The gastrointestinal tract harbours an extensive array of different microorganisms, known as the 
gut microbiome. It is estimated that up to 500 to 1000 different microbial species colonize the 
gastrointestinal tract, especially the small and large intestines. An emerging and therapeutically 
promising area of research is the application of specific probiotics in order to maintain or restore 
gut homeostasis by modulation of the inflammatory reactions induced by gut microbiota. Probiotics 
are defined as live bacteria that confer a health benefit to the host. This includes the prevention of 
gut colonization by pathogenic microorganisms and the induction of anti-inflammatory pathways. 
In Chapter 5, we addressed the question which immune pathways are activated by probiotic strains. 
The studied bacterial strains comprise Bifidobacterium and Lactobacillus spp., strains that are 
currently used as food supplements and which are thought to contribute to intestinal homeostasis 
and could dampen gut inflammation in Crohn’s disease patients (7). The role of several Toll-like 
receptors (TLRs) for recognition of these bacterial strains are elucidated and production of pro- and 
anti-inflammatory cytokines are measured. The immunomodulatory capacity of these probiotic 
strains has been assessed as described in Chapter 6. In vitro, co-incubation and preconditioning 
experiments were performed to analyze whether probiotics can modulate the immune response 
to inflammatory stimuli such as PRR ligands or to the complete microorganism Candida albicans, a 
fungus associated with the etiology of Crohn’s disease (8). This important link of Candida albicans 
with Crohn’s disease prompted us to investigate the genetic correlation between a recently 
characterized polymorphism in the gene encoding the β-glucan receptor dectin-1 (designated as 
CLEC7A) with Crohn’s disease susceptibility and severity, as outlined in Chapter 7. This polymorphism 
(Tyr238X) leads to a premature stop in the amino acid sequence and consequently in a truncated 
and non-functional protein (9). Due to the fact that the fungal cell wall consists for a large part of 
β-glucans, dectin-1 is one of the major PRRs recognizing and initiating innate immunity pathways 
in response to Candida albicans (10). Protein expression of dectin-1 in intestinal tissues has been 
assessed and a large Crohn’s disease cohort was analyzed and compared to a group of ulcerative 
colitis patients and healthy controls. In Chapter 8, a similar type of study has been performed in 
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a cohort of rheumatoid arthritis patients since reports on experimental arthritis described a pro-
inflammatory role for dectin-1 in this context (11). For these investigations we had access to clinical 
data on susceptibility and severity scores of inflammation and bone erosion. On the functional 
level, macrophages bearing different dectin-1 genotypes were tested for their cytokine production 
capacity.   
In the second part of this thesis, “Genetic variation and anti-Candida host response”, consisting 
of Chapter 9-16, we have changed the focus and the approach of the study to concentrate on one 
important human pathogen: Candida albicans. C. albicans is often part of the flora residing in the 
human oral, gastrointestinal and genital tracts. Under physiological conditions, Candida albicans 
will not cause disease. However, when mucosal or skin barriers are damaged or the immune system 
is compromised, susceptibility to disseminated fungal infection is increased (12). In addition to 
disseminated infections, a large number of patients suffer from mucosal Candida infections 
such as oropharyngeal and vulvovaginal candidiasis. However, despite the presence of similar 
predisposing factors, susceptibility to any type of Candida infection differs significantly between 
individual patients. Genetic variation in the innate immune system could potentially account 
for these differences. To verify this hypothesis, cohorts of patients with various manifestations 
of Candida infections have been recruited and polymorphisms in genes known to be involved in 
anti-Candida host defense were selected (13). Chapter 9 describes the genetic association study 
between the dectin-1 Tyr238X polymorphism and susceptibility to Candida colonization and 
candidemia after hematopoietic stem cell transplantation. Additionally, functional consequences 
of the polymorphism are assessed in primary monocytes. In Chapter 10 we investigated five 
families that suffer from severe forms of autosomal dominant chronic mucocutaneous candidiasis 
(AD-CMC). As the immunological defects and the genetic cause of this primary immunodeficiency 
had so far remained elusive, we addressed this problem by a systematic approach that comprised 
both functional and genetic studies. Subsequently, extensive molecular studies were performed in 
an attempt to elucidate in detail the disease mechanisms in AD-CMC, as reported in Chapter 11. 
Another type of Candida infection, oropharyngeal candidiasis (OPC), is a common manifestation 
in HIV-patients in their progression to AIDS (14). Besides low CD4+ T-cell counts, genetic variation 
in innate immunity could confer susceptibility to OPC. To assess the role of genetic variation in 
pattern-recognition receptor genes, including Toll-like and C-type lectin receptors, in susceptibility 
to oropharyngeal candidiasis in HIV-patients, in Chapter 12 the prevalence and functional effects of 
common polymorphisms in these genes were investigated in an East-African group of HIV patients. 
Similarly to mucosal infections, susceptibility to bloodstream infections with Candida spp. could be 
influenced by genetic variants in innate immunity genes, as has been demonstrated for other types 
of systemic fungal infections including aspergillosis (15). In these studies, that comprise Chapter 
13 to 15, the largest currently available cohort of candidemia patients and non-infected matched 
controls is investigated to verify the hypothesis that common genetic variants, that affect protein 
function or expression of pattern-recognition receptors, their intracellular adaptor proteins and/or 
cytokine (receptor) genes, influence susceptibility or the clinical outcome of Candida bloodstream 
infection. To summarize the current insights in host defense against Candida spp. and to underline 
the major role that genetic variants of immune genes play in predisposition to Candida infection, 
in Chapter 16 we present an overview of these genetic determinants and their concomitant 
immune defects that represent novel immunotherapeutic targets. A summary of the findings and 
conclusions of this thesis are described in Chapter 17.
115
Introduction and outline of the thesis
References
1. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how 
selection shapes host defence genes. Nat Rev Genet 2010; 11(1):17-30.
2. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances 
endotoxin-induced IL-1beta production. Nature 2008; 456(7219):264-268.
3. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous 
SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 
39(2):207-211.
4. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through 
muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278(11):8869-8872.
5. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by 
recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 
2010; 11(1):55-62.
6. Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immunity 2007; 
27(1):11-21.
7. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95(1 
Suppl):S2-S4.
8. Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in 
familial Crohn’s disease. Am J Gastroenterol 2009; 104(7):1745-1753.
9. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and 
mucocutaneous fungal infections. N Engl J Med 2009; 361(18):1760-1767.
10. Gow NA, Netea MG, Munro CA, et al. Immune recognition of Candida albicans beta-
glucan by dectin-1. J Infect Dis 2007; 196(10):1565-1571.
11. Yoshitomi H, Sakaguchi N, Kobayashi K, et al. A role for fungal {beta}-glucans and their 
receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible 
mice. J Exp Med 2005; 201(6):949-960.
12. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 
2011; 11(2):142-151.
13. Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of 
Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6(1):67-78.
14. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus 
infection. J Oral Pathol Med 1989; 18(10):554-564.
15. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis 
in stem-cell transplantation. N Engl J Med 2008; 359(17):1766-1777.
16
Part 1
Modulation of the inflammatory reaction
17
18
Crişan TO, Plantinga TS, van de Veerdonk FL, Farcaş MF, Stoffels M, Kullberg BJ, van der Meer JWM, 
Joosten LAB, Netea MG.
Chapter 2
Inflammasome-Independent Modulation of 
Cytokine Response by Autophagy in Human 
Cells
PLoS ONE 2009 6(4): e18666
19
20
21
2
Autophagy and cytokine responses
Abstract
Autophagy is a cell housekeeping mechanism that has recently received attention in relation to its 
effects on the immune response. Genetic studies have identified candidate loci for Crohn’s disease 
susceptibility among autophagy genes, while experiments in murine macrophages from ATG16L1 
deficient mice have shown that disruption of autophagy increases processing of IL-1β and IL-18 
through an inflammasome-dependent manner. Using complementary approaches either inducing 
or inhibiting autophagy, we describe modulatory effects of autophagy on proinflammatory cytokine 
production in human cells. Inhibition of basal autophagy in human peripheral blood mononuclear 
cells (PBMCs) significantly enhances IL-1β after stimulation with TLR2 or TLR4 ligands, while at the 
same time reducing the production of TNFα. In line with this, induction of autophagy by starvation 
inhibited IL-1β production. These effects of autophagy were not exerted at the processing step, 
as inflammasome activation was not influenced. In contrast, the effect of autophagy on cytokine 
production was on the transcription level, and possibly involving the inhibition of p38 mitogen 
activated protein kinase (MAPK) phosphorylation. In conclusion, autophagy modulates the 
secretion of proinflammatory cytokines in human cells through an inflammasome-independent 
pathway, and this is a novel mechanism that may be targeted in inflammatory diseases.
Introduction
Autophagy is a conserved mechanism for degradation of defective organelles and long-lived 
proteins, that plays an important role in the homeostasis of the cell by recycling cytoplasmic cargo 
for amino acid and energy re-use (1). Autophagy comprises three main processes – chaperone-
mediated autophagy, microautophagy and macroautophagy. The latter, henceforth referred to as 
autophagy, is characterized by the sequestration of cytosolic proteins and organelles into double-
membrane vesicles called autophagosomes. These autophagosomes maturate through fusion with 
lysosomes, a process that will eventually lead to the breakdown of the protein content (2). Through 
these effects, autophagy has been demonstrated to be a biological response of the cell in stressful 
situations, traditionally during starvation and growth factor deprivation, ensuring the degradation 
of old structures with the purpose of sustaining the essential anabolic processes of the cell (3). 
Consequently, through its main roles in survival and housekeeping, the process of autophagy has 
gained relevance in the context of human pathologies like neurodegenerative diseases (4), cancer 
(5), lysosomal diseases (6) and ageing (1).
In addition to its role in cell survival, autophagy is emerging as a process of high importance for the 
host defense, influencing both the innate and adaptive immune responses (7). This role is exerted 
at three levels (8): direct involvement in engulfment and removal of intracellular pathogens 
(9;10), facilitation of the MHC class II antigen presentation (11), and support of the T-lymphocyte 
development and survival for optimal protective immune responses (12;13). Whether the 
involvement of autophagy in the immune processes is due to the autophagic mechanism itself or 
to independent effects of autophagy-related genes (14), is still a matter of debate. 
Genetic studies (15-17) have identified allelic variants of the autophagy genes ATG16L1 (autophagy 
related 16-like 1) and IRGM (immunity related GTP-ases, M) as important risk factors for Crohn’s 
disease, an autoinflammatory disease characterized by severe chronic inflammation of the 
gut mucosa (18;19). One possible explanation for the involvement of defective autophagy in 
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Crohn’s disease inflammation couples the risk alleles of ATG16L1 and NOD2 (nucleotide-binding 
oligomerization domain containing 2) to an impaired clearance of microorganisms (20;21). The 
persistence of bacteria in the mucosa could induce an inflammatory reaction, leading to the clinical 
features of Crohn’s disease. An alternative explanation has also been proposed by Saitoh et al., 
who demonstrated that the disruption of autophagy in ATG16L1-deficient murine macrophages 
enhances the LPS-induced IL-1β production through an inflammasome-dependent pathway (22). 
However, whether autophagy has similar inhibitory effects in human cells is not known.
In the present study, we assessed the effect of autophagy on the production of proinflammatory 
cytokines in human cells. By stimulating human peripheral blood mononuclear cells (PBMCs), 
we show that the inhibition of autophagy increases IL-1β production after stimulation with TLR2 
or TLR4 ligands. These effects were specific for the modulation of IL-1β secretion, while TNFα 
production was significantly reduced by agents that inhibited autophagy. In contrast to murine 
macrophages, these effects on human cells were exerted at the transcriptional level, rather than at 
the level of the inflammasome. 
Materials and methods
Reagents
3-Methyl Adenine (3MA) was purchased from Sigma (St. Louis, MO, USA). LPS (E. coli serotype 
055:B5) was purchased from Sigma. Synthetic Pam3Cys was purchased from EMC Microcollections 
(Tubingen, Germany). Anti-actin (A2066) antibody was purchased from Sigma; anti-human caspase-1 
p10 (sc515) antibody was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA); anti-
human/mouse LC3B antibody (NB600-1384) was purchased from Novus Biologicals (Cambridge, 
UK); anti-human total p38 antibody (CS9212) and phosphorylated p38 antibody (Phospho p38 
MAPK Thr180/Tyr182 Antibody, CS4511) were purchased from Cell Signaling (Danvers, MA, USA). 
oxATP was purchased from Sigma. SB202190 p38/Rip2 MAPK inhibitor (p38i); SP600125, JNK1/2/3 
inhibitor (JNKi) and U0126 MEK1/2 inhibitor (MEKi) were purchased from Superarray Bioscience 
Corporation (Bethesda, MD, USA). In experiments using pharmacological inhibitors, control cells 
were treated with an equivalent concentration of vehicle (0.1% DMSO). 
PBMC isolation and stimulation
Peripheral blood was harvested from the antecubital vein of healthy volunteers, after obtaining 
informed consent. The PBMC fraction was obtained by differential centrifugation over Ficoll-Paque 
(Sigma). Cells adjusted to 5x106 cells/ml were suspended in culture medium RPMI 1640, supplemented 
with 50 µg/ml gentamicin, 2 mM L-glutamine and 1 mM pyruvate. All cytokine induction experiments 
were performed in duplicate wells. Cells were pre-incubated for 1 hour at 37°C in culture medium 
or in the presence of 3MA (10 mM). After the pre-treatment, RPMI (negative controls), purified LPS 
(10 ng/ml) or Pam3Cys (10 µg/ml) was added to the cells. In separate experiments, cells were first 
incubated for 1hour with RPMI, MEK inhibitor (5 µM), JNK inhibitor (20 µM) or p38 inhibitor (1 µM) 
before performing the steps described above. After 24 hours, the supernatants were collected and 
stored at -20°C until assayed.   
To investigate the effect of 3MA on the ATP-dependent IL-1β release, cells pre-treated for 1 hour 
with RPMI with or without 10 mM 3MA and were stimulated for 4 hours with LPS (10 ng/ml or 1 
µg/ml). After the stimulation, supernatants were discarded and refreshed with RPMI containing 
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1mM ATP, after which the cells were incubated for another 15 minutes. The LPS-dependent IL-1b 
production during the first 4 hours, and the ATP-dependent IL-1b secretion after the additional 15 
minutes, was assessed in the supernatant. 
Autophagy induction was performed in adherent monocytes using starvation medium, Earle’s 
Balanced Salt Solution, EBSS (Invitrogen, Carlsbad, CA, USA). PBMCs were incubated for 1 hour 
after which the supernatant containing the non-adherent lymphocytes was discarded. Adherent 
cells were pre-treated for 2 hours with starvation medium. Subsequently, cells were stimulated for 4 
hours with LPS or Pam3Cys prepared in starvation medium. In parallel, controls were given the same 
treatment using RPMI. After 4 hours, supernatants were discarded and TRIzol Reagent was added to 
the cells which were subsequently frozen and stored at -80°C until assayed. In different experiments, 
3MA was also used in combination with starvation medium to investigate whether the effects of 
starvation are reversed by 3MA.
Both experiments involving stimulation or inhibition of autophagy were performed with cells 
isolated from the same healthy volunteers. However, in some experiments in which not all 
conditions could be performed with blood collected from the same volunteers, studies were done 
in cells collected from additional healthy volunteers.
Cytokine measurements
Cytokine concentrations were determined using specific sandwich ELISA kits for IL-1b, TNFα (R&D 
Systems), and IL-10 (Sanquin). 
RT-PCR
Samples stimulated for 4 hours at 37°C were treated with TRIzol Reagent (Invitrogen) and 
total RNA purification was performed according to manufacturer’s instructions. Isolated RNA 
was subsequently transcribed into complementary DNA using iScript cDNA Synthesis Kit 
(Bio-Rad) followed by quantitative PCR using the SYBR Green method. The following primers 
were used in the reaction: IL-1b forward 5’-GCCCTAAACAGATGAAGTGCTC-3’ and reverse 
5’-GAACCAGCATCTTCCTCAG-3’, TNFα forward 5’-TGGCCCAGGCAGTCAGA-3’ and reverse 
5’-GGTTTGCTACAACATGGGCTACA-3’, b2-microglobulin forward 5’-ATGAGTATGCCTGCCGTGTG-3’ 
and reverse 5’-CCAAATGCGGCATCTTCAAAC-3’ (Biolegio). Results are shown as fold increases in 
mRNA levels in stimulated samples compared to controls. Quantitative PCR for cytokines was 
used especially in short-term induction of autophagy experiments using starvation medium, in 
which long-term incubation led to a high percentage of cell death, and in which ELISA cytokine 
measurements in the supernatants were not able to provide an appropriate assessment of cytokine 
stimulation.
Western blot
For western blotting of actin, caspase-1 and p38 MAPK (total and phosphorylated), 5x10 6 cells were 
lysed in 100 µl lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1% 
Triton X-100, 40 mM β-glycerophosphate, 50 mM sodium fluoride, 200 µM sodium orthovanadate, 
complete mini EDTA-free protease inhibitor cocktail (Roche) and PhosSTOP Phosphatase Inhibitor 
Cocktail (Roche)). The homogenate was stored at -20°C. When needed, samples were thawed, then 
centrifuged for 10 minutes at 14,000 rpm, and the supernatant was taken for western blotting. 
Equal amounts of protein were subjected to SDS-PAGE electrophoresis using 12% polyacrylamide 
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gels at a voltage of 100V. After separation, proteins were transferred to polyvinylidene fluoride 
(PVDF) membrane using the dry blotting method (iBlot™, Invitrogen). The membrane was blocked 
with 5% (w/v) milk powder in Tris-buffered saline/Tween 20 (TBST) for 1 hour at room temperature 
followed by incubation overnight at 4°C with the primary antibody 1:500 in 5% (w/v) BSA/TBST 
(5% bovine serum albumin / TBST). After overnight incubation the blots were washed three times 
with TBST and incubated with HRP-conjugated anti-rabbit antibody at a dilution of 1:5000 in 5% 
(w/v) milk powder in TBST for 1 hour at room temperature. After washing three times with TBST 
the blots were developed using ECL Plus Western Blot Detection Reagents (Amersham Biosciences, 
Buckinghamshire, UK). For western blotting of LC3, an amount of 10x106 cells were lysed after 
being cultured in media containing the inhibitors of lysosomal fusion, ammonium chloride, 20 
mM, and leupeptine, 100 µM. After protein electrophoresis in 15% polyacrylamide gel, the transfer 
was performed on nitroglycerine membranes using the wet blotting method (Bio-Rad) and was 
followed by blocking, incubation with first and then second antibody, each time using 5% (w/v) 
milk powder in Tris-buffered saline/Tween 20 (TBS-T). After washing 3 times with TBST, blots were 
developed using the Super Signal® West Femto Maximum Sensitivity Substrate (Thermo Scientific, 
Rockford, IL, USA) according to the manufacturer’s instructions. Quantitative assessment of band 
intensity was performed by Image Lab statistical software (Bio-Rad, CA, USA).
Statistical analysis
The differences were analyzed using Wilcoxon signed rank tests and were considered statistically 
significant at a p-value<0.05. Data are shown as cumulative results of levels obtained in all 
volunteers (means + SEM).
Results
Western blot assessment of autophagy marker LC3-II shows that starvation induces, whereas 3MA 
treatment inhibits, the autophagic process
Microtubule associated protein 1 light chain 3 (LC3) is one of the autophagy-related 
proteins involved in the direct formation of the autophagosome. Through conjugation with 
phosphatidylethanolamine, the cytosolic LC3-I is transformed to LC3-II which is then bound to the 
autophagosomal membrane, being indicative of autophagic activity inside the cell (23). In order 
to verify the modulation of autophagy using the typical induction method by starvation and the 
inhibition method using the pharmacological inhibitor 3-Methyl Adenine (3MA) in the human 
PBMCs system used in this study, Western blotting of the two LC3 fractions was performed. Freshly 
isolated human PBMCs treated with the starvation medium EBSS (Earle’s Balanced Salt Solution) 
showed a markedly increased level of LC3-II compared to RPMI controls. Moreover, when 3MA 
was added, the LC3-II fraction was decreased (Figure 1), attesting to the validity of the classical 
autophagy methodologies in human PBMCs.
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Figure 1. Assessment of LC3-I and LC3-II levels in PBMCs under starving conditions or pharmacological 
treatment with 3MA. Human PBMCs were pre-incubated for 1 hour at 37°C in either RPMI, starvation medium 
(EBSS) or EBSS with 3MA (10 mM) in which inhibitors of lysosomal fusion have been added: Ammonium chloride 
20mM and Leupeptine 100μM. This was followed by 3 hours stimulation with culture medium, LPS (10 ng/ml) 
or Pam3Cys (10 µg/ml) prepared in the corresponding media (RPMI or EBSS). Cells were lysed and western blot 
of LC3 fractions LC3-I and LC3-II has been performed. 
Figure 2. Modulation of inflammatory cytokine production by autophagy inhibition. Freshly isolated human 
PBMCs were pre-incubated for 1 hour at 37°C in culture medium in the presence or absence of 3MA (10 
mM) and afterwards stimulated with culture medium, LPS (10 ng/ml) or Pam3Cys (10 µg/ml). After 24 hours 
incubation, IL-1β (A), TNFα (B) and IL-10 (C) were measured in the supernatant by specific ELISA. Data are 
presented as means + SEM of cells harvested from 15 volunteers, **p<0.01, ***p<0.001. 
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Figure 3. The effects of 3MA on transcription and processing of inflammatory cytokines. Cells pre-treated for 
1 hour with culture medium with or without 3MA (10 mM) were stimulated for 4 hours with RPMI, LPS (10 ng/
ml) or Pam3Cys (10 µg/ml). RT-PCR was performed and relative levels of IL-1β (A) and TNFα (B) mRNA were 
determined in 4 volunteers. (C) Western blot of p35 caspase-1 after 1 hour pre-incubation with or without 3MA 
(10 mM in RPMI), followed by 2 hours stimulation with LPS (10 ng/ml). The picture is representative for results 
obtained from 6 volunteers.
Figure 4. The influence of 3MA on the ATP-dependent release of IL-1b. PBMCs were pre-incubated for 1 hour 
in the presence or absence of 3MA and were stimulated for 4 hours with LPS (10 ng/ml). After the stimulation, 
supernatants were discarded and refreshed with RPMI or with RPMI containing 1mM ATP and cells were 
incubated for another 15 minutes. Data are shown as mean + SEM of supernatant IL-1b levels obtained in 8 
volunteers, **p<0.01. 
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Inhibition of autophagy enhances IL-1β production while decreasing TNFα in human PBMCs
To assess its effect on the cytokine production, autophagy was inhibited using 3MA, a blocker of 
the Beclin-1 complex that regulates the initiation of autophagy. PBMCs treated with 3MA showed 
a significant higher IL-1β secretion after stimulations with TLR2 or TLR4 ligands (Figure 2A). In 
contrast, TNFα production was diminished in cells conditioned with 3MA compared to controls 
(Figure 2B). No specific trend for the effect of 3MA on IL-10 production was observed (Figure 2C). 
The modulation of IL-1β and TNFα production is regulated at the transcriptional level
To identify the level in the cytokine production which is modulated by 3MA, we assessed its effect 
on transcription and processing of IL-1β. IL-1β mRNA levels were increased in human PBMCs in the 
presence of 3MA (Figure 3A). Similarly, RT-PCR for TNFα mRNA revealed that the inhibitory effect 
of 3MA on TNFα production starts with the decrease of the TNFα transcription rate (Figure 3B). On 
the other hand, Western blot analysis of caspase-1 did not show an increased caspase-1 activation 
(p35 fragment) by 3MA compared to controls (Figure 3C). 
3MA has an inhibitory effect on the ATP-dependent release of IL-1β
It is known that the inflammasome activator ATP (adenosine triphosphate) is a potent stimulator 
of IL-1β processing and release (24). In experiments aiming to assess how this effect is influenced 
in the circumstances of autophagy inhibition, control PBMCs showed a significantly higher increase 
(5.73 fold) of secreted IL-1β when exposed to ATP then in samples treated with 3MA (2.25 fold 
increase) (Figure 4). 
Induction of autophagy by starvation inhibits IL-1β transcription
In an additional set of experiments, we pursued to verify whether consistent findings with those 
revealed when inhibiting autophagy could be seen in the context of autophagy induction, typically 
obtained during starvation. In line with the effects observed by the experiments using 3MA, 
starvation reduced the transcription of IL-1β after LPS or Pam3Cys stimulation of cells (Figure 5A). 
Furthermore, these effects of starvation were reversed by 3MA, demonstrating the involvement 
of autophagy in the effects of starvation (Figure 5B). In contrast to its effect on IL-1β, starvation 
inhibited TNFα mRNA, but 3MA decreased even further TNFα transcription. This observation is 
consistent with the experiments showed earlier that 3MA reduces the TNFα gene transcription.  
The role of MAP kinases for the modulatory effects of autophagy inhibition by 3MA
Mitogen-activated protein kinases (MAPKs) such as ERK1/2 (activated by MEK), JNK or p38 are 
important intracellular mediators of the stimulation of pro-inflammatory cytokine production 
during innate immune responses (25). In order to decipher the mechanism through which 
autophagy inhibition modulates cytokine transcription, we investigated the effects of MAPK 
inhibition on the 3MA-dependent variation of cytokine production. Cells pre-treated with inhibitors 
of MEK, JNK or p38 in the presence or absence of 3MA have further been stimulated with LPS and 
Pam3Cys and cytokine production is depicted in Figure 6 (panels A and B for IL-1β; C and D for 
TNFα). With all inhibitors, except p38i, 3MA had similar consequences on the cytokine production, 
consisting in increasing IL-1β and decreasing TNFα secretion after both LPS and Pam3Cys 
stimulation. Nevertheless, when using p38i, lower IL-1β concentrations were measured in samples 
treated with 3MA after Pam3Cys stimulation than in controls. Consequently, in order to test the 
hypothesis of p38 being involved in the effects of 3MA, we performed Western blots of total and 
phosphorylated (active) p38 which revealed that in samples treated with the autophagy inhibitor, 
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the phosphorylated fraction of p38 is lower than in controls, after TLR4 or TLR2 stimulations (Figure 
6E). Furthermore, the slight induction of TNFα and IL-1β by 3MA alone was shown to be dependent 
on p38 MAPK signaling (3MA: IL-1β 665±135 pg/ml, TNFα 215±45 pg/ml and 3MA+p38i: IL-1β 
20±10 pg/ml, TNFα 40±15 pg/ml; p<0.05 for both IL-1β and TNFα).  
Figure 5. The effects of starvation on mRNA levels of inflammatory cytokines. Cells pre-incubated for 2 hours 
in either starvation medium (Earle’s Balanced Salt Solution) or RPMI were stimulated for 4 hours with medium, 
LPS (10 ng/ml) or Pam3Cys (10 μg/ml) prepared respectively in starvation medium or RPMI. Subsequently, RT-
PCR was performed and IL-1β mRNA levels are depicted as mean +SEM of cells harvested from 6 volunteers, 
*p<0.05 (A). RT-PCR results of IL-1β (B) and TNFα (C) mRNA levels in cells pre-incubated for 2 hours with RPMI, 
starvation medium or starvation medium and 3MA (10 mM) followed by 4 hours stimulation with RPMI or LPS 
(10 ng/ml). Results are shown as mean + SEM of data obtained in 4 volunteers.
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Figure 6. MAPK infl uence on the 3MA-dependent modulati on of IL-1β and TNFα producti on. PBMC samples 
conditi oned for 1 hour in either medium or in the presence of MAPK inhibitors: MEK inhibitor (5 µM), JNK 
inhibitor (20 µM) or p38 inhibitor (1 µM) were subjected to 1 hour treatment with RPMI or 3MA (10 mM), 
followed by sti mulati on with RPMI, LPS (10 ng/ml) or Pam3Cys (10 μg/ml). Aft er 24 hours incubati on, specifi c 
ELISA was performed to determine the level of IL-1β in response to LPS (A) and Pam3Cys (B) sti mulati ons, same 
as for TNFα (panels C and D, respecti vely). Data from 6 volunteers are shown as mean + SEM. (E) Western blot 
of total and phosphorylated p38 in cells pre-treated for 1 hour with RPMI or 3MA (10 mM) and subjected to 1 
hour sti mulati on with  RPMI, LPS (10 ng/ml) or Pam3Cys (10 μg/ml). (F) Quanti fi cati on of the eff ect of 3MA on 
the phosphorylati on of p38.
Discussion
Earlier studies linked autophagy to innate immunity as a defense system against invading pathogens 
in non-phagocyti c cells (26). Later it has been also demonstrated that autophagy regulates pathogen-
associated molecular patt ern (PAMP) recogniti on by facilitati ng TLR sti mulati on in response to viral 
anti gens (27). Subsequently, it has been discovered that components of the autophagy machinery 
are used for intracellular degradati on of bacteria and MHC-II dependent acti vati on of specifi c 
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immunity (9). These effects could prove very relevant, as genetic polymorphisms of the autophagy 
genes ATG16L1 and IRGM are associated with Crohn’s disease (15-17). In addition, deletion of the 
autophagy gene ATG16L1 in mice resulted in inflammasome activation and more severe experimental 
colitis (22). However, the effect of autophagy on IL-1β production was demonstrated only in murine 
cells, and no information was available whether similar effects may be exerted in human cells. In 
the present study, using a complementary approach by both inhibition and induction of autophagy 
as verified using the LC3-II marker, we show that autophagy has strong inhibitory effects on IL-1β 
production. These results add to the increasing body of evidence showing that basal autophagy in 
physiological conditions has important modulatory effects on inflammation (22;28). However, in 
contrast to murine cells, autophagy did not inhibit inflammasome activation in human PBMCs, and 
its effects were the consequence of the modulatory effect on transcription of cytokine genes. These 
data point out once again that inflammasome activation and regulation differs greatly in human 
PBMCs and murine macrophages, as inflammasome activation is constitutive in human monocytes, 
but not in mouse macrophages (29). Subsequently, in human PBMCs, caspase-1 activation is not 
increased by autophagy inhibition. In addition, the assessment of ATP/inflammasome-dependent 
release of IL-1β shows that this is not increased in the presence of 3MA compared to controls. This 
would suggest that although the cytokine release appears to be slightly inhibited on the short term 
(15 minutes after ATP addition), transcriptional regulation is sufficient to determine the higher 
levels obtained in longer stimulations. These findings confirm that the increase of IL-1β production 
during autophagy inhibition is determined by the activation of transcription and is not due to the 
influence on the subsequent steps of processing by caspase-1 or secretion from the intracellular 
compartment. 
In the attempt to point out to the mechanism underlying the effect of autophagy on gene 
transcription, we have tested the importance of several MAPK-dependent mechanisms and 
observed that the only condition that reversed the stimulatory effects of 3MA was the p38 inhibitor 
SB202190. As there is evidence of this inhibitor also influencing Rip2 activation (30), the observed 
effect might also be involving other p38-related MAP kinases in addition to p38. However, while 
these results have led us to the hypothesis that p38 activation might be important for the effect 
of 3MA on IL-1β, this was not confirmed by Western blot analysis, as phosphorylated p38 (active 
form) was decreased in 3MA treated samples. However, in line with earlier evidence showing that 
p38 phosphorylation is positively linked to the process of autophagy (31;32), 3MA treatment led to 
inhibition of p38 phosphorylation and this could, at least in part, represent a pathway of autophagy 
effect on TNFα release. In summary, while the inhibitory effects of 3MA on p38 phosphorylation 
can explain its effect on TNFα production, this cannot be the cause of the potentiation of IL-1β 
transcription, and further studies are needed to decipher this aspect.
Recently, two new studies have also reported that the peptidoglycan receptor NOD2, whose gene 
is considered a susceptibility locus for Crohn’s disease, is linked to autophagy by recruiting ATG16L1 
at the site of the microbial entry within the infected cell (21), directing microbial engulfment in the 
autophagosome and inducing antigen presentation (20). These latest two studies represent the 
connection between the two genetic pathways that induce susceptibility to Crohn’s disease: NOD2 
and autophagy. Crohn’s disease is a chronic inflammatory reaction in the gut mucosa, and recent 
studies strongly suggested a role of autophagy in this process. On the one hand, autophagy seems 
to be crucial for the homeostasis of Paneth cells. Mice with defective ATG16L1 display abnormal 
Paneth cells with a lower amount of granules containing antibacterial defensins, while in turn 
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displaying an increased IL-1β production (28). These effects could lead to bacterial persistence 
in the mucosa and overwhelming inflammation. The studies by Cooney et al. (20) and Travassos 
et al. (21) show for the first time that a decreased autophagy in humans can lead to decreased 
bacterial clearance, while our study provides evidence that diminished autophagy in human cells 
(e.g. through pharmacological inhibition as shown here, or through genetic mutations in Crohn’s 
disease) could lead to uncontrolled IL-1β production. 
The differential findings in mice and humans concerning the modulation of IL-1β by autophagy, 
transcription in humans and caspase-1 activation in mice, remains to be elucidated. One possible 
explanation lies in the different cell populations studied: monocytes in our study in humans versus 
macrophages in the mouse studies. We have previously shown clear differential regulation of the 
caspase-1 inflammasome in monocytes (constitutive activation) versus macrophages (inducible 
activation) (29). Another source of difference could be species specificity, an aspect which in terms 
of the autophagy-inflammation interaction is still largely unknown. This is an aspect which certainly 
deserves attention in future studies, and the present study represents an important first step in this 
direction. 
In conclusion, this study is the first attempt to investigate the modulation of inflammatory 
cytokines by the process of autophagy in humans. We have shown that disruption of autophagy 
has an important impact on inflammatory cytokine modulation, determining a remarkable and 
specific increase of IL-1β secretion, while decreasing TNFα production. We demonstrate that the 
inflammasome activation is not influenced in human PBMCs and that the changes are exerted at 
the gene transcription level. Although the p38 MAPK pathway seems to be linked to the autophagy 
process and our findings may explain the effects on TNFα production through modulation of p38 
phosphorylation, this is probably not the mechanism of the observed higher IL-1β mRNA levels in 
the circumstances of autophagy inhibition. Further assessment of the mechanisms through which 
inflammation is regulated by autophagy may bring new opportunities for the understanding and 
treatment of autoinflammatory disorders such as Crohn’s disease.   
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Abstract
Objective: Autophagy has recently been shown to modulate pro-inflammatory cytokine production 
and to contribute to antigen processing and presentation through the major histocompatibility 
complex. Genetic variation in the autophagy gene ATG16L1 has been recently implicated in Crohn’s 
disease pathogenesis. The mechanisms underlying this association are not yet known, although 
experimental models suggest an inhibitory effect of autophagy on IL-1β responses. Here, the effect 
of ATG16L1 genetic variation on cytokine responses has been assessed in humans.
Design and setting: Peripheral blood mononuclear cells from healthy individuals and Crohn’s 
disease patients with different ATG16L1 genotypes were stimulated with ligands for TLR2, TLR4 and 
NOD2, with or without the autophagy inhibitor 3MA. Induction of cytokine production and related 
factors were measured at the mRNA and protein level. Furthermore, protein levels of ATG16L1 
were assessed by Western blot.
Results: The present study demonstrates that cells isolated from individuals bearing the ATG16L1 
Thr300Ala risk variant, that it is shown to affect ATG16L1 protein expression upon NOD2 
stimulation, display an increased production of the pro-inflammatory cytokines IL-1β and IL-6, 
specifically after stimulation with NOD2 ligands. In contrast, no differences were found when cells 
were stimulated with TLR2 or TLR4 agonists. These findings were confirmed in two independent 
cohorts of volunteers and in a group of Crohn’s disease patients. The increased production could 
be ascribed to increased mRNA expression, while processing of pro-IL-1β by caspase-1 activation 
was not affected. The effect of the ATG16L1 polymorphism was abrogated when autophagy was 
blocked. 
Conclusions: The present study is the first to link the ATG16L1 polymorphism with an excessive 
production of IL-1β and IL-6 in humans, which may explain the effects of this polymorphism on the 
inflammatory process in Crohn’s disease. 
Introduction
Eukaryotic cells are equipped with a machinery for collecting and degrading cellular constituents, 
designated as cellular self-digestion or autophagy (1). In general, activation of autophagy is 
triggered by conditions that are threatening for cell survival, including nutritional starvation and 
hypoxia, and is an important strategy to prevent cell death. Upon activation, cellular components 
such as cytoplasmic organelles and long-lived proteins are captured into double-membraned 
vesicles called autophagosomes that fuse with lysosomes for the degradation of its contents (2). 
Recruitment of autophagy has also been implicated in host defence to intracellular bacteria that can 
escape from innate recognition by membrane receptors upon engulfment, such as Mycobacterium 
tuberculosis (3;4), Salmonella typhimurium (5) and adherent-invasive Escherichia coli (6) and which 
is designated as xenophagy (7). In this respect, after the fusion of lysosomes with autophagosomes 
that have encapsulated bacteria, the bacteria are degraded and its antigens loaded on major 
histocompatibility complex class II to activate T-cell receptor mediated adaptive immune responses 
(8;9). One of the main proteins involved in autophagosome formation is autophagy related 16-like 1 
(ATG16L1), which is highly homologous to Atg16 in S. cerevisiae. ATG16L1 is a component of a large 
protein complex together with ATG5 and ATG12 that is essential for autophagosome formation. 
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Autophagy, and ATG16L1 in particular, has recently been implicated in the pathogenesis of Crohn’s 
disease (CD). A non-synonymous polymorphism in ATG16L1, Thr300Ala (c.898A>G, rs2241880), 
was demonstrated to be associated with higher susceptibility to CD (10;11). Functional studies have 
revealed that this ATG16L1 polymorphism affects the phenotype of Paneth cells (12) and impairs 
autophagosome formation specifically after activation of NOD2 (13;14). However, no abnormalities 
were observed when autophagy was activated through TLR2 or TLR4 signalling. Recently it has 
been demonstrated by Saitoh et al. that macrophages derived from ATG16L1 knockout mice, 
which completely lack autophagy, exhibit elevated IL-1β production after stimulation with 
lipopolysaccharide (LPS), suggesting an inhibitory role of autophagy on the production of this 
cytokine (15). While the functional consequences of the ATG16L1 Thr300Ala polymorphism 
have been demonstrated with regard to the capacity to induce autophagy, no studies have been 
performed to elucidate its effect on the production of pro-inflammatory cytokines such as IL-1β, 
that drive the inflammatory process in the inflamed gut mucosa of CD patients. 
In the present study we demonstrate that the genetic variant of human ATG16L1 conferring higher 
risk for CD is associated with elevated production of pro-inflammatory cytokines after engagement 
of NOD2, thereby providing an explanation for the excessive inflammatory response to the gut 
residing microorganisms, which is observed in CD. We have assessed production of the pro-
inflammatory cytokines IL-1b, TNFα and IL-6 due to their crucial role for the inflammation in CD.
Materials and methods
Genotyping for ATG16L1 Thr300Ala polymorphism
DNA was isolated from whole blood by using the isolation kit Puregene (Gentra Sytems, MN, USA), 
according to the manufacturers’ protocol. Genotyping for the presence of the ATG16L1 Thr300Ala 
polymorphism was performed by applying the TaqMan single nucleotide polymorphism (SNP) assay 
C_9095577_20 on the 7300 ABI Real-Time polymerase chain reaction system (Applied Biosystems, 
CA, USA). Two independent cohorts of healthy volunteers have been assessed (N=46 and N=90). 
We also selected five patients homozygous for the 300Thr allele, five patients homozygous for the 
300Ala allele, and five heterozygous patients from a cohort of 74 Crohn’s disease patients, and 
from these 15 patients we isolated cells for the cytokine stimulation assays. All volunteers gave 
written informed consent, and the study was approved by the Ethical Committee of the Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands.
PBMC stimulation assays
Venous blood was drawn from the cubital vein of healthy volunteers or Crohn’s disease patients 
into 10 ml EDTA tubes (Monoject). In a separate experiment, cells isolated from four individuals 
homozygous for the NOD2 3020insC mutation were stimulated in order to assess the role of NOD2 
for cytokine production. At time of blood donation, Crohn’s disease patients were in a quiescent 
phase, defined as a prolonged period of at least three months of mild disease without relapses or 
exacerbations in the absence of immunomodulatory therapy. The mononuclear cell fraction was 
obtained by density centrifugation of blood diluted 1:1 in pyrogen-free saline over Ficoll-Paque 
(Pharmacia Biotech, PA, USA). Cells were washed twice in saline and suspended in culture medium 
(RPMI, Invitrogen, CA, USA) supplemented with gentamicin 10 µg/ml, L-glutamine 10 mM and 
pyruvate 10 mM. Cells were counted in a Coulter counter (Coulter Electronics) and the number 
was adjusted to 5 x 106 cells/ml. A total of 5 x 105 mononuclear cells in a 100 µl volume was added 
39
ATG16L1 genetic variation and cytokine responses
3
to round-bottom 96-wells plates (Greiner) and incubated with either 100 µl of culture medium 
(negative control), or the various stimuli: E.coli lipopolysaccharide (LPS, 10 ng/ml, Sigma, MO, USA), 
Pam3Cys (10 µg/ml, EMC Microcollections, Tübingen, Germany) or muramyl dipeptide (MDP, 10 
µg/ml, Sigma. MO, USA), IL-1 receptor antagonist (10 μg/ml, Amgen, Breda, The Netherlands). 
Autophagy was inhibited by 3-methyl adenine (3MA, 10 mM, Sigma) or was activated by EBSS 
starvation medium (Invitrogen, CA, USA). Cytokine measurements of IL-1β, IL-6 and TNFα were 
performed in the supernatants, whereas pro-IL-1β was measured intracellularly. All cytokines were 
measured after 24 hours incubation, using commercial ELISA kits (R&D Systems, MN, USA (TNFα, 
IL-1β, pro-IL-1β) or Sanquin, Amsterdam, The Netherlands (IL-6)). 
Real-Time PCR
PBMCs stimulated for 4 or 24 hours at 37°C were treated with TRIzol Reagent (Invitrogen, CA, USA) 
and total RNA purification was performed according to manufacturer’s instructions. Isolated RNA 
was subsequently transcribed into complementary DNA using iScript cDNA Synthesis Kit (Bio-Rad, 
CA, USA) followed by quantitative PCR using the SYBR Green method (Applied Biosystems, CA, USA). 
The following primers were used: for IL-1β forward 5’-GCCCTAAACAGATGAAGTGCTC-3’ and reverse 
5’-GAACCAGCATCTTCCTCAG-3’, for ATG16L1 forward 5’-ACGTACCAAACAGGCACGAG-3’ and reverse 
5’-CAGGTCAGAGATAGTCTGCAAAC-3’. Data were corrected for expression of the housekeeping 
gene β2 microglobulin, for which the primers forward 5’-ATGAGTATGCCTGCCGTGTG-3’ and reverse 
5’- CCAAATGCGGCATCTTCAAAC-3’ were used.
Western blot
For Western blotting, 5 × 106 cells were lysed in 100 ml of lysis buffer (50 mM Tris (pH 7.4), 150 
mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% glycerol, 1% Triton X-100, 40 mM a-glycerophosphate, 
50 mM sodium fluoride, 200 mM sodium vanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 
mM pepstatin A, and 1 mM phenylmethylsulfonyl fluoride). The homogenate was frozen, then 
thawed and centrifuged at 4°C for 10 min at 15,000 × g, and the supernatant was taken for Western 
blot analysis. Equal amounts of protein were subjected to SDS-PAGE using 10%, 12% and 15% 
polyacrylamide gels at a constant voltage of 100 V. After SDS-PAGE, proteins were transferred to 
nitrocellulose membrane (0.2 mm). The membrane was blocked with 5% (wt/vol) milk powder 
in TBS/Tween 20 for 1 hour at room temperature, followed by incubation overnight at 4°C with a 
caspase-1 p10 antibody (SC-515; Santa Cruz Biotechnology, CA, USA) in 5% BSA/TBS/Tween 20 or 
with an ATG16L1 antibody (NB110-60928, Novus Biologicals, CO, USA) in 5% milk powder in TBS/
Tween 20. After overnight incubation, the blots were washed three times with TBS/Tween 20 and 
then incubated with HRP-conjugated swine anti-rabbit antibody at a dilution of 1:5.000 in 5% (wt/
vol) milk powder in TBS/Tween 20 for 1 hour at room temperature. After being washed three times 
with TBS/Tween 20, the blots where developed with ECL (GE Healthcare, PA, USA) according to 
the manufacturer’s instructions. The intensity of the bands on the Western blots were assessed by 
Image Lab statistical software (Bio-Rad, CA, USA).
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Figure 1. Autophagy, ATG16L1 genotype and cytokines. (A) IL-1β production by PBMCs after stimulation for 24 
hours at 37°C with the NOD2 ligand MDP, in the absence or presence of 3-methyl adenine (3MA), an inhibitor 
of autophagy (N=4). Values are mean ± SD, *P < 0.05. (B) IL-1β mRNA expression after stimulation of PBMCs 
unstimulated or stimulated with MDP, cultured either in nutrient rich medium (RPMI) or in EBSS starvation 
medium (N=4). Values are means ± SD, *P<0.05. (C) Cytokine production capacity of TNFα, IL-1β and IL-6 by 
PBMCs obtained from healthy volunteers after stimulation for 24 hours with MDP, Pam3Cys or LPS, stratified for 
ATG16L1 Thr300Ala genotype (A allele equals 300Thr allele, G allele equals 300Ala allele). For MDP stimulation 
PBMCs from two independent cohorts of healthy volunteers are shown, for LPS and Pam3Cys stimulation only 
the largest cohort. Values are means ± SEM, *P<0.05, **P<0.005.
A B
C
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Figure 1 (continued). (D) Cytokine production capacity of IL-1β by PBMCs obtained from Crohn’s disease 
patients with functional NOD2 after stimulation for 24 hours with MDP, Pam3Cys or LPS, stratified for ATG16L1 
Thr300Ala genotype (A allele equals 300Thr allele, G allele equals 300Ala allele). Values are means ± SEM, 
*P<0.05. (E) IL-1β dependent IL-6 production. PBMCs were stimulated with MDP with or without IL-1 receptor 
antagonist (IL-1RA) for 24 hours (N=4).
Statistical analysis
Differences in cytokine production capacity between groups were analyzed using the Mann-
Whitney U test. Data on mRNA expression levels and immunoblot intensity values were statistically 
tested with Student’s t-tests. Differences were considered statistically significant at P < 0.05.
Results
Autophagy blockade and activation modulates MDP induced IL-1β
To assess the role of autophagy in the induction of IL-1β by NOD2 signalling, peripheral blood 
mononuclear cells (PBMCs) obtained from healthy volunteers were stimulated with the NOD2 
ligand MDP alone or in combination with the autophagy inhibitor 3MA for 24 hours (Figure 1A). 
The production of IL-1β was higher when cells were stimulated with both MDP and 3MA compared 
to MDP alone. In contrast, when autophagy was induced in cells by culturing in starvation medium 
(EBSS), the MDP induced IL-1β response was decreased compared to MDP stimulation of cells in 
nutrient rich medium (Figure 1B).
ATG16L1 Thr300Ala genotype and MDP induced cytokine responses
The effect observed by blocking autophagy on MDP-induced IL-1β responses led to the hypothesis 
that the ATG16L1 Thr300Ala genotype may influence these responses in a similar manner. Thus, 
PBMCs obtained from healthy volunteers with different ATG16L1 Thr300Ala genotypes were 
stimulated with LPS, Pam3Cys or MDP for 24 hours (Figure 1C). Significantly higher production of 
IL-1β and IL-6, but not TNFα, was observed in the individuals homozygous for the 300Ala allele 
D
E
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compared to individuals homozygous or heterozygous for the 300Thr allele, after stimulation of 
the cells with MDP. However, no differences were observed after stimulation with either Pam3Cys 
or LPS. These effects were consistent and reproducible in two independent cohorts of volunteers 
(Figure 1C) and in a group of Crohn’s disease patients (Figure 1D). Of note, none of these individuals 
were bearing CD associated NOD2 variants (including R702W, G908R and 1007fsinsC). To study the 
role of IL-1β in the observed increased production of IL-6, PBMCs were stimulated with MDP with 
or without IL-1 receptor antagonist for 24 hours. IL-1 receptor antagonist significantly decreased 
the MDP-induced production of IL-6 (Figure 1E).
Figure 2. (A) Production capacity of IL-1β by PBMCs after stimulation for 24 hours with MDP, 3MA or the 
combination, stratified for ATG16L1 Thr300Ala genotype (A allele equals 300Thr, G allele equals 300Ala). 
Data are mean ± SEM, *P<0.05. (B) Production capacity of IL-1β by PBMCs from healthy volunteers and NOD2 
deficient Crohn’s disease patients stimulated with MDP for 24 hours (N=4).
A
B
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Figure 3. IL-1β mRNA expression, pro-IL-1β measurements and caspase-1 activation in relation to the 
ATG16L1 Thr300Ala genotype (A allele equals 300Thr, G allele equals 300Ala). (A) IL-1β mRNA expression in 
cells stimulated for 24 hours with the indicated stimuli and stratified for ATG16L1 Thr300Ala genotype. Data are 
mean ± SEM, *P<0.05. (B) Intracellular pro-IL-1β in cells stimulated for 24 hours with MDP, stratified for ATG16L1 
Thr300Ala genotype. Data are mean ± SEM, *P<0.05. (C) Western blot of the active p35 subunit of caspase-1 
and β-actin as loading control after incubation of PBMCs for 4 hours, either unstimulated or stimulated with 
MDP, stratified for the ATG16L1 Thr300Ala genotype.
A
B
C
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ATG16L1 Thr300Ala genotype and MDP stimulation in relation to 3MA induced IL-1β
In order to examine whether the effect of the ATG16L1 polymorphism on IL-1β responses is 
mediated through autophagy, PBMCs collected from individuals with different ATG16L1 genotypes 
were stimulated for 24 hours with either MDP, 3MA or the combination of these two stimuli. 
Indeed, when autophagy was completely blocked, the IL-1β response was similar between the 
genotypes. Notably, as also shown in Figure 1A, 3MA also induces secretion of IL-1β (Figure 2A). 
To confirm that NOD2 mutations lead to a completely defective MDP induced IL-1β production, 
cells from Crohn’s disease patients and healthy volunteers were stimulated with MDP for 24 hours 
and IL-1β was measured in the supernatants. MDP-induced production of IL-1b was completely 
dependent on recognition of MDP by NOD2 (Figure 2B).
IL-1β mRNA expression, pro-IL-1β measurements and caspase-1 activation
To further dissect the mechanism underlying the effect of the ATG16L1 Thr300Ala genotype on 
NOD2 induced IL-1β responses, we assessed transcriptional and post-transcriptional mechanisms 
of IL-1β regulation. Firstly, IL-1β mRNA expression was measured after stimulation of PBMCs with 
MDP for 24 hours. An increased mRNA expression of IL-1β was observed in the cells isolated from 
individuals homozygous for the ATG16L1 300Ala allele, as compared to cells from individuals 
heterozygous or homozygous for the 300Thr allele (Figure 3A). Similarly, an increased concentration 
of intracellular pro-IL-1β was observed in cells homozygous for the 300Ala allele (Figure 3B). In 
contrast, no difference could be observed between the ATG16L1 genotypes regarding caspase-1 
activation, either in the unstimulated condition or after stimulation with MDP. The active p35 
subunit of caspase-1 could be detected in both the unstimulated and MDP stimulated condition, 
and was not influenced by the ATG16L1 genotype (Figure 3C).
ATG16L1 mRNA and protein expression
Expression levels of ATG16L1 at the mRNA level were assessed between cells with different ATG16L1 
genotypes that were left unstimulated or were stimulated with either Pam3Cys, LPS or MDP for 
24 hours. No differences were observed that would explain the effect of the ATG16L1 Thr300Ala 
polymorphism on NOD2 induced IL-1β (Figure 4A). To study ATG16L1 protein expression, Western 
blot was performed with cell lysates obtained from PBMCs, either homozygous for the 300Thr 
allele or homozygous for the 300Ala allele, that were left unstimulated or stimulated with MDP, 
Pam3Cys or LPS for 3 hours (Figure 4B). It can be clearly observed that there are large differences 
in the amount of ATG16L1 between the genotypes comparing the unstimulated and stimulated 
conditions. In fact, in cells homozygous for the 300Thr allele, ATG16L1 protein expression is 
enhanced after MDP, Pam3Cys or LPS stimulation, whereas in cells homozygous for the 300Ala 
allele the amount of ATG16L1 protein remains unchanged. In addition, the absolute amount of 
protein after stimulation is higher in the 300Thr genotype compared to the 300Ala genotype. These 
differences in ATG16L1 protein expression are quantified and shown in Figure 4C.
Discussion
Variation in the autophagy gene ATG16L1 has emerged as a major genetic susceptibility factor for 
Crohn’s disease (CD). The present study provides functional data that complement this genetic 
association, by demonstrating that immune cells that bear the risk variant of ATG16L1 display 
enhanced production of pro-inflammatory cytokines after activation of NOD2. 
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Autophagy, a basic machinery in eukaryotic cells responsible for bulk degradation of cellular 
constituents, is also indispensable in host defence against intracellular bacteria. In this respect, 
autophagosomes are formed that encapsulate bacteria upon their entry into innate immune cells. 
Next, lysosomes fuse with the assembled autophagosomes, after which its content is degraded 
and made available for antigen presentation. One of the crucial proteins involved in this process is 
ATG16L1, of which a genetic variant is linked to CD.
Figure 4. ATG16L1 mRNA and protein expression. (A) ATG16L1 mRNA expression after incubation of PBMCs 
for 24 hours, either unstimulated or stimulated with MDP, LPS or Pam3Cys, stratified for ATG16L1 Thr300Ala 
genotype (A allele equals 300Thr, G allele equals 300Ala). Data are mean ± SEM. (B) Western blot of ATG16L1 
protein and β-actin as loading control after incubation of PBMCs for 3 hours, either unstimulated or stimulated 
with MDP, P3C (Pam3Cys) or LPS, stratified for the ATG16L1 Thr300Ala genotype. Picture is representative of 
three independent experiments with different donors. (C) Intensity of ATG16L1 bands on the Western blot 
corrected for the intensity of the corresponding β-actin bands. Data are based on three experiments with 
different donors. Data are mean ± SD, *P<0.05.
A
B
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Recent studies on the functional consequences of the risk variant of ATG16L1 have focussed on 
the capacity to form autophagosomes after microbial stimulation. Indeed, in these studies it could 
be demonstrated that the risk variant of ATG16L1 is associated with an impaired induction of 
autophagy specifically after NOD2 engagement (13;14), which could favour bacterial persistence 
and secondary inflammation. Interestingly, studies with cells derived from ATG16L1 knockout 
mice have demonstrated a pivotal role of this protein for the inhibition of IL-1β production after 
endotoxin treatment in a TRIF and caspase-1 dependent manner (15). This initial finding in mice 
that autophagy can modulate cytokine responses upon microbial triggering of immune cells, led 
us to hypothesize that genetic variation in human ATG16L1 could modulate cytokine responses, 
especially IL-1β.
An initial argument for a role of autophagy in NOD2-induced IL-1β responses was that inhibition 
of autophagy by 3MA led to a robust increase in secretion of IL-1β, while activation of autophagy 
by culturing the cells in starvation medium decreased the IL-1b response after stimulation of 
PBMCs with a pure NOD2 ligand, MDP. To examine whether the ATG16L1 Thr300Ala polymorphism 
exerts a similar effect on cytokine responses, PBMCs obtained from a large group of healthy 
volunteers were stimulated with ligands for TLR2, TLR4 and NOD2. Strongly increased IL-1β and 
IL-6 responses were observed when cells from individuals bearing the ATG16L1 genotypes that 
confer an increased susceptibility to CD were stimulated with MDP, whereas TNFα responses were 
not different. Similarly, no differences were observed after stimulation of PBMCs with either LPS 
or Pam3Cys. As a confirmation, these findings were reproduced in a second set of experiments in 
PBMCs from another independent cohort of healthy subjects. Furthermore, similar experiments 
with PBMCs obtained from a group of Crohn’s disease patients also revealed the specific effect of 
the ATG16L1 T300A polymorphism on NOD2-induced IL-1b. Interestingly, similar experiments with 
cells stimulated with MDP alone or in combination with the autophagy inhibitor 3MA, resulted in a 
loss of the difference between the ATG16L1 genotypes, indicating that the autophagy machinery is 
indeed involved in the effect on cytokine production. One may hypothesize whether these effects 
of ATG16L1 polymorphisms are dependent on mutations in NOD2 that are known to increased 
susceptibility to CD. However, no role for NOD2 mutations in the observed differences in IL-1β 
production could be demonstrated, since these mutations lead to a complete deficiency of NOD2 
signalling, as reported previously (16;17).
To study the mechanism underlying the effect of the ATG16L1 genotype on MDP induced IL-1β, 
several stages of transcriptional and translational regulation of IL-1β were investigated. In line with 
the increased secretion, higher IL-1β mRNA expression and intracellular pro-IL-1β were observed. 
However, no difference in caspase-1 activation was apparent between cells with different ATG16L1 
genotypes, arguing for an effect on the transcription level of IL-1β. Interestingly, caspase-1 was 
demonstrated to be constitutively active when cells were left unstimulated. This constitutive active 
state of caspase-1, expressed in the monocyte fraction of PBMCs, is in line with a previous study 
that demonstrated that the regulatory step of IL-1β production in human monocytes is represented 
by transcription, and not inflammasome activation (18). 
The increased production of IL-6 concomitantly with IL-1β is most probably a consequence of 
increased IL-1β production, since it is demonstrated that signalling through the IL-1 receptor is a 
major inducer of IL-6 (19;20), as we have confirmed in the present study. Interestingly, transcription 
of TNFα was not affected by the ATG16L1 genotype, which argues for different pathways of gene 
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transcription induction for IL-1β and TNFα. Indeed, recent studies suggest that TNFα transcription 
is mainly induced by p38 MAPK and NF-κB, whereas IL-1β transcription also involves Erk/NF-κB 
pathways (21;22). 
Measurements of ATG16L1 mRNA and protein demonstrated that ATG16L1 expression is not 
influenced by the ATG16L1 genotype on the transcriptional level. However, an evident effect of the 
polymorphism on ATG16L1 protein expression could be observed. Stimulation with either MDP, 
Pam3Cys or LPS led to either an increase in or an unchanged amount of ATG16L1 protein compared 
to unstimulated cells, depending on the ATG16L1 genotype. Also, a higher total amount of ATG16L1 
protein was observed after stimulation in cells bearing the 300Thr genotype compared to cells 
with the 300Ala genotype. Together with the recent finding that NOD2 specifically interacts with 
ATG16L1 in a direct fashion (13), these observations could provide an explanation for the specific 
effect of the polymorphism on NOD2 induced cytokine responses. 
The exact mechanism underlying enhanced production of IL-1β upon MDP stimulation by cells 
bearing the ATG16L1 300Ala allele remains to be examined in further detail. Previously it has 
been shown that the polymorphism affects ATG16L1 protein expression (23). Hence, one possible 
explanation could be that the extent of NF-κB activation by NOD2 is influenced by this lower 
availability of the ATG16L1 300Ala variant. Importantly, our findings also pinpoint to an effect of the 
polymorphism on protein expression. Consequently, the balance between the two effects exerted 
by NOD2, i.e. binding to ATG16L1 to induce autophagy on the one hand and activating NF-κB on 
the other hand, could be skewed in favour of Erk/NF-κB activation and IL-1β production in the 
case of autophagy defects in individuals bearing the ATG16L1 polymorphism. This would implicate 
this polymorphism to be a modulator of the balance between NOD2 induced autophagy versus 
cytokine production. 
Some important differences in the effect on regulation of IL-1β responses are apparent between 
mouse ATG16L1 knockout cells and the human genetic variants of ATG16L1. Studies on ATG16L1 
knockout mouse cells revealed an inhibitory role of the protein on caspase-1 activation, whereas the 
human genetic variants of ATG16L1 exert an effect on IL-1β mRNA expression. These discrepancies 
emphasize that important differences exist between mice and humans, but also between a 
complete knockout and a non-synonymous polymorphism leading to an amino acid substitution. 
Innate immune responses mediated by NOD2, including cytokine production and induction of 
autophagy, have appeared to play a central role in Crohn’s disease pathogenesis. At first, this was 
demonstrated by genetic association studies that revealed NOD2 mutations as a risk factor for 
developing Crohn’s disease (24;25). Secondly, the role of innate host responses for the pathogenesis 
of Crohn’s disease is further emphasized by the association of genetic variants of ATG16L1 and 
IRGM with Crohn’s disease, and the influence of these variants specifically on NOD2-induced 
immune responses. This has already been shown concerning the induction of autophagy by NOD2 
signalling, which is affected by the ATG16L1 genotype (13;14). In addition to these findings, the 
present study demonstrates the association of ATG16L1 genotype with increased NOD2 induced IL-
1β responses, providing a direct link of the CD risk-associated ATG16L1 300Ala allele with excessive 
inflammation that is pathognomonic of CD.  
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Abstract
Autophagy, the cellular machinery for targeting intracellular components for lysosomal 
degradation, is critically involved in the host defence to pathogenic microorganisms. Recent studies 
have unveiled several aspects of the immune response that are regulated by autophagy, including 
antigen presentation and production of proinflammatory cytokines. Polymorphisms in autophagy 
genes result in dysregulation of these processes and affect gut homeostasis. Genetic variants 
in autophagy genes are associated with Crohn’s disease, a disease in which an overwhelming 
cytokine production induces inflammation on the one hand, while a defective antigen presentation 
is also found on the other hand. This review summarizes the recent advances in understanding 
the complex interaction between innate immunity pathways and autophagy, with a focus on the 
modulatory effects of autophagy on inflammation. 
Introduction
Macroautophagy, hereafter referred to as autophagy, is the process of recycling cellular components, 
such as cytosolic organelles and protein aggregates, through degradation mediated by lysosomes. 
All eukaryotic cells are equipped with this highly conserved mechanism. Autophagy is activated 
in conditions of cell stress, hypoxia, starvation, or growth factor deprivation, and it promotes cell 
survival by generating free metabolites and energy. In recent years, autophagy has gained broad 
interest in several fields of research, including cancer, neurodegenerative diseases, ageing, but also 
autoimmune and inflammatory diseases. Here we review the recent progress in understanding the 
interplay between autophagy and inflammation, with the focus on most recently published data.
Execution of the autophagy process is mediated by a large family of Atg proteins, of which more 
than 30 have been identified in yeasts (1). Two separate pathways of autophagosome assembly 
involving Atg proteins can be distinguished. Upon autophagosome formation, they converge and 
both end products of these two pathways become part of the phagosomal double membrane 
(Figure 1). It has been suggested that the ATG5-ATG12-ATG16L1 protein complex is able to catalyze 
the lipidation of ATG8/LC3, suggesting an interplay between these apparently distinct pathways 
(2;3). 
Potentiation of antimicrobial defence by autophagy
In addition to its primordial functions in cell homeostasis, autophagy is also involved in innate 
and adaptive immunity to intracellular pathogens, due to its capacity to sequester and digest 
microorganisms. Autophagosome engulfment of microorganisms delivers pathogenic determinants 
for stimulation of type I IFN production in endosomes and contributes to transferring foreign 
antigens onto minor histocompatibility complexes of antigen presenting cells (APCs), designated as 
xenophagy (4;5). These processes are essential for eradication of intracellular bacteria but also of 
viruses and parasites (6-9). Activation of the autophagy pathway for pathogen degradation can be 
augmented by co-stimulation of the cells with bacterial components such as the Toll-like receptor 
(TLR) 4 ligand lipopolysaccharide (10). 
The selection of cargo to be degraded by autophagy is mediated through the binding of anchor 
proteins, and thereby contributes to removal of intracellular pathogens. Furthermore, autophagy 
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plays a crucial role in loading antigens onto MHC class II molecules of APCs to induce adaptive 
immunity by coupling to the T-cell receptor of CD4+ T-cells. To facilitate antigen presentation, 
autophagosomes that contain microbial cargo fuse with late endosomes to degrade the microbial 
constituents into small peptides. The role of autophagy in adaptive immunity could imply that 
autophagy is involved in selecting the type of T-cell activation induced by the presentation of a 
particular antigen and, consequently, either activation or induction of tolerance may ensue. 
Figure 1. Molecular Machinery of Macroautophagy. Beclin-1 is part of the type III PI3K complex that initiates 
autophagosome formation. Two ubiquitin-like systems are required for formation of the isolation membrane; 
I. coupling of LC3 (ATG8) to phosphatidylethanolamine (PE) and II. Conjugation of ATG12 to ATG5 and ATG16L1. 
The five C-terminal amino acids of LC3 (unconjugated LC3-I) are cleaved of by ATG4, which is required to link 
the protein after activation by ATG7 and ligation by ATG3 to PE in the autophagosomal membrane (conjugated 
LC3-II, circles). Similarly, ATG7 and ATG10 couple ATG12 to ATG5 and ATG16L1. This complex then localizes 
to the outer membrane of the forming autophagosome (squares). Upon autophagosome completion, the 
ATG12-ATG5-ATG16L1 complex recycles from the outer membrane, and only LC3 remains associated with the 
completed autophagosome. Autophagosomes then fuse with late endosomes and lysosomes for degradation 
of their cargo and their intravesicular membranes.
This is essential for thymic selection of T-cells (11), but also for modulation of adaptive immunity in 
peripheral lymph nodes (12;13).
Autophagy in innate immunity
In contrast to aspecific substrate selection by autophagy in conditions of starvation, activation 
of autophagy within the framework of the immune response is specifically aimed to degrade 
encountered foreign substrates. One of the main pathways for activation of innate immunity is 
the triggering by pattern-recognition receptors (PRRs) that can recognize conserved microbial 
structures designated as pathogen-associated molecular patterns. In turn, these PRRs induce 
55
Modulation of inflammation by autophagy
4
intracellular downstream signalling to evoke production of inflammatory mediators and elicit 
phagocytosis. Ultimately, the interplay between several signalling pathways determines the specific 
immune response directed at clearing the pathogen and resolving the infection (14). 
The best-characterized class of PRRs are the Toll-like receptors (TLRs). These are membrane-bound 
receptors either expressed on the cell surface or in endosomes. They require either MyD88 or TIR-
domain-containing adapter-inducing interferon-β (TRIF) as adapter proteins to induce intracellular 
signalling. All known TLRs in mammals are type I integral membrane glycoproteins; they contain an 
extracellular domain with leucine-rich repeats responsible for ligand recognition and a cytoplasmic 
Toll/Interleukin-1 receptor homology (TIR) domain required for initiating signalling. Other classes of 
PRRs comprise Nod-like receptors (NLRs), C-type lectin receptors (CLRs) and retinoic acid–inducible 
gene I (RIG-I) like helicases (RLRs) including RIG-I and MDA5 (15). Both TLR and NLR receptors are 
able to induce autophagy through activation of Beclin-1 (16-18), while other PRRs display inhibitory 
capacities on autophagy induction (19). In addition, TLRs must often cooperate with other PRRs for 
eliciting immune responses including autophagy; thus, TLR2 acts in concert with the CLR dectin-1 
to recognize the yeast cell wall extract zymosan and to induce autophagy (17). In contrast, TLR2 
engagement alone is unable to induce LC3-II puncta formation upon stimulation with the pure 
ligand for either TLR1-2 (Pam
3
CSK
4
) or TLR2-6 (Pam
2
CSK
4
) heterodimers (17). 
Besides PRRs as potent modulators of autophagy, type I (IFN-α/-β) and type II interferons (IFN-g) 
are major factors in activating these processes. For instance, activation of macrophages by IFN-g is 
crucial for intracellular killing of Mycobacterium tuberculosis (20;21), as are type I interferons for 
host defence against viral infections (22). In mice, IFN-g induces the expression of autophagic p47 
immunity-related GTPases (IRG) proteins, with IRGM as the best-known member. However, IRGM 
is constitutively expressed at high levels in human cells and cannot be induced by IFN-g (21). IRGM 
is an important player in inducing antimycobacterial autophagy and in promoting CD4+ effector 
T-cell expansion through inhibition of IFN-g induced cell death. These findings are underscored by 
genetic association of an IRGM genetic variant with M. tuberculosis infection in West-Africans, and 
increased BCG vaccination efficacy through enhanced antigen presentation (23-25). Another pro-
inflammatory cytokine, TNFα, induces NF-κB which in turn inhibits mTOR, resulting in autophagy 
activation (26). Similar effects have been described for the interaction between CD40 and CD40 
ligand, both members of the TNF (receptor) superfamily (27). In contrast to these pro-inflammatory 
factors, T helper 2 (Th2) type cytokines such as interleukin (IL)-4 and IL-13 antagonize autophagy 
induction through activation of mTOR (28). Altogether, the T-helper1/T-helper2 (Th1/Th2) 
responses seem to be correlated to the activation of autophagy, with active autophagy in Th1 type 
responses and downregulated autophagy when Th2 responses are elicited.
Autophagy and proinflammatory cytokine production
An effective immune response against invading pathogens critically depends on the production 
of proinflammatory cytokines aimed to recruit and activate innate immune cells and to elicit 
(memory) T-cell responses. Recently, an important modulating role for autophagy in production 
of proinflammatory cytokines, IL-1β in particular, has emerged. Saitoh et al. reported that foetal 
macrophages obtained from ATG16L1 knockout mice exhibit elevated production of IL-1β and IL-
18 after stimulation with TLR4 ligands. This was demonstrated to be caused by higher activation 
of caspase-1 in the ATG16L1-deficient mice, mediated by the adapter molecule TRIF, and was 
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the first study demonstrating a link between autophagy defects and a dysregulated production 
of IL-1b and IL-18 in mice (29). This was complemented by the finding of specific degradation of 
pro-IL-1b in autophagosomes in mouse macrophages (30). These and other studies in mice point 
towards a regulatory effect of autophagy on caspase-1 activation through modulation of the NLRP3 
inflammasome, the protein complex that mediates recognition of various microbial components 
(e.g. muramyl dipeptide (MDP), bacterial RNA) and double-stranded DNA from damaged 
mitochondria (31-33).  
The important role of autophagy for IL-1b secretion was also confirmed in human primary cells, 
in which specific inhibition of autophagy leads to increased production of IL-1b (34). Interestingly, 
the same study in humans demonstrated that TNFα production was decreased by autophagy 
inhibition, suggesting divergent effects of autophagy on the production of these cytokines (34). 
Important differences exist between mice and humans regarding the effect of autophagy on IL-1b 
production. In mice, this effect is ascribed to increased activation of the inflammasome, whereas 
in humans IL-1b mRNA transcription was elevated when autophagy was inhibited, while no effects 
were observed on caspase-1 activation (29;30;34). These discrepancies between mice and humans 
emphasize that caution should be exercised when extrapolating studies from mice to humans. An 
overview of the interplay between autophagy and cytokine production pathways is depicted in 
Figure 2.
Autophagy and Crohn’s disease
The observation that gut microorganisms are essential for developing inflammatory bowel disease 
(IBD) has led to the identification of IBD-associated microorganisms (35;36). Crohn’s disease (CD) 
is one of the most frequent forms of IBD, a chronic inflammatory disorder of the bowel that causes 
segmental lesions in the gastrointestinal tract (37). The consensus is that the disease is precipitated 
by the combination of ubiquitous commensal bacteria and ‘hyperactive’ host mucosal immune 
responses. However, the molecular mechanisms that cause the disease are not yet completely 
understood. Recent genome-wide association studies in large cohorts of CD patients have revealed 
an important pathogenetic role for genetic variants of two autophagy genes, ATG16L1 and IRGM. 
A non-synonymous polymorphism in ATG16L1 on chromosome 2q37.1 (p.Thr300Ala, c.898A>C, 
rs2241880) and two polymorphisms in IRGM on chromosome 5q33.1 were significantly associated 
with CD risk (38;39). Another study revealed a significant association of CD susceptibility with an 
intronic polymorphism in the autophagy gene ULK1 (40). These genetic studies, unravelling an 
important role for autophagy in gut homeostasis, have led to investigations aiming to dissect the 
molecular mechanisms of this phenomenon. For the IRGM polymorphisms it was demonstrated 
that these SNPs affect its protein expression, in part by means of microRNA miR-196, and hence 
also affect the ability to execute autophagic processes (41;42).
Loss-of-function mutations in NOD2, the molecule that recognizes the lysosomal breakdown 
product of bacterial peptidoglycan, MDP, were the first genetic variants linked to CD (43;44). This 
implies that impaired immune activation through NOD2 in response to gut microbiota might lead 
to loss of surveillance activity and consequently bacterial overgrowth, which may be central in CD 
pathogenesis. With autophagy defects reported in individuals bearing NOD2 mutations, this points 
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Figure 2. Modulation of inflammation by autophagy. The autophagy machinery is induced by multiple signals 
downstream of TLRs and NOD2. In turn, autophagy modulates production of proinflammatory cytokines on the 
level of transcription, protein degradation and inflammasome inhibition. More specifically, autophagy inhibits 
production of IL-1β, but augments production of TNFα. TLR: Toll-like receptor; NLRP3: Nod-like receptor P3; 
ASC: Apoptotic Speck Protein Containing a Caspase Recruitment Domain; 3MA: 3-methyl adenine.
out once more towards impaired bacterial clearance and increased bacterial persistence in CD 
patients (45). However, inadequate induction of immune tolerance through autophagy could also 
be envisaged in these patients. Bacterial pathogens such as M. avium subspecies paratuberculosis, 
Yersinia spp., L. monocytogenes, and adherent-invasive Escherichia coli have been incriminated 
in the pathogenesis of CD. An intact autophagy machinery is required for the clearance of these 
microorganisms when they invade the mucosa. Defective autophagy can lead on the one hand to 
ineffective clearance, and on the other hand to dysregulated inflammation (9;20;45). 
ATG16L1 and Crohn’s disease
As mentioned above, a polymorphism in the WD-domain of ATG16L1 is associated with CD, 
implicating defective autophagy in disease pathogenesis. ATG16L1 knockout mice exhibit elevated 
IL-1b and IL-18 responses in response to microbial stimuli, and these mice are more susceptible 
to DSS-induced colitis (29). The consequences of the ATG16L1 Thr300Ala polymorphism for IL-
1b production have recently been studied. The ATG16L1 300Ala risk allele was associated with 
elevated production of IL-1b and IL-6 that was only observed when cells were stimulated with the 
NOD2 ligand MDP, in contrast to normal cytokine production upon stimulation with TLR2 and TLR4 
ligands (46). This effect was exerted at the level of IL-1b mRNA expression and was independent 
of inflammasome activation. Studying the same polymorphism (ATG16L1 Thr300Ala) in human 
dendritic cells, Cooney et al. reported defective NOD2-induced, but not TLR-induced, autophagy and 
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antigen presentation (16). Furthermore, effects of this polymorphism on antibacterial autophagy 
in epithelial cells have been observed (47). All in all, this suggests that defects in autophagy, in this 
case specifically downstream of NOD2 signalling, lead to increased inflammation, as reflected by 
elevated IL-1b secretion. The specific effect of the ATG16L1 polymorphism on the NOD2 pathway 
could be explained by the recent finding that NOD2 and ATG16L1 form a protein complex essential 
for NOD2-induced autophagosome formation (48). As the Thr300Ala polymorphism is described to 
affect protein stability (46;49), this could indeed explain the defective induction of autophagy and 
therefore the enhanced IL-1b mRNA transcription upon triggering of NOD2 (Figure 2). Strikingly, 
despite the central role of ATG16L1 in canonical autophagy, general autophagy processes in 
conditions of homeostasis or cell stress seem not to be affected by the ATG16L1 genotype (50).
Concluding remarks
Recent studies have demonstrated the importance of autophagy in regulation of inflammation 
and host defence. A major effect of autophagy in inflammation is modulation of the production 
of the proinflammatory cytokines IL-1b and TNFα. These discoveries may not only change our 
understanding of the regulation of inflammatory responses, but also reshape our insights into 
the pathogenesis of inflammatory diseases. Future studies are warranted to obtain deeper 
understanding of the molecular mechanisms involved, with the ultimate goal to develop novel 
treatments in inflammatory and infectious diseases. 
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Abstract
The use of probiotics as food supplement has gained tremendous interest in the last few years 
as beneficial effects were reported in gut homeostasis and nutrient absorption, but also in 
immunocompromised patients to support protection from colonization or infection with pathogenic 
bacteria or fungi. As treatment approach to inflammatory bowel diseases, a suitable probiotic 
strain would ideally be one with a low immunogenic potential. Insight into the immunogenicity and 
type of T-cell responses induced by potentially probiotic strains allows for a more rational selection 
of a particular strain. In the present study, the bacterial strains Bifidobacterium breve (NumRes 
204), Lactobacillus rhamnosus (NumRes1) and Lactobacillus casei (DN-114 001) were compared 
concerning their capacity to induce inflammatory responses in terms of cytokine production 
by human and mouse primary immune cells. It could be demonstrated that the B. breve strain 
induced lower levels of the pro-inflammatory cytokine IFN-g than the tested L. rhamnosus and L. 
casei strains. Both B. breve and Lactobacilli induced cytokines in a TLR9 dependent manner, while 
the lower inflammatory profile of B. breve was due to inhibitory effects of TLR2. No role for TLR4, 
NOD2 and C-type lectin receptors was apparent. In conclusion, TLR signalling is involved in the 
differentiation of inflammatory responses between probiotic strains used as food supplements. 
Introduction
In recent years probiotic supplements have been suggested to provide health benefits. 
Subsequently, the use of specific probiotic strains as safe supplements for human consumption 
has been approved. Probiotic strains are classified as being live microorganisms which, when 
administered in sufficient amounts, confer a health benefit to the host (1). This health benefit 
could comprise more efficient digestion, nutrient absorption, or higher resistance to pathogenic 
bacteria in the gut.
Microorganisms from the genera Lactobacillus and Bifidobacterium are often considered as 
probiotic candidates. All these bacteria are Gram-positive, (facultative) anaerobe microorganisms, 
that are common commensals in the human gastrointestinal tract. These bacteria are currently 
used in probiotic dietary products and several lines of evidence have demonstrated their beneficial 
effects on gut homeostasis (2-6). In addition, mouse studies have been conducted to investigate 
the immunomodulatory capacity of these potential probiotics, with similar findings (7-10). These 
effects range from downregulating cytokine responses in immune cells to induction of apoptosis in 
T-cells and vaccine improving properties (11-15). 
Previous studies indicate that the ability of probiotics to induce the secretion of various cytokines 
is mediated to a large extent by cell wall components (15-17). Cell wall components elicit these 
responses through recognition by pattern recognition receptors (PRRs), germ-line encoded 
receptors expressed on innate immune cells that are specialized to bind these bacterial substances. 
Examples of these receptors, either membrane-bound or localized intracellularly, are the Toll-like 
receptors (TLRs), C-type lectin receptors (CLRs, such as dectin-1, mannose receptor or DC-SIGN) and 
nucleotide-binding oligomerization domain (NOD) like receptors (NLRs, such as the peptidoglycan 
receptor NOD2). For the triggering of intracellular receptors the process of phagocytosis is 
required, whereas membrane-bound receptors detect their ligand on the cell surface and in some 
cases facilitate phagocytosis (18). Subsequently, downstream intracellular signalling from these 
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receptors results in the modulation of cytokine responses (19).
The PRRs that are responsible for the recognition of these strains resulting in induction of cytokine 
responses and activation of the immune system remain elusive. Therefore, in the present study the 
capacity of the bacterial strains Bifidobacterium breve (NumRes204) and Lactobacillus rhamnosus 
(NumRes1) and L. casei (DN-114 001) to induce immune responses in peripheral blood mononuclear 
cells (PBMCs) has been examined in both healthy volunteers and NOD2 deficient Crohn’s disease 
patients. Furthermore, the role of several PRRs of the innate immune system that could mediate 
these immune responses, including TLRs, CLRs and NLRs, has been investigated both in human and 
mouse cells. 
Material and methods
Subjects
Healthy volunteers and Crohn’s disease patients were recruited at the Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands. The study was approved by the Ethical Committee of 
the Radboud University, and the volunteers have given informed consent. At the time of donation, 
Crohn’s disease patients homozygous for the NOD2 frameshift mutation were in a quiescent phase, 
i.e. a prolonged period of at least three months of mild disease without relapses or exacerbations 
in the absence of immunomodulatory therapy. Also, they were receiving no immunomodulatory or 
anti-inflammatory medications for the last three months. 
Mice
Wild-type C57BL/6 mice were obtained from Charles River WIGA GmbH (Sulzfeld, Germany). 
TLR2 knockout mice and TLR4 knockout mice, with C57BL/6 background, were kindly provided by 
Dr. S. Akira (Osaka University, Osaka, Japan) (20). All animal experiments were approved by the 
Animal Experimental Committee of Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands and were performed in accordance with institutional and national guidelines.
Reagents
Blocking monoclonal antibodies of the innate immune receptors TLR2 (clone T2.5) and DC-SIGN 
(clone AZND1) including IgG1 isotype control were purchased from eBioscience, Coulter Beckman 
and R&D Systems, respectively, and were all used in a concentration of 10 µg/ml. Blocking reagents 
of the receptors TLR4 (B. quintana lipopolysaccharide, (21), 1 µg/ml), TLR9 (CpG ODN TTAGGG, 
Invivogen, 25 µg/ml), mannose receptor (mannan, Sigma, 100 µg/ml), dectin-1 (laminarin, Sigma, 
100 µg/ml) and of phagocytosis (cytochalasin B, BIOMOL International, 1 µg/ml) were used. 
Bacterial fermentation and enumeration
Two Lactobacillus strains (NumRes1 and DN-114 001) and a Bifidobacterium breve strain 
(NumRes204) were grown at 37°C in a 400 ml reactor containing MRS supplemented with 0.5 
g/l L-cysteine for Bifidobacteria. The pH was maintained at 6.5 by addition of NaOH. To ensure 
anaerobic conditions the headspace was flushed with N
2
 or a gas mixture consisting of 5% H
2
, 5% 
CO
2
 and 90% N
2
 for Bifidobacteria. Bacteria were harvested in the early stationary phase, washed in 
PBS and stored with glycerol 20% (w/v), in aliquots at -80°C. Cell counts were determined by plating 
serial dilutions (CFU) and fluorescent microscopy by staining with DAPI.
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PBMC stimulation experiments
Venous blood was drawn from the cubital vein of healthy volunteers into 10 ml EDTA tubes 
(Monoject). The mononuclear cell fraction was obtained by density centrifugation of blood diluted 
1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells were washed twice 
in saline and suspended in culture medium (DMEM, Invitrogen, CA, USA) supplemented with 
gentamicin 50 µg/ml, L-glutamine 10 mM and pyruvate 10 mM. Cells were counted in a Coulter 
counter (Coulter Electronics) and the number was adjusted to 5 x 106 cells/ml. A total of 5 x 105 
MNCs in a 100 µl volume were added to round-bottom 96-wells plates (Greiner) and incubated 
with either 100 µl of culture medium (negative control), or with B. breve , L. rhamnosus or L. casei 
(all 107 microorganisms/well) at a ratio of 20:1 bacterial cells : MNCs for 24 hours, 48 hours or seven 
days, alone or in combination with one of the above mentioned receptor blockers or inhibitors. 
Splenocyte stimulation experiments
Wild-type, TLR2KO and TLR4KO C57Bl/6 mice were sacrificed and spleens were collected. From 
each total spleen a cell suspension was made in culture medium (IMDM, Invitrogen, CA, USA) 
supplemented with gentamicin 10 μg/ml, ultraglutamine 1mM and 9% Foetal Calf Serum. A total 
of 2 x 106 splenocytes/100 μl volume were added to round-bottom 96-well plates (Greiner) and 
incubated with either 100 μl of culture medium (negative control), or the various bacterial strains: 
B. breve, L. rhamnosus and L. casei , all in a concentration of 4 x 106 microorganisms/well (bacterial 
cell : MNCs = 2:1). After 48 hours of incubation at 37°C, supernatants were collected and IFN-g 
detection was performed. A limited amount of cell death was observed (but with total viability 
higher than 90%), and no significant differences were seen in cell death between the different 
bacterial strains.
Transfection and stimulation of TLR2 expressing HEK293 cells
Stable TLR2 expressing HEK293 cells (Invivogen, CA, USA), containing a NFκB luciferase reporter 
construct (pNIFTY, Invitrogen, CA, USA) were maintained in DMEM + 10% FCS and the appropriate 
antibiotics. Cells were seeded in 96-wells plates and overnight incubated with bacteria at different 
ratios of cells : bacteria. Luciferase activity present in cell lysates was determined by detecting 
chemiluminesence after incubation with BriteLite (Perkin Elmer, MA, USA).
Generation and stimulation of mouse bone marrow derived dendritic cells (BMDCs)
Femurs and tibiae of female 6-12 weeks old C57BL/6 mice were removed and purified from 
surrounding muscle tissue. The protocol used for cell isolation and BMDC culture with only GM-CSF 
was adapted from previous publications (22;23). Modifications were the following. At day 0 cells 
were plated in Petri dishes (Greiner, 10 cm) at 4 x 10 6 cells per well. The medium contained 20 ng/
ml of mouse GM-CSF (Peprotech). At day 3, 4 ml of medium was added containing 37.2 ng/ml GM-
CSF. At day 6 again 1 ml of medium was added, now containing 158 ng/ml GM-CSF. Immature DCs 
were harvested at day 7 and used in the cytokine assay. A cell suspension was made (1 x 106 cells/
ml) and the cells were plated into 96-well plates. To the BMDCs either probiotics (bacterial cell : 
BMDC = 1:1) or Pam3Cys (4 μg/ml) was added. DCs were incubated with these stimuli either 24 
hours or 48 hours depending on the cytokine to be measured.
Cytokine measurements
Cytokine production capacity was measured by ELISA according to the manufacturer’s protocol. 
ELISA kits were purchased from R&D Systems (MN, USA) for TNFα, IL-1β and IL-17, and from Sanquin 
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(Amsterdam, The Netherlands) for IL-6, IL-10 and IFN-g. Mouse IFN-g cytokine production capacity 
was measured by ELISA according to the protocol as reported previously (46). In brief, MaxiSorp 
96-wells plates (Nunc, Roskilde, Denmark) were coated with 1 µg/ml purified rat anti-mouse IFN-g 
(capture Ab, BD Pharmingen) overnight at 4°C in 0.1M carbonate buffer. Plates were washed with 
0.05% Tween/PBS, blocked with 1% BSA, 1% FCS in PBS for 1 hour at room temperature (RT). Plates 
were washed and the samples and standards were incubated for 1 hour at 37°C. Subsequently, wells 
were washed and incubated with 0.5 µg/ml biotin-conjugated rat anti-mouse IFN-g (Biolegend, 
clone XMG1.2) in 0.1% BSA, 0.1%FCS in PBS for 1 hour at RT followed by streptavidin-horseradish 
peroxidase (Invitrogen) and tetramethylbenzidine substrate (SFRI Laboratories, Berganton, France). 
The reaction was stopped with 2M H
2
SO
4
, and adsorption was measured at 450 nm using a Bio-Rad 
Multiplate Reader (Bio-Rad Laboratories, Veenendaal, The Netherlands).
Statistics
Differences in cytokine production capacity between groups were analyzed using the Mann-
Whitney U test. Differences were considered statistically significant at P < 0.05.
Figure 1. Cytokine production capacity of PBMCs collected from healthy volunteers and stimulated with the 
bacterial strains for 24 hours (IL-1β, TNFα, IL-6), 48 hours (IL-10, IFN-g) and 7 days (IL-17). Values are means ± 
SEM, N=4, *P<0.05 when compared to both stimulations with L. rhamnosus or L. casei.
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Figure 2. Cytokine production capacity of TNFα, IL-1β and IFN-g by PBMCs obtained from healthy volunteers 
and stimulated with the bacterial strains together with a TLR2 blocking antibody or a TLR4 inhibitor. Values 
are means ± SEM, N=6, *P<0.05.
Results
Cytokine production capacity of PBMCs induced by potentially probiotic strains
To study the immunostimulatory capacity of the bacterial strains B. breve, L. rhamnosus and L. 
casei, PBMCs were stimulated with bacterial cells at a ratio of 20:1, and cytokines were measured 
at different time points. Important differences were observed between induction of cytokine 
production by the bacterial strains. Most importantly, while all monocyte-derived cytokines can be 
induced by all probiotic strains studied, only Lactobacilli, but not B. breve, stimulated production 
of IFN-g (Figure 1). 
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Role of membrane-bound receptors 
To study the role of particular PRRs in the cytokine responses induced by the bacterial strains, 
several PRR specific blocking agents were applied to the PBMCs before administration of the 
bacterial strains. Surprisingly, blocking of TLR2 resulted in increased production of IL-1β, TNFα and 
IFN-g when cells were stimulated with B. breve (Figure 2). However, no differences were observed 
when TLR2 was blocked either in production of IL-6, IL-10 and IL-17 (data not shown) or after 
stimulation with L. rhamnosus or L. casei (Figure 2). Stimulation of mouse BMDCs with Pam3Cys or 
either Lactobacillus strain also demonstrated a minor role for TLR2 in recognition of these strains 
(Figure 3A). Accordingly, additional experiments in TLR2 transfected HEK293 cells revealed that B. 
breve but not L. rhamnosus or L. casei induces TLR2 signalling (Figure 3B). Blocking of TLR4 had no 
effect on cytokine production. These experiments were also performed with mouse splenocytes, 
either wild-type, TLR2 KO or TLR4 KO. Consistent with the human data, IFN-g responses in TLR2 
KO cells but not in TLR4 KO cells were different compared to wild-type cells after stimulation with 
B. breve (Figure 3C). As compared to the human data, the TLR2 KO splenocytes also exhibited a 
further increase in the production of IFN-g relative to wild-type splenocytes after stimulation with 
L. rhamnosus and L. casei, whereas the TLR4 KO cells did not. Blocking the C-type lectin receptors 
dectin-1, mannose receptor and DC-SIGN did not significantly influence probiotics induced cytokine 
production (data not shown).
Figure 3. (A) Production of IL-12, IL-10 and TNFα after stimulation of mouse bone marrow derived dendritic 
cells with Pam3Cys, L. rhamnosus or L. casei for 24 or 48 hours. Values are means ± SEM, N=4. (B) NF-κB 
activity after overnight stimulation of TLR2 transfected HEK293 cells with different CFU/cell ratios of B. breve, 
L. rhamnosus or L. casei. Fold induction was calculated as the ratio of experimental activity to control activity. 
Values are means ± SD, N=4. (C) Cytokine production capacity of IFN-g by splenocytes obtained from wild-type, 
TLR2KO and TLR4 KO mice stimulated with the bacterial strains. Values are means ± SEM, N=6, *P<0.05.
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Role of intracellular receptors 
Microbial recognition at the level of the cell membrane is complemented by pattern recognition 
in the intracellular compartment, by TLRs (e.g. TLR9) or NLRs (e.g. NOD2). Therefore, the role 
of phagocytosis was studied by using the phagocytosis inhibitor cytochalasin B. Cytochalasin B 
decreased cytokine responses for virtually all cytokines, suggesting an important role for intracellular 
recognition receptors (Figure 4). Therefore, the role of intracellular PRRs for recognition of these 
bacterial strains, such as TLR9 and NOD2 were studied. Blocking of the TLR9 receptor resulted in 
a profound decrease in IL-10 and IFN-g responses after stimulation of cells with either bacterial 
strain (Figure 5). For the other cytokines measured; TNFα, IL-1β and IL-6 concentrations revealed 
no differences between the conditions (data not shown). To assess the role of the intracellular 
PRR NOD2, cells from healthy subjects with functional NOD2 were compared with cells obtained 
from Crohn’s disease (CD) patients that are homozygous for the 1007fsinsC frameshift mutation in 
NOD2 leading to a loss-of-function of the protein. These analyses revealed no apparent differences 
between the two groups after stimulation of these cells with the bacterial strains (Figure 6).
Discussion
Nowadays, dietary products are widely supplemented with probiotics, i.e. live micro-organisms 
that may have the ability to provide a health benefit to the host. Desirable features of a probiotic 
strain are protective colonization of the intestinal tract, increasing efficiency of digestion and 
nutrient absorption, but also a low capacity to deviate immune responses towards Th1 and/or 
Th17 immune responses that are associated with intestinal pathology (24-26). Hence, the potential 
of probiotics as a therapeutic moiety in diseases involving the gastrointestinal tract (e.g. infections, 
inflammatory bowel disease and colon cancer) has been suggested (27-29). The rational use 
of probiotics in health and disease needs however a detailed understanding of the recognition 
pathways that can activate host defence by probiotics.
The potential of probiotics to modulate immune responses may represent an important factor for 
their therapeutic application. In fact, it is known that the release of TNFα by inflamed Crohn’s disease 
mucosa can be significantly reduced by coculture with L. casei DN-114 001 (30). More specifically, L. 
casei can counteract the pro-inflammatory effects of E. coli on Crohn’s disease inflamed mucosa by 
specific downregulation of key pro-inflammatory mediators (31).In the present study, we compared 
the inflammatory properties of three different bacterial strains, B. breve NumRes204, L. rhamnosus 
NumRes1 and L. casei DN-114 001, that belong to genera that are all widely used strains in dietary 
products, in their capacity to evoke and thereby skew immune responses towards distinct T helper 
mediated responses (i.e. immune deviation). When compared with Lactobacilli, B. breve was less 
capable of inducing IFN-g responses in human primary immune cells. The differential stimulation 
of cytokine production by B. breve and Lactobacilli was mediated by differences in recognition by 
PRRs with either stimulatory or inhibitory effects on cytokine responses.
Specific blocking of particular PRRs enabled us to elucidate what receptors are involved in the 
activation of cytokine production. The first important observation was that cytokine induction by 
both B. breve and Lactobacilli is strongly dependent on TLR9. Blocking of TLR9 resulted in severely 
decreased production of IL-10 and IFN-g, indicating that these bacterial strains contain immune 
stimulatory dsDNA containing unmethylated CpG sequences. In contrast, no differences were 
observed when the action of other PRRs was inhibited, such as TLR4, dectin-1, mannose receptor, 
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DC-SIGN and NOD2, indicating that these receptors have a minor role in recognition of the bacterial 
strains. The role of TLR9 for recognition of bacterial (32;33) and fungal DNA is well known, however 
its role in the induction of innate immune responses by probiotics in primary human cells has not 
been demonstrated until now.
In contrast to TLR9, recognition of B. breve by TLR2 had an opposite effect. Blocking TLR2 with a 
specific antibody stimulated cytokine responses induced by B. breve, including TNFα, IL-1β and 
IFN-g. Interestingly, no role for TLR2 could be demonstrated in L. rhamnosus and L. casei induced 
cytokine responses, indicating that these bacteria either lack TLR2 ligands in their cell wall or, perhaps 
more likely, that potential TLR2 ligands are masked. Of note, also bone marrow derived murine 
dendritic cells, which are highly susceptible to TLR2 agonists, failed to elicit noteworthy cytokine 
responses after exposure to these bacterial strains. In addition, data from TLR2 overexpressing 
human embryonic kidney (HEK293) cells containing a NF-κB reporter construct showed NF-κB 
induction upon incubation with B. breve whereas L. rhamnosus and L. casei were unable to do so. 
To complement and support the human data, additional experiments were performed with mouse 
splenocytes either wild-type or deficient in TLR2 or TLR4. In these experiments, IFN-g production 
was increased in TLR2 KO cells but was similar in TLR4 KO cells compared to wild-type, which is 
consistent with the human data. These findings suggest that TLR2 induces an intracellular inhibitory 
signal to downstream pathways that elicit cytokine production, such as the TLR9 pathway. Indeed, 
this anti-inflammatory role of TLR2 has been demonstrated before, both in vitro and in vivo (34-37). 
Moreover, TLR2 has also been implicated in the induction of regulatory T-cell responses, further 
emphasizing the immunosuppressive potential of TLR2 signalling (38-40).
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Figure 4. Cytokine production capacity of TNFα, IL-1β, IL-6, IL-10 and IFN-g by PBMCs obtained from healthy 
volunteers and stimulated with the bacterial strains in the absence or presence of cytochalasin B. Values are 
means ± SEM, N=6, *P<0.05.
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Figure 5. Cytokine producti on capacity of IL-10 and IFN-g by PBMCs obtained from healthy volunteers and 
sti mulated with the bacterial strains for 48 hours together with a TLR9 blocking agent. Values are means ± 
SEM, N=6, *P<0.05.
Figure 6. Cytokine producti on capacity of TNFα, IL-1β and IL-6 by PBMCs obtained from healthy volunteers or 
CD pati ents homozygous for the frameshift  mutati on in NOD2 (1007fsinsC) and sti mulated with the bacterial 
strains for 24 hours. Values are means ± SEM, N=4.
Also, a Bifi dobacterium strain has been shown to be able to induce T regulatory cells (8). However, 
it remains to be elucidated whether TLR2 is involved in this process, although previously indeed 
a immunoregulatory role of TLR2 in recogniti on of probioti c strains has been described (41-43).
When considering the potenti al therapeuti c applicati ons of these probioti c strains, one could draw 
useful informati on from the in vitro features of these strains. The data presented here suggest that 
B. breve may be more suitable than Lactobacilli in the context of infl ammatory bowel diseases (and 
especially Crohn’s disease), based on its lower infl ammatory potenti al. Th1 responses, as refl ected 
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by IFN-g production, are poorly induced by B. breve, while they are known to be crucial for the 
pathogenesis of Crohn’s disease (44;45). Beneficial effects of the inhibition of IFN-g production by 
B. breve, as compared to e.g. anti-TNFα treatment, may result in a tolerant state with decreased 
Th1 immune responses in the gut, whereas other (e.g. IL-1b and TNFα driven) immune pathways 
remain intact, thereby sustaining immunocompetence of the host. However, further in vivo studies 
need to be performed to confirm these findings and to assess its effect on relevant animal models, 
such as experimental colitis.
In conclusion, the observed differences in the capacity to induce cytokine secretion in human 
primary immune cells between the Bifidobacterium and Lactobacillus strains is most likely due to 
the differential recognition by TLRs. TLR9 mediates proinflammatory signals induced by both B. 
breve, L. rhamnosus and L. casei . In contrast, TLR2 exerts inhibitory effects upon recognition of B. 
breve, but not Lactobacilli. It is to be hoped that these data would contribute to the decision for a 
deliberate choice on what probiotic to use in a given application. 
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Modulation of Toll-like receptor ligands 
and Candida albicans-induced cytokine 
responses by specific probiotics
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Modulation of C. albicans induced cytokine responses by probiotics
Abstract
Probiotics have been proposed as modulators of gut inflammation, especially in inflammatory 
bowel disease (IBD). In order to be able to use them in these clinical conditions, their capacity 
to modulate immune responses towards other stimuli or microorganisms has to be thoroughly 
understood. In the present study, three different potentially probiotic strains, Bifidobacterium 
breve (NumRes 204), Lactobacillus rhamnosus (NumRes1) and Lactobacillus casei (DN-114 001), 
have been studied for their potential to modulate responses to stimulation with pure pattern-
recognition receptor (PRR) ligands or to the gut commensal fungus Candida albicans. Cytokine 
production induced by PRR ligands or C. albicans was assessed in conditions of simultaneous 
stimulation or preincubation of primary immune cells with Bifidobacterium or Lactobacillus spp. 
Results indicate that simultaneous stimulation leads to potentiation of IL-1β and IL-6 production, 
while the TNFα and IFN-g production was inhibited. In settings of pre-incubation with these 
potentially probiotic strains, lower production of TNFα was observed in the presence of B. breve. 
Moreover, C. albicans-induced IL-17 production was decreased after pre-incubation with both 
Bifidobacterium or Lactobacillus probiotic strains. Whereas C. albicans induced cytokines are 
dampened by the tested probiotic strains, TNFα and IL-6 production by pure pattern-recognition 
receptor ligands are potentiated. Interestingly, an important role of Toll-like receptor 9 signalling 
that involves JNK kinase in the modulatory effects of these probiotic strains has been identified. 
In conclusion, specific probiotic strains exhibit cross-tolerance effects towards other inflammatory 
stimuli, especially C. albicans, which might have beneficial effects on gut inflammation.  
Introduction
The gastrointestinal tract harbours an extensive array of different microorganisms, known as the 
gut microbiome. It is estimated that up to 500 – 1000 different microbial species colonize the 
gastrointestinal tract, especially the small and large intestines. This microbiome is required for 
gut homeostasis and regulates processes including nutrient digestion, as well as the uptake and 
prevention of colonization with pathogenic microorganisms (1;2).
The complex architecture of the gut mucosa, comprising intestinal epithelial cells, Paneth cells 
and immune cells, together with the colonization with different species of microorganisms ranging 
from bacteria to fungi, raises the concept of a complex interplay between these components 
that results in a tightly controlled balance to insure gut homeostasis. However, in conditions of 
inflammatory bowel disease (IBD), this balance is disturbed, leading to chronic inflammation of the 
gut mucosa. One of the major features of the inflammation in Crohn’s disease is the occurrence 
of anti-Saccharomyces cerevisiae antibodies (ASCA) in the serum of these patients (3;4). These 
antibodies, however, are not specific for S. cerevisiae, but display cross-reactivity with other fungi, 
i.e. Candida spp. of which C. albicans is the most abundant (5). The presence of ASCA antibodies in 
Crohn’s disease patients suggests therefore that C. albicans colonization of the gut contributes to 
disease pathogenesis, reinforced by the finding that the presence of ASCA antibodies is a risk factor 
for Crohn’s disease susceptibility and severity (6-8), which is also correlated with the degree of C. 
albicans gut colonization (9). Consequently, dampening of C. albicans induced immune responses 
in the gut could be beneficial in the treatment of Crohn’s disease. 
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An emerging and therapeutically promising area of research is the application of specific probiotics 
to Crohn’s disease patients in order to restore gut homeostasis by modulation of the inflammatory 
reactions induced by gut microbiota. Probiotic strains are classified as being live microorganisms 
which, when administered in sufficient amounts, confer a health benefit to the host (10). 
Microorganisms from the genera Lactobacillus and Bifidobacterium are often considered as 
probiotic candidates. All these bacteria are Gram-positive, (facultative) anaerobe microorganisms, 
that are common commensals in the human gastrointestinal tract. These bacteria are currently 
used in probiotic dietary products and several lines of evidence have demonstrated their beneficial 
effects on gut homeostasis (11-15). Also, beneficial effects of these potentially probiotic strains, 
especially Lactobacillus spp., have been described in preventing C. albicans colonization and C. 
albicans-induced inflammation (16-18).  
Microorganisms elicit inflammatory responses through engagement of pattern recognition 
receptors (PRRs), germ-line encoded receptors expressed on innate immune cells that are 
specialized to recognize conserved components of these microorganisms. Examples of PRRs are 
the families of Toll-like receptors (TLRs), C-type lectin receptors (CLRs) and nucleotide-binding 
oligomerization domain (NOD) like receptors (NLRs). Triggering of these receptors leads to 
downstream intracellular signalling that results in the induction of cytokine responses (19). For 
the specific probiotic strains investigated in the present study, it was previously determined that 
especially TLR2 and TLR9 are involved in their recognition (20). However, little is known about the 
modulatory capacity of these bacteria on immune responses induced by other microbial stimuli, 
which is highly relevant in settings of tissues densely populated with microorganisms such as the 
gut microenvironment. 
In the present study, we assessed the immunomodulatory effect of specific probiotic strains on 
the cytokine production induced by TLR ligands or C. albicans in primary human peripheral blood 
mononuclear cells. These experiments revealed that the tested probiotics possess the potential 
to modulate cytokine responses induced by microbial components and the fungal pathogen C. 
albicans. 
Materials and methods
Subjects
Human primary peripheral blood mononuclear cells (PBMCs) were isolated from buffycoats 
obtained from healthy blood donors at the Bloodbank of Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands. For the experiments with cells obtained from NOD2 deficient 
Crohn’s disease patients, blood was drawn into 10 ml EDTA tubes. The study was approved by the 
Ethical Committee of the Radboud University Nijmegen Medical Centre, and the volunteers have 
given written informed consent. At the time of donation, Crohn’s disease patients homozygous for 
the NOD2 frameshift mutation were in a quiescent phase, i.e. a prolonged period of at least three 
months of mild disease without relapses or exacerbations in the absence of immunomodulatory 
therapy. 
Reagents
Blocking monoclonal antibodies of the innate immune receptors TLR2 (clone T2.5), including 
the corresponding IgG1 isotype control antibody, were purchased from eBioscience and Coulter 
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Beckman, respectively, and were used in a concentration of 10 µg/ml. Blocking reagents of the 
receptors TLR4 (B. quintana lipopolysaccharide (21), 1 µg/ml), TLR9 (CpG ODN TTAGGG, Invivogen, 
25 µg/ml) were used. Kinase inhibitors for Mek/Erk (U0126, Promega, WI, USA), JNK (SP600125, 
A.G. Scientific Inc., CA, USA) or p38 kinase (SB 202190, Sigma-Aldrich, MO, USA) were applied 
in a concentration of 5 µM, 20 µM and 1 µM, respectively. The PRR ligands Pam
3
CysSK
4
 (EMC 
Microcollections, Tübingen, Germany), LPS (lipopolysaccharide, LPS, Sigma, MO, USA) and MDP 
(muramyl dipeptide, Sigma, MO, USA) were used in a concentration of 10 µg/ml, 10 ng/ml and 10 
µg/ml, respectively.
Bacterial fermentation and enumeration
Two Lactobacillus strains (NumRes1 and DN-114 001) and one Bifidobacterium breve strain 
(NumRes204) were grown at 37°C in a 400 ml reactor containing MRS supplemented with 
0.5 g/l L-cysteine for Bifidobacteria. The pH was maintained at 6.5 by addition of NaOH. To 
ensure anaerobic conditions the headspace was flushed with N
2
 or a gas mixture consisting of 
5% H
2
, 5% CO
2
 and 90% N
2
 for Bifidobacteria. Bacteria were harvested in the early stationary 
phase, washed in PBS and stored with glycerol 20% (w/v), in aliquots at -80°C. Cell counts were 
Figure 1. The interaction between probiotics and TLR ligands for cytokine production. Cytokine production 
capacity of TNFα, IL-1β , IL-6, IL-10, IFN-g and IL-17 by PBMCs obtained from healthy volunteers simultaneously 
stimulated with the bacterial probiotic strains together with pure ligands for TLR4 (LPS), TLR2 (Pam3CysSK4), or 
NOD2 (MDP). Values are means ± SEM, N=4, *P<0.05.
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Figure 2. Pre-incubation with probiotics modulates cytokine production. Cytokine production capacity of 
TNFα, IL-1β , IL-6, IL-10, IFN-g and IL-17 by PBMCs obtained from healthy volunteers and pre-incubated with 
the bacterial strains. After 24 hours pre-incubation, cells were restimulated for 24 hours, 48 hours or seven days 
with pure ligands for TLR4 (LPS), TLR2 (Pam3CysSK4), or NOD2 (MDP) or with heat-killed C. albicans. Values are 
means ± SEM, N=10, *P<0.05.
determined by plating serial dilutions (colony-forming units) and fluorescent microscopy by staining 
with 4’,6-diamidino-2-phenylindole (DAPI).
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PBMC stimulation experiments
The mononuclear cell fraction was obtained by density centrifugation of blood diluted 1:1 in 
pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells were washed twice 
in saline and suspended in culture medium (DMEM, Invitrogen, CA, USA) supplemented with 
gentamycin 50 µg/ml, L-glutamine 10 mM and pyruvate 10 mM. Cells were counted in a Coulter 
counter (Coulter Electronics) and the number was adjusted to 5*106 cells/ml. A total of 5*105 MNCs 
in a 100 µl volume were added to round-bottom 96-wells plates (Greiner) and incubated with either 
100 µl of culture medium (negative control), or with B. breve, L. rhamnosus or L. casei (all 1*105 
microorganisms/well) at a ratio of 1:5 bacterial cells : PBMCs for 24 hours (TNFα, IL-1b, IL-6) and 48 
hours (IL-10, IFN-g) without serum or seven days (IL-17) with 10% serum supplemented medium. 
Simultaneous stimulation assays were performed with probiotic strains alone or in combination 
with either pure PRR ligands or with 1*105 heat-killed C. albicans (ATCC reference strain UC820). In 
settings of pre-incubation with probiotic strains, PBMCs were preconditioned with 1*105 bacteria 
of each probiotic strain for 24 hours. Subsequently, after removing the supernatant and washing 
of the cells, cells were restimulated with PRR ligands or with 1*106 C. albicans in the presence or 
absence of the above mentioned TLR blockers or kinase inhibitors.
Cytokine measurements
Cytokine production capacity was measured in culture supernatants at indicated time points by 
ELISA according to the manufacturer’s protocol. ELISA kits were purchased from R&D Systems (MN, 
USA) for TNFα, IL-1β and IL-17, and from Sanquin (Amsterdam, The Netherlands) for IL-6, IL-10 and 
IFN-g.
Statistics
Differences in cytokine production capacity between groups were analyzed using the Mann-
Whitney U test. Differences were considered statistically significant at P < 0.05.
Results
Cytokine responses induced by specific probiotic strains and modulation by PRR ligands
To assess the effect of the specific probiotic strains on cytokine production induced by triggering 
pattern recognition receptors, PBMCs were stimulated with either B. breve, L. rhamnosus or L. 
casei with or without the simultaneous addition of ligands for TLR2 (Pam
3
CysSK
4
), TLR4 (LPS) or 
NOD2 (MDP). Measurement of cytokine concentrations in the supernatant for TNFα, IL-1b, IL-6, 
IL-10, IFN-g and IL-17 revealed significant reduction of TNFα and IFN-g release when cells were 
costimulated with either Lactobacillus strain and with the TLR2 ligand Pam
3
CysSK
4
, as compared 
to stimulation with these specific probiotic strains alone (Figure 1). In contrast, IL-1b and IL-6 
production is significantly increased by all three probiotic strains tested in combination with LPS for 
IL-1b and MDP for IL-6 (P<0.05). Overall, IL-10 and IL-17 production was minimal in all conditions 
(Figure 1).
Induction of cross-tolerance by pre-incubation with probiotic strains
To study the immunomodulatory potential of specific probiotic strains in a preconditioning fashion, 
PBMCs were pre-incubated with a suboptimal dose of either B. breve or L. rhamnosus alone 
for an initial 24 hours, after which the cells were restimulated for 24 hours, 48 hours or seven 
days with either PRR ligands or heat-killed C. albicans. Cytokine production was assessed in the 
88
Chapter 6
supernatants for TNFα, IL-1b, IL-6, IL-10, IFN-g and IL-17. The results indicate that pre-incubation 
with B. breve leads to diminished production of TNFα induced by C. albicans. Also a strong 
dampening effect of preincubation was observed for C. albicans induced IL-17, an effect that was 
Figure 3A. The effect of TLR inhibitors and NOD2 deficiency on the modulation of cytokines by probiotics. 
Cytokine production capacity of TNFα, IFN-g  and IL-17 by PBMCs obtained from healthy volunteers. After 24 
hours preincubation with the probiotic strains, PBMCs were stimulated for 24 hours, 48 hours or seven days 
with heat-killed C. albicans, with or without an isotype control, a TLR2 blocking antibody, a TLR4 inhibitor or a 
TLR9 inhibitor. Values are means ± SEM, N=6, *P<0.05.
observed for all the probiotic strains tested. Furthermore, potentiation of TNFα and IL-6 production 
was observed for LPS, Pam
3
CysSK
4
 and MDP stimulation after Lactobacillus spp. preincubation as 
compared to the combined cytokine production induced separately by either stimulation with 
these ligands or preincubation with these probiotic strains (Figure 2). 
Role of pattern-recognition receptors and downstream intracellular kinases on induction of cross-
tolerance by probiotic strains
PRR blockers and inhibitors of the most important intracellular kinases involved in pathways 
downstream of PRRs were applied to dissect the pathways responsible for the dampening effect 
induced by B. breve and L. rhamnosus. As TLRs such as TLR2, TLR4 and TLR9 have been previously 
suggested to mediate the effects induced by certain probiotics, we have assessed the role of TLR 
inhibitors on the modulatory effects of these specific probiotic strains. TLR9 blockade augmented 
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the inhibitory effect on TNFα and IL-17 production in conditions of preincubation with either 
B. breve or L. rhamnosus followed by C. albicans restimulation. IFN-g production was low in all 
conditions, and no differences could be observed (Figure 3A). In order to study the role of the 
NOD-like receptor NOD2 in this context, similar experiments with cells obtained from NOD2 
deficient Crohn’s disease patients were performed and revealed a significant effect of L. rhamnosus 
preincubation on C. albicans induced TNFα as compared to wild-type cells (Figure 3B). No significant 
differences were observed in cytokine production for any other cytokine measured, i.e. IL-1b, IL-6, 
IL-8, IFN-g and IL-10, as compared to cells with functional NOD2 (data not shown). Inhibition of the 
activity of the intracellular kinase JNK also augmented the inhibitory effect of the tested probiotics 
on TNFα production, while Erk and p38 inhibition did not have a significant effect. IFN-g and IL-17 
responses were not modulated by either of these kinase inhibitors (Figure 4).
Figure 3B. The effect of TLR inhibitors and NOD2 deficiency on the modulation of cytokines by probiotics. 
Cytokine production capacity of TNFα by PBMCs obtained from healthy volunteers or NOD2 deficient Crohn’s 
disease patients. After 24 hours pre-incubation with the probiotic strains, PBMCs were restimulated for 24 
hours or 48 hours with TLR ligands or Candida albicans. Values are means ± SEM, N=4, *P<0.05.
Discussion
The gut is a complex environment in which the presence of commensal microorganisms together 
with intestinal epithelial cells enables the host to absorb nutrients from the gut lumen and to 
protect itself from pathogenic invaders. In this environment the microbiota interacts with host 
cells, including epithelial cells, but also macrophages, dendritic cells and T-cells residing in the 
mucosal layer. Probiotic strains are suggested to have beneficial effects on gut homeostasis, but 
the exact mechanisms remain elusive. We have hypothesized that one potential beneficial effect 
of some specific probiotic bacteria could be the modulation of the immune responses to other gut 
microorganisms that in certain conditions exhibit inflammatory effects, such as has been suggested 
for C. albicans in Crohn’s disease (6;9).
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To investigate whether specific probiotic strains of the genera Bifidobacterium and Lactobacillus 
possess the capacity to influence immune responses by purified PRR ligands or whole 
microorganisms such as C. albicans, experiments were performed with these strains in settings 
of either simultaneous stimulation, or after pre-incubation of human PBMCs followed by 
stimulation with PRR ligands or C. albicans. At first, cells were exposed to a low dose of either B. 
breve, L. rhamnosus or L. casei together with pure PRR ligands including Pam
3
CysSK
4
, LPS or MDP. 
Synergistic effects of these probiotics and LPS on IL-1b production have been observed, as well as 
between probiotics and MDP for IL-6 production. On the contrary, TNFα and IFN-g stimulation by 
Lactobacillus, but not B. breve, strains was decreased by co-incubation with Pam
3
CysSK
4
, indicating 
an inhibitory effect of TLR2 signalling on the production of these cytokines. These findings are in 
line with previous reports demonstrating an inhibitory role for TLR2 on IFN-g production induced 
by both probiotics (20) as well as other bacterial stimuli (22-25). 
Preincubation of PBMCs with either B. breve, L. rhamnosus or L. casei resulted in decreased 
immune activation by C. albicans with regard to production of TNFα. This effect was stronger after 
preconditioning of cells with B. breve. IL-17 induction by C. albicans was significantly reduced after 
preincubation of PBMCs with either probiotic strain. These findings indicate that immune cells, 
when pretreated with specific probiotic strains, are less potent in their capacity to elicit TNFα 
and IL-17 responses upon other stimuli, which can be designated as induction of cross-tolerance. 
Suppression of TNFα and IL-17 could be of high therapeutic potential, since these cytokines are 
known to be involved in chronic gut inflammation (26;27). This inhibitory effect could potentially be 
due to the modulation of cytokines crucial for Th17 development, such as IL-23. Another cytokine 
important for Th17 activation is IL-1b. However, pre-incubation with the specific probiotic strains 
followed by PRR ligands or C. albicans leads to similar or a tendency of increased IL-1b production, 
which consequently cannot explain the decreased IL-17 response. In contrast to the effects of 
preincubation with probiotic strains for C. albicans induced cytokines, opposite findings were 
obtained when PBMCs were cultured with pure PRR ligands following preincubation with probiotic 
strains; TNFα and IL-6 responses were significantly potentiated in these conditions as compared to 
the single stimulations.
In an attempt to unravel the molecular mechanisms that account for the observed capacity of cross-
tolerance induction by probiotics on C. albicans induced cytokine release, specific Toll-like receptor 
and intracellular kinase pathways were inhibited during cross-tolerance experiments. Interestingly 
however, blocking TLR9 led to a further decrease in the secondary induction of TNFα and IL-17, which 
indicates that the function of TLR9-mediated signals is to counteract the cross-tolerance induction 
by B. breve and L. rhamnosus. A similar effect was observed when JNK kinase was inhibited, indirectly 
suggesting that the TLR9 signals induced by these specific probiotic strains may be mediated through 
JNK kinase. Indeed, previous studies have demonstrated the involvement of JNK in TLR9 signalling 
(28;29). No effects were observed when TLR2/TLR4, or the p38 and Erk kinases, were inhibited. 
However, the cross-tolerance effect of B. breve and L. rhamnosus on C. albicans induced cytokines 
could not be reversed by any of the TLR or kinase inhibitors, suggesting that other mechanisms are 
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Figure 4. The effect of kinase inhibitors on the modulation of cytokines by probiotics. Cytokine production 
capacity of TNFα, IFN-g and IL-17 by PBMCs obtained from healthy volunteers. After 24 hours preincubation 
with the probiotic strains, PBMCs were stimulated for 24 hours, 48 hours or seven days with heat-killed C. 
albicans, with or without a p38, JNK or Erk inhibitor. Values are means ± SEM, N=8, *P<0.05.
responsible for the inhibitory effect. Experiments with primary cells from NOD2 deficient Crohn’s 
disease patients indicate that L. rhamnosus induced cross-tolerance towards C. albicans-induced 
TNFα might be partly NOD2 dependent. However, no effects of NOD2 deficiency could be observed 
in production capacity of other cytokines, indicating that cross-tolerance is elicited mainly through 
a NOD2 independent pathway. One potential other mechanisms that could be responsible for 
the cross-tolerance induced by Bifidobacterium and Lactobacillus strains, especially regarding 
the modulation of IL-17 production, is the apparent ability of these probiotic strains to induce 
hyporesponsiveness and even apoptosis of T-cells (11;30). It remains to be determined whether 
indeed the phenotype or fate of T-cells is modulated in our experimental settings.
92
Chapter 6
In conclusion, cytokine responses are modulated by the presence of Bifidobacterium and 
Lactobacillus probiotic strains. In simultaneous cocultures with PRR ligands, probiotic strains 
have synergistic effects on IL-1b and IL-6 production, but inhibitory effects on TNFα and IFN-g. 
Moreover, upon pre-incubation of a suboptimal dose of either Bifidobacterium or Lactobacillus 
spp., C. albicans-induced TNFα and IL-17 production was significantly dampened, whereas PRR 
ligand induced TNFα and IL-6 release was elevated. These findings indicate that probiotics can 
modulate the inflammatory response in vitro, and this biological effect may be harnessed for the 
design of novel therapies. Future studies are warranted to confirm these findings in vivo.
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Abstract
Background: Dectin-1 is a pattern recognition receptor (PRR) expressed by myeloid cells that 
specifically recognizes β-1,3 glucan, a polysaccharide and major component of the fungal cell wall. 
Upon activation, dectin-1 signaling converges, similar to NOD2, on the adaptor molecule CARD9 
which is associated with inflammatory bowel disease (IBD). An early stop codon polymorphism 
(c.714T>G) in DECTIN-1 results in a loss-of-function (p.Y238X) and impaired cytokine responses, 
including TNFα, interleukin (IL)-1β and IL-17 upon in vitro stimulation with Candida albicans or 
β-glucan. The aim of the present study was to test the hypothesis that the DECTIN-1 c.714T>G 
(p.Y238X) polymorphism is associated with lower disease susceptibility or severity in IBD and 
to investigate the level of dectin-1 expression in inflamed and non-inflamed colon tissue of IBD 
patients. 
Methodology: Paraffin embedded tissue samples from non-inflamed and inflamed colon of IBD 
patients and from diverticulitis patients were immunohistochemically stained for dectin-1 and 
related to CD68 macrophage staining. Genomic DNA of IBD patients (778 patients with Crohn’s 
disease and 759 patients with ulcerative colitis) and healthy controls (N=772) was genotyped for 
the c.714T>G polymorphism and genotype-phenotype interactions were investigated. 
Principal findings: Increased expression of dectin-1 was observed in actively inflamed colon tissue, 
as compared to non-inflamed tissue of the same patients. Also an increase in dectin-1 expression 
was apparent in diverticulitis tissue. No statistically significant difference in DECTIN-1 c.714T>G 
allele frequencies was observed between IBD patients and healthy controls. Furthermore, no 
differences in clinical characteristics could be observed related to DECTIN-1 genotype, neither 
alone, nor stratified for NOD2 genotype. 
Conclusions: Our data demonstrate that dectin-1 expression is elevated on macrophages, 
neutrophils, and other immune cells involved in the inflammatory reaction in IBD. The DECTIN-1 
c.714T>G polymorphism however, is not a major susceptibility factor for developing IBD. 
Introduction
Inflammatory bowel disease (IBD), is an idiopathic, chronic, relapsing inflammatory disorder of the 
gastrointestinal tract. It is commonly accepted that IBD is caused by an exaggerated cell-mediated 
immune response to intestinal microbiota in genetically susceptible individuals (1;2). IBD mainly 
involves two distinct diseases, which show some overlap: Crohn’s disease (CD) and ulcerative colitis 
(UC). Genetic susceptibility is more pronounced in CD compared to UC (3). Several susceptibility 
loci for developing CD have been identified in the past decades including the NOD2 gene within the 
IBD1 locus (4). The established association of NOD2 (CARD15) with CD emphasizes the important 
role of the intestinal microbiota in the pathogenesis of CD, since NOD2 acts as an intracellular 
pattern recognition receptor (PRR) recognizing bacterial peptidoglycans (5;6).   
Dectin-1 (CLEC7A) is a pattern-recognition receptor expressed by myeloid cells which specifically 
recognizes β-(1,3)-glucan, a polysaccharide and component of the fungal cell wall. As a result, 
dectin-1 is involved in recognition of fungi such as Candida albicans and Aspergillus fumigatus. 
Upon activation, dectin-1 recruits spleen tyrosine kinase (Syk) which in turn activates NF-κB, 
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requiring the adaptor molecule Caspase Activating Recruitment Domain 9 (CARD9), a key adaptor 
for non-Toll Like Receptor (TLR) signal transduction (7). Although not the exclusive pathway, CARD9 
also has a critical function in NOD2-mediated activation of the kinases p38 and Jnk, required for the 
production of pro-inflammatory cytokines in innate immune responses to intracellular pathogens 
(8). LeibundGut-Landmann et al. showed that dectin-1-Syk-CARD9 signaling induces dendritic cell 
(DC) maturation and secretion of pro-inflammatory cytokines like interleukin (IL)-6, TNFα, IL-17 
and IL-23 (9). Furthermore, Zhernakova et al. identified CARD9 as a susceptibility locus for IBD (10). 
Recently, the DECTIN-1 polymorphism c.714T>G on chromosome 12p13 has been described, with 
a transition from a tyrosine to an early stop codon on amino acid position 238 (p.Y238X) (11). The 
functional consequence of this polymorphism is a complete loss-of-function, and immune cells 
expressing this truncated protein produce significantly less cytokines, including TNFα, IL-1β and 
IL-17, upon in vitro stimulation with β-glucan or Candida albicans (12).
Th17 responses are considered to be involved in the pathogenesis of auto-immune diseases. This 
T-cell subset appears to play a role in the etiology of CD since IL-17 is upregulated in the intestine 
of IBD patients (13). Interestingly, both NOD2 and dectin-1 are shown to be capable of inducing 
Th17 responses after activation (9;14). In this respect, the DECTIN-1 c.714T>G polymorphism could 
influence the Th17 response towards fungi such as Candida albicans, a commensal microorganism 
of the gastrointestinal tract. Candida albicans is also one of the immunogens for developing 
antibodies against Saccharomyces cerevisiae (ASCA), which are regularly observed in patients with 
CD (15;16). Taking together the data from various studies, a dysregulation of the immune response 
to the commensal Candida albicans through dectin-1 and IL-17 release might play a role in the 
pathogenesis of CD.
As stated above, activation of NOD2 and dectin-1 leads to signaling through a shared pathway 
(CARD9) . The importance of this pathway in CD is demonstrated by the fact that mutations in 
NOD2 and CARD9 and the presence of circulating ASCA, are associated with CD. Since the c.714T>G 
polymorphism within DECTIN-1 results in a loss of function, we hypothesized that this polymorphism 
could be potentially protective against developing IBD. Therefore, we aimed to elucidate the role of 
the DECTIN-1 c.714T>G (p.Tyr238X) polymorphism in patients with IBD, focusing on the occurrence 
and the clinical severity of IBD.
Materials and Methods
Patients
Patients with a diagnosis of IBD were recruited from the outpatient clinics of three university 
hospitals in the Netherlands: Radboud University Nijmegen Medical Centre (CD: N=161, UC: 
N=212), VU University Medical Centre Amsterdam (CD: N=177, UC: N=148) and the University 
Medical Centre Groningen (CD: N=308, UC: N=214), and one regional hospital: St. Anna Hospital, 
Geldrop (CD: N=132, UC: N=185). Healthy controls were recruited at the Radboud University 
Nijmegen Medical Centre and at the University Medical Centre Groningen (N=772). Diagnosis of 
IBD was based on accepted clinical, endoscopic, radiological and histological findings (17). Clinical 
data on patients were retrieved by retrospective collection from patients’ clinical charts. Clinical 
data on patients from the VU University Medical Centre were collected prospectively. The following 
data were obtained from patients with CD: age, age at diagnosis, gender, familial or sporadic IBD, 
disease localization and behavior of disease (according to the Vienna classification (18)), extra-
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intestinal manifestations, peri-anal disease, and surgery for CD. For patients with UC, the following 
data were obtained: age, age at diagnosis, disease location (according to the Montreal classification 
(19)), familial or sporadic IBD, extra intestinal manifestations, surgery for UC, and occurrence of 
colorectal cancer. The ethical committee of region Nijmegen and Arnhem reviewed and approved 
the protocol under number CWOM-nr 9804-0100. Verbal informed consent was obtained from 
each patient before study participation in agreement with the approval and all samples were 
anonymized. Given the fact that all research data were anonymously collected, at least verbal 
informed consent was needed according to national regulations. Therefore, since written informed 
consent was not required, no written informed consent procedure was introduced at time of data 
collection.
Genotyping of c.714T>G polymorphism in DECTIN-1
Genomic DNA was isolated from peripheral venous blood using standard techniques and stored 
at 4°C. Genotyping of the c.714T>G (p.Y238X) polymorphism in exon 6 of the DECTIN-1 gene in 
the patient and healthy control groups from Nijmegen, Amsterdam and Geldrop was performed 
by applying the predesigned TaqMan SNP assay C_33748481_10 (rs 16910526) on the 7300 
ABI Real-Time PCR system (both from Applied Biosystems, Foster City, CA, USA) using 96-well 
plates. Genotyping of the IBD cohort and healthy controls from Groningen, was performed at the 
Department of Genetics, UMC Groningen, the Netherlands, applying the same predesigned TaqMan 
SNP assay, using the 7900 ABI Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). 
The patient and control DNA samples from Groningen were processed in 384-well plates and each 
plate also contained 16 genotyping controls (4 duplicates of the Centre d’Etudes du Polymorphisme 
Humain (CEPH) DNA samples 123002,102405,090203 and 081505). For all polymorphisms we 
obtained > 99.8% concordance between our CEPH genotype data and the CEU (European ancestry) 
data available from HapMap. 
Genotyping of NOD2 variants
Data on the three common NOD2 variants were available for CD patients from Groningen and 
Nijmegen (p.Arg702Trp; N=437, p.Gly908Arg; N=446, p.Leu1007ProfsX2; N=436). Genotyping of 
these three NOD2 variants (c.2104C>T (p.Arg702Trp), c.2722G>C (p.Gly908Arg), c.3019_3020insC 
(p.Leu1007ProfsX2)) has been described before (20).
Immunohistochemical staining 
Dectin-1 and CD68 protein expression were evaluated by immunohistochemical staining in paraffin 
embedded normal and inflamed colon tissue of five IBD patients and 4 patients with diverticulitis, 
all homozygous for the DECTIN-1 wild-type allele (T/T). The applied primary antibodies were a 
monoclonal mouse-anti-human dectin-1 antibody (MAB 1859, purchased from R&D Biosystems, 
Minneapolis, MN, USA), used in a concentration of 5 µg/ml and a monoclonal mouse-anti-human 
antibody against CD68 (MCA1815T, purchased from AbD Serotec, Oxford, UK) which was diluted 
100 times before use. After overnight incubation with the primary antibody, the tissue sections 
were incubated for 1 hour with a secondary antibody after washing with PBS. Subsequently the 
staining was visualized by applying ABC complex and DAB solution. Sections were counterstained 
with haematoxylin.    
Statistics
Statistical analysis was performed by using SPSS statistical software, version 16.0 (SPSS Inc., Chicago, 
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IL). Controls and IBD patients were tested for Hardy Weinberg equilibrium. Allele frequencies were 
compared between patients and controls using the χ2 test. P-values were obtained by comparing 
individuals carrying at least one DECTIN-1 G allele (G/G genotype and T/G genotype) with wild-type 
individuals (T/T genotype). Continuous variables were compared using Student t-tests. Strength of 
association between genotype and phenotype is given as odds ratio with 95% confidence interval 
(CI). Statistical interaction between NOD2 variants and the c.714T>G polymorphism regarding 
clinical characteristics, was investigated by comparing patients carrying a NOD2 susceptibility allele 
in combination with carrying one or two copies of the DECTIN-1 G allele, to patients not bearing 
any of these NOD2 or DECTIN-1 minor alleles. This combined analysis for c.714T>G and NOD2 
was performed for each of the three NOD2 susceptibility alleles. A P-value < 0.05 was considered 
significant.
Figure 1. Representative immunohistochemical staining of DECTIN-1 and CD68 in inflamed and non-
inflamed intestine of the same specimen in Crohn’s disease (250x magnified). Macrophages are present in 
non-inflamed intestinal tissue but are present in increased numbers in inflamed tissue (pictures A and C). The 
expression of DECTIN-1 is increased in inflamed intestinal tissue compared to non-inflamed intestinal tissue 
(pictures B and D).
Results
Protein expression of dectin-1 in intestinal tissue
Dectin-1 and CD68 staining was performed on matched intestinal tissue samples from five IBD 
patients, either inflamed or non-inflamed, as depicted in Figure 1. Dectin-1 expression is mainly 
present on macrophages as showed by staining for CD68 (Figure 1). Furthermore, dectin-1 also 
appears to be weakly expressed on neutrophils, the membrane of endothelial and epithelial 
cells and in the submucosal neuronal plexus of Meissner (not shown). Dectin-1 appeared to be 
upregulated within inflamed colon tissue due to increased expression of dectin-1 on inflammatory 
cells and increased influx of inflammatory cells. In order to test whether this increased expression 
of dectin-1 is IBD specific, additional staining was performed on matched intestinal tissue samples 
from 4 patients with diverticulitis. As shown in Figure 2, increased expression of dectin-1 was 
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observed in patients with severe diverticulitis compared to mild diverticulitis. As is true for patients 
with IBD, expression of dectin-1 is mainly present on macrophages as shown by CD68 staining. 
Figure 2. Representative immunohistochemical staining of dectin-1 and CD68 in mild and severe diverticulitis 
(250x magnified). Macrophages are present in intestinal tissue of mild diverticulitis but are present in increased 
numbers in severe diverticulitis (pictures A and B). Also, the expression of dectin-1 is increased in severe 
diverticulitis compared to mild diverticulitis (pictures C and D).
Distribution of the DECTIN-1 c.714T>G polymorphism in IBD patients and healthy controls
Characteristics of the study population and healthy controls are depicted in Table 1. Genotype 
frequencies of healthy controls were in Hardy Weinberg equilibrium. Carriage of at least one copy 
of the G allele of the DECTIN-1 polymorphism was 14% in the CD, 14% in the UC and 17% in the 
healthy control group. The frequency of the G allele was 9.8% in the healthy controls, 8.1% in 
CD patients and 7.7% in UC patients. Overall, no significant differences were observed between 
patients with IBD and healthy controls regarding allele frequencies of the DECTIN-1 polymorphism. 
However, a slight trend towards association of homozygosity for the DECTIN-1 G allele with IBD 
was observed (G allele frequency of 1.0% in healthy controls vs. 0.5-0.6% in CD and UC, Table 1).
Table 1. Distribution of genotypes of wild-type, heterozygous and homozygous individuals for the 
DECTIN-1 c.714T>G polymorphism.
DECTIN-1 status Controls Crohn’s disease P-value* Ulcerative colitis P-value*
Total cohort,  
number
772 (100%) 778 (100%) 759 (100%)
T/T 642 (83.2%) 667 (85.7%) 0.16 655 (86.3%) 0.09
T/G 122 (15.8%) 106 (13.6%) 100 (13.2%)
G/G 8 (1.0%) 5 (0.6%) 4 (0.5%)
Values are presented as absolute numbers (percentages). *Healthy controls versus patients with IBD; carriers of 
the mutant allele (T/G and G/G) were compared to wild-types (T/T).
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Correlation of the DECTIN-1 c.714T>G polymorphism with clinical characteristics of IBD patients
Patients with CD carrying one or two copies of the DECTIN-1 G allele were compared to patients 
with the wild-type genotype T/T with regard to age at diagnosis, gender, family history of IBD, 
localization of disease and disease behavior, extra intestinal and peri-anal disease and surgery 
related to CD (Table 2). Patients with UC were likewise compared according to the DECTIN-1 
genotypes regarding age at diagnosis, gender, localization of disease, extra-intestinal disease, 
development of malignancies, surgery related to UC and a positive family history for IBD (Table 
3). No statistical significant associations were observed between the c.714T>G polymorphism and 
specific phenotypes. 
The DECTIN-1 c.714T>G polymorphism stratified by NOD2 status and clinical characteristics 
of IBD patients
CD patients carrying one or two copies of the G allele of the DECTIN-1 gene were stratified by NOD2 
status. A NOD2 risk genotype was defined as carrying at least one of the three common NOD2 
disease susceptibility alleles (c.2104C>T (p.Arg702Trp), c.2722G>C (p.Gly908Arg), c.3019_3020insC 
(p.Leu1007ProfsX2)). Combinations of NOD2 risk carriers and DECTIN-1 c.714T>G carriers were 
compared to patients not bearing any of these NOD2 or DECTIN-1 minor alleles, regarding clinical 
characteristics. No statistical significant interaction between DECTIN-1 c.714T>G and one of the 
NOD2 variants was observed (data not shown).
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Table 3. Association between DECTIN-1 genotypes and clinical characteristics in a subset of 
ulcerative colitis patients from whom detailed phenotypic data were available (N=759).
Characteristic Total 
cohort 
UC
(%) T/T (%) T/G (%) G/G (%) Odds 
ratio*
95% CI*
Age at diagnosis 
(SD)
36.3 (± 14.4) 33.9 (± 12.9) 35.5 (± 10.4)
Male gender 401 (52.8) 346/ 
655 
(52.8) 52/ 100 (52.0) 3/ 4 (75.0)
Localization 
(Montreal) (N=721)
 E1 (Proctitis) 124 (17.2) 110/ 
623 
(17.7) 14/ 95 (14.7) 0/ 3 (0) 0.78 0.43 - 
1.42
E2 (Left 
sided)
245 (44.0) 212 (34.0) 33 (34.7) 0 (0) 0.98 0.63 - 
4.51
E3 
(Extended/
pancolitis)
352 (48.8) 301 (48.3) 48 (50.5) 3 (100) 1.16 0.76 - 
1.79
Extraintestinal 
disease (N=228)
42 (18.4) 33/183 (18.0) 8/ 43 (18.6) 1/ 2 (50) 1.14 0.50 - 
2.59
Surgery (N=759) 145 (19.1) 120/ 
655 
(18.3) 24/ 100 (24.0) 1/ 4 (25.0) 1.41 0.86 - 
2.31
Malignancy  
(N=384)
2 (0.5) 1/ 329 (0.3) 1/ 53 (1.9) 0/ 2 (0) 6.07 0.37 - 
98.57
Family diagnosis of 
IBD (N=547)
81 (14.8) 72/ 472 (15.3) 9/ 72 
 
(12.5) 0/ 3 (0) 0.76 0.36 - 
1.59
Values are presented as absolute numbers (percentages). *Carriers of the mutant allele (T/G and 
G/G) were compared to wild-types (T/T).
Discussion
Signaling through dectin-1, known for its recognition of the fungal component β-glucan, has been 
described to be involved in several immunological pathways. Dectin-1 amplifies pro-inflammatory 
cytokine production induced by TLR2 and TLR4, and primes Th1, Th17 and cytotoxic T-cell responses 
induced by dendritic cells (9;21). The DECTIN-1 c.714T>G polymorphism results in a loss-of-function 
of dectin-1, and we hypothesized that this polymorphism could be potentially protective in either 
the susceptibility to or the disease severity of IBD.
As shown by immunohistochemical staining of intestinal tissue, dectin-1 is mainly present on 
macrophages, but also weakly on epithelial and endothelial layers of the intestine. Similar findings 
in mice have been demonstrated by Wong and co-workers, who demonstrated that dectin-1 is 
mainly expressed on populations of myeloid cells (monocyte/ macrophage and neutrophil lineages) 
(22). In addition, they demonstrated that dectin-1 is also expressed in the Peyer’s patches and along 
the lamina propria of the mouse intestine (23;24). Interestingly, dectin-1 expression appeared to be 
elevated in inflamed intestinal tissue compared to normal tissue, due to the increased infiltration of 
immune cells and increased dectin-1 expression on the cell membrane of immune cells. However, 
intestinal expression of dectin-1 did not appear to be disease specific but rather dependent on 
influx of macrophages. In fact, expression of dectin-1 was also present in intestinal samples from 
patients with diverticulitis. Increased infiltration of macrophages in severe diverticulitis showed 
an increased expression of dectin-1, compared to mild diverticulitis which is accompanied by less 
infiltration of macrophages. 
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Cohorts of CD (N=778) and UC (N=759) patients were screened for the DECTIN-1 c.714T>G 
polymorphism and compared to a group of healthy subjects (N=772). Subsequently, these genetic 
data were correlated with clinical parameters reflecting disease severity. This analysis revealed 
no statistical significant association between the prevalence of the DECTIN-1 c.714G allele 
and IBD, neither in disease occurrence nor in disease severity. However, one can observe that 
homozygous individuals bearing the DECTIN-1 polymorphism were twice as frequent in healthy 
controls compared to IBD patients. This may suggest that complete absence of dectin-1 function 
could protect against IBD. It is important to realize that the only two dectin-1 isoforms capable of 
binding β-glucans (isoforms A and B) are structurally equally affected by the DECTIN-1 c.714T>G 
polymorphism (25). The occurrence of splicing isoforms with residual function could therefore be 
excluded. The potential mechanism of protection are likely to include the lower production of pro-
inflammatory cytokines, including IL-17, in the individuals with defective dectin-1. In these series, 
statistical power to preclude any functional difference is insufficient due to the low prevalence of 
homozygous individuals. Additional studies in homozygous and heterozygous subpopulations are 
needed to confirm the reported observations. 
All together, the reports of the association of mutations within NOD2 and CARD9 in patients with 
CD, the presence of ASCA, and the shared signaling pathway of dectin-1 and NOD2, points toward 
a possible link between NOD2 and dectin-1 (26). Since mutations in NOD2 in CD patients are 
associated with ileal involvement and increased need for surgery and stricturing disease (27), a 
potential interaction between NOD2 mutations and the DECTIN-1 c.714T>G polymorphism with 
regard to phenotypical characteristics was investigated. However, no statistical interaction could be 
demonstrated (data not shown). 
In conclusion, our data demonstrate that dectin-1 expression is elevated on macrophages, 
neutrophils, and other immune cells involved in the inflammatory reaction in IBD. The DECTIN-1 
c.714T>G polymorphism is not a major susceptibility factor for protection against IBD, although 
a trend towards a lower frequency of the polymorphism in CD and UC cohorts was observed, in 
particular in the number of individuals homozygous for the DECTIN-1 polymorphism. These genetic 
findings warrant further investigation of this pathogenetic pathway.
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Abstract
Introduction: Dectin-1, a pattern recognition receptor expressed by the innate immune system, 
is known to be a major receptor inducing Th17-type adaptive immune responses that have been 
demonstrated to mediate autoimmunity. In this study, dectin-1 mRNA and protein expression 
as well as the recently characterized DECTIN-1 Y238X early stop polymorphism, were studied in 
relation to RA susceptibility and severity.
Methods: Dectin-1 mRNA expression was measured in synovial tissue specimens of RA, OA and 
non-rheumatic patients. Dectin-1 protein expression and localization were assessed in RA synovial 
tissue specimens. Macrophages from individuals with different DECTIN-1 genotypes were examined 
for differences in cytokine responses upon dectin-1 stimulation. Furthermore, clinical parameters 
of inflammation and bone destruction of 262 RA patients were correlated with the presence of the 
DECTIN-1 Y238X polymorphism.
Results: Evaluation of dectin-1 mRNA expression in synovial tissue biopsies revealed an increased 
expression in RA specimens, compared to biopsies from OA and non-rheumatic patients. Accordingly, 
dectin-1 protein expression in RA synovial tissue biopsies was moderate to high, especially on 
macrophage-like cells. Cytokine production capacity of macrophages bearing the DECTIN-1 Y238X 
polymorphism was demonstrated to be impaired upon dectin-1 stimulation. However, the presence 
of the DECTIN-1 Y238X polymorphism was not associated with RA susceptibility or disease severity.
Conclusions: Although expression of dectin-1 was high in synovial tissue of RA patients and reduced 
cytokine production was observed in macrophages of individuals bearing the DECTIN-1 Y238X 
polymorphism, loss of one functional allele of DECTIN-1 is not associated with either susceptibility 
to or severity of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that results in severe cartilage 
damage and bone destruction in synovial joints. Despite unclear disease aetiology, it is commonly 
appreciated that both genetic and environmental factors are underlying risk factors in the 
pathogenesis of RA. In recent years an important role for innate immune receptors in RA has 
emerged, especially focused on members of the Toll-like receptor (TLR) family (1;2). These innate 
responses have been recently suggested to modulate and induce the autoimmune related Th17 
responses (3;4). 
A different class of innate immune receptors involved in microbial recognition and subsequent 
immune signalling are C-type lectins, of which dectin-1 is one of the most well characterized 
members. After its discovery as a receptor for fungal derived 1,3-β-glucans (5), its intracellular 
signalling has been demonstrated to be mediated by Raf-1 and Syk-CARD9 dependent pathways to 
induce production of pro-inflammatory cytokines and reactive oxygen species (6-10). Other studies 
have uncovered that dectin-1 converges with TLR signalling (11;12) for the induction of cytokine 
responses and is able to promote Th17 and cytotoxic T-cell responses through activation of dendritic 
cells (13;14). It has been well established that fungal particles, either intact yeast or fungal cell wall 
components that can be recognized by dectin-1 such as zymosan, can act as adjuvants in several 
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experimental models of RA (15-19). In addition, a study by Yoshitomi et al. revealed that β-glucan 
induced autoimmune arthritis in genetically susceptible SKG mice could be prevented by blocking 
the dectin-1 receptor (20). 
These studies imply that dectin-1 plays a pivotal role in the innate immune system and is able 
to modulate adaptive immune responses, of which especially Th17 responses are implicated in 
immunopathology. Furthermore, dectin-1 is involved in induction of arthritis in mouse models 
through induction of intracellular signalling upon recognition of fungal components. As a 
consequence, dectin-1 mediated inflammatory responses could contribute to the aetiology or 
disease severity of RA. 
Recently we characterised an early stopcodon polymorphism Y238X (c.714T>G, rs16910526) 
in DECTIN-1 (21), that was demonstrated to result in a complete loss-of-function of the protein. 
Cytokine production capacity of peripheral blood mononuclear cells (PBMCs) from individuals 
homozygous for the DECTIN-1 Y238X polymorphism upon β-glucan or C. albicans exposure are 
impaired, including TNFα, interleukin (IL-)1β, IL-6 and IL-17 responses. In the same stimulation 
assays, individuals heterozygous for the DECTIN-1 Y238X polymorphism exhibited intermediate 
cytokine responses compared to wild-type individuals (22). 
Considering both the involvement of dectin-1 in pro-inflammatory responses and the significant 
consequences of the Y238X polymorphism for dectin-1 function, it is compelling to assess whether 
dectin-1 and the DECTIN-1 Y238X polymorphism play a role in the pathogenesis or disease severity 
of RA. In the present study mRNA expression of dectin-1 was assessed in synovial tissue biopsies 
obtained from RA patients and compared to synovial tissue specimens from osteoarthritis (OA) 
patients and from patients with other underlying joint pathology not related to RA. In addition, 
dectin-1 protein expression was assessed in tissue sections of synovial lesions obtained from RA 
patients. The functional consequences of the presence of the DECTIN-1 Y238X polymorphism on 
cytokine production capacity of macrophages were studied by stimulating the cells with β-glucans. 
Furthermore, the presence of the DECTIN-1 Y238X polymorphism was correlated with disease 
susceptibility in a cohort of 262 RA patients, and within this cohort clinical parameters of joint 
inflammation and bone destruction were compared after stratifying for the DECTIN-1 genotype. 
Materials and methods
Patients
For assessing the effect of the DECTIN-1 Y238X polymorphism on the disease course, patient data 
were used from the early RA inception cohort at our clinic, described in more detail elsewhere (23). 
Patients were included in this cohort if they fulfilled the ACR (American College of Rheumatology) 
classification criteria for RA, were at least 18 years of age, had a disease duration not exceeding 1 
year, and did not use DMARDs or biological response modifiers. Age, gender and IgM-rheumatoid 
factor were determined at baseline. At baseline and every 3 months thereafter patients were 
assessed by specialized research nurses who assigned joint inflammation scores and drew a blood 
sample for determination of erythrocyte sedimentation rate. The patients indicated their global 
disease activity on a Visual Analogue Scale. These data were used to calculate the disease activity 
score (DAS28) according to the original formula (24). X-rays of the hand and feet were made at 
baseline, year 1, 2, and 3, and every third year thereafter. Radiographs of hands and feet were 
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read in chronological order by one of four raters, according to the Ratingen score using reference 
pictures (25). The Ratingen score (range 0 – 190) is a modification of the Larsen score and evaluates 
joint surface destruction, graded from 0 to 5, in 38 hand and feet joints, separately. The inter-rater 
reliability was ICC=.85, tested previously with the 4 raters in 10 patients over 9 years. Clinical data 
were entered in a computerized database. 
From 2006 to 2008 additional blood was collected in a convenience sample of the cohort, used for 
genotyping for the DECTIN-1 Y238X polymorphism. For the current study, data from cohort patients 
were included if there was availability of a blood sample and a joint damage assessment at year 
3. Consequently, 262 patients were included. The study was approved by our institutional review 
board and informed consent of the patients was obtained before enrolment. The study has been 
performed according to the principles of the Declaration of Helsinki.
RNA isolation from synovial tissue  
Synovial tissue samples of RA, OA and non-rheumatic patients were dissected during surgery or by 
fine-needle arthroscopy under a camera supervision. The tissue samples were stored at a tissue 
bank under liquid nitrogen till further processing. Total RNA was isolated and purified on an affinity 
resin (RNeasy Kit for fibrous tissues, Qiagen) according to the manufacturer’s instructions. Quantity 
and purity were assessed by using Agilent bioanalyzer (Agilent Technologies, CA) and integrity by 
using Nanodrop (Thermo Scientific, DE) according to the manufacturer’s instructions. Total RNA 
was stored at -80°C until further processing. 
Oligonucleotide array
To measure dectin-1 mRNA expression 100 ng of total RNA was used as starting material for cDNA 
preparation. A two-cycle amplification protocol was followed. Generation of biotinylated cRNA 
and subsequent hybridization to U133Plus 2.0 oligonucleotide arrays (Affymetrix, Santa Clara, 
CA), washing and staining were performed according to Affymetrix Expression Analysis Technical 
Manual for two-cycle amplification (26). The arrays were then scanned using a laser scanner 
GeneChip®Scanner (Affymetrix) and analyzed by using Affymetrix GeneChip Operating Software 
(GCOS version 1.4) according to the manufacturer’s instruction. Array normalization and model-
based calculation of expression values were performed using DNA-Chip Analyzer (dChip) version 
1.3 (www.dchip.org). The Invariant Set Normalization method and the model-based method were 
used for computing expression values (27). These values were expressed as mean and standard 
errors (SE). 
Quantitative (q)-RT-PCR
RNA samples were reverse transcribed by using oligo-dT primers and MMLV reverse transcriptase. 
Primers were designed with Primer Express (Applied Biosystems, CA, USA). Q-PCR was 
performed using the ABI Prism 7000 sequence detection system (Applied Biosystems, CA, USA) 
for an amount of 10 ng cDNA with SYBR Green Master mix. Quantification of the PCR signals 
was performed by comparing the cycle threshold value (Ct) of the gene of interest of each 
sample with the Ct values of
 the reference gene GAPDH (DCt), and expressed as 2-ΔCt multiplied 
by arbitrary factor. Fold change is calculated as the mean ratio between the relative transcript 
level. The sequences of primer sets used were: 5’-TTCCCCATGGTGTCTGAGC-3’ (GAPDH forward) , 
5’-ATCTTCTTTTGCGTCGCCAG-3’ (GAPDH reverse), 5’-TGACTCCTACCAAAGCTGTCAAAAC-3’ (dectin-1 
forward), 5’- TTCTCATATATAATCCAATTAGGAGGACAAG-3’ (dectin-1 reverse). 
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Immunohistochemical staining in synovial tissue
In specimens obtained from knee surgery, dectin-1 protein expression was evaluated by 
immunohistochemical staining in paraffin-embedded inflamed synovial tissue sections of RA 
patients. The applied primary antibody was a monoclonal mouse-anti-human dectin-1 antibody 
(MAB 1859, purchased from R&D Biosystems, MN, USA), used in a concentration of 5 µg/ml. After 
overnight incubation with the primary antibody, the tissue sections were incubated for 1 hour with 
a secondary antibody after washing with PBS. Subsequently the staining was visualised by applying 
ABC complex and DAB solution. Sections were counterstained with haematoxylin. Staining with a 
mouse IgG2b isotype control antibody served as a negative control.
In vitro macrophage stimulation assays
PBMCs were obtained from healthy donors, either wild-type or heterozygous for the Y238X 
polymorphism. Cells homozygous for the DECTIN-1 Y238X polymorphism were obtained from three 
members of a family previously analyzed for mucocutaneous Candida infections (22). PBMCs were 
isolated from peripheral blood as described previously (11). The PBMC fraction was plated in flat-
bottom 96-well plates. After 4 hours of culture at 37°C, cells were washed three times with culture 
medium and the non-adherent cells were removed. The adherent monocytes were cultured for 
6 days in culture medium with 10% heat-inactivated pooled human serum, until the monocytes 
exhibited macrophage-like morphology and expressed characteristic surface markers analyzed by 
flow cytometry. On day 6 of culture, after washing three times with fresh medium, macrophages 
were stimulated for 24 hours with β-glucan (10 µg/ml), Pam3Cys (10 µg/ml) or with a combination 
of the two stimuli. Cytokine production was measured by ELISA (purchased from R&D Systems, 
MN, USA) according to the guidelines of the manufacturer. Detection levels were 10 pg/ml for TNFα 
and 20 pg/ml for IL-1b.
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Figure 1. (A) Dectin-1 mRNA expression of human synovial tissue obtained from six non-rheumatic control 
individuals, 20 rheumatoid arthritis patients (RA) and 10 osteoarthritis patients (OA). Dectin-1 mRNA expression 
was analysed by oligonucleotide array (Affymetrix system). Values represent computed expression values. (B) 
Confirmation of microarray data by qPCR. Data are based on four control samples, seven samples obtained 
from RA patients and 6 samples from OA patients. Relative expression is depicted compared to expression of 
the housekeeping gene GAPDH. Data are mean ± SD, * P ≤ 0.05, n.s. = not significant.
Genotyping for DECTIN-1 Y238X polymorphism 
Genomic DNA was isolated from peripheral venous blood using standard techniques and stored 
at 4°C. Genotyping for the presence of the Y238X polymorphism in exon 6 of the DECTIN-1 gene 
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(also known as CLEC7A) in the patient and healthy control groups was performed by applying the 
predesigned TaqMan SNP assay C_33748481_10 on the 7300 ABI Real-Time PCR system (both 
from Applied Biosystems, CA, USA). We declare that all the subjects included in this study have 
prospectively been asked to provide consent in regard to the use of clinical data as well as DNA 
samples for future investigations. All patients have given informed consent, as required by our local 
ethics committee and in accordance with the Declaration of Helsinki. 
Statistics
Statistical analysis for the oligonucleotide array-based gene expression was performed using dChip. 
The t-statistic was computed as (mean1 – mean2) / ), its P-value is computed 
based on the t-distribution and the degree of freedom is set according to Welch modified two-
sample t-test (27). Statistical analysis on the gene expression data obtained by quantitative PCR 
and on the cytokine measurements obtained by ELISA was performed by applying the Mann-
Whitney U test. Concerning the correlation of the DECTIN-1 genotype with clinical RA parameters, 
the following statistical tests were applied. Between-group differences between DECTIN-1 wild-
type and heterozygous patients were analyzed using a chi-square test, a t-test or a Wilcoxons’ 
test, as appropriate. To test the effect of the DECTIN-1 genotype on progression of joint damage, 
for every patient the annual joint damage progression rate was calculated by subtracting the last 
available joint damage score from the baseline joint damage score, and dividing the joint damage 
progression by follow-up time. The difference between wild-type and heterozygous patients 
was tested using a linear regression model with uptake of confounders. Regression assumptions 
were tested using residual plots and predicted-versus-observed plots. The analysis was repeated 
using longitudinal regression analysis (mixed models), using all available data while correcting for 
repeated measurements within patients. For all statistical analyses a P-value ≤ 0.05 was considered 
significant.
Results
Dectin-1 mRNA and protein expression in synovial tissue
To gain insight in the distribution and amount of dectin-1 expression in human synovial tissue, 
dectin-1 mRNA expression was measured in synovial tissue from RA, OA and non-rheumatic 
patients by an oligonucleotide array and re-evaluated by quantitative PCR. Microarray analysis 
revealed a four times elevated mRNA expression in RA synovial lesions compared to OA and 
non-rheumatic synovial tissues (Figure 1A). These findings were confirmed by quantitative PCR 
(Figure 1B). Furthermore, synovial biopsies from RA patients were immunohistochemically stained 
for dectin-1 protein expression. Dectin-1 protein appeared to be moderately to highly expressed 
in RA lesions and was preferentially expressed on the membrane of macrophage-like cells that 
have infiltrated into the synovial tissue, which were present in the synovial sublining and in close 
proximity to blood vessels (Figure 2). 
In vitro macrophage stimulation assays
Since especially macrophages are known to express dectin-1 in high amounts and are possibly 
involved in RA pathogenesis, we analyzed the functional consequences of the DECTIN-1 Y238X 
polymorphism for the inflammatory response of these cells upon dectin-1 stimulation. Monocytes 
were differentiated into macrophages in vitro and were stimulated for 24 hours with β-glucan, the 
TLR2 agonist Pam3Cys and both ligands simultaneously. After stimulation with β-glucan, cytokine 
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Figure 2. Immunohistochemical staining for decti n-1 on paraﬃ  n embedded synovial ti ssue specimens 
obtained from RA pati ents. Pictures are representati ve of staining on synovial ti ssue biopsies from fi ve pati ents. 
A/B anti -decti n-1 staining, C isotype control anti body. Original magnifi cati on: A/C (200x) and B (400x).
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Figure 3. Cytokine production capacity of TNFα (A) and IL-1β (B) after stimulation of monocyte derived 
macrophages during 24 hours with β-glucan, Pam3Cys or β-glucan+Pam3Cys. Cells were obtained from 
individuals being wild-type (WT, N=6), heterozygous (HET, N=4) and homozygous (HOM, N=4) for the DECTIN-1 
Y238X polymorphism. Cytokine concentrations were determined by ELISA. Data are mean values ± SD, * P ≤ 
0.05.
measurements revealed a diminished TNFα and IL-1β production capacity in cells from individuals 
homozygous for the Y238X polymorphism compared to cells from wild-type individuals. In cells 
from heterozygous individuals, these responses were intermediate. Moreover, the previously 
described synergy between dectin-1 and TLR2 induced responses (11;12) regarding TNFα and IL-
1β production was abolished in cells isolated from individuals with the polymorphism. The TLR2/
dectin-1 synergism was reduced in cells isolated from heterozygous individuals and completely 
absent in cells obtained from individuals homozygous for the Y238X polymorphism compared to 
the individuals bearing only the wild-type dectin-1 allele (Figure 3).
Genotyping of RA patients compared to healthy controls
To assess whether the DECTIN-1 Y238X polymorphism is associated with an altered susceptibility 
to RA, a cohort of 262 RA patients and a cohort of healthy individuals (N=284) were screened for 
the presence of the polymorphism. The allele frequency of the polymorphism was 7.8% in the RA 
cohort, compared to 7.6% in the cohort of healthy individuals (P=0.87). All individuals bearing the 
polymorphism were heterozygous (Table 1).
Effects of DECTIN-1 genotype on clinical parameters of rheumatoid arthritis 
The clinical data of the 262 cohort patients are shown in Table 2. At the different time points, there 
appeared to be no differences in joint damage and a tendency for higher DAS28 values between 
the patients with a heterozygous or wild-type DECTIN-1 genotype. Follow-up time was similar in 
both genotype groups; 50% was followed for 9 years, while 70% was followed for at least 6 years. 
The mean annual joint damage progression rate was 3.33 per year in patients bearing the wild-
type DECTIN-1 compared to 3.38 per year in patients heterozygous for the DECTIN-1 Y238X allele. 
The uncorrected between-group difference was nearly zero, with an estimated mean annual joint 
damage progression of 0.05 with P=0.95 (Table 3). When corrected for joint damage at baseline, 
rheumatoid factor positivity and the average DAS28 as possible confounders, the between-group 
difference remained insignificant, P=0.57. Regression assumptions were met. The results of the 
longitudinal regression analysis (mixed models) were not different (not shown).
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Table 1. Genetic distribution of the DECTIN-1 Y238X polymorphism in a patient cohort of 
rheumatoid arthritis (N=262) and in a group of healthy controls (N=284).
DECTIN-1 genotype Allele frequency
Cohort Wild-type Heterozygous Homozygous Wild-type Derived
RA (N=262) 84.4% (221) 15.6% (41) 0 92.2% 7.8%
Controls (N=284) 84.9% (241) 15.1% (43) 0 92.4% 7.6%
Table 2. Joint inflammation and bone destruction. Baseline and follow-up values of disease 
markers of joint inflammation and bone destruction of 262 RA patients, stratified by DECTIN-1 
genotype. Values are numbers (percentage), medians (p25-p75), or means (SD) as indicated by the 
notation.
Variable N
Homozygous wild-type 
for DECTIN-1 N
Heterozygous for 
DECTIN-1 Y238X P-value
Age 221 53 (14) 41 53 (13) 0.87
Female 221 147 (66%) 41 25 (61%) 0.49
Rheumatoid Factor + 220 163 (74%) 41 34 (83%) 0.23
DAS28 baseline 212 5.2 (1.5) 40 5.3 (1.4) 0.55
Average DAS28 year 0-3 214 3.9 (1.1) 41 4.1 (1.2) 0.37
Average DAS28 year 4-6 203 3.5 (1.1) 35 3.9 (1.3) 0.05
Average DAS28 year 7-9 166 3.5 (1.2) 28 4.0 (1.3) 0.07
Joint damage score 
baseline 
221 0 (0-2) 41 0 (0-3) 0.87
Joint damage score year 3 221 6 (1-15) 41 5 (0-18) 0.70
Joint damage score year 6 154 13 (2-26) 29 14 (3-26) 0.98
Joint damage score year 9 109 20 (8-35) 24 20 (3-37) 0.98
Discussion
Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disorder with autoimmune 
characteristics that affects 0.5-1.0% of the Western population. RA causes progressive cartilage 
damage and often concomitant bone destruction, which tremendously impairs joint movement. It 
is generally accepted that a complex interplay of genetic and environmental factors contribute to 
the aetiology of RA.
Dectin-1, a member of the C-type lectin receptor family and the main β-glucan receptor, has recently 
been demonstrated to be involved in promoting pro-inflammatory responses. Dectin-1 synergizes 
with TLR signalling pathways (11;12) and contributes to induction of T-cell responses including 
Th17 (14;28). Several animal models of experimentally induced arthritis have been shown to be 
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induced or exacerbated by administering fungal derived particles such as zymosan and glucans that 
can be recognized by and signal through dectin-1. Moreover, a more specific role for dectin-1 in RA 
pathogenesis has been investigated in arthritis prone SKG mice, in which β-glucan induced arthritis 
could be prevented by competitively blocking the dectin-1 receptor (20). 
Table 3. Between-group differences for DECTIN-1 Y238X genotype in joint damage progression. 
Results of the linear regression model with 262 RA patients. The upper model tests the difference 
in annual joint damage progression rate between wild-type patients and patients heterozygous for 
the DECTIN-1 Y238X polymorphism indicated by the estimate of DECTIN-1 genotype (P=0.95). The 
lower model tests the same (P=0.57) with addition of baseline joint damage, rheumatoid factor 
positivity and the time-averaged DAS28 as confounders. *Time-averaged DAS28 was centered.
Parameter Estimate SE P-value
Intercept 3.32 0.32 <0.0001
DECTIN-1 genotype 0.05 0.79 0.95
Intercept 1.07 0.58 0.065
DECTIN-1 genotype -0.40 0.71 0.57
Joint damage at baseline 2.65 0.53 <0.0001
Rheumatoid factor + 1.28 0.63 0.043
Average DAS28* 1.26 0.24 <0.0001
Very recently the functional consequences of the Y238X early stopcodon polymorphism in 
DECTIN-1 have been studied in detail. This polymorphism was demonstrated to result in a complete 
loss-of-function of the protein to bind β-glucan and, as a consequence, cells homozygous for this 
polymorphism are unable to induce intracellular signalling and subsequent cytokine production 
upon exposure to β-glucans (21;22).
In this study, dectin-1 and the DECTIN-1 polymorphism Y238X (c.714T>G, rs16910526), are 
examined concerning their role in RA pathogenesis. Dectin-1 mRNA expression was measured 
by an oligonucleotide expression array and confirmed by quantitative PCR in synovial tissue 
biopsies from RA patients and compared to OA and non-rheumatic synovial tissue. Dectin-1 mRNA 
expression was 4-fold higher in RA synovial tissue, compared to synovial tissues obtained from 
OA, in which immune mechanisms are minimally involved, and non-rheumatic patients. Dectin-1 
protein expression in RA synovial tissue was shown to be moderate to high, mostly located on 
infiltrating macrophage-like cells residing in the synovial sublining and around blood vessels. This 
indicates that dectin-1 is present in high amounts in RA synovial tissue and therefore can contribute 
to the inflammatory response exerted by macrophages in this setting.  
Subsequently, since dectin-1 appeared to be highly expressed on infiltrating macrophages, the 
consequences of the DECTIN-1 Y238X polymorphism for dectin-1 mediated cytokine production 
capacity of macrophages were studied. Macrophages from individuals bearing the DECTIN-1 
polymorphism exhibited an impaired capacity to produce cytokines induced by dectin-1 signalling. 
This was demonstrated for TNFα and IL-1β, both crucial cytokines in RA pathogenesis (29;30).    
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Considering the important consequences for the function of the protein, it was analyzed whether 
the presence of the DECTIN-1 Y238X polymorphism is correlated with the susceptibility and 
clinical severity of RA in a Dutch cohort of 262 RA patients. An overall allele frequency of 7.8% 
was obtained and was not significantly different compared to a healthy control group (N=284) 
with an allele frequency of 7.6% (P=0.87, Table 1). All individuals tested were heterozygous for 
the polymorphism. The correlation of clinical parameters, i.e. inflammation markers and degree 
of bone destruction, also revealed no statistically significant differences (Table 2). Finding no 
difference in bone destruction in RA patients homozygous and heterozygous for the DECTIN-1 
Y238X polymorphism could also be a problem of statistical power. However, the difference we 
found was nearly zero indeed. With the group sizes we obtained, adopting a 2-sided alpha of 0.05 
and a ‘power’ of 0.80 and a SD of 3 in the usual power calculation formula, we would have been 
able to detect a difference in annual joint damage progression in Ratingen score of 1.5, which we 
regard as reasonably small.
These data imply that, despite the lower cytokine responses exhibited by individuals heterozygous 
for the DECTIN-1 Y238X polymorphism upon stimulation of dectin-1, partial dectin-1 deficiency 
has neither a major influence on disease susceptibility nor on the degree of inflammation and 
bone destruction in RA patients. Whether homozygosity for the DECTIN-1 Y238X polymorphism 
may result in a different susceptibility to RA remains to be investigated in studies large enough to 
identify the rare homozygous individuals. 
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Abstract
Background: Intensive treatment of hematological malignancies with hematopoietic stem 
cell transplantation (HSCT) is accompanied by a high incidence of opportunistic invasive fungal 
infections, but individual risk varies significantly. Dectin-1, a C-type lectin which recognizes 
1,3-β-glucans from fungal pathogens including Candida species is involved in the initiation of the 
immune response against fungi.
Methods: Screening for the DECTIN-1 Y238X polymorphism within a group of 142 patients receiving 
HSCT was correlated with Candida colonization and candidaemia. Furthermore, functional studies 
were performed on the consequences of the polymorphism. 
Results: Patients bearing the Y238X polymorphism in the DECTIN-1 gene were more commonly 
colonized with Candida spp. compared to patients bearing wild-type DECTIN-1, necessitating more 
frequent use of fluconazole in the prevention of systemic Candida infection. Functional assays 
demonstrated a loss-of-function phenotype of the polymorphism as shown by the decreased 
cytokine production by immune cells bearing this polymorphism.
Conclusions: The Y238X polymorphism is associated with increased oral and gastrointestinal 
colonization with Candida spp. This suggests a crucial role played by dectin-1 for the mucosal 
antifungal mechanisms in immunocompromised hosts. The finding of DECTIN-1 polymorphisms 
rendering HSCT patients at increased risk for fungal complications may contribute to the selection 
of high-risk patients that should be considered for antifungal prophylaxis in order to prevent 
systemic candidiasis.
Introduction
The treatment of patients with hematological malignancies with a hematopoietic stem cell 
transplantation (HSCT) following myeloablative conditioning is accompanied by complications that 
include mucosal barrier injury, prolonged neutropenia, and graft-versus-host disease (GvHD), all 
of which contribute to fungal and other opportunistic infections (1;2). Traditional risk factors are 
predictive for incidence of invasive fungal disease in general, but the individual risk is more difficult 
to determine, although this is needed for a more guided use of antifungal prophylaxis and therapy. 
Dectin-1 is a member of the C-type lectin receptor family that recognizes the β-1,3-glucan motif of 
the cell wall of pathogenic fungi (3). Dectin-1 is mainly expressed by immune cells of the myeloid 
lineage (neutrophils, macrophages, and dendritic cells). Several studies have shown that dectin-1 
belongs to the armamentarium of immune cells against fungal pathogens, including Candida 
species and Aspergillus species (4;5). Furthermore, dectin-1 synergizes with TLR2 and TLR4 signals 
and promotes Th1 and Th17 responses to activate antifungal host defense (6–8). Recently, we have 
demonstrated that a polymorphism in DECTIN-1 (Y238X, rs 16910526) is responsible for recurrent 
mucocutaneous fungal infections in a Dutch family (unpublished data). This polymorphism results 
in an early stop codon, which leads to the loss of the last 10 amino acids of the extracellular domain, 
and in a diminished capacity to bind β-glucans. To test the hypothesis that DECTIN-1 variants 
influence the susceptibility to fungal infection in general and to Candida infection in particular for 
HSCT recipients, we first assessed the frequency of DECTIN-1 polymorphisms in a healthy Dutch 
population. We identified the Y238X mutation as an important polymorphism and the only one 
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with significant functional consequences for the recognition of Candida species. Subsequently, we 
have investigated the impact of this DECTIN-1 polymorphism on the incidence of mucosal Candida 
colonization and the occurrence of candidemia and other invasive fungal infections among 142 
patients who received a sibling T-cell depleted allogeneic HSCT.
Patients, materials and methods
Genetic screening for DECTIN-1 polymorphisms
DNA template of the DECTIN-1 gene (also named CLEC7A) was taken from GenBank, chromosome 
position 12p13, NC_000012.10. Sequencing of the exonic and nearby intronic regions of the 
DECTIN-1 gene in the 138 healthy volunteers was performed by applying the primers and conditions 
depicted in Table 1. Genotyping for the presence of the Y238X polymorphism in the patient and 
donor groups was performed by applying the TaqMan single-nucleotide polymorphism (SNP) assay 
C_33748481_10 on the 7300 ABI Real-Time polymerase chain reaction system (Applied Biosystems, 
CA, USA). Patients, donors, and healthy volunteers had given informed consent to prospective 
collection of DNA samples for investigational use. 
Flow cytometry
For staining of membrane-bound dectin-1, monocytes were incubated with 5 mg/mL murine anti–
dectin-1 directed towards the stalk region (BD6) conjugated with biotin, or mouse immunoglobulin 
(Ig) G2b isotype control, followed by streptavidin–allophycocyanin conjugated goat anti-mouse 
antibody (Pharmingen). Dectin-1 expression was determined by flow cytometry (FACScalibur; BD 
Biosciences). 
Confocal microscopy
Confocal laser scanning microscopy was performed as described by Meyer-Wentrup et al (9). Cells 
were stained with 10 mg/mL mouse anti–dectin-1 (clone 259931; R&D Systems) or mouse IgG2b 
isotype control, followed by goat anti-mouse-Alexa647–conjugated secondary antibody (Molecular 
Probes). Samples were mounted in mowiol and analyzed by confocal laser scanning microscopy 
(Olympus FV1000).
Cytokine stimulation assays
Isolation of mononuclear cells was performed as described previously (6). Cells were incubated at 
37°C for the indicated duration (4 hours or 48 hours) with either culture medium or the various 
stimuli: 105 heat-killed Candida albicans (heat-killed by incubation at 56°C for 30 min), the TLR2 
agonist Pam3Cys (10 mg/mL) and β-glucan (10 mg/mL) or a combination of Pam3Cys and β-glucan. 
In a part of the experiments, after peripheral blood mononuclear cell (PBMC) isolation, monocytes 
were purified by CD14+ MACS MicroBeads (Miltenyi Biotec) and stimulated as described above. 
Cytokine production was measured by enzyme-linked immunosorbent assay (R&D Systems, MN, 
USA).
Patients and donors 
We performed a retrospective analysis involving 142 Dutch patients undergoing HSCT because 
of hematological malignancies. The patients and donors were consecutively admitted to our 
transplant unit from May 1996 through September 2007 for a human leukocyte antigen–identical 
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sibling, partially T-cell depleted allogeneic HSCT. The characteristics of patients, donors, and HSCT 
procedures are given in Table 2.
Treatment protocol
The treatment protocol has been described in detail elsewhere (10). The conditioning regimen 
consisted of cyclophosphamide (60 mg/kg for 2 days) in combination with either total body 
irradiation (4.5 Gy for 2 days) or busulfan (4 mg/kg for 4 days). Idarubicin (42 mg/kg in 48h) was 
often added to these conditioning regimen to reduce the risk of relapse in the setting of T-cell 
depleted HSCT (11). On day 0, all patients were given an allogeneic HSCT containing 3.2*106 CD34+ 
cells/kg (range, 0.6–11.6 CD34+ cells/kg) and 0.5*106 CD3+ cells/kg (range, 0.1–0.8 CD3+ cells/
kg). Antimicrobial prophylaxis consisted of 500 mg of ciprofloxacin given twice daily and 500 mg 
of valaciclovir given 3 times daily. Surveillance cultures for Candida were collected twice weekly 
from hospital admission until hospital discharge, with the first culture samples obtained on the 
day of hospital admission, before the start of conditioning. Fluconazole (200 mg daily) was only 
prescribed to those who were colonized with C. albicans, Candida tropicalis, or Candida parapsilosis 
(not Candida krusei or Candida glabrata) when the yeast was present in both fecal cultures and 
mouth washes obtained on the same day, or when obtained from the same site on 2 consecutive 
occasions (12). Invasive fungal infections were defined according to the European Organization for 
the Treatment of Cancer/Mycoses Study Group consensus guidelines, designating invasive fungal 
disease as possible, probable, or proven (13). Oral mucositis was graded daily according to the 
validated Nijmegen Nursing Mucositis Scoring System (NNMSS) (14). Acute GvHD was diagnosed 
by clinical signs or pathological examination of skin, gut, or liver biopsy samples and was graded 
according to the criteria of Glucksberg et al (15).
Statistical analysis
In multivariable logistic regression analyses, we investigated the association of the DECTIN-1 status 
of the patient with Candida colonization, controlling for underlying hematological disease, age, and 
sex of the patient. In the analysis on the impact of early candidemia, the DECTIN-1 status of only 
patients, but not of the donors, was considered of importance. Early candidemia was defined as 
that occurring on day 21 or earlier. In myeloablative stem cell transplantation, monocyte recovery 
usually occurs only 3–4 weeks after HSCT (16), and therefore, the genetic make-up of the donor is 
not considered to be relevant for the susceptibility to early candidemia. The association between 
the DECTIN-1 status of the patient and the occurrence of early candidemia was studied using logistic 
regression models that accounted for confounding by including the age of patient, the underlying 
disease, the duration of neutropenia, the presence of colonization at hospital admission, and 
the presence of GvHD. In contrast, in the analysis of the impact of proven and probable invasive 
mold infections up to day 100, the DECTIN-1 status of both patients and donors was included. To 
compare percentages between 2 independent groups, we used the Χ2 test or Fisher’s exact test 
when appropriate. Differences in the cytokine production capacity were tested by the Student’s t 
test. P < 0.05 was considered to represent a statistically significant difference.
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Table 1. Primers and polymerase chain reaction conditions applied to amplify every exon and 
proximal intronic regions of the DECTIN-1 gene to perform sequence analysis.
Exon Primer Primer sequence (5’-3’) MgCl2 (mM) Annealing temperature
1 Forward TTTCACCACGTTAGCCAAGCT 2.5 52°C
Reverse CTGAAATAGTTTGCATCGGTT
2 Forward CCCTTTATAAGTGAAATGGGC 1.75 60°C
Reverse ACCGTGCAAGGCCAGATTTT
3 Forward 1 GCCAGTGATAAATCAGTTACT 3.5 56°C
Reverse 1 TTCTTCTTCTCCACCTTCTT
Forward 2 TGGCAACATTTTCCCTTCTT 3.5 56°C
Reverse 2 GGCAAGGGCATAGTTAAAGG
4 Forward TCATTACCTGGAATCTCCCTCT 2.5 56°C
Reverse TGGCAACTAATTGGTTATTTCA
5 Forward GCTGCTCGACAGAGGTTTTC 1.75 62°C
Reverse GGATGGTCTCGATCTCCTGA
6 Forward AATCACAGCCTCTCCCTTCA 2.5 60°C
Reverse GATTTAAGCCTCCTTTTCCAA
Note. For all amplicons, sequence analyses were carried out with the forward and the reverse 
primer. For the sequences of exon 3, technical difficulties were encountered. Therefore, we 
amplified exon 3 with 2 different primer pairs and aligned both forward assays after sequence 
analysis.
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Table 2. Clinical characteristics of the study group.
Variable Homozygous wild-type 
for DECTIN-1
Heterozygous for DECTIN-1 
Y238X
P
Nr. of recipients 126 15
Nr. of donors 116 22
Male sex (%)
    Recipients 65 60 0.78
    Donors 56 64 0.64
Age, mean years (range)
    Recipients 47.5 (18.5-64.4) 42.8 (19.2-59.8) 0.11
    Donors 47.4 (14-75.6) 43.3 (23.8-67.6) 0.24
Diagnosis 0.79
    AML/ALL 60 (47.6) 8 (53.3)
    CML/MPS 26 (20.6) 3 (20)
    MDS 23 (18.3) …
    Lymphoma/CLL 17 (13.5) 4 (26.7)
Conditioning regimen 0.25
    Ida-Cyclo-TBI 79 (62.7) 10 (66.7)
    Ida-Cyclo-Bus 15 (11.9) 1 (6.7)
    Cyclo-TBI 27 (21.4) 1 (6.7)
    Cyclo-Bus 5 (4.0) 3 (20)
    TBI 106 (84.1) 11 (73.3)
Stem cell source >0.99
    Peripheral blood 72 (57.1) 9 (60.0)
    Bone marrow 54 (42.9) 6 (40.0)
T-cell depletion 0.43
    CD34 selection 61 (48.5) 9 (60.0)
    Counterflow elutriation 41 (32.5) 4 (26.7)
    CD3/CD19 selection 24 (19.0) 2 (13.3)
Duration of neutropeniaa, mean days 
(range)
11.9 (6-20) 11.0 (6-15) 0.23
Acute GvHD 0.77
    Grade 0-I 81 (64.3) 11 (73.3)
    Grade II-IV 39 (31.0) 4 (26.7)
    Grade III-IV 10 (7.9) 1 (6.7)
    NA 6 (4.7) …
Note. Data are nr. (%) of patients, unless otherwise indicated. All patients received a human 
leukocyte antigen–matched sibling partially T-cell depleted hematopoietic stem cell transplant. 
Graft-versus-host disease (GvHD) prophylaxis consisted of only cyclosporine for all patients. 
Differences between the study groups were compared using the Pearson Χ2 test or Fisher’s exact test 
and with the use of the independent Student’s t test where appropriate. No statistically significant 
differences were obtained. AML/ALL, acute myeloid and lymphatic leukemia; Bus, busulphan; CLL, 
chronic lymphatic leukemia; CML/MPS, chronic myeloid leukemia/myeloproliferative syndrome; 
Cyclo, cyclophosphamide; Ida, idarubicin; MDS, myelodysplastic syndrome; NA, not applicable; TBI, 
total body irradiation. a Neutropenia was defined as ≤ 0.1 x 109 cells/l. 
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Results
DECTIN-1 polymorphism screening in healthy individuals
Genetic variation in the DECTIN-1 gene was investigated for 138 Dutch healthy volunteers and 
revealed the polymorphisms shown in Figure 1. A small number of polymorphisms were identified, 
with the Y238X (rs16910526) in exon 6 being the only exonic polymorphism. This polymorphism 
was present in 19 (13.8%) of 138 individuals, all of whom were heterozygous, resulting in an allele 
frequency of 6.9%. This polymorphism was identified earlier in a family that had previously been 
analyzed for mucocutaneous Candida infection (unpublished data); 3 members of this family were 
homozygous for the Y238X polymorphism.
Dectin-1 protein expression 
We investigated the consequence of the polymorphism on dectin-1 expression and localization at 
the protein level. Monocytes isolated from individuals who were homozygous for the wild-type 
DECTIN-1 allele and from individuals heterozygous or homozygous for the Y238X polymorphism 
were analyzed for dectin-1 expression by flow cytometry and confocal microscopy. Monocytes 
from the individuals homozygous for the Y238X polymorphism exhibited no dectin-1 expression 
on the cell surface, whereas cells from individuals heterozygous for the Y238X polymorphism had 
intermediate cell surface expression, compared with cells from individuals with the wild-type allele 
(Figure 2A). In line with this, no cell surface expression of dectin-1 could be detected on monocytes 
isolated from individuals who were homozygous for the Y238X polymorphism, in contrast with wild-
type cells, when monocytes were analyzed by confocal microscopy (Figure 2B). However, dectin-1 
mRNA expression was demonstrated to be equal between the genotypes (data not shown). Thus, 
these findings demonstrate that dectin-1 protein expression is absent from the cell membrane of 
monocytes from individuals who are homozygous and intermediate on monocytes from individuals 
who are heterozygous for the Y238X polymorphism. 
Figure 1. Schematic drawing of the DECTIN-1 gene (also known as CLEC7A), consisting of an N-terminal 
cytoplasmatic tail (Cyto), encoded by exon 1, a transmembrane region (TM; exon 2), a stalk region (exon 3), 
and the carbohydrate recognition domain (CRD; exon 4–6). Intronic polymorphisms were detected in 5’UTR, 
intron 2, intron 3, exon 6, and 3’UTR. All variations are depicted together with their corresponding chromosome 
location and rs number, if available.
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Figure 2. Flow cytometry graphs of extracellular dectin-1 staining (A) and (B) fluorescent confocal staining 
of dectin-1 (right panel) and light microscopic image (left panel) on unstimulated monocytes derived from 
individuals homozygous for the wild-type DECTIN-1 allele (WT) and heterozygous (HET) or homozygous 
(HOM) for the DECTIN-1 Y238X polymorphism.
Cytokine production
Functional consequences of theY238X polymorphism were investigated in monocytes and PBMCs 
isolated from individuals bearing only the wild-type DECTIN-1 allele and individuals who were 
heterozygous or homozygous for the Y238X polymorphism. Interleukin (IL)–1b induction by C. 
albicans was lower in cells from individuals bearing the Y238X polymorphism (Figure 3A; P < 0.05). 
Dectin-1 has been previously demonstrated to amplify TLR2 signaling (6); this effect was absent 
in cells isolated from individuals homozygous for the Y238X allele (Figure 3B). In contrast, IL-18 
and interferon (IFN)–γ production was not defective in cells isolated from these individuals (Figure 
3C; P = not significant). Although a tendency towards a lower IL-18 production capacity has been 
observed in cells from individuals heterozygous for Y238X, compared with cells bearing only the 
wild-type DECTIN-1 allele, this did not reach statistical significance. IL-18 production in cells from 
individuals homozygous for the Y238X mutation was similar to production in cells from individuals 
with the wild-type allele. Furthermore, IFN-γ production capacity is practically equal between the 
genotypes.
DECTIN-1 Y238X polymorphism in patients and donors
The DECTIN-1 genetic status could be determined for 141 patients and 138 donors. Insufficient 
amounts of DNA precluded the determination of genetic status in 1 patient and 4 donors. Fifteen 
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(10.6%) of 141 patients and 22 (15.9%) of 138 donors had the DECTIN-1 Y238X polymorphism; all 
individuals were heterozygous. In nine patient-donor pairs, both individuals were heterozygous 
for the polymorphism. There were no statistically significant differences between the clinical 
characteristics of patients with and patients without the DECTIN-1 Y238X polymorphism (Table 2). 
No difference was detected in the severity of mucositis between patients with and patients without 
the DECTIN-1 Y238X polymorphism, with a mean NNMSS score of 3.8 vs. 3.9 on day 0 and 7.2 vs. 
7.6 on day 7 (P = not significant).
Candida species colonization
Seven patients who received secondary antifungal prophylaxis at hospital admission were excluded 
from the study, as were 11 patients with missing colonization data, leaving 124 patients eligible 
for analysis of Candida colonization. At hospital admission, 46 (37.1%) of 124 patients were 
colonized with Candida species. Patients who were heterozygous for the Y238X polymorphism 
were statistically significantly more often colonized than were patients with DECTIN-1 wild-type 
alleles (11 [84.6%] of 13 vs. 35 [31.5%] of 111; P < 0.001) (odds ratio [OR], 11.9; 95% confidence 
interval [CI], 2.5–56.8). After adjusting for diagnosis, the OR was 12.2 (95% CI, 2.5–59.7); after 
adjusting for patient age and sex, the OR was 12.0 (95% CI, 2.5–57.1). On the day of HSCT (day 0), 
this difference persisted: 12 (92.3%) of 13 patients vs. 50 (45.1%) of 111 patients (P=0.001). The 
unadjusted OR was 14.6 (95% CI, 1.8–116.5) and the OR adjusted for diagnosis, patient age, and sex 
was 15.5 (95% CI, 1.9–125.6). Patients with a DECTIN-1 polymorphism were more likely than other 
patients to receive fluconazole (9 [69.2%] of 13 vs. 42 [37.8%] of 111; P=0.03) (Table 3). Among 
those patients who received fluconazole, eradication was achieved in 1 (11.1%) of 9 patients 
who were heterozygous for the Y238X polymorphism, compared with 14 (33.3%) of 42 patients 
who bore only the wild-type DECTIN-1 allele (P= 0.25). Colonizing species were C. albicans (87% 
of patients), C. glabrata (8.1%), and sporadically, C. krusei, Candida kefyr, Candida parapsilosis, 
and Candida dubliniesis (1.6% each). No difference in the frequency of colonization with particular 
Candida species was observed between patients who were heterozygous for Y238X and patients 
who bore only the wild-type DECTIN-1 allele. 
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Figure 3. Cytokine production capacity of interleukin (IL)–1β, IL-18, and interferon (IFN)–g after stimulation of 
monocytes during 4 h (A) or peripheral blood mononuclear cells (PBMCs) during 48 h with β-glucan, Pam3Cys, 
or β-glucan/Pam3Cys (B) or with heat-killed Candida albicans (C). Cells were obtained from individuals with 
the wild-type allele (WT; N=5) or individuals heterozygous (HET; N=4) or homozygous (HOM; N=3) for the 
DECTIN-1 Y238X polymorphism. Data are percentages compared with WT (± standard deviation). *P < 0.05.
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Invasive fungal disease
Patients who received early antifungal prophylaxis with either itraconazole, voriconazole, or 
posaconazole, starting from day 0 or earlier and until day 21, were excluded (18 patients, 7 of 
whom had received secondary prophylaxis and 11 of whom had participated in antimicrobial 
studies). The overall incidence of candidemia until day 21 was 8.9% (11 of 123 patients). There 
was no statistically significant difference in the incidence of early candidemia between patients 
with and patients without the DECTIN-1 Y238X polymorphism (2 [18.2%] of 11 vs. 9 [8.0%] of 
112; P= 0.26) (Table 3); the OR was 2.5 (95% CI, 0.5–13.6). However, this study was not designed 
to detect differences in the risk of developing invasive candidiasis, because patients who were 
colonized were prescribed fluconazole to prevent systemic Candida infection, and the study was 
underpowered to find a difference. Candidemia was caused by C. albicans in 7 of 11 cases, with 
the remainder of the cases being due to C. glabrata (1 case), C. parapsilosis (2), and C. dubliniesis 
(1). Eight (15.7%) of 51 patients who were colonized and received fluconazole experienced 
candidemia. Two (3.6%) of 55 patients who were not colonized and who therefore received no 
fluconazole developed candidemia. The incidence of proven and probable invasive mold infection 
up to day 100 was 3.3% (4 of 120 patients), with 4 probable and no proven mold infections. Three 
probable cases were due to Aspergillus species, and 1 probable case was due to Rhizomucor 
species. There was no statistically significant difference between pairs with and without a DECTIN-1 
Y238X polymorphism; 1 (5.0%) of 20 patients with the Y238X polymorphism had a probable case, 
compared with 3 (3.0%) of 100 patients with the DECTIN-1 wild-type allele (P = 0.52) (Table 3). 
However, the study was underpowered to detect a difference, especially because of the very low 
incidence of mold infection.
Table 3. Observed Candida species colonization and invasive fungal disease among hematopoietic 
stem cell transplant recipients.
Percentage ratio of recipients
Clinical outcome Homozygous wild-
type for DECTIN-1
Heterozygous for 
DECTIN-1 Y238X
P OR
Candida species colonization at hospital 
admission
31.5 (35/111) 84.6 (11/13) < 0.001 11.9
Candida species colonization on day of HSCT 
(day 0)
45.1 (50/111) 92.3 (12/13) 0.001 14.6
Surveillance-culture guided fluconazole 
therapy
37.8 (42/111) 69.2 (9/13) 0.03 3.7
Early candidemia (day 21 or earlier) 8.0 (9/112) 18.2 (2/11) 0.26 2.5
Invasive mold disease (day 100 or earlier) 3.0 (3/100) 5.0 (1/20) 0.52 1.7
 
Discussion
In this study, we demonstrate that a newly characterized polymorphism in DECTIN-1 is associated 
with increased susceptibility to fungal colonization among HSCT recipients. As a consequence, 
among patients who were immunocompromised as a result of HSCT, the need to prescribe 
fluconazole to prevent systemic Candida infection was, in part, defined by the presence of this 
polymorphism. Dectin-1 is one of the most important pattern recognition receptors for fungal 
pathogens in general and Candida species, in particular. Polymorphisms in pattern recognition 
receptors are known to be associated with an increased susceptibility to fungal infection (17;18). 
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We hypothesized that genetic variants of DECTIN-1 could influence susceptibility to Candida 
colonization and infection in HSCT recipients. Screening of all 6 exons of the DECTIN-1 gene in a 
healthy Dutch population revealed one exonic polymorphism and several intronic SNPs. Because 
the intronic SNPs are not likely to affect dectin-1 function, we considered the Y238X polymorphism 
to be the only polymorphism that could alter dectin-1 function and could influence susceptibility 
to fungal infection.
To characterize the functional consequences of the Y238X polymorphism in more detail, flow 
cytometry and confocal microscopy were performed. Expression of dectin-1 was absent on the 
cell membrane of cells isolated from individuals who were homozygous for the Y238X allele, which 
suggested a defective transport of the mutated form of dectin-1 to the cell membrane. Accordingly, 
dectin-1 expression was intermediate on cells from individuals who were heterozygous for the 
polymorphism. After stimulation with heat-killed C. albicans or b-glucan, IL-1b secretion was 
intermediate in cells isolated from individuals who were heterozygous for the Y238X polymorphism 
and low in cells from individuals who were homozygous for this polymorphism, compared with 
secretion in cells from individuals who were homozygous for the wild-type allele. Moreover, the 
previously described synergism between TLR2 and dectin-1 signals (6) was completely absent in 
individuals homozygous for the Y238X polymorphism. These data demonstrate the loss-of-function 
effect of the Y238X polymorphism for dectin-1 activity. However, no difference in the production of 
IL-18 and IFN-g could be observed between the different DECTIN-1 genotypes. This could well be 
because of a certain redundancy of dectin-1 signaling in production of these cytokines, and this is 
accompanied by a normal Candida-killing activity by neutrophils from individuals bearing the Y238X 
polymorphism (data not shown), resulting in an adequate host defense in systemic infections. 
In the follow-up of these genetic and immunological studies, we demonstrate that this polymorphism 
has a significant impact on oral and gastrointestinal mucosal colonization with Candida species 
in HSCT recipients, which defined the need for the use of fluconazole in our approach. This is in 
line with the finding of recurrent mucocutaneous candidiasis in a family with individuals who 
were homozygous for the DECTIN-1 polymorphism (unpublished data). The overall rate of fungal 
colonization at hospital admission was comparable to that in earlier studies, with colonization rates 
of 28%–57% (19;20). These data strongly support a role of dectin-1 mediated mechanisms for 
mucosal anti-Candida defense. 
The mechanisms of the increased susceptibility to mucosal colonization with Candida in individuals 
bearing the DECTIN-1 polymorphism cannot be definitively pinpointed, although the defective 
cytokine responses are probably involved. Although monocytes are important for mucosal 
defenses, epithelial cells may also contribute to these effects. Interestingly, the expression of 
dectin-1 on epithelial cells has been recently demonstrated, and the interaction of these cells with 
fungal pathogens leads to chemokine release (21). One has to consider, however, that in the setting 
of HSCT, both monocytes and epithelial cells of the mucosa are damaged for a prolonged period, 
although they are largely intact at hospital admission and during the first days of conditioning. On 
the other hand, the residential macrophages of the mucosa are less affected, and it is most likely 
that the impact of the DECTIN-1 polymorphism is exerted at their level. 
The presence of the DECTIN-1 polymorphism did not result in a significantly higher incidence of 
candidemia, although that might have been expected, because mucosal colonization is associated 
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with systemic candidiasis in HSCT recipients who experience mucosal barrier injury (22;23). 
Importantly, in this cohort, patients were prescribed oral fluconazole when colonized, which is 
known to reduce the incidence of candidemia (20;24). Therefore, fluconazole was most likely a 
confounding factor, precluding a definitive conclusion regarding the role of the DECTIN-1 Y238X 
polymorphism for susceptibility to early candidemia, although our data may suggest an increased 
risk (OR 2.5; 95% CI, 0.5–13.6). 
In addition, our study was underpowered to study the impact of the polymorphism on the 
occurrence of invasive mold infections because of the low incidence of these infections. In our 
culture-guided approach, fluconazole could safely be withheld for those individuals who were not 
colonized with Candida species, preventing overtreatment and accompanied adverse effects and 
costs. However, those individuals who were colonized remained at significant risk for candidemia, 
necessitating better ways to predict, determine, and treat colonization at an early stage. Determining 
the DECTIN-1 status before HSCT might be a factor contributing to a more risk-adapted prophylactic 
approach. Because Candida colonization is associated with invasive disease among HSCT recipients, 
we propose that patients bearing the polymorphism should be considered for antifungal prophylaxis 
to prevent systemic candidiasis. Nevertheless, future studies in prospective trials are necessary to 
further confirm the impact of this newly characterized DECTIN-1 polymorphism and to define its 
role in selecting adequate prophylaxis or early treatment for HSCT recipients.
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Summary
Background: Chronic mucocutaneous candidiasis (CMC) is characterized by susceptibility to Candida 
infections of skin, nails and mucous membranes. Patients with recessive CMC and autoimmunity 
have mutations in AIRE; the cause of autosomal dominant CMC (AD-CMC) is unknown.
Methods: We characterized fourteen patients from five families with AD-CMC. We incubated their 
blood mononuclear cells with different combinations of stimuli to test the integrity of pathways 
that mediate immunity, leading us to select 100 genes most likely to contain the genetic defect. We 
used an array-based sequence capture assay, followed by next-generation sequencing, to identify 
mutations.
Results: We observed poor production of interferon-g, interleukin (IL)-17 and IL-22 by the 
mononuclear cells of affected persons, suggesting that the defect lay within the IL-12R and IL-23R 
signaling pathway. We identified heterozygous missense mutations in DNA sequence encoding the 
CC domain of STAT1 in affected persons. The IFN-γR pathway was intact in these persons.
Conclusions: Mutations in the CC domain of STAT1 underlie AD-CMC. These mutations lead to 
defective Th1 and Th17 responses, which may explain increased susceptibility to fungal infection.
Introduction
Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency characterized by 
susceptibility to infections of skin, nails and mucous membranes caused by Candida species 
and dermatophytes (1). There are several CMC subtypes: autosomal recessive autoimmune 
polyendocrinopathy candidiasis with ectodermal dystrophy (APECED), autosomal dominant CMC 
with or without thyroid disease, and autosomal recessive, isolated CMC. 
The defect in APECED resides in the AIRE gene (autoimmune regulator), which has a key role 
in immunotolerance (2). Susceptibility to Candida in APECED is attributed to autoantibodies to 
interleukin-17 (IL-17) and IL-22 (3), as Th17 cytokines are crucial for mucosal antifungal immunity 
(4). Little is known about the defects underlying susceptibility to Candida in non-APECED patients 
with autosomal dominant CMC (AD-CMC). Previously we demonstrated defective Th1/interferon-
gamma (IFN-g) responses in AD-CMC (5); a more recent study also found defective Th17 responses 
in AD-CMC (6). Defective recognition of Candida due to mutations in the dectin-1/CARD9 pathway 
leads to increased susceptibility to fungi (7;8), but the clinical picture is less severe than AD-CMC. 
We sought the genetic cause of susceptibility to mucocutaneous fungal infections in families with 
AD-CMC.
Methods
Family #1 
The clinical characteristics and pedigree of a non-consanguineous family of Dutch descent in which 
the father, daughter and son have suffered from severe CMC since early youth are represented 
in Table S1, Figure 1A and Table S2. The patients have severe oropharyngeal chronic candidiasis 
and severe dermatophytosis and candidiasis of the feet (Figure 1B). The father has autoimmune 
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hepatitis, his daughter suffers from autoimmune hemolysis and pernicious anemia; she has anti-
phospholipid antibodies, had pulmonary embolism, and recently Pneumocystis jirovecii pneumonia 
with symptomatic cytomegalovirus infection. The son has extensive dermatophytosis (Trichophyton 
rubrum) of the feet, but no autoimmune phenomena. We characterized the immune responses of 
peripheral blood mononuclear cells (PBMCs) of the three affected family members, the unaffected 
mother and three healthy controls. The father has nine unaffected siblings (Figure 1A). We carried 
out genetic analysis of all affected and unaffected family members.
Figure 1. The pedigree of a family with autosomal dominant CMC of Dutch ancestry. (A) Clinical symptoms 
characteristic for CMC were recorded in a Dutch family #1, with three patients affected (closed black symbols 
are family members affected) from two generations. (B) Pictures of clinical signs from affected family members 
with CMC. 
Family #2, #3, and #4 
Nine patients with AD-CMC with hypothyroidism, from three unrelated families of European descent 
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from the United Kingdom, were immunologically and genetically analyzed. Their characteristics are 
reported elsewhere (9,10) and summarized in Table S1. One patient (family #2) has oral squamous 
cell carcinoma; the father in family #4 died of esophageal cancer (9). All patients were screened 
for AIRE mutations to exclude APECED syndrome (11). We also analyzed unaffected members of 
family #4.
Family #5 
We analyzed two members with CMC and three unaffected members of a Dutch family. Both P1 
and her mother suffered from esophageal cancer (Table S1).
Unaffected Individuals 
301 unrelated healthy Dutch controls and 56 healthy British controls of European ancestry were 
assessed for the genetic mutations of CMC. An in-house Nijmegen database of 100 exome datasets 
derived from healthy individuals of European ancestry without signs of CMC was also analyzed. A 
questionnaire pertaining to ethnic origin of parents and grandparents of the healthy individuals 
confirmed their West-European (Dutch and UK) ancestry. 
Ethics Approval
The study was approved by the Ethics Committee of Radboud University Nijmegen Medical Center, 
and the Newcastle and North Tyneside Local Research Ethics Committee. Written Informed consent 
was obtained from all family members and healthy controls.  
Immunological studies
We incubated PBMCs (5 x 106/ml) obtained by density centrifugation at 37°C in 96-well plates 
(Greiner, Nuremberg, Germany) (12), with or without heat-killed Candida albicans 1x106 
microorganisms/ml (strain UC820), E. coli lipopolysaccharide (LPS, Sigma-Aldrich, 1 ng/ml), IL-1b 
(10 ng/ml), IL-12 (10 ng/ml), IL-18 (50 ng/ml), IL-23 (10 ng/ml) (R&D systems), or IFN-γ (1 µg/ml, 
Boehringer). After 24 hours, 48 hours (without serum) or 5 days of incubation (in the presence of 
10% serum), we assayed cytokine concentrations by commercial ELISA: IL-1β, TNFa, IL-17, IL-22 
(R&D Systems); IFN-g, IL-6 (Pelikine). All experiments were performed at least thrice.
Sequence Capture and DNA Sequencing 
We applied array-based sequence capture followed by Roche 454 next generation sequencing to 
analyze 100 genes (Table S3) from known immunologic pathways, as described in the Supplemental 
Appendix. See the Appendix for details of coverage statistics (Tables S5, S6 and S7).
Validation of STAT1 and AIRE Mutations  
To validate the presence of STAT1 mutations in affected persons, we amplified their DNA using 
PCR and sequenced the amplified DNA fragments by Sanger’s method. All coding exons of the CC 
domain of STAT1, including exon 10, were amplified and analyzed. AIRE mutations were excluded 
by sequencing the gene as previously described (13).
Haplotype Analysis
We used Affymetrix 250K SNP arrays (15) and Sanger sequencing to determine haplotypes 
associated with the STAT1 mutations.
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Results
Immunological Defects in Family #1
Quantities of the cytokine proteins IL-1b, IL-6 and TNFa secreted by the PMBCs of unaffected family 
members in response to Candida were normal (Figure 2A, Figure S1A), as were the TLR4, TLR2 and 
dectin-1 receptor signaling pathways (Figure 2B) (15). In contrast, production of Th cytokines IFN-g, 
IL-17, and IL-22 by PBMCs from those with AD-CMC in response to Candida was feeble (Figure 2C). 
We subsequently probed the pathways leading to production of IFN-g, IL-17, and IL-22 by the 
patients’ T-cells. Induction of IFN-g on exposure of these cells to a combination of IL-12 and IL-18 
was partially impaired (Figure 2D). Exposure to IL-12 alone resulted in undetectable IFN-g (Figure 
2D) and exposure to IL-23 and IL-1b resulted in no detectable IL-17 and IL-22 production (Figure 
2E, Figure S1B). Mitogenic stimulation, however, induced normal IFN-g production in AD-CMC (not 
shown). Normal production of IL-6 in response to IL-1b proved that the IL-1RI-dependent pathway 
was intact (Figure 2E). We concluded that both the IL-12 and IL-23 pathways are perturbed in 
affected family members (Figure 2F). 
Missense Mutation in STAT1 
STAT3 mutations (known to cause hyper IgE syndrome (HIES) and involved in the IL-23R and IL-
12R signaling pathways) were not present in the three affected members of Family #1. Neither 
did we find mutations in STAT4 (the protein product of which is also involved in both IL-23R and 
IL-12R pathways) or in AIRE. Based on the cytokine defects found, we selected 100 genes encoding 
proteins relevant in Th1/Th17 responses (Table S3). 
Sequence Analysis of 100 Candidate Genes 
Using array-based sequence capture followed by next-generation sequencing, we observed an 
average of 723 variants per sample. Considering the rare nature of the disease and a dominant 
disease model, we decided to filter these variants against known SNP variants. Of the 723 
identified variants, 651 corresponded with known SNPs or located in a known polymorphic region. 
After excluding those variants detected by exome-sequencing projects, (16;17) in an in-house 
database, and through the 1000 genomes project, an average of 38 novel variants, per person, 
remained (Table S8). Of these variants, only four per person were non-synonymous coding variants 
and of these, none to four were called in at least 20% of all reads, and therefore considered as 
heterozygous candidate variants. Of the eleven candidate variants, only seven were observed in 
diseased individuals, of which three co-segregated in the three affected individuals from family #1 
(Table S9). These individuals each harbored a heterozygous variant in exon 10 of the STAT1 gene 
mapping to chromosome 2 (c.820C>T; p.Arg274Trp). The mutation predicts an amino acid change 
(arginine to tryptophan) in the CC domain of STAT1 (Figure S2A-C and Figure S3). In each affected 
individual, STAT1 was the only gene with a heterozygous, non-synonymous coding variant, making 
it the most likely candidate gene. One unaffected member of the family (spouse of P1 and mother 
of P2 and P3) and two unrelated healthy individuals did not harbor any mutation in STAT1. Of all 
novel, heterozygous, non-synonymous coding variants, those in STAT1 affected amino-acid residues 
that showed the strongest conservation over 44 vertebrate species. 
STAT1 Mutations in Other Affected Persons 
Next we investigated three British families of European descent with AD-CMC (Figure 3, Table 
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S1, and Table S10). Using the same technique, we observed a diff erent STAT1 variant (c.800C>T; 
p.Ala267Val) also aff ecti ng exon 10, in an aff ected individual. Another aff ected person from an 
independent UK family (pati ent 5 of family #2) showed very poor coverage for exon 10 of STAT1, 
however manual read inspecti on showed the same variant in 2 out of 5 reads. We confi rmed this 
mutati on in each of the aff ected persons by PCR amplifi cati on of the DNA sequence encoding the 
CC domain of STAT1, followed by Sanger sequencing (Figure 3 and Table S10). 
Figure 2. Immunological defects in the Dutch family with CMC. Human PBMCs from two unrelated healthy 
controls, the unaff ected spouse of P1 and mother of P2 and P3, and three aff ected members of the Dutch 
family #1 with CMC (P1, P2, P3) were sti mulated with (A) heat-killed Candida albicans (1x106 microorganisms/
ml) for 24 hours, (B) LPS (1 ng/ml), Pam3Cys (10mg/ml), b-glucan (10mg/ml), or a combinati on of b-glucan and 
Pam3Cys for 24 hours, (C) heat-killed C. albicans (1x106 microorganisms/ml) for 5 days (IL-17) and 48 hours 
(IFN-g), (D) IL-12 (10 ng/ml)/IL-18 (50 ng/ml) for 48 hours, (E) IL-1b (10 ng/ml)/IL-23 (10 ng/ml) for 5 days and 
IL-6 (10 ng/ml) for 24 hours. Cytokines were measured by ELISA. (F) Scheme of molecules shared by the IL-12 
and IL-23 pathway.
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Figure 3. Confirmation of STAT1 Mutations in Patients with Chronic Mucocutaneous Candidiasis (CMC). 
Shown are the pedigrees of four additional families with autosomal dominant CMC: three families from the 
United Kingdom with CMC and thyroid disease (Families #2, #3, and #4) and one Dutch family with CMC and 
esophageal carcinoma (Family #5). In these families, 11 patients were tested for STAT1 mutations. Patients in 
Families #2, #3, and #5 were found to have mutation Ala267Val, and those in Family #4 were found to have 
mutation Arg274Trp. NT denotes not tested.
Sequence analysis of STAT1 in additional affected persons revealed the Arg274Trp variant in a 
member of a third independent UK family and the Ala267Val variant in two patients from a second 
Dutch family with AD-CMC (Figure 3). We did not identify the Ala267Val or the Arg274Trp variants 
in 301 unrelated healthy Dutch controls and 56 healthy British controls. Nor did we observe them 
in 100 exome datasets from individuals of Dutch ancestry, or in the 179 individuals of European 
descent sequenced as part of the 1000 genomes project (18). Further analysis of the 100 in-house 
exomes identified only a single novel missense change in the STAT1 gene (c.314T>C), which we 
attribute to a mapping artifact due to an underlying repeat element in exon 5.
Haplotype Analysis
To determine whether the STAT1 mutations are founder mutations, we performed haplotype 
analysis using high-density SNP arrays and Sanger sequencing of genomic DNA of affected and 
unaffected members of all families. We thus deduced that the Arg274Trp and the Ala267Val 
mutations lie on different haplotypes (Table S11). Furthermore, each mutation lies on a distinct 
haplotype that is common to all families bearing the mutation, suggesting a founder effect for each 
mutation, although it is possible that the same mutation may have occurred more than once, on 
a common haplotype, by chance. The latter is corroborated by the fact that in family #1 only P1 is 
affected, and nine siblings are unaffected (suggesting, but not proving the existence of a de novo 
mutation).
Functional Studies
Cytokine analysis of PBMCs of persons with CMC in the confirmation study revealed similar defects 
as those observed in family #1: defective IFN-g production in response to IL-12, and no IL-22 
production in response to IL-1b and IL-23 (Figure S6A). In the patients from family #1 we found that 
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the addition of IFN-g to LPS resulted in increased TNFa production, demonstrating that the IFN-g 
signaling pathway is intact (Figure S6B).
Discussion
Mutations affecting the CC domain of STAT1 are a major defect in AD-CMC. They lead to defective 
Th1 and Th17 responses, characterized by low production of IFN-g, IL-17 and IL-22, crucial cytokines 
in the antifungal defense of skin and mucosa. Affected members of Family #1 showed normal 
monocyte-dependent cytokine responses, but severely impaired Th1 and Th17 responses. These 
findings are in line with reports showing defective IFN-g, IL-17, and IL-22 production in CMC (5;6) 
and HIES (19), and with the susceptibility to oral candidiasis in IL-17-defective mice (4). 
STAT1 mutations have been described in patients with increased susceptibility to viruses and 
mycobacteria (20-23). These mutations are located in regions of STAT1 that encode the SH2 or DNA-
binding domains of the protein and result in defective signaling of IFN-g and type-I IFN receptor 
pathways (20-23). A mutation in the CC domain of STAT1 (F172S) resulted in decreased STAT1 
expression (24), while other mutations in the CC domain block dimerization of non-phosphorylated 
molecules (25). The mutations affecting the CC domain that we observed in CMC patients 
exclusively affect Th1 and Th17 responses, possibly by modifying the interaction of STAT1 with its 
binding partners STAT3 and STAT4 (26). STAT1/STAT1 homodimers mediate signaling by the IFN-γ 
receptor, which induces resistance to intracellular microorganisms (26); IFN-g-receptor signaling 
was preserved in CMC patients, which may explain their normal susceptibility to mycobacteria 
and viruses. However, infections other than those caused by Candida and dermatophytes occurred 
in the Dutch and UK patients, ranging from bacterial chest infections to Pneumocystis and 
cytomegalovirus infections. 
Affected members in two of the families with the Arg274Trp mutation showed autoimmune 
phenomena. STAT1 and also IL-17 have been reported to be involved in the pathogenesis of 
autoimmune diseases (27). Owing to its low level of production by PBMCs of affected persons, IL-17 
seems unlikely to be the cause of these phenomena. Three affected individuals have hypothyroidism, 
two of them bearing the c.800C>T mutation, and one bearing the c.820C>T mutation. It is known 
that thyroid stimulating hormone (TSH) induces Suppressor of Cytokine Signaling 1 (SOCS-
1), which in turn can alter STAT1 phosphorylation (28). TSH might act as a cytokine inhibitor in 
thyroid tissue and mutated STAT1 may hamper the rescue of thyroid cells by TSH and contribute 
to hypothyroidism. In addition, there may be decreased iodine accumulation, as is the case with 
Stat1-deficient mice (38). Finally, one of the affected Dutch persons (and her deceased mother) 
and two members of the UK families, all of whom carried the Ala267Val mutation, suffered from 
esophageal/oral carcinoma (9). Loss of function of STAT1 has been linked to esophageal carcinoma 
(30;31). 
In conclusion, mutations affecting the CC domain of STAT1 is the cause of autosomal dominant 
CMC. Mutant STAT1 most probably affects host defense against Candida spp. through abnormal Th1 
and Th17 responses. These findings will facilitate the diagnosis in patients with chronic candidiasis. 
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Methodology
Custom 12-plex sequence capture followed by Roche 454 sequencing
We applied array-based sequence capture followed by Roche 454 next generation sequencing to 
simultaneously analyze 100 genes (Table S3) from known immunologic pathways. We designed a 
custom-made 12-plex sequence capture array (Roche NimbleGen, Madison, WI, USA) including all 
known exons and untranslated regions (UTRs). In total, 1134 exons (1059 coding exons) from 100 
RefSeq genes were selected, targeting 485,768 bases. After stringent probe selection by NimbleGen 
(Roche NimbleGen, Madison, WI, USA), a total of 443,488 bases (1215 regions) were represented 
on an HD2 array, with 12-times 135,000 oligonucleotide probes targeting these regions. Sequence 
capture was performed according to the manufacturer’s instructions with a ‘Titanium-optimized 
protocol’ (Roche NimbleGen). 3µg of genomic DNA from each of the 12 individuals were used 
for sequence-capture hybridization. This included Titanium-optimized sequence primers with MID 
tags for barcoding (Table S4). After independent pre-hybridization ligation-mediated (LM-) PCR 
per DNA, a final amount of 1.125 µg DNA was hybridized for 72h to the customized array each 
one DNA to an individual sub-array, together with 37,5 µg Cot1 DNA and 0,24 µl of each 1 mM 
barcode complementary blocking oligos (Table S4). Subsequently, all 12 DNAs were eluted together 
and amplified by ligation-mediated PCR. This pooled DNA library was used for massive parallel 
sequencing, with the use of a Roche 454 GS FLX sequencer with Titanium series reagents. All 
target and tiled regions are given in Supplemental Table S4, a heatmap representing the individual 
coverage is given in Figure S4, and an overview of this workflow in Figure S5.
Coverage statistics
Of the twelve DNA samples hybridized, i.e. enriched together on the customized 12-plex array 
and sequenced together, only eight were part of this project. The other four DNAs were part of 
another research study. To simplify the results of this study those results are not included, however 
sequencing statistics were very similar. The pooled sample was sequenced by using one full 
Roche-sequencing run, yielding on average 15.9 Mb of map-able sequence data per individual. 
Approximately 85.3% of the sequence data mapped back to unique regions of the human genome 
(hg18, NCBI Build 36.1), with the use of the Roche Newbler software (version 2.3). Of all mapped 
reads, 98.2% was located on or near the targeted regions (i.e. within 500 bp target proximity). 
This was sufficient to reach an average target coverage of 23.1-fold per individual (Table S6). For 
all regions of interest, only 5 regions were not covered at all in any individual. All of these were 
located in GC-rich or repeat rich regions, therefore representing most likely an enrichment bias 
(Table S7). We observed a range of 5-29 regions without coverage per individual (on average 12 
regions per individual). The Roche software detected on average 723 nucleotide variations per 
individual compared to the reference genome (Table S8). We used a custom-made data analysis 
pipeline to annotate detected variants with various kinds of information, including known single-
nucleotide polymorphisms (SNPs), amino acid consequences, genomic location, and evolutionary 
conservation. Individual coverage statistics is given in Supplemental Table S5.
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Table S1. Clinical characteristics of 14 patients with autosomal dominant CMC from 5 families.
G
ender &
 age
O
rigin
Fungal 
infecti
on
H
ypo-
thyroidism
Thyroid 
anti
bodies
other A
ID
1
Eczem
a boils
Enam
el 
dysplasia
O
ther diseases
M
utati
on 
identi
fi
ed by
2
Family #1
Patient 1
Male, 
67 y
NL
Oral, nails, 
skin
no no AI hepatitis yes no Chest infections NGS
Patient 2
Female 
38 y
NL
Oral, nails, 
skin
no no
AI hemolytic 
anemia Anti-
phospholipid 
antibodies
no no
Chest infections 
Bronchiectasis 
Pneumocystis 
pneumonia CMV 
Pulm. embolism
NGS
Patient 3
Male  
37 y
NL
Oral, nails, 
skin
no no no no no no NGS
Family #2
Patient 1
Female 
59 y
UK
Oral, nails, 
skin
yes yes no yes yes
Oral cancer 
Blepharitis Iron-
deficient anemia
Sanger
Patient 2
Male   
36 y
UK
Oral, nails, 
skin
no no no yes yes
Chest infections 
Blepharitis
Sanger
Patient 3
Male   
29 y
UK
Oral, nails, 
skin
no yes no yes yes
Blepharitis Reflux 
disease
Sanger
Patient 4
Female 
27 y
UK
Oral, nails, 
skin
no no no yes yes
Blepharitis 
Keratopathy Iron-
deficiency Reflux 
disease 
Sanger
Patient 5
Female 
6 y
UK Oral, skin no no no no no No NGS
Family #3
Patient 1
Female 
37 y
UK
Oral, nails, 
skin, vagina
no no no yes no
Iron-deficient 
anemia
NGS
Patient 2
Male  
32 y
UK
Oral, nails, 
skin
yes no no yes no Blepharitis Sanger
Patient 3
Male
 5 y
UK Oral, skin no no no yes no No Sanger
Family #4
Patient 1
Female 
40 y
UK
Oral,nails, 
skin, vagina
yes yes no no no
Chest infections 
Iron-deficient 
anemia
Sanger
Family #5
Patient 1
Female 
48 y
NL
Oral, nails, 
skin
no no no no yes
oesophageal 
cancer
Sanger
Patient 2 Male     
15 y
NL Oral, skin no no no no yes Sanger
 
 1AID = autoimmune disease
2NGS= Next generation sequencing
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Table S2. Cellular differentials of peripheral blood obtained from CMC patients in family #1. 
Values are means or percentages (± SD). Values are based on at least seven measurements at 
different time points.
Parameter Family #1, patient 1 Family #1, patient 2 Family #1, patient 3
Thrombocytes (109/ltr.) 237 (94) 131 (34) 256 (26)
Leukocytes (109/ltr.) 7.9 (2.3) 9 (2.1) 7.2 (0.9)
Differentiated
Neutrophils (%) 87 (4.9) 80 (7.8) 82 (6.2)
Lymphocytes (%) 7 (5.1) 12 (4.9) 8 (4.7)
Monocytes (%) 6 (3.4) 5 (2.2) 6 (3.2)
Eosinophils (%) 0.2 (0.4) 0.8 (0.8) 0.3 (0.3)
Basophils (%) 0.1 (0.05) 0.6 (0.4) 0.2 (0.4)
Table S3: Genes targeted by sequence capture. This table contains the common gene name, the 
genomic position (hg18), the total number of exons, the total number of coding exons and the 
transcript ID of the largest isoform.
Gene Genomic position (hg18) Total number of 
exons
Coding exons Isoform
AHR chr7:17338276-17385775 12 11 NM_001621
AKT1 chr14:104306732-104333125 15 13 NM_001014432
FOS chr14:74815284-74818665 4 4 NM_005252
ATF2 chr2:175647252-175741143 15 12 NM_001880
ATM chr11:107598769-107745036 63 62 NM_000051
BATF chr14:75058537-75083086 3 3 NM_006399
Bcl10 chr1:85504048-85516171 4 3 NM_003921
CARD9 chr9:138377262-138387939 13 12 NM_052813
CARD11 chr7:2912295-3050105 25 24 NM_032415
CD207 chr2:70910855-70916461 6 6 NM_015717
TYROBP chr19:41087143-41091026 5 5 NM_003332
CLEC6A chr12:8499858-8522193 6 6 NM_001007033
MAPK1 chr22:20443947-20551970 9 8 NM_002745
FCRLB chr1:159959067-159964557 8 6 NM_001002901
FOXP3 chrX:48993841-49008232 12 11 NM_014009
GADD45b chr19:2427135-2429257 4 4 NM_015675
GADD45G chr9:91409748-91411289 4 4 NM_006705
IDO1 chr8:39890485-39905104 10 10 NM_002164
IFNA2 chr9:21374254-21375396 1 1 NM_000605
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IFNAR1 chr21:33619084-33653998 11 11 NM_000629
IFNAR2 chr21:33524101-33558690 9 8 NM_207585
IFNGR2 chr21:33697072-33731698 7 7 NM_005534
CHUK chr10:101938114-101979334 21 21 NM_001278
IKBKB chr8:42247986-42309122 22 21 NM_001556
IKBKE chr1:204710419-204736845 22 20 NM_014002
IL10RB chr21:33,562,103-33,591,390 7 7 NM_000628
IL12A chr3:161189323-161196500 7 7 NM_000882
IL12B chr5:158674369-158690059 8 6 NM_002187
IL12RB1 chr19:18031371-18058742 17 17 NM_005535
IL12RB2 chr1:67545635-67635171 16 15 NM_001559
IL17A chr6:52159144-52163395 3 3 NM_002190
IL17RA chr22:15,945,849-15,971,389 13 13 NM_014339
IL18 chr11:111519186-111540050 6 5 NM_001562
IL18BP chr11:71387606-71391498 7 5 NM_001039659
IL18RAP chr2:102401686-102435456 12 10 NM_003853
IL21 chr4:123753233-123761661 5 5 NM_021803
IL22 chr12:66928292-66933548 5 5 NM_020525
IL23A chr12:55018930-55020461 4 4 NM_016584
IL23R chr1:67404757-67498238 11 10 NM_144701
IFNW1 chr9:21130631-21132144 1 1 NM_002177
IL21R chr16:27321924-27369616 9 8 NM_181078
IL6R chr1:152644293-152706812 10 10 NM_000565
IL22RA2 chr6:137506650-137536478 7 6 NM_052962
IL22RA1 chr1:24318848-24342198 7 7 NM_021258
IRF1 chr5:131846684-131854326 10 9 NM_002198
IRF2 chr4:185545870-185632720 9 8 NM_002199
IRF3 chr19:54854641-54860944 8 7 NM_001571
IRF4 chr6:336752-356443 9 8 NM_002460
IRF5 chr7:128365230-128377324 9 8 NM_001098630
IRF6 chr1:208027885-208046102 9 7 NM_006147
IRF7 chr11:602555-605999 11 10 NM_001572
IRF8 chr16:84490275-84513712 9 8 NM_002163
IRF9 chr14:23699569-23705614 9 8 NM_006084
JAK1 chr1:65071494-65204775 25 24 NM_002227
JAK2 chr9:4975245-5117995 25 23 NM_004972
JAK3 chr19:17796593-17819841 24 23 NM_000215
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Malt1 chr18:54489598-54568350 17 17 NM_006785
MRC1 chr10:17891368-17993184 30 30 NM_002438
IL8 chr4:74825139-74828297 4 4 NM_000584
NFATc1 chr18:75261314-75390311 10 10 NM_006162
ST13 chr22:39550547-39582633 12 12 NM_003932
PIK3CG chr7:106293160-106334828 11 10 NM_002649
PIAS1 chr15:66133626-66267458 14 14 NM_016166
PIAS3 chr1:144287345-144297903 14 14 NM_006099
PRKD3 chr2:37331150-37397726 18 18 NM_005813
PRKCE chr2:45732547-46268633 15 15 NM_005400
SPI1 chr11:47332985-47356703 5 5 NM_001080547
GNB2L1 chr5:180596534-180603512 8 8 NM_006098
RASGRP3 chr2:33514920-33643162 19 16 NM_170672
RELB chr19:50196552-50233292 12 12 NM_006509
RIPK1 chr6:3021997-3060420 10 10 NM_003804
RORA chr15:58576755-58707024 12 12 NM_134260
RORC chr1:150045171-150070972 11 11 NM_005060
RUNX1 chr21:35081968-35343465 9 8 NM_001754
Smad2 chr18:43613464-43711510 11 10 NM_001003652
Smad3 chr15:65145249-65274587 9 9 NM_005902
Smad4 chr18:46810581-46865409 13 11 NM_005359
SOCS1 chr16:11255775-11257540 2 1 NM_003745
SOCS3 chr17:73864457-73867753 2 1 NM_003955
SOCS5 chr2:46779603-46843431 2 1 NM_144949
SpiB chr19:55614028-55624060 6 6 NM_003121
STAT1 chr2:191542007-191587221 25 23 NM_007315
STAT2 chr12:55021649-55040176 24 23 NM_005419
STAT5B chr17:37604721-37681950 19 18 NM_012448
STAT6 chr12:55775460-55791428 22 22 NM_003153
SUMO1 chr2:202779148-202811567 5 5 NM_003352
Syk chr9:92603891-92698304 14 13 NM_003177
MAP3K7IP2 chr6:149680756-149774440 7 6 NM_015093
TANK chr2:161701712-161800928 8 7 NM_004180
TBK1 chr12:63132204-63182158 21 20 NM_013254
TGFBR1 chr9:100907233-100956294 9 9 NM_004612
TLR3 chr4:187227303-187243246 5 4 NM_003265
TLR4 chr9:119506431-119519587 4 2 NM_138554
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TRAF3 chr14:102313569-102442381 12 10 NM_145725
TRAF6 chr11:36467299-36488398 8 6 NM_145803
TICAM2 chr5:114942247-114989610 4 1 NM_021649
TICAM1 chr19:4766992-4769451 1 1 NM_182919
TRIM21 chr11:4362703-4371502 7 6 NM_003141
TxK chr4:47763167-47831030 15 15 NM_003328
TYK2 chr19:10322204-10352248 25 23 NM_003331
Table S4: Oligonucleotides used as bar-coded adaptors (Titanium optimized), and enhancing 
oligos for 12-plex sequence capture and subsequent 454 sequencing.
OLIGO NAME OLIGO SEQUENCE (5-prime to 3-prime orientation)
Ti-MID1-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGACGAGT*G*C*G*T
Ti-MID2-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGACGCTC*G*A*C*A
Ti-MID3-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGAGACGC*A*C*T*C
Ti-MID4-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGAGCACT*G*T*A*G
Ti-MID5-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGATCAGA*C*A*C*G
Ti-MID6-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGATATCG*C*G*A*G
Ti-MID7-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGCGTGTC*T*C*T*A
Ti-MID8-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGCTCGCG*T*G*T*C
Ti-MID10-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGTCTCTA*T*G*C*G
Ti-MID11-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGTGATAC*G*T*C*T
Ti-MID13-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGCATAGT*A*G*T*G
Ti-MID14-A C*C*A*T*CTCATCCCTGCGTGTCTCCGACTCAGCGAGAG*A*T*A*C
Ti-MID1-Aprime A*C*G*C*ACTCGTCTGAGTCG*G*A*G*A
Ti-MID2-Aprime T*G*T*C*GAGCGTCTGAGTCG*G*A*G*A
Ti-MID3-Aprime G*A*G*T*GCGTCTCTGAGTCG*G*A*G*A
Ti-MID4-Aprime C*T*A*C*AGTGCTCTGAGTCG*G*A*G*A
Ti-MID5-Aprime C*G*T*G*TCTGATCTGAGTCG*G*A*G*A
Ti-MID6-Aprime C*T*C*G*CGATATCTGAGTCG*G*A*G*A
Ti-MID7-Aprime T*A*G*A*GACACGCTGAGTCG*G*A*G*A
Ti-MID8-Aprime G*A*C*A*CGCGAGCTGAGTCG*G*A*G*A
Ti-MID10-Aprime C*G*C*A*TAGAGACTGAGTCG*G*A*G*A
Ti-MID11-Aprime A*G*A*C*GTATCACTGAGTCG*G*A*G*A
Ti-MID13-Aprime C*A*T*A*GTAGTGCTGAGTCG*G*A*G*A
Ti-MID14-Aprime C*G*A*G*AGATACCTGAGTCG*G*A*G*A
Ti-MID-B /5BioTEG/C*C*T*A*TCCCCTGTGTGCCTTGGCAGTC*T*C*A*G
Ti-MID-Bprime C*T*G*A*GACT*G*C*C*A
Ti MID_1 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ACG AGT GCG T/3ddC/
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Ti MID_2 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ACG CTC GAC A/3ddC/
Ti MID_3 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG AGA CGC ACT C/3ddC/
Ti MID_4 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG AGC ACT GTA G/3ddC/
Ti MID_5 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ATC AGA CAC G/3ddC/
Ti MID_6 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG ATA TCG CGA G/3ddC/
Ti MID_7 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG CGT GTC TCT A/3ddC/
Ti MID_8 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG CTC GCG TGT C/3ddC/
Ti MID_10 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG TCT CTA TGC G/3ddC/
Ti MID_11 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG TGA TAC GTC T/3ddC/
Ti MID_13 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG CAT AGT AGT G/3ddC/
Ti MID_14 Hyb enhancing oligo CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG CGA GAG ATA C/3ddC/
Titanium Hyb enhancing B CCT ATC CCC TGT GTG CCT TGG CAG TCT CAG /3ddc/
 
Each oligonucleotide should have phosphorothioate modifications in both the first four and 
the last four bases of the oligomers 
The adapter B long oligonucleotide Ti-MID-B must be synthesized with a 5-prime biotin-TEG 
moiety 
All oligonucleotides must be purified using HPLC 
Oligos may be ordered lyophilized or in solution (TE, pH 8.0) at at fixed concentration (100µM) 
100 nmole scale (adapter A) and 1 micromole scale (adapter B) is for 40 libraries
Table S5: Individual coverage statistics of all sequenced regions by next generation sequencing.
Available upon request.
Table S6: Statistics on the target sequence coverage for 454 sequencing run.
Fam
ily #1, 
pati
ent 1 
Fam
ily #1, 
pati
ent 2
Fam
ily #1, 
pati
ent 3
Fam
ily #2, 
pati
ent 5
Fam
ily #3, 
pati
ent 1
Fam
ily #1, 
unaff
ected
U
nrel. healthy 
control 1
U
nrel. healthy 
control 2 
A
verage
Total mapped 
bases [Mb]
16.502 14.188 16.285 6.913 27.974 17.672 12.416 15.067 15.877
On target* 73.4% 73.9% 73.8% 73.4% 75.8% 72.9% 71.6% 73.3% 73.5%
Near target** 24.9% 24.4% 24.1% 25.1% 21.9% 25.3% 26.8% 24.9% 24.7%
Off target*** 1.7% 1.6% 2.2% 1.6% 2.2% 1.8% 1.6% 1.9% 1.8%
Average target 
coverage
23.8 20.7 23.7 10.3 41.5 25.3 17.6 21.7 23.1
 
* On target: mapping to bases included in the array design 
** Near target: In 500 basepair (approximate fragment length) proximity of array targets 
*** Off target: Mapping to other genomic positions in the genome
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Table S7: Regions without coverage in all 8 CMC individuals.
Chromosome Start position End position Length Target
chr14 102,313,490 102,313,823 334 TRAF3 UTR
chr14 104,332,786 104,333,180 395 AKT1 UTR
chr17 37,681,695 37,682,027 333 STAT5B UTR
chr9 100,907,145 100,907,367 223
TGFBR1 UTR and partial 
exon1
chr9 100,907,373 100,907,472 100 TGFBR1 partial exon1
Table S8: Statistics on variants called.
F #1, 
P1
F #1, 
P2
F #1,
 P3
F #2,
 P5
F #3,
 P1
F #1, un-
aff
ected
U
nrel. healthy
 control 1
U
nrel. healthy
 control 2
A
verage
Total variants 740 730 707 443 918 847 673 723 723
     of those SNVs 659 661 631 416 791 781 611 656 651
     of those indels 81 69 76 27 127 66 62 67 72
Known SNPs (db SNP 130) 698 680 655 427 810 793 644 681 674
In house variants 9 14 16 8 14 15 7 7 11
Novel variants 33 36 36 8 94 39 22 35 38
     of those coding (non- 
     synonymous)
5 2 4 3 7 4 4 2 4
     of those minimal 20% 
     variant reads
2 1 1 2 1 0 3 1 1
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Table S9: Summary of all novel non-synonymous variants identified in 8 individuals (5 CMC 
patients, 3 controls) (with STAT1 variants in bold).
Sam
ple ID
Chr.
Start
End
Ref.
Var.
N
o. reads
N
o. var. reads
%
 var.
G
ene
Ref. A
A
Var. A
A
phyloP
G
rantham
 score
SelfChain repeat score
Family #1,  
patient 3
2 191,568,156 191,568,156 G A 16 10 62 STAT1 R W 6.78 177 0
Family #1,  
patient 3
8 42,294,370 42,294,370 T A 20 4 20 IKBKB F L 0.40 22 0
Family #1,  
patient 2
2 191,568,156 191,568,156 G A 17 9 53 STAT1 R W 6.78 177 0
Family #1,  
patient 1
2 191,568,156 191,568,156 G A 23 11 48 STAT1 R W 6.78 177 0
Family #2,  
patient 5
4 187,234,943 187,234,943 C A 22 9 41 TLR3 T N 5.05 65 0
Family #2,  
patient 5
19 4,769,178 4,769,178 C T 14 6 43 TICAM1 R Q -2.04 68 26.8
Family #3,  
patient 1
2 191,568,176 191,568,176 G A 41 26 63 STAT1 A V 6.78 64 0
Unrel. hc 1 9 5,068,411 5,068,411 C T 31 13 42 JAK2 P S 5.40 103 29.8
Unrel. hc 1 6 137,517,930 137,517,930 T - 25 10 40 IL22RA2 K KX 0.56 * 0
Unrel. hc 1 9 119,516,114 119,516,114 G T 26 9 35 TLR4 M I -0.42 10 0
Unrel. hc 2 11 4,363,464 4,363,464 T C 25 8 32 TRIM21 E G 0.92 98 31.5
* no representative Grantham score for frameshift variants;  
Abbreviations: Chr., chromosome; Ref., reference; Var., variant; No., number; hc, healthy control 
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Table S10. Summary of the STAT1 mutations identified in patients and the genotype of their 
unaffected family members. 
Fam
ily
Pati
ent/unaff
ected 
no.
G
ene
Chrom
osom
e
G
enom
ic positi
on 
(+ strand)
cD
N
A
 positi
on
Protein positi
on
#1 Patient 1 STAT1 2q32.2 g.191568156G>A c.820C>T p.Arg274Trp
Patient 2 STAT1 2q32.2 g.191568156G>A c.820C>T p.Arg274Trp
Patient 3 STAT1 2q32.2 g.191568156G>A c.820C>T p.Arg274Trp
Unaffected 1 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 2 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 3 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 4 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 5 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 6 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 7 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 8 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
Unaffected 9 STAT1 2q32.2 g.191568156G>A c.820C Wild-type
#2 Patient 1 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 2 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 3 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 4 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 5 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
#3 Patient 1 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 2 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 3 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Unaffected 1 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
Unaffected 2 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
Unaffected 3 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
Unaffected 4 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
#4 Patient 1 STAT1 2q32.2 g.191568156G>A c.820C>T p.Arg274Trp
#5 Patient 1 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Patient 2 STAT1 2q32.2 g.191568176G>A c.800C>T p.Ala267Val
Unaffected 1 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
Unaffected 2 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
Unaffected 3 STAT1 2q32.2 g.191568176G>A c.800C Wild-type
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Table S11. Haplotype analysis of STAT1 mutant allele.
Fam
ily
N
ati
onality
M
utati
on* ID
rs7597768
rs2280234
rs2280233
rs2066804
rs78181481
rs41507345
rs11693463
#1 Dutch WT Unaffected AA GG CC TT CC GG GG
Dutch R274W P1 GA GA CT CC GG TT AA
Dutch R274W P2 GA GA CT TC GC GT GA
Dutch R274W P3 GA GA CT TC GC GT GA
DISEASE 
ALLELE
G A T C G T A
#2 UK A267V P1 AA GA CT CT GC GT GA
UK A267V P2 GA GA CT CT GC GT GA
UK A267V P3 AA GA CT CT CC GG GG
UK A267V P4 AA GA CT TT GC GT GA
UK A267V P5 AA GG CC CT GC GT GA
DISEASE 
ALLELE
A G C T C G G
#3 UK A267V P1 AA GG CT CT GC GT GA
UK A267V P2 GA GA CT CT GC GT GA
UK A267V P3 GA GA CT CT GC GT GA
UK WT Unaffected GA AA TT CC GG TT AA
DISEASE 
ALLELE
A G C T C G G
#4 UK R274W P1 GG AA TT CC GG TT AA
DISEASE 
ALLELE
G A T C G T A
#5 Dutch WT Unaffected GA GA CT CT GC GT GA
Dutch WT Unaffected GA GA CT CT GC GT GA
Dutch WT Unaffected GG AA TT CC GG TT AA
Dutch A267V P1 GA GA CT CT GC GT GA
Dutch A267V P2 AA GG CC TT CC GG GG
DISEASE 
ALLELE
A G C T C G G
*WT = wild-type
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Figure S1. Immunological defects in the Dutch family with CMC. Human PBMCs from healthy controls (N=2), 
the mother and three affected members of the Dutch family #1 with CMC (P1, P2, P3) were stimulated with (A) 
heat-killed Candida albicans (1x106 microorganisms/ml) for 24 hours, (B) IL-1b (10 ng/ml)/IL-23 (10 ng/ml) for 
5 days. Cytokines were measured by ELISA.
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Figure S2. Next generation sequencing coverage and mutation detection for STAT1 in patient P1 from family 
#1. (A) Sequence read histogram uploaded to UCSC genome browser, displaying the sequencing depth of all 
exons of STAT1. Tracks displayed: Scale, chromosomal position, read depth histogram per bp (between 0 and 70-
fold coverage), target regions, tiled regions (oligos represented on sequence capture array), refseq gene track. 
(B) Next generation sequencing read coverage of STAT1 exons 9 and 10. Tracks displayed: Scale, chromosomal 
position, individual 454 sequencing reads, target regions, tiled regions refseq gene track. (C) Mutation 
visualization in the IGV browser. Individual reads overlapping with the mutation are displayed, showing the 
heterozygous G>A mutation at genomic position chr2:191,568,156 (the reads are mapped and displayed on the 
+ strand). The inserted caption displays the Sanger sequencing validation of the mutation (sequencing of the - 
strand shows heterozygous C>T mutation).
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Figure S3. Next generation sequencing coverage and mutation detection for STAT1. (A) Sequence read 
histograms uploaded to UCSC genome browser, displaying the sequencing depth of all exons of STAT1 for all 
patients included in the next generation sequencing assay. Tracks displayed: Scale, chromosomal position, read 
depth histogram per bp (between 2 and 135-fold coverage), target regions, tiled regions (oligos represented 
on sequence capture array), refseq gene track. (B) Mutation visualization in the IGV browser. Individual reads 
overlapping with the mutation are displayed, showing the heterozygous G>A mutation at genomic position 
chr2:191,568,156 (the reads are mapped and displayed on the + strand) of all affected individuals in family 
#1 (first four panels). Likewise, individual reads overlapping with the mutation are displayed for patient 5 
from family #2 and patient 1 from family #3, showing the heterozygous G>A mutation at genomic position 
chr2:191,568,176 (the reads are mapped and displayed on the + strand). (C) Sanger sequencing validation of 
the respective mutations (sequencing of the - strand shows heterozygous C>T mutation) for patients 1, 2, 3, and 
the unaffected mother from family #1 and for patient 5 from family #2 and patient 1 from family #3.
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Figure S4. Heatmap representi ng the individual coverage of the complete 454 next generati on sequencing 
array. 
174
Chapter 10
Figure S5. Flowgram illustrating the experimental order of the sequence capture followed by next generation 
sequencing. 
Figure S6. The IL-12 and IL-23 pathway is defect in patients with a mutation in the CC domain of STAT1, but 
the IFN-g pathway is intact. (A) Human PBMCs from healthy controls (N=4), and CMC patients (N=6) were 
stimulated with IL-12 (10 ng/ml) for 48 hours or IL-1b (10 ng/ml)/IL-23 (10 ng/ml) for 5 days. (B) Human PBMCs 
from healthy controls (N=3), and CMC patients (N=3) were stimulated with LPS (1 ng/ml) with or without IFN-g 
(1 mg/ml) for 24 hours. Cytokines were measured by ELISA. 
Plantinga TS*, Smeekens SP*, van de Veerdonk FL*, Heinhuis B, Hoischen A, Joosten LAB, 
Arkwright PD, Gennery A, Kullberg BJ, Veltman JA, Lilic D, van der Meer JWM#, Netea MG#.
* These authors contributed equally. 
# These authors share senior authorship.
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STAT1 hyperphosphorylation and defective 
IL12R/IL23R signaling underlie defective 
immunity in autosomal dominant chronic 
mucocutaneous candidiasis
PLoS ONE 6(12): e29248
175
176
1177
11
STAT1 mutations and IL12R and IL23R receptor signaling in AD-CMC
Abstract
We recently reported the genetic cause of autosomal dominant chronic mucocutaneous 
candidiasis (AD-CMC) as a mutation in the STAT1 gene. In the present study we show that STAT1 
Arg274Trp mutations in the coiled-coil (CC) domain is the genetic cause of AD-CMC in three families 
of patients. Cloning and transfection experiments demonstrate that the mutated STAT1 inhibits 
IL12R/IL-23R signaling, with hyperphosphorylation of STAT1 as the likely underlying molecular 
mechanism. Inhibition of signaling through the receptors for IL-12 and IL-23 leads to strongly 
diminished Th1/Th17 responses and hence to increased susceptibility to fungal infections. The 
challenge for the future is to translate this knowledge into novel strategies for the treatment of this 
severe immunodeficiency.
Introduction
Chronic mucocutaneous candidiasis (CMC) is a hereditary primary immunodeficiency characterized 
by severe skin and mucosal Candida infections, dermatophytosis and onychomycosis (1). CMC is a 
heterogeneous syndrome, the best characterized clinical entities being the autosomal recessive 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) syndrome and 
autosomal dominant CMC (AD-CMC) (2). 
APECED is due to mutations in the gene autoimmune regulator (AIRE) (3), and these explain the 
autoimmune phenomena, including autoantibodies against the antifungal cytokines interleukin 
(IL)-17A, IL-17F and IL-22 (4;5). In contrast, the genetic cause of AD-CMC has remained unknown 
until very recently. In a study performed in 5 families with AD-CMC, we reported that the disease 
is caused by mutations in the gene coding for the Signal Transducer and Activator of Transcription 
(STAT)1 signaling molecule (6). The discovery of STAT1 mutations as cause of AD-CMC was 
remarkable, as STAT1 deficiency had been previously reported to be associated with mycobacterial 
and viral, but not fungal, infections (7;8). The presence of the AD-CMC mutations in the coiled-coil 
(CC) domain of STAT1, rather than in the Src homology 2 (SH2) or DNA-binding domains of the 
protein as in patients with mycobacterial/viral infections, is believed to explain the difference (6). 
Nevertheless, the cellular and molecular mechanisms responsible for the increased susceptibility 
to fungal infections in patients with AD-CMC and STAT1 mutations remains to be deciphered.
In the present study we assessed the presence and function of STAT1 mutations in the index family 
published previously (6), and in two additional previously unreported families with AD-CMC. We 
also assessed the immune abnormalities underlying the increased susceptibility to infections in 
these patients.
Patients and methods
Family #1 
The clinical characteristics and pedigree of a Dutch Caucasian non-consanguinous family are 
represented in Figure 1A and in Supplemental Table 1. The patients of the first two generations 
have been previously presented (6). Since then, the son of one of the patients from the second 
generation was also diagnosed with the disease. The patients have severe chronic oropharyngeal 
candidiasis and dermatophytosis of the feet. 
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Family #2
The clinical characteristics and pedigree of a non-consanguineous British Caucasian family are 
presented in Figure 1B and in Supplemental Table 1. Three generations are affected with severe 
persistent candidiasis of the oropharynx, nails and skin (perineum in the child), all have iron-
deficiency anemia. The grandmother and daughter have hypothyroidism while the boy has thyroid 
(peroxidise) autoantibodies but has still not developed clinical hypothyroidism.
Family #3
The clinical characteristics and pedigree of a non-consanguineous British Caucasian family are 
presented in Figure 1C and Supplemental Table 1. The mother, her son and daughter all suffer 
with oral candidiasis and hypothyroidism. The children unusually also suffer with mouth ulcers and 
herpetic whitlow. 
Ethics approval
The study was approved by the Ethics Committee of Radboud University Nijmegen Medical Centre, 
and the Newcastle and North Tyneside Local Research Ethics Committee. Informed consent was 
obtained from all family members and healthy controls.
Sequencing of STAT1 and AIRE mutations
To assess for the presence of STAT1 mutations in the patients, conventional PCR and Sanger 
sequencing were performed. All coding exons of the CC domain of STAT1, including exon 10, were 
amplified and analyzed. AIRE mutations were excluded by sequencing the gene as previously 
described (13).
Cell isolation and stimulation
PBMCs were isolated by density gradient centrifugation of PBS-diluted blood (1:1) over Ficoll-
Paque, as previously described (6). T-cells were positively selected using CD4 microbeads (130-045-
101, Miltenyi Biotec, Utrecht, the Netherlands). Cells (5 x 106/ml) were stimulated in 96-well plates 
(Greiner, Nuremberg, Germany), with combinations of IFN-g (1 μg/mL) (Boehringer Ingelheim, 
Alkmaar, the Netherlands) and LPS (1 ng/ml), IL-1b (10 ng/ml) and IL-23 (10 ng/mL), or IL-12 (1 
ng/ml) and IL-18 (10 ng/ml). After 24 or 48 hours (without serum) or 5 days of incubation (in the 
presence of 10% serum), cytokine concentrations were measured using ELISA: TNFα, IL-17, IL-22 
(R&D Systems); IFN-g (Pelikine).
Western blotting
For immunoblotting, 10x106 cells were lysed in 100 ml lysis buffer (50 mM Tris, 1 mM EDTA, 150 
mM NaCl, 1% ND40, 5 mM NaF, 0.05% Sodium Deoxycholate, PhosSTOP and cOmplete proteinase 
inhibitor cocktail (Roche, Almere, the Netherlands)). The homogenate was frozen, thawed then 
centrifuged at 4°C for 10 minutes at 14,000 rpm, and the supernatant was taken for Western 
blotting. Equal amounts of protein were subjected to SDS-PAGE using 10% and 15% polyacrylamide 
gels at a constant voltage of 100V. After SDS-PAGE, proteins were transferred to nitrocellulose 
membrane (0.2 mm). The membrane was blocked with 5% (w/v) milk powder in PBS for 1 hour 
at room temperature followed by incubation overnight at 4°C with a STAT1 or pSTAT1 (Tyr701) 
antibody (9172 and 9167 respectively, Cell Signaling, Leiden, the Netherlands) in 5% BSA/TBS/T (5% 
bovine serum albumin/ Tris-buffered saline/Tween 20). After overnight incubation the blots were 
washed three times with TBS/T and incubated with HRP-conjugated goat anti-rabbit antibody at a 
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dilution of 1:10,000 in 5% (w/v) milk powder in PBS for 1 hour at room temperature. After washing 
the blots three times with TBS/T, the blots where developed with ECL according to manufacturer’s 
instructions (GE Healthcare, Diegem, Belgium).
STAT1 Immunofluorescence
CD4+ cells were stimulated for 10 minutes with IFN-g on cover slides. Subsequently, the cells were 
fixed with 10% PFA, and stained with α-pSTAT1 (Tyr701) or α-STAT1 and goat anti-rabbit Alexa 
488 according to manufacturer instructions. The coverslides were mounted using Vectashield 
containing DAPI.
STAT1 cloning and transfection experiments
The Arg274Trp mutation was introduced into a plasmid containing the human STAT1α gene 
(pUNO-hSTAT1a, Invivogen, Toulouse, France), using the QuickChangeTM Site-Directed Mutagenesis 
Kit (200518, Stratagene, Eindhoven, the Netherlands). The following primers were used for 
the PCR reaction: 5’- GAGAGTCTGCAGCAAGTTTGGCAGCAGCTTAAAAAG-3’ (forward) and 
5’-CTTTTTAAGCTGCTGCCAAACTTGCTGCAGACTCTC-3’ (reverse). Human CD4+ cells were transfected 
using HIPerfect reagent (Qiagen, Venlo, the Netherlands), according to manufacturer instructions.
Quantitative PCR of IL-12R/IL-23R/IFN-g-responsive genes
One million freshly isolated PBMCs or (transfected) CD4+ cells were stimulated with IFN-g, 
IL-β and IL-23 or IL-12 and IL-18. After two hours, total RNA was extracted in 400 μL TRIzol 
reagent (Invitrogen). Isolated RNA was reverse transcribed into complementary DNA using 
oligo(dT) primers and MMLV reverse transcriptase. PCR was performed using a 7300 Real-
Time PCR system (Applied Biosystems, Lennik, Belgium). PCR conditions were as follows: two 
minutes at 50°C and 10 minutes at 95°C, followed by 40 cycles of PCR reaction at 95°C for 15 
seconds, and 60°C for one minute. Primer sequences used for RT-PCR assessment were: STAT4: 
5’-ACAATGAAACCATGGCAACGA-3’ (forward) and 5’-TGAAATTTTCCCTGAAGGACCTTC-3’ (reverse); 
ICAM: 5’-TTGAACCCCACAGTCACCTAT-3’ (forward) and 5’-CCTCTGGCTTCGTCAGAATC-3’ (reverse); 
MCP-1: 5’-CCAGTCACCTGCTGTTATAAC-3’ (forward) and 5’-TGGAATCCTGAACCCACTTCT-3’ (reverse); 
PD-L1: 5’-GCTGAACGCATTTACTGTCACG-3’ (forward) and 5’-AGTGCAGCCAGGTCTAATTGT-3’ 
(reverse). B2M was used as a reference housekeeping gene, for which the primers were: 5’- 
ATGAGTATGCCTGCCGTGTG-3’ (forward) and 5’- CCAAATGCGGCATCTTCAAAC-3’ (reverse).
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Figure 1. Pedigrees of three families with AD-CMC. (A) Pedigree of a Dutch family with four patients affected 
from 3 generations. (B) Pedigree of a UK sample with 3 patients affected from 3 generations. (C) Pedigree of a 
UK sample with 3 patients affected from 2 generations. Patients with candidiasis = closed black symbols; male 
patients = squares; female patients = circles.
Results and Discussion
In the present study we report that mutations in the CC domain of STAT1, the genetic cause of AD-
CMC, lead to hyperphosphorylation of STAT1 resulting in increased responsiveness to IFN-g and 
impaired IL-12 and IL-23 signaling pathways. We strengthened our recent observation that STAT1 
mutations are responsible for AD-CMC (6) by showing the Arg274Trp mutation in the CC-domain of 
STAT1 in patients from three additional families with AD-CMC. These data further establish the role 
of STAT1-mediated signaling as a crucial mechanism for mucosal antifungal defense.
Missense mutation in STAT1
Individual P4 from the Dutch family (#1) (Figure 1A) was demonstrated to carry the Arg274Trp 
mutation in exon 10 of STAT1 similar to his father (P3), aunt (P2) and grandfather (P1) (6). The same 
STAT1 variant (c.820C>T; p.Arg274Trp) was detected in all three individuals from the British family 
#2 (Figure 1B), and all three individuals from British family #3 (Figure 1C). The discovery of STAT1 
mutations as a cause of AD-CMC was rather surprising, as mutations in the SH2 or DNA-binding 
domains of the protein had been previously shown to be associated with mycobacterial and viral, 
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but not fungal, infections (9;10). We therefore sought to identify the molecular mechanism behind 
this difference.
Lower production of IFN-g and IL-17 in AD-CMC patients. 
IL-12 induced no IFN-g production in cells obtained from AD-CMC patients (Figure 2A), and IL-
1β and IL-23 induced less IL-17 production in cells from P3 and P4 from family #1 (Figure 2B). In 
contrast, production of TNFα in response to IFN-g and LPS was higher in PBMCs from CMC patients 
compared to healthy controls (Figure 2C). With these findings we have confirmed our observations 
in experiments with cells from other AD-CMC patients, as reported previously (6).
Arg274Trp STAT1 inhibits signaling via IL-12R and IL-23R 
The transcription of several IFN-g-regulated genes was measured in CD4+ T-cells from healthy 
controls transfected with either wild-type STAT1 plasmid or mutant STAT1 plasmid. The cells were 
stimulated for 24 hours with either IFN-g (1 μg/mL), or IL-β (10 ng/mL) and IL-23 (50 ng/mL), or 
IL-12 (10 ng/ml) and IL-18 (10 ng/ml). In line with the experiments performed in the primary cells 
isolated from AD-CMC patients, CD4+ T-cells transfected with the mutated STAT1 allele, but not with 
the wild-type allele, exhibited decreased transcription of STAT4 after exposure to IL-1b and IL-23 
(Figure 2D), and decreased transcription of MCP1 upon IL-12 and IL-18 stimulation (Figure 2E). In 
contrast, CD4+ T-cells transfected with the mutant STAT1 plasmid showed increased transcription 
of PD-L1 upon stimulation with IFN-g (Figure 2F). Cells that were transfected with STAT1 plasmid 
exhibited highly increased expression of STAT1 as compared to untransfected cells. Furthermore, 
no difference in STAT1 mRNA expression was observed between cells either transfected with wild-
type or mutant STAT1 plasmid (Supplemental Figure 1). These data correct for the possibility that 
the observed effects are due to a differential expression of the wild-type compared to the mutant 
STAT1 plasmid. 
Based on the results of these transfection studies, it can be concluded that the differences in gene 
expression observed in AD-CMC patients as compared to healthy controls can be fully ascribed to 
the presence of the Arg274Trp mutation in STAT1.
Increased phosphorylation and activity of STAT1 in AD-CMC patients. 
The consistent finding of increased responsiveness to IFN-g in cells from patients and in cells 
transfected with the mutated STAT1 suggested a gain of function of STAT1. We therefore 
assessed whether the Arg274Trp mutation affects phosphorylation of STAT1. PBMCs 
were incubated with various stimuli and STAT1 phosphorylation was assessed by Western 
blotting. Phosphorylation of STAT1 after IFN-g stimulation was higher in AD-CMC patients 
than in healthy controls (Figure 3A). The lower bands observed on the Western blot of 
phosphorylated STAT1 very likely represent breakdown products of the phosphorylated 
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Figure 2. AD-CMC cells or transfection of cells with the mutated STAT1 inhibited IL-12R- and IL-23R-induced 
genes, but increased IFN-g signaling. Defective IL-12R (A) and IL-23R (B) pathways in cells isolated from AD-
CMC patients. Data represent mean + SEM from 3 healthy controls and 3 AD-CMC patients (P3 and P4 from 
family #1 and P3 from family #2). (C) Stimulation of the IFN-g receptor pathway results in increased production 
of the proinflammatory cytokine TNFα. Data represent mean + SEM from 3 healthy controls and 3 AD-
CMC patients. CD4+ T-cells from healthy controls were transfected with wild-type or mutant STAT1 plasmid. 
(D) Decreased transcription of STAT4 upon stimulation with IL-1b (10 ng/mL) and IL-23 (50 ng/mL), (E) and 
decreased transcription of MCP1 upon IL-12 (10 ng/mL) and IL-18 (10 ng/mL) stimulation. (F) The CD4+ cells 
transfected with mutant STAT1 plasmid showed increased transcription of PD-L1 upon stimulation with IFN-g (1 
μg/mL). Data represent mean + SEM from 6 healthy controls from 3 separate experiments.
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Figure 3. Increased STAT1 phosphorylation in cells of AD-CMC patients. (A) PBMC from two healthy controls 
and two AD-CMC patients were stimulated for two hours with culture medium, IFN-β (500 U/mL), IFN-g (1 
μg/mL), IL-23 (50 ng/mL) or IL-12 (10 ng/mL). Cells were lysed, and total STAT1, phosphorylated STAT1 and 
actin were assessed by Western blot. Figure is representative of two separate experiments. (B) Increased 
immunofluorescence of pSTAT1 in IFN-g-stimulated CD4+ cells from AD-CMC patients. Figure is representative 
of three separate experiments. (C) PBMCs from three controls and two AD-CMC patients were stimulated with 
culture medium, IFN-β, or IFN-g for two hours. The transcription of ICAM1 and MCP-1 was measured using RT-
PCR. Bars represent means + SEM.
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STAT1 protein. Immunofluorescence microscopy also demonstrated increased phosphorylated 
STAT1 in IFN-g-stimulated CD4+ cells from AD-CMC patients, but no difference in total STAT1 (Figure 
3B). These data are supported by Begitt et al., demonstrating that mutations in the CC domain of 
STAT1 result in hyperphosphorylation and prolonged entrapment of STAT1 in the nucleus, leading 
to inhibited nuclear export of STAT1 (11). Also, Lui et al. demonstrated that the Arg274Trp mutation 
in STAT1 leads to increased phosphorylation of STAT1 (12).
Upon IFN-g stimulation through the IFN-g receptor in physiological conditions, the downstream 
signaling molecules JAK1, JAK2 and STAT1 are activated (13). Upon activation, STAT1 forms 
homodimers, which translocate to the nucleus, in order to induce transcription of numerous genes, 
including ICAM-1 (14) and MCP-1 (15). We measured the transcription of several IFN-g regulated 
genes in AD-CMC patients and in healthy controls, to determine whether the Arg274Trp mutation in 
STAT1 affects its function as a transcription factor. When PBMCs were stimulated for two hours with 
IFN-g (1 μg/mL), AD-CMC patients showed increased transcription of ICAM1 and MCP-1 compared 
to healthy controls (Figure 3C). The transcription of STAT1, STAT3, IDO and PD-L1 was also increased 
(data not shown), supporting a gain of function mechanism for STAT1 in AD-CMC. Moreover, also 
unstimulated cells from AD-CMC patients exhibited elevated expression of these genes compared 
to cells from healthy controls, which could potentially be ascribed to the presence of constitutively 
phosphorylated STAT1 in these cells.
How do these molecular mechanisms explain the defective antifungal defense in AD-CMC patients? 
In the present study we show that these patients display significant deficiencies in the capacity to 
mount Th1 and Th17 responses, due to defective IL-12R and IL-23R pathways. The contributing 
role of a defective IL-12R signaling for CMC is strengthened by the observation that 23% of patients 
with isolated IL-12R deficiency have a mild form of CMC (16). However, STAT1 mutations in the CC 
domain additionally lead to a defective response to the cytokines IL-1b and IL-23. These cytokines 
play an important role in the development of Th17 responses, which in turn are crucial in the 
host defense against mucosal fungal infections. This notion is derived from the observation that 
APECED patients develop neutralizing anti-IL-17 and anti-IL-22 antibodies during the course of the 
disease (4), and that hyper-IgE syndrome patients, who suffer from chronic onychomycosis and 
oropharyngeal candidiasis, display defective Th17 responses due to STAT3 defects (17). In line with 
this, we and others have also reported chronic fungal infections in patients with defects in the 
dectin-1/CARD9 pathway, leading to defective Th17 responses (18;19). We have also previously 
reported decreased IL-17 production and Th-17 cell proliferation in patients with AD-CMC (20). 
Defective Th17 responses, in turn, are accompanied by decreased production of IL-17 and IL-22 
which translates into decreased production of antifungal beta-defensins as well as impaired influx 
of neutrophils (21;22). Therefore, the combined deficiency in IL-12R signaling and impaired Th17 
responses are likely to explain the susceptibility to fungal infections in patients with AD-CMC.
In conclusion, we strengthen the very recent observations that STAT1 mutations in the CC domain 
are the genetic cause of AD-CMC. Moreover, we have now deciphered the cellular and molecular 
mechanisms leading to this clinical phenotype: hyperphosphorylation of STAT1, resulting in hyper-
responsiveness to IFN-g stimulation, but defective IL-12R and IL-23R pathways. In the end, these 
defects result in markedly diminished Th1/Th17 immunity leading to increased susceptibility to 
fungal infections. Future studies are warranted to investigate the disease mechanisms in more 
detail, especially to elucidate the extent of which STAT1-STAT3 and STAT1-STAT4 heterodimers are 
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formed in AD-CMC patients upon stimulation with either IL-12 or IL-23. Furthermore, the challenge 
for the future will be to assess the proportion of patients with AD-CMC, but also sporadic CMC, 
that harbor STAT1 mutations, but especially to translate this knowledge into novel strategies for the 
treatment of this severe immunodeficiency.
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Supplemental information.
Supplemental Table 1. Clinical characteristics of 8 patients with AD-CMC from 3 families.
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disease
Eczem
a boils
O
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utati
on 
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fi
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2
Family #1
Patient 1 * Male, 67 y NL
Oral, 
nails, skin
no AI hepatitis yes Chest infections NGS
Patient 2 *
Female 
38 y
NL
Oral, 
nails, skin
no
AI hemolytic 
anemia Anti-
phospholipid 
antibodies
no
Chest infections 
Bronchiectasis 
Pneumocystis 
pneumonia   CMV 
Pulm. embolism
NGS
Patient 3 * Male  37 y NL
Oral, 
nails, skin
no no no no NGS
Patient 4
Male 
6y
NL Oral, nails no no no no Sanger
Family #2
Patient 1
Female, 
47 y
UK
Oral, 
nails, skin
yes
Irritable 
bowel 
syndrome
yes
Chest & sinus 
infections
Fe-deficiency 
anemia
Sanger
Patient 2
Female 
19 y
UK
Oral, 
nails, skin
yes no no
Fe-deficiency 
anemia
Sanger
Patient 3
Male 
2 y UK
Oral, 
nails, 
perineum
no
no
Chest infections
Fe-deficiency 
anemia
Sanger
Family #3
Patient 1 *
Female
40 y UK
Oral
Nails
Skin
Vaginal
yes no yes
Chest
infections
Fe-deficient
anemia
Sanger
Patient 2
Male
9 y
UK
Oral
yes
AI hepatitis
no
Mouth ulcers
Herpetic whitlow
Sanger
Patient 3
Female
7 y
UK Oral yes no no
Mouth ulcers
Herpetic whitlow
Sanger
*These patients have been previously reported in van de Veerdonk et al., NEJM 2011.
Supplemental Figure 1. STAT1 expression 
in transfected CD4+ T-cells. STAT1 mRNA 
expression in CD4+ T-cells untransfected or 
transfected with wild-type or mutant STAT1 
plasmid. Cells were left unstimulated or 
stimulated with IFN-g for 1 hour.
Plantinga TS, Hamza OJM, Willment JA, Ferwerda B, van de Geer NMD, Verweij PE, Matee MIN, 
Banahan K, O’Neill LAJ, Kullberg BJ, Brown GD, van der Ven AJAM, Netea MG.
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Abstract
Background: The occurrence of oropharyngeal candidiasis (OPC) in combination with HIV disease 
progression is a very common phenomenon. However, not all HIV-infected patients develop OPC, 
even when they progress to low CD4+ T-cell counts. Because T-cell immunity is defective in AIDS, 
the innate defence mechanisms are likely to have a central role in antifungal immunity in these 
patients. We investigated whether genetic variations in the innate immune genes DECTIN-1, TLR2, 
TLR4, TIRAP and CASPASE-12 are associated with the presence of OPC in HIV-infected subjects from 
East-Africa. 
Methods: A total of 225 HIV patients were genotyped for several single nucleotide polymorphisms 
(SNP) and this was correlated with the occurrence of OPC in these patients. In addition, primary 
immune cells obtained from individuals with different genotypes were stimulated with C. albicans 
and cytokine production was measured. 
Results: The analysis revealed that no significant differences in the polymorphism frequencies 
could be observed, although a tendency towards a protective effect on OPC of the DECTIN-1 I223S 
SNP was apparent. Furthermore, IFN-g production capacity was markedly lower in cells bearing the 
DECTIN-1 SNP I223S. It could also be demonstrated that the 223S mutated form of the DECTIN-1 
gene exhibits a lower capacity to bind zymosan. 
Conclusion: These data demonstrate that common polymorphisms of TLR2, TLR4, TIRAP and 
CASPASE-12 do not influence susceptibility to OPC in HIV-infected patients in East-Africa but suggest 
an immunomodulatory effect of the I223S SNP on dectin-1 function and possibly the susceptibility 
to OPC in HIV patients. 
Introduction
Candida albicans is an ubiquitous dimorphic fungal microorganism, often colonizing the 
gastrointestinal and reproductive tracts. The commensal carriage of C. albicans elicits and sustains 
an acquired immune response, including the production of C. albicans antigen specific IgA and 
IgG antibodies (1). Infection by Candida spp. in the mouth and upper digestive tract, designated 
as oropharyngeal candidiasis (OPC), is a very common mucosal infection in individuals that are 
infected with human immunodeficiency virus (HIV). OPC is an opportunistic infection, almost 
entirely caused by C. albicans and occurs in 50 to 95% of HIV-seropositive patients at least once 
during their progression to AIDS (2-4). In many patients, OPC is often the first clinical sign of HIV-
seropositivity and is included in the clinical staging system of HIV-infection from the World Health 
Organization (WHO). Recently, a significant improvement in morbidity rates was observed after the 
introduction of highly active antiretroviral therapy (HAART) (5-7). OPC remains however the most 
frequent HIV-associated oral disease in Sub-Saharan Africa where access to HAART is still limited.  
It is well established that low CD4+ T-cell counts are a major determinant for the occurrence of OPC 
in HIV-infected subjects (4). A critical threshold is 200 cells/μl. This knowledge is supported by the 
observation that an effective immune response towards C. albicans is Th1 dependent, although 
recently also a role for Th17 cells in mucosal fungal host defence has emerged (8). Furthermore, 
in vitro peripheral blood mononucleated cells (PBMCs) stimulated with C. albicans antigens are 
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known to respond with the production of Th1 and Th17 cytokines (9-11). However, not all patients 
with low CD4+ T-cell counts display OPC, while others with relatively high T-cell counts do suffer 
from OPC. These observations suggest that the susceptibility to OPC in HIV-infected patients cannot 
be fully ascribed to the impaired acquired immune response (i.e. low CD4+ T-cell counts) and point 
towards an important role for the innate immune cells that reside in the mucosal layers of the 
upper digestive tract.
Recognition of C. albicans by the innate immune system and subsequent induction of pro-
inflammatory cytokines is mediated by a broad panel of pattern recognition receptors (PRR), 
recognizing conserved bacterial and fungal motifs called pathogen-associated molecular patterns 
(PAMPs). These PRR include Toll-like receptors (TLRs), such as TLR2, -4 and -6, and C-type lectin 
receptors (CLRs) like dectin-1 and the mannose receptor (reviewed in (12)). Intracellular signalling 
of TLRs is mediated by several adaptor molecules, such as MyD88 (Myeloid Differentiation primary 
response gene 88) and Mal (MyD88 Adapter-Like, also known as TIRAP) that positively regulate 
transcription factor activation and are crucial for downstream signalling (reviewed in (13)).
Single nucleotide polymorphisms (SNPs) in TLRs and their adaptor molecules have been reported 
to influence the susceptibility towards infectious diseases. For instance, the TLR2 R677W SNP has 
been demonstrated to increase susceptibility to lepromatous leprosy (14) and tuberculosis (15) and 
another SNP in TLR2, R753Q, has been proposed to predispose to Candida sepsis (16). Similarly, 
TLR4 polymorphisms D299G alone or in co-segregation with T399I are reported to account for 
higher susceptibility to Gram-negative osteomyelitis (17), disseminated candidiasis (18), pulmonary 
aspergillosis (19) and tuberculosis (20). Recently a common polymorphism has been described in 
DECTIN-1, which leads to an early stopcodon and is associated with mucocutaneous candidiasis 
(21). In addition, the HapMap database also displays an additional polymorphism of DECTIN-1 
in African populations, namely I223S. Furthermore, the TIRAP variant S180L is correlated with 
resistance to bacterial infections and malaria (22). Another well characterized SNP, in CASPASE-12, 
that leads to an inactive truncated protein, has been suggested to modulate proinflammatory 
cytokine responses, and protects against mortality due to sepsis (23). The ancestral variant is still 
present in African populations, of which 20-30% express the active variant of caspase-12.
Whether genetic variants of DECTIN-1, TLR2, TLR4, TIRAP and CASPASE-12 modulate the host 
defence against C. albicans is largely unknown. Moreover, the role of the polymorphisms in 
these genes in determining the susceptibility of HIV-seropositive patients towards OPC has not 
been studied to date. In the present study we assessed whether single nucleotide polymorphisms 
(SNPs) in DECTIN-1 (I223S, rs16910527 and Y238X, rs16910526), TLR2 (R753Q, rs5743708; P631H, 
rs5743704 and R677W, rs unknown), TLR4 (D299G, rs4986790 and T399I, rs4986791), TIRAP 
(S180L, rs8177374) and/or CASPASE-12 (T/C, nucleotide 125) contribute to the susceptibility of HIV-
seropositive patients towards oropharyngeal candidiasis in an HIV/AIDS condition. We have also 
investigated whether these polymorphisms are correlated with differential cytokine production 
capacity induced after in vitro stimulation of whole blood with C. albicans.
Patients, materials and methods
Study design, patients and setting 
The role of the various polymorphisms in the susceptibility to OPC was assessed in a group of 
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225 HIV-seropositive patients. An independent physician, who categorized them in accordance 
with the WHO clinical staging criteria (24), performed clinical examination of all study patients. 
A standard oral examination method recommended by WHO was used (25). The intraoral tissues 
were examined for changes in size, colour and shape of anatomical areas as well as for clinical 
signs of OPC. Specimens were obtained by firmly swabbing the lesion site with a sterile cotton 
wool swab. The swabs were sent immediately to the laboratory for microbiological confirmation 
using 10% KOH. Among them, 117 patients had OPC and 108 patients never have developed OPC. 
Participants were recruited at the Muhimbili National Hospital (MNH) HIV-clinic in Dar es Salaam, 
Tanzania, from April 2007 until August 2008. Clinical manifestations of OPC in these 117 patients 
were pseudomembranous candidiasis only (65%), or a combination of pseudomembranous 
and erythematous, hyperplastic or angular cheilitis. In one subject only angular cheilitis was 
observed. OPC clinical score indicated that 95% had moderate to severe infections. Other clinical 
characteristics of the patients are presented in Table 1. The functional consequences on the effect 
of the various SNPs on the capacity of cytokine production were investigated in a group of 48 
African healthy volunteers who were not infected with HIV.
Table 1. Clinical characteristics of the 225 Tanzanian HIV-seropositive patients. The HIV treatment 
consisted of a HAART of different reverse transcriptase inhibitors, in most cases stavudine, 
lamivudine and nevirapine, received by 86% of treated patients. Antibacterial drugs, if prescribed, 
was cotrimoxazole.
Patient subgroup OPC positive (N=117) OPC negative (N=108) P-value
Age (mean(range)) 35 (18-61) 35 (18-63) 0.78
Gender (male- female) 29-88 25-83 0.74
HAART use (number (%)) 48 (41%) 56 (52%) 0.16
Duration of HAART use (months(range)) 12 (1-40) 13 (2-29) 0.79
CD4+ T-cell counts (mean±SEM) 126 ± 9 217 ± 16 <0.0001
Smoking 5 (4.3%) 4 (3.7%) 0.82
Antifungal drug use 77 (66%) 7 (6%) <0.0001
Antibacterial drug use 55 (47%) 29 (27%) 0.002
Blood collection and CD4+ T-cell counts
Five ml blood samples were collected from patients and transferred to EDTA tubes. The same day 
cell pellets were separated and enumeration of CD4+ T-cells was done using a flow cytometry count 
machine after staining patients’ blood with anti-CD4 monoclonal antibodies (26). 
DNA isolation and SNP detection
DNA was isolated from whole blood using the isolation kit Puregene (Gentra Sytems, Minneapolis, 
MN, USA), according to the manufacturers’ protocol. Detection of the SNPs in TLR4, CASPASE-12 and 
TIRAP was performed as described earlier (18;22;23). The presence of TLR2 P631H was assessed 
by applying a predesigned TaqMan SNP assay C_25607736_10 on the 7300 ABI Real-Time PCR 
system (both from Applied Biosystems, Foster City, CA, USA). Detection of the TLR2 SNPs R753Q 
and R677W and of the DECTIN-1 SNPs, conventional PCR and sequence analysis were performed. 
For the TLR2 R753Q SNP the forward primer 5’-TTCAAGTTGTGTCTTCATAAGCG-3’ and the reverse 
primer 5’-CAGATTTACCCAAAATCCTTCC-3’ were used. For the detection of TLR2 R677W these were 
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forward 5’-ATTTGTTTCTTACAGTGAGCGGG-3’ and reverse 5’-GGAAATGGGAGAAGTCCAGTTC-3’. 
For detection of the two DECTIN-1 SNPs one single primer pair was used, with forward 
5’-AATCACAGCCTCTCCCTTCA-3’ and reverse 5’-GATTTAAGCCTCCTTTTCCAA-3’. Conditions were 
equal for these PCR reactions, except for the annealing temperature, which was 56°C for TLR2 
R753Q, 58°C for TLR2 R677W and 60°C for the DECTIN-1 SNPs.  
Cloning and transfection of wild-type and 223S mutated dectin-1
DECTIN-1 isoforms A and B were amplified with the following primers; reverse 
5’-CCCTTCCTCGAGCATTGAAAACTTC-3’, containing the Xho-1 site for the inframing cloning of an HA 
tag, and the forward primer 5’-AAAGGATCCAGGGGCTCTCAAGAACAATG-3’ has a BamHI site, which 
allows cloning into pFB-neo vectors containing the HA tag. For the construction of the mutant dectin-1 
protein the following overlapping primers were used to introduce the I to S mutation (ATT to AGT): 
forward 5’-TGTGTATGGAGTCACGTGTCAG-3’ and reverse 5’-AAATGACTGACACGTGACTCCATAC-3’. 
These primers were used together with the above mentioned forward and reverse primers to 
introduce the SNP and the fragments were cloned into the HA-tagged pFB-neo vector. Surface 
expression of the various dectin-1 constructs was assessed using anti-HA antibody (Covance, 
Princeton, NJ, USA) and anti-mouse-RPE (Jackson ImmunoResearch, West Grove, PA, USA). NIH3T3 
cells were transduced and FITC-zymosan (Sigma, St. Louis, MO) (25 particles/cell) binding assays for 
1hour at 37°C, with or without laminarin (Sigma, St. Louis, MO, USA) pretreatment (100 µg/ml, 20 
min, 4°C) were performed as previously described (27).  
In vitro whole blood stimulation
Blood was collected from 48 healthy volunteers by venous puncture and directly stimulated with 
106/ml heat-killed C. albicans for 24 hours at 37°C. C. albicans had previously been incubated for 30 
minutes at 56°C to heat-kill. After stimulation, concentrations of the cytokines TNFα, IL-1β, IFN-g 
and IL-10 were measured by ELISA (R&D Systems, MN, USA), using the manufacturer’s protocol. 
Ethical issues
The ethics committee of the Muhimbili University of Health and Allied Sciences (MUHAS) and 
Muhimbili National Hospital, Dar es salaam, Tanzania approved the study protocol. All participants 
gave informed written consent. The following information was provided to ensure that patients had 
the information necessary to make an informed choice: a complete description of the aim of the 
study, potential benefits and risks, blood collection procedures and assurance of confidentiality of 
any information given as well as test results. Study personnel provided any additional information 
required by the patients. All patients seen in this study received appropriate care and treatment 
according to national guidelines on care and treatment of HIV-infected individuals. All patient 
information and test results were confidentially kept.
Statistical analysis
Statistics on the CD4+ T-cell counts, clinical characteristics and on the cytokine data were performed 
by using the SPSS program (Rel. 14.0.2, 2006; SPSS, Chicago, IL), and differences were tested by 
the χ2 test or Mann–Whitney U test, when appropriate. Differences in genotype frequencies were 
statistically tested by using the χ2 test. P ≤ 0.05 was considered to represent a statistically significant 
difference.
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Results
The influence of DECTIN-1, TLR2, TLR4, TIRAP and CASPASE-12 polymorphisms on OPC
In general, the OPC negative group had a significantly higher average CD4+ T-cell count, as expected 
(see Table 1). As a consequence, antifungal and antibacterial drugs were more frequently prescribed 
in the OPC positive group due to higher prevalence of infectious complications. As shown in Table 2, 
the frequency of TLR4 D299G and the TIRAP S180L was similar between patients with and without 
OPC. The mentioned TLR2 SNPs and the TLR4 T399I were all absent in the cohort. No differences 
were detected regarding CASPASE-12 SNP frequencies (15.0% versus 14.4%) in HIV-seropositive 
patients with and without OPC. The studied polymorphisms in DECTIN-1; the Y238X allele was 
present in a very low, but equal frequency in both groups. For the I223S polymorphism a marked 
difference in allele frequency was observed (7.4% in the group without OPC compared to 4.3% in 
the group with OPC, RR=0.58), although the difference did not reach statistical significance (P> 
0.05). The comparison of the genetic distribution of the genotyped SNPs between OPC positive and 
OPC negative HIV patients stratified for CD4+ T-cell count intervals revealed similar findings (Table 
3), with the difference in DECTIN-1 I223S frequency reaching statistical significance in the subgroup 
with CD4+ T-cell counts <100 (P=0.048). 
The functional effects of TLR4, CASPASE-12 and DECTIN-1 polymorphisms on cytokine production.
In order to link these genotype data to the function of these receptors in 
mediating cytokine production, in vitro stimulations with heat killed C. albicans in 
whole blood were performed in a group of 48 healthy volunteers. No significant 
differences in cytokine production could be detected after comparing stimulation 
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Table 2. SNP frequencies in TLR4, TIRAP, CASPASE-12 and DECTIN-1 in a cohort of HIV-infected 
Tanzanian patients.
Polymorphism OPC status Total Homozygous  
wild-type
Heterozygous Homozygous  
mutant
Allele frequencies
Wild-type           Mutant
TLR4 D299G OPC 117 107 10 0 95.6% 4.3%
No OPC 108 99 9 0 95.7% 4.2%
TIRAP S180L OPC 117 113 4 0 98.3% 1.7%
No OPC 108 104 3 1 97.7% 2.3%
CASPASE-12 S/L OPC 117 83 33 1 85.0% 15.0%
No OPC 108 79 27 2 85.6% 14.4%
DECTIN-1 Y238X OPC 117 115 2 0 99.1% 0.9%
No OPC 108 106 2 0 99.1% 0.9%
DECTIN-1 I223S OPC 117 108 8 1 95.7% 4.3%
No OPC 108 94 12 2 92.6% 7.4%
Table 3. Genetic distribution of SNPs in TLR4, TIRAP, CASPASE-12 and DECTIN-1 stratified for CD4+ 
T-cell count intervals.
CD4+ T-cell count intervals and minor allele frequency of the SNPs (%) 
OPC positive – OPC negative
Polymorphism < 100 (N=67) 100–200 (N=94) 200–300 (N=38) >300 (N=26)
TLR4 D299G 2% – 4%        7% – 5% 4% – 0% 8% – 6%
TIRAP S180L 1% – 0% 3% – 3% 0% – 0% 0% – 3%
CASPASE-12 S/L 20% – 15% 14% – 15% 11% – 14% 0% – 21%
DECTIN-1 Y238X 0% – 0% 2% – 1% 0% – 0% 0% – 3%
DECTIN-1 I223S 2% – 14% * 5% – 5% 11% – 9% 8% – 9%
* Indicates statistically significant difference
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Figure 1. Cytokine concentrations measured after 24 hours at 37°C of whole blood stimulation with 
106/ml heat-killed C. albicans in blood collected from 48 volunteers, corrected for background. Cytokines were 
detected by ELISA. Results are stratified by (A) TLR4 D299G genotype (44 homozygous for the wild-type allele, 
3 heterozygous and 1 homozygous for 299G), (B) CASPASE-12 genotype (26 homozygous for the short variant 
S, 21 heterozygous and 1 homozygous for the long variant L) and (C) DECTIN-1 I223S genotype (43 homozygous 
for the wild-type allele, 3 heterozygous and 2 homozygous for 223S). Values are mean ± SD. * P ≤ 0.05.
198
Chapter 12
of cells from volunteers homozygous for the wild-type genotype with stimulation of cells from 
volunteers either heterozygous or homozygous for the variants of TLR4 (Figure 1A), CASPASE-12 
(Figure 1B) or TIRAP (not shown). In contrast, the IFN-g production capacity was lower in cells from 
individuals heterozygous and homozygous for the DECTIN-1 223S SNP compared to cells from wild-
type individuals. The production of the other cytokines was, in contrast, comparable between the 
different DECTIN-1 genotypes (Figure 1C). Similar to the HIV-infected individuals, the TLR4 T399I 
SNP and the studied TLR2 SNPs were completely absent in the healthy volunteers as well.
We have identified one subject who was homozygous for the TLR4 299G allele and displayed 
lower cytokine production for all four cytokines tested compared to wild-type and heterozygous 
individuals (Figure 1A). In contrast, the one individual homozygous for the long form of caspase-12 
produced normal amounts of cytokines upon stimulation with heat-killed C. albicans (Figure 1B). 
Functional consequences of DECTIN-1 SNP I223S
In order to assess whether the mutated dectin-1 protein, bearing 223S, is indeed functionally 
different from the wild-type receptor, both the wild-type and the mutated form of DECTIN-1 
were cloned and transfected into NIH3T3 cells. The binding to fluorescently labelled zymosan 
was measured in the cells expressing the wild-type or the 223S mutated dectin-1 protein. The 
binding of zymosan by the mutated dectin-1 was diminished compared to the wild-type dectin-1 
on isoforms A and B, both known to be expressed on the cell membrane and able to bind β-glucan. 
The dectin-1 antagonist laminarin blocked the binding to zymosan to both isoforms A and B of 
the wild-type dectin-1, demonstrating the specificity of β-glucan by dectin-1 binding in this assay 
(Figure 2A). Furthermore, protein expression of the 223S mutated dectin-1 was largely absent on 
the membrane of NIH3T3 cells, whereas the wild-type dectin-1 protein was clearly present on the 
cell membrane (Figure 2B).  
Discussion
In the present study we have investigated the role of genetic variants of DECTIN-1, TLR2, TLR4, 
TIRAP and CASPASE-12 for the susceptibility to OPC in East-African HIV-seropositive patients. 
Host defence to C. albicans in general, and OPC in particular, is believed to be dependent on a 
combination of innate and acquired immune responses. The importance of the latter has become 
apparent during the AIDS pandemics, as OPC is one of the most common opportunistic infections 
in HIV-infected patients. However, the variations in the susceptibility to OPC between individuals 
with low CD4+ T-cell counts suggest an additional important role for innate immune responses. This 
is supported by the fact that the C. albicans infection remains restricted to the mucosal layers and 
that disseminated candidiasis in HIV-seropositive patients is rare. Finally, oral burdens of C. albicans 
have been shown to be augmented in HIV-infected patients even prior to the first episode of OPC 
(28;29), and before a decline in CD4+ T-cell count could be observed. 
Fungal pathogens in general, and C. albicans in particular, are recognized by pattern recognition 
receptors such as TLRs and C-type lectins, that subsequently activate antifungal inflammatory 
reactions. SNPs in DECTIN-1, TLR2, TLR4, TIRAP and CASPASE-12 are demonstrated to influence the 
susceptibility to different infectious diseases and we have assessed their role for the susceptibility 
to OPC in HIV-infected patients (17-20;22;23;30;31). In the present study, no association could be 
established between heterozygosity for TLR4 299G or CASPASE-12 long variant and susceptibility 
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to OPC. The studied TLR2 SNPs were all absent in this Tanzanian cohort, which is in accordance 
with a similar study in a West-African population (32). Furthermore, TLR4 T399I, TIRAP S180L 
and DECTIN-1 Y238X were not detected or present in low frequencies in the cohort studied. In 
contrast, the frequency of the DECTIN-1 I223S SNP was lower in the group of patients with HIV 
and OPC (4.3% vs. 7.4%), which may suggest a protective effect of this polymorphism against the 
occurrence of OPC in HIV patients. After stratifying for intervals of CD4+ T-cell counts, this difference 
reached statistical significance in the subgroup with CD4+ T-cell counts below 100. The allele 
Figure 2. (A) Binding assay of fluorescently labelled zymosan to the wild-type (wt) and the 223S mutated (mut) 
form of dectin-1 cloned and transfected with an hemagglutinin tag in NIH3T3 cells, including competitive 
blocking by laminarin, on the dectin-1 isoforms A and B. Values are relative fluorescent units (RFU). (B) 
Evaluation of membrane expression of the cloned dectin-1 constructs, wild-type (wt) and 223S mutant (mut) 
of both isoforms A and B, transfected with an hemagglutinin tag in NIH3T3 cells and measured by using HA-
antibodies and flow cytometry.  
A
B
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frequency of this SNP was demonstrated to be 6.6% in a group of 91 healthy Tanzanian subjects, 
which was similar to the HIV-infected patients that did not develop OPC. 
We performed functional cytokine assays with cells from healthy volunteers to accompany 
the genetic studies. Although blood from healthy volunteers contains higher numbers of CD4+ 
T-cells than HIV patients, it is reasonable that the potential effect of the studied SNPs on cytokine 
responses would display similar trends. The epidemiological data are supported by the cytokine 
studies, because no significant differences were observed between individuals homozygous for 
wild-type TLR4 or CASPASE-12, and individuals bearing polymorphisms in these genes. Interestingly, 
the release of cytokines, IL-1β in particular, is not different between individuals with different 
CASPASE-12 genotypes. This difference in regulation of IL-1β release between different CASPASE-12 
genotypes was previously suggested by Saleh et al. (23). In contrast, our findings bring into question 
whether human caspase-12 is involved in modulating IL-1β processing. However, it should be noted 
that clinical outcome (i.e. sepsis versus mucosal candidiasis) and origin of the populations (African-
American (Saleh et al.) versus East-African in our study) was different. 
We have identified one individual homozygous for the TLR4 299G allele, and his cells produced 
significantly lower amounts of cytokines compared to wild-type individuals (Figure 1A). It remains 
to be demonstrated whether this tendency is reproducible in other individuals homozygous for the 
TLR4 299G polymorphism. In contrast, heterozygous individuals for this SNP exhibited a slightly 
higher TNFα production capacity, which is consistent with previous findings (33). 
The presence of the DECTIN-1 I223S polymorphism was accompanied by a lower IFN-g production 
capacity upon stimulation with heat-killed C. albicans. In contrast, the production of the other 
cytokines measured appear not be affected by this DECTIN-1 genotype, although dectin-1 is known 
to be involved in these cytokine responses. The release of IL-12p40 and IL-18 cytokines, known to be 
involved in IFN-g induction, were not markedly different between the different DECTIN-1 genotypes 
(data not shown). This suggests that a different mechanism accounts for the differences observed 
in the IFN-g response. The lower IFN-g response in the individuals bearing the DECTIN-1 223S allele 
has been supported by molecular studies. For both isoforms A and B an altered binding capacity 
of the 223S mutated form of dectin-1 to zymosan was demonstrated by cloning the receptor and 
subsequent transfection studies. Furthermore, after transfection, the cell surface expression of the 
dectin-1 223S mutated form was reduced compared to the wild-type dectin-1, which was true 
for both isoforms A and B. This finding is in contrast with a study from Adachi et al. (34), in which 
the equivalent amino acid in murine dectin-1 (I222) was mutated into an alanine, which did not 
affect β-glucan binding. However, in this same study mutating the adjacent amino acids (W121 and 
H223) into alanine diminished the capacity of β-glucan binding tremendously. This implies that this 
protein region consisting of these three amino acids is important for β-glucan recognition. Both 
the differences between murine and human dectin-1 regarding their protein sequence and the 
different amino acid alterations that were studied (from isoleucine to serine instead of alanine) 
could explain the discrepancy between the studies.  
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Less efficient binding of zymosan to dectin-1 would imply a less effective recognition of C. albicans 
by innate immune cells in the mucosa and consequently a less profound immune response. This 
finding seems contradictory to the certain degree of protection against OPC offered by this SNP. 
The precise mechanism mediating this protection remains elusive. However, one could speculate 
that the lower IFN-g responses that are observed as a consequence of the presence of the 
DECTIN-1 I223S SNP could lead to less T-cell activation and therefore less clonal expansion. This 
could result in a reduced spread of HIV virus particles, which might be beneficial for mucosal anti-
Candida responses. This seems true specifically in case CD4+ T-cell counts are very low, which is 
indicative for a predominant role of the innate immune system in resistance to OPC when CD4+ 
T-cell responses are severely impaired. On the other hand, the differences of the prevalence of the 
DECTIN-1 polymorphism was borderline statistically significant between patients with or without 
OPC, and one may question the importance of this polymorphism for the susceptibility to OPC.  
The TLR4 polymorphism studied in the present study has been previously reported to be associated 
with disseminated candidiasis (18). However, two important differences with the present study are 
important in this respect. Firstly, disseminated candidiasis has a different pathogenesis than OPC, 
with innate responses likely to be more important in systemic candidiasis. Secondly, the distribution 
of the TLR4 SNPs D299G and T399I is different between populations in Europe and Africa. In 
Caucasian populations, from which a cohort has been analysed in the previous study, the D299G 
and T399I SNPs are in complete linkage, determining a different TLR4 haplotype than that in African 
populations in which the T399I SNP is largely absent. The difference in TLR4 haplotypes (299/399 
co-segregation in Europe versus 299 alone in Africa) was also demonstrated to have functional 
consequences for TLR4 signalling, and therefore a comparison between the TLR4 polymorphisms 
between these two studies cannot be made (33). 
Also HIV viral load is a predictive factor of the occurrence of OPC in HIV patients (35). Unfortunately, 
no data were available on HIV viral load of the patients in our cohort which would have allowed us 
to correct for this potential confounding factor.
In conclusion, no differences have been observed in the frequency of the studied SNPs in the 
genes encoding TLR2, TLR4, Mal/TIRAP and caspase-12 in Tanzanian HIV-seropositive patients with 
and without OPC. In addition, these different genotypes also did not have an effect on cytokine 
responses after an in vitro challenge with heat-killed C. albicans. One possible exception may be 
constituted by individuals homozygous for TLR4 299G, which seems to result in a reduced cytokine 
production capacity after C. albicans stimulation. However, the low frequency of homozygous 
individuals bearing this SNP in the study population precludes us from any conclusions regarding 
a putative increase in the susceptibility to OPC. The frequency of the DECTIN-1 polymorphism 
I223S that has the tendency towards an association with protection from OPC in this cohort of 
HIV-infected patients, was associated with lower IFN-g responses and a decreased capacity to bind 
zymosan. However, further investigation in larger cohorts is warranted to determine whether this 
DECTIN-1 SNP has indeed a protective effect against OPC in HIV-seropositive patients.
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Abstract
Background: Candidemia is a severe invasive fungal infection with high mortality. Recognition 
of Candida spp. is mediated through pattern recognition receptors such as Toll-like receptors 
(TLRs). This study assessed whether genetic variation in TLR signaling influences susceptibility to 
candidemia.
Methods: Thirteen mostly non-synonymous single nucleotide polymorphisms (SNPs) in genes 
encoding TLRs and signaling adaptors MyD88 and Mal/TIRAP were genotyped in 338 patients (237 
Caucasian, 93 African-American, 8 other race) with candidemia and 351 non-infected controls 
(263 Caucasian, 88 African-American). SNPs significant in univariate analysis were further analyzed 
with multivariable logistic regression to determine association with clinical outcomes. Functional 
consequences of these polymorphisms were assessed via in vitro stimulation assays.
Results: Analyses of TLR SNPs revealed that three TLR1 SNPs (R80T, S248N, I602S) were significantly 
associated with candidemia susceptibility in Caucasians. This association was not found in African-
Americans, likely due to lower power in this smaller study population. Furthermore, these TLR1 
polymorphisms displayed impaired cytokine release by primary monocytes. No associations with 
susceptibility to candidemia were observed for SNPs in TLR2, TLR4, TLR6, TLR9, MYD88 or TIRAP.
Conclusions: Non-synonymous SNPs in TLR1 are associated with impaired TLR1 function, decreased 
cytokine responses, and predispose to candidemia in Caucasians.
Introduction
Candidemia, i.e. bloodstream infection with Candida spp., is the fourth most common nosocomial 
infection in immunocompromised patients and one of the systemic infections with the highest 
mortality rate, reaching up to 30 to 40% in intensive care unit (ICU) patients (1;2). It is well 
established that main risk factors for candidemia comprise neutropenia, mucosal barrier injury, 
solid organ or stem cell transplantation, treatment with immunosuppressive drugs, broad spectrum 
antibiotics, prolonged ICU stay and central venous catheterization (3-5). However, among patients 
with similar predisposing factors, the risk of systemic Candida infection and its clinical outcome 
varies significantly. 
Several Candida species, of which C. albicans is the most prevalent, have been isolated from the 
bloodstream of patients with candidemia. However, in recent years there has been a trend towards 
increased prevalence of non-albicans species such as C. glabrata and C. krusei, with increasing 
reports of resistance to antifungal azoles (6;7), which may be in part promoted by the frequent use 
of antifungal prophylaxis, pre-emptive therapeutic strategies in high-risk patients, or alteration of 
host status (8;9). Antifungal prophylaxis remains the most effective way to prevent systemic Candida 
infection, due to the lack of specific clinical and laboratory parameters to diagnose candidemia at 
an early stage (10;11). Due to all these facts, there is urgent need to identify host factors that 
predispose to candidemia, in order to be capable of establishing a well-defined predictive profile 
for patients at risk to develop infection. 
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Toll-like receptors (TLRs) are transmembrane proteins on immune cells that recognize conserved 
microbial molecular motifs designated as pathogen-associated molecular patterns (PAMPs). TLRs 
interact with several adaptor proteins including Myeloid Differentiation primary response gene 88 
(MyD88) and MyD88-adaptor-like/Toll-interleukin 1 Receptor domain-containing Adaptor Protein 
(Mal/TIRAP) to activate transcription factors, leading to production of pro-inflammatory cytokines 
and subsequent induction of adaptive immunity. Recognition of Candida species by innate immune 
cells has been demonstrated to be mediated through several TLRs, which in turn leads to a potent 
host defense activation against the yeast (12). Genetic variants of TLRs and their adaptors MYD88 
and TIRAP have been associated with increased susceptibility to bacterial infections (13-17). A 
number of studies have proposed associations of TLR2 and TLR4 polymorphisms with increased 
risk of aspergillosis and candidemia (18-21). However, most of these studies have been performed 
in very small cohorts of patients, and a systematic genetic study investigating variation in pattern 
recognition receptors in a large cohort of patients at risk of candidemia, comprising infected 
patients and non-infected control patients, has not been performed to robustly interrogate the 
importance of this innate pathway for protection against Candida spp. 
In the present study, we hypothesized that certain polymorphisms in TLR genes or in genes 
encoding their signaling adaptors may influence host susceptibility to the most common invasive 
fungal disease, candidemia. To test this hypothesis, we analyzed the prevalence of mostly non-
synonymous single nucleotide polymorphisms (SNPs) in five candidate TLR genes and genes 
encoding their adaptors MYD88 and TIRAP in a cohort of 338 candidemia patients and 351 non-
infected controls that had similar underlying predisposing factors. The genetic study was further 
complemented and supported with functional assays that assessed the consequences of these 
specific polymorphisms on the cytokine production capacity of primary human blood mononuclear 
cells, in order to validate the mechanistic association of the susceptibility trait.
Materials and Methods
Ethics statement and subjects
Adult subjects were enrolled after informed consent (or waiver as approved by the Institutional 
Review Board) at Duke University Hospital (DUMC, Durham, North Carolina, USA) and Radboud 
University Nijmegen Medical Centre (RUNMC, Nijmegen, The Netherlands). Race of the patients 
was self-reported; all Dutch RUNMC patients were of Caucasian descent. The study was approved 
by the Institutional Review Boards at each study centre, and enrollment occurred between January 
2003 and January 2009. The study was performed in accordance with the declaration of Helsinki.
Susceptibility to Infection
Infected subjects were enrolled consecutively and must have had ≥1 positive blood culture for a 
Candida species while hospitalized at the participating center. Non-infected controls must have 
been hospitalized with no history or evidence of candidemia, or any invasive fungal infection. 
None of the control patients were on antifungal therapy/prophylaxis. While it was impracticable to 
match controls on specific risk factors, non-infected controls were recruited consecutively from the 
same hospital wards/services as infected patients during the study period, with a similar balance 
of medical, surgical, and oncology patients in case and control groups. Immunocompromised 
status was a combined variable based on a broad definition including: neutropenia, CD4+ 
lymphopenia (HIV-associated or otherwise), chronic steroid use or receipt of immunosuppressive 
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chemotherapy/ immunosuppressant medications within 30 days prior to baseline, diabetes 
mellitus, and/or end-stage renal disease requiring hemodialysis. Acute renal failure was defined 
based on clinical diagnosis, including doubling of serum creatinine and/or requirement for acute 
dialysis (intermittent hemodialysis or CVVHD). Intergroup comparisons between the two groups 
of non-infected subjects and between the two groups of infected subjects (at DUMC and RUNMC) 
were performed regarding similarity in genetic distribution of the studied SNPs prior to further 
statistical analysis of infected versus non-infected subjects. 
Genetic association with clinical outcomes
Due to the lack of detailed clinical data on the Dutch candidemia patients (N=40) recruited at 
RUNMC, the correlations of the genetic data with clinical outcome was performed only within 
the North-American patients (N=298) from DUMC. Infected subjects at DUMC were followed 
prospectively for up to 12 weeks following diagnosis of candidemia to determine clinical outcome. 
Mortality data, including date of death, was ascertained from hospital records and/or the National 
Social Security Death Index. Disseminated infection was defined as the presence of Candida spp. at 
normally sterile body sites outside the bloodstream (excluding the urine). Persistent fungemia was 
defined as ≥ 5 days of persistently positive blood cultures. 
Genetic analysis
Genomic DNA was isolated from whole blood using standard procedures (22). Coding non-
synonymous SNPs and a few SNPs in untranslated regions of the analyzed genes were selected 
based on previously published associations with human diseases and/or known functional effects 
on protein function or gene expression. A total of 13 SNPs in TLR1, TLR2, TLR4, TLR6, TLR9, TIRAP 
and MYD88 were genotyped (Table 1) with the use of a mass-spectrometry genotyping platform. 
Quality control was performed by duplicating samples within and across plates and by the 
incorporation of positive and negative control samples. 
In vitro PBMC stimulation assays
Isolation and stimulation of peripheral blood mononuclear cells (PBMCs) was performed as 
described previously (23). In brief, PBMCs obtained from 49 healthy Caucasian volunteers were 
incubated at 37°C for 24 hours with either culture medium, the TLR1/2 agonist Pam3Cys (10 µg/ml, 
EMC Microcollections, Tübingen, Germany), or the TLR4 agonist lipopolysaccharide (E.coli O55:B5 
LPS, 10 ng/ml, Sigma-Aldrich, MO, USA). Cytokine production of IL-1β, IL-6 and IL-8 was measured 
in the PBMC supernatants by enzyme-linked immunosorbent assay (R&D Systems, MN, USA).
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Table 1. Genotyped SNPs in genes encoding TLRs and associated adaptor molecules.
Gene SNP ID Gene region Amino acid change
MYD88 rs4988453 Promoter -
rs6853 3’ UTR -
TIRAP rs595022 Intron 1 -
rs8177374 Exon 5 Non-synonymous S180L
TLR1 rs4833095 Exon 4 Non-synonymous S248N
rs5743611 Exon 4 Non-synonymous R80T
rs5743618 Exon 4 Non-synonymous I602S
TLR2 rs5743704 Exon 3 Non-synonymous P631H
rs5743708 Exon 3 Non-synonymous R753Q
TLR4 rs4986790 Exon 3 Non-synonymous D299G
rs4986791 Exon 3 Non-synonymous T399I
TLR6 rs5743810 Exon 1 Non-synonymous S249P
TLR9 rs5743836 Promoter -
UTR = untranslated region
Statistical Analysis
Chi-square tests of deviation from Hardy Weinberg Equilibrium (HWE) for all thirteen SNPs were 
calculated in cases and controls separately using PLINK statistical software (24). Single locus tests 
of association were performed with logistic regression (or exact logistic regression, in the case 
of African-Americans) using a dominant model (e.g. minor allele homozygote combined with the 
heterozygote as risk genotypes), using SAS (version 9.2, SAS Corporation, Cary, NC, USA). Model 
selection was based upon genotype frequencies. Standard summary statistics (Odds Ratio (OR) and 
95% confidence interval (CI)) were reported for these tests of association. Baseline demographic 
and clinical categorical variables in the case and control groups were compared by χ2 analysis or 
Fisher’s exact test (as appropriate), and variables with p<0.05 were analyzed as confounders of any 
SNP significantly associated with susceptibility to infection using logistic regression (or exact logistic 
regression as appropriate). Standard summary statistics for pairwise linkage disequilibrium (LD), D’ 
and r2, were calculated using Haploview. Haplotype blocks were assigned using the D’ confidence 
interval algorithm created by Gabriel et al (25). 
Data on susceptibility to infection were analyzed for Caucasian descendents separately from 
African-Americans since allelic frequencies were expected to differ among these two populations 
and controls, and examination of race-stratified genotype frequencies for the tested polymorphisms 
confirms this expectation (Table 4) (26;27). Statistical analysis of the cytokine data was performed 
by using the Mann-Whitney U test. A P-value < 0.05 was considered statistically significant.
Within the infected DUMC cohort, allelic frequencies were further assessed in association with 
three pre-specified clinical outcomes: (1) disseminated disease, (2) persistent fungemia, and 
(3) all-cause mortality at 30 days. This analysis was performed in the entire infected cohort of 
DUMC Caucasians and African-Americans, as the progression of the disease once occurring is not 
expected to differ between Caucasian and African-American patients, and race was considered 
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as covariate in the analysis. Variables with P-value <0.2 were further assessed in a multivariable 
logistic regression model, using backwards elimination. Variables with P<0.05 were retained in the 
final predictive model. Odds Ratios and 95% Confidence Intervals were reported for variables that 
remained significant in the final multivariable model.
Table 2. Demographics for DUMC and RUNMC Adult Study Subjects. 
Infected Cohort (N=338)
% (N)
Non-Infected Controls (N=351)
% (N)
Race 
Caucasian
African-American
Other
70% (237)
28% (93)
2% (8)
75% (263)
25% (88)
0% (0)
Sex
Male
Female
59% (199)
41% (139)
52% (184)
48% (167)
 
Results
Demographics
338 adult patients (298 North-American, 40 Dutch) and 351 adult controls (300 North-American, 
51 Dutch) had genetic and clinical data available for this analysis. Demographics for study subjects 
are presented in Table 2 (including Dutch and North-American subjects), and major clinical features 
among the infected and non-infected cohort are presented in Table 3 (including the North-
American subjects only). As expected, the groups were similar in regards to primary admitting 
service/primary presenting problem. 
Genetic analysis
Data from adult patients (N=338) and controls (N=351) were included in the analysis for genetic 
association with susceptibility to infection. The intergroup comparison between the Dutch RUNMC 
and North-American Caucasian DUMC non-infected controls and between the infected subjects 
recruited at DUMC and RUNMC revealed a similar genetic distribution of the genotyped SNPs, 
which allowed the groups to be merged into one group of non-infected controls and one group 
of infected subjects (data not shown). A post-hoc analysis of the interaction between SNPs and 
race supported our stratification of this analysis by race. Genotyping of candidemia patients and 
non-infected controls for polymorphisms in genes encoding TLRs and their adaptor molecules 
MyD88 and Mal/TIRAP revealed a significantly different distribution of three TLR1 polymorphisms 
when comparing infected patients and non-infected controls in the Caucasian adults (Table 4). All 
genotyped SNPs were in Hardy-Weinberg equilibrium (data not shown). LD analysis revealed that 
alleles at rs4833095 (S248N) and rs5743618 (I602S) were strongly in LD (r2=0.8) with each other 
but not with alleles at rs5743611 (R80T, r2<0.03, Figure 1). No associations were observed with 
polymorphisms in TLR2, TLR4, TLR6, TLR9, MYD88 and TIRAP and susceptibility to candidemia in 
Caucasians (data not shown). 
No significant associations with susceptibility to candidemia were observed in the African-American 
cohort, neither with SNPs in TLR1 (Table 4) nor in the other analyzed genes (data not shown).
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Figure 1. Linkage disequilibrium (LD) analysis of TLR1 SNPs R80T (rs5743611), S248N (rs4833095) and I602S 
(rs5743618) in Caucasian individuals. Pairwise LD was assessed using the correlation coefficient (r2). Percentage 
correlation between the two markers is noted in each box.
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Table 3. Baseline Patient Characteristics for DUMC Infected Cohort (N=298) and Control Cohort 
(N=300), including Caucasian and African-American Adult patients.
Variable Infected cohort, % Control cohort, % p value
Median age [IQR] (years) 58.7 [43.0-68.1] 58.7 [45.0-69.6] 0.407
Primary Admitting Service/ Primary Problem
     Medical 50% 54% 0.306
     Surgical 33% 31% 0.640
     Oncology 17% 15% 0.355
Median Length of Hospitalization [IQR] (days) ** 9 [2-18] 6 [4-12] 0.795
Immunocompromised State 59% 42% <0.0001
Hematopoietic stem cell transplantation (HSCT) 1% 0% 0.124
Solid organ transplant 12% 2% <0.0001
Active Malignancy*  
Solid Tumor
Leukemia
Lymphoma
32%
23%
7%
4%
20%
12%
5%
4%
0.002
0.269
0.292
1
Chemotherapy within past 3 months 16% 11% 0.029
Neutropenia (ANC <500 cells/mm3) 10% 4% 0.001
HIV-infected 1% 0.1% 0.061
Surgery within past 30 days 43% 48% 0.246
Receipt of Total Parenteral Nutrition 19% 4% <0.0001
Dialysis dependent 12% 7% 0.019
Acute Renal Failure 34% 22% 0.001
Liver Disease 25% 4% <0.0001
Intensive Care Unit Admission within past 14 days 49% 33% <0.0001
Central Intravascular Catheter 82% 41% <0.001
Peripheral Intravenous Catheter 100% 97% 0.004
Baseline Serum Creatinine, Median [IQR] (mg/dL) 1.3 [0.8-2.3] 1.0 [0.8-1.5] 0.001
Median Baseline WBC count [IQR] (cells/mm3) 10.5 [6.0-17.1] 8.6 [6.4-12.4] 0.036
Candida spp. ***
albicans
glabrata
parapsilosis
tropicalis
krusei
other Candida spp.
42%
29%
16%
13%
4%
3%
-
 
*subjects could have more than one; ** til index blood culture for cases; ***16 subjects had >1 
species isolated 
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Table 4. Distribution of TLR1 genotypes in the Caucasian (245 adult candidemia patients, 263 non-
infected adult controls) and African-American (93 adult candidemia patients, 88 non-infected 
adult controls) cohorts. 
Caucasians (245 infected, 263 non-infected)                                      MAF p-value OR (95% CI)*
TLR1 R#80T GG# GC CC 0.023 1.82 (1.12-2.98)
Non-infected 88.2% 9.9% 1.91% 0.068
Infected 80.2% 18.9% 0.86% 0.103
TLR1 S248N# GG GA AA# 0.038 0.68 (0.47-0.96)
Non-infected 5.3% 41.8% 52.9% 0.262
Infected 7.2% 30.1% 62.7% 0.223
TLR1 I602S# TT TG GG# 0.015 0.69 (0.49-0.80)
Non-infected 7.6% 44.7% 47.7% 0.300
Infected 10.2% 33.1% 56.8% 0.268
African-Americans (93 infected, 88 non-infected)                            MAF    p-value OR (95% CI)**
TLR1 R#80T GG# GC CC 0.621 2.92 (0.23-155.70)
Non-infected 98.9% 1.1% 0% 0.006
Infected 96.8% 3.2% 0% 0.016
TLR1 S#248N GG GA AA# 0.094 3.862 (0.71-39.15)
Non-infected 63.6% 28.4% 7.95% 0.222
Infected 69.9% 27.9% 2.15% 0.161
TLR1 I#602S TT TG GG# 0.604 3.12 (0.25-166.7)
Non-infected 76.1% 20.5% 3.4% 0.137
Infected 80.2% 18.7% 1.1% 0.105
# Reference (= major) allele in entire study population; * Logistic Regression, dominant model; ** 
Exact Logistic Regression, MAF = minor allele frequency.
Association of polymorphisms with clinical outcome
Among the 298 DUMC adult infected subjects, 18% (54) developed disseminated disease and 15% 
(45) experienced persistent fungemia, while mortality rate was 28% (83) and 39% (116) at 30 and 90 
days after initial blood culture, respectively. The most common type of infection complicating the 
bloodstream was abdominal abscess/peritonitis (55%) followed by hepatosplenic candidiasis (13%) 
and endocarditis/vascular sites (11%). Persistence occurred at similar rate among those with and 
without central catheters (13% vs. 15%) (p=0.671), and with and without central catheter removal 
by day 5 (19% and 25%, p=0.327), respectively. Median [IQR] time to antifungal therapy (2 [1.75-3] 
days vs. 2 [1-3] days, p=0.359) was also similar in those with and without persistence, respectively. 
Univariate and subsequent multivariate analysis assessing baseline patient characteristics and 
polymorphisms in TLR1, TLR2, TLR4, TLR6, TLR9, MYD88 and TIRAP (data not shown) indicated that 
there was no association between presence of polymorphisms at these loci and outcomes such as 
dissemination, persistence and mortality. 
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In vitro stimulation assays
Functional consequences of the three TLR1 polymorphisms were studied by stimulating PBMCs 
obtained from 49 Caucasian healthy volunteers bearing different TLR1 haplotypes with Pam3Cys, a 
specific agonist of the TLR1/TLR2 heterodimer. Cytokine production capacity of IL-1β, IL-6 and IL-8 
was measured after 24 hours stimulation (Figure 2). Unstimulated cells produced no detectable 
cytokine concentrations (data not shown). Dramatically decreased cytokine production was 
observed in cells bearing one, two or three multi-locus genotypes in TLR1 that are associated 
with higher susceptibility to candidemia (bold) compared to haplotypes of wild-type alleles (not 
bold). Cytokine responses in relation to previously reported associations of TLR2 (R753Q, Pam3Cys 
stimulation) and TLR4 (D299G/T399I, LPS stimulation) polymorphisms with candidemia were also 
evaluated, but revealed no significant differences (Figure 3). 
Discussion
The present study demonstrates the association of three TLR1 polymorphisms with an increased 
susceptibility for candidemia in patients of Caucasian ethnicity. In addition to the genetic association 
between TLR1 polymorphisms and candidemia, cells isolated from individuals bearing the TLR1 
variants that predispose to candidemia have shown functional consequences with decreased 
cytokine responses upon in vitro stimulation with specific TLR1/TLR2 ligands. In contrast to TLR1, 
no influence of TLR2, TLR4, TLR6, TLR9, MYD88 or TIRAP SNPs on the susceptibility to candidemia 
was observed. 
Several TLRs have been reported to be involved in recognition of C. albicans, among which TLR2 
mediates recognition of phospholipomannan (28), TLR4 of O-bound mannan (29) and TLR9 of fungal 
DNA (30). TLR6 has also been demonstrated to contribute to Candida mediated cytokine responses 
(31), while TLR1 forms functional heterodimers with TLR2 (32). As identified genetic variants of TLRs 
have recently been reported to influence function of these proteins and susceptibility to infections 
(33), we assessed the role of SNPs in these receptors and their adaptor molecules MyD88 and Mal/
TIRAP for potential insights into the susceptibility to Candida bloodstream infections.
Among the genes and SNPs tested, we found that three polymorphisms in TLR1 were associated 
with increased susceptibility to development of candidemia in hospitalized patients at risk for 
this fungal disease..While two of these polymorphisms (S248N and I602S) were strongly (80%) 
linked, the third (R80T) was not linked to the first two. When the two groups of subjects recruited 
at DUMC and RUNMC were considered separately, this trend of association could be observed 
also in the smaller RUNMC group. Due to the common West-European ancestry of the two 
groups, they were analyzed together. Importantly, frequencies of the TLR1 polymorphisms in the 
Caucasian non-infected controls were fairly equal compared to the general population, as assessed 
by genotyping 152 Caucasian healthy controls for these SNPs (data not shown), indicating that 
TLR1 polymorphisms confer a higher risk for developing candidaemia, but not for underlying 
predisposing factors. The observation that all three SNPs influence susceptibility to candidemia 
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Figure 2. Correlation of TLR1 haplotypes with cytokine measurements of IL-1β, IL-6 and IL-8, 24 hours after in 
vitro stimulation of peripheral blood mononuclear cells from healthy volunteers with the TLR1/TLR2 agonist 
Pam3Cys (10 µg/ml). On the x-axis the different TLR1 haplotypes are depicted, protective genotypes (not bold) 
and risk genotypes (bold). Data are presented as means ± SEM (Mann Whitney U test, *P≤0.05, **P≤0.005). 
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strengthens the conclusion that there is an important role for TLR1 in influencing the susceptibility to 
the infection. Moreover, the genetic data were complemented by functional studies demonstrating 
that TLR1 genotypes predisposing to candidemia are associated with decreased pro-inflammatory 
cytokine release upon stimulation. 
One study in mice did not identify a non-redundant role of TLR1 in the host defense against 
disseminated candidiasis (31). Hence, our data suggest that important differences exist between 
the role of TLR1 in mice and humans. Furthermore, the high inocula mouse model of disseminated 
candidiasis may very well differ from the clinical course of infection in humans with their 
heterogeneous and dynamic risk factors. 
TLR1 is known to form heterodimers with TLR2, which has been shown to be involved in Candida 
recognition. For one of the TLR1 polymorphisms, I602S, it was demonstrated that the TLR1 
protein bearing 602S is associated with impaired cell surface trafficking resulting in a decreased 
availability of TLR1 on the cell membrane (34). Consequently, lower availability of TLR1 could 
skew the configuration of TLR2 from heterodimers attached to TLR1 towards predominantly TLR2 
homodimers or TLR2/TLR6 heterodimers. This, in turn, could alter intracellular signaling and 
cytokine production induced after Candida spp. encounter innate immune cells which might result 
in deleterious effects during systemic fungal infections. 
Another mechanism through which TLR1 could exert its effect on antifungal host defense is that 
beta-defensin-3 activates immune cells through TLR1/TLR2 (35). Beta-defensin-3 has an important 
lytic activity against C. albicans and its expression is induced in mucosal layers after fungal 
recognition (36). As a consequence, diminished TLR1 function could impair mucosal antifungal 
defense, enabling Candida to invade the tissue defenses and reach the bloodstream. Of note, 
the main route of Candida spp. to invade the bloodstream and cause invasive infection is indeed 
through crossing the epithelial layers of the skin and the intestine (37). Furthermore, it cannot be 
excluded that other still unidentified endogenous danger associated molecular patterns, which are 
possibly elicited in the context of candidemia, are able to induce TLR1 signaling and contribute to 
activation of antifungal mechanisms. 
In contrast to the effects of TLR1 SNPs in Caucasian patients, no significant association of TLR1 
polymorphisms with susceptibility to candidemia was detected in patients of African-American 
origin. This is likely due to the smaller sample size of African-Americans in our study population 
and consequently lower statistical power, as well as a different distribution of these polymorphisms 
compared to those observed among Caucasians. It has been previously noted that there are large 
differences in the genetic distribution of these TLR1 polymorphisms between African-American and 
Caucasian populations (38). In particular, the alleles encoding S248N and I602S polymorphisms are 
distributed very differently throughout the populations, and this may provide a partial explanation 
for the absence of association of TLR1 polymorphisms with candidemia in our smaller African-
American cohort. On the other hand, no substantial differences were observed between Caucasian 
and African American patients with regard to basic clinical characteristics.
Clinical parameters of infection comprising dissemination, persistent fungemia and 30-day 
mortality were not associated with any of the polymorphisms analyzed in this study, including 
polymorphisms in TLR1. This may imply that TLR1 is mainly involved in the early host response, 
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thereby preventing bloodstream infection with Candida rather than determining the outcome of 
established candidemia. Of note, previous studies with mouse models of disseminated candidiasis 
in TLR1 knockout mice have only addressed the latter condition (31), which may provide an 
additional explanation for the differences observed in the role of TLR1 in candidemia between 
mice and humans.
Our results demonstrating important effects of TLR1 polymorphisms on Candida bloodstream 
infections are strengthened by studies reporting similar effects on genetic susceptibility 
to aspergillosis (19), bacterial sepsis (39) or mycobacterial infections (40). Interestingly, a 
recent study on the evolutionary genetics of Toll-like receptors reported a high variation 
in TLR1, with important evolutionary pressures exerted by infections on this receptor 
(38). We must however concede that these specific pressures were most likely exerted by 
Figure 3. Correlation of TLR2 R753Q (A) and TLR4 D299G/T399I (B) genotypes with cytokine measurements 
of IL-1β, IL-6 and IL-8, 24 hours after in vitro stimulation of peripheral blood mononuclear cells from healthy 
volunteers with either Pam3Cys (panel A, 10 µg/ml) or LPS (panel B, 10 ng/ml). Data are presented as means 
± SEM.
bacterial infections, and not by fungal infections that are primarily caused by modern medical 
circumstances (e.g. chemotherapy, stem cell transplantation and invasive procedures). 
Among DUMC Caucasians and African-Americans, a number of baseline risk factors were significantly 
more common among infected subjects on univariate analysis (data not shown). Although these 
differences were unavoidable due to the nature of the pathologies associated with candidemia, 
none of these variables were significantly associated with presence of the TLR1 polymorphisms 
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in either infected patients or non-infected controls. Therefore it is highly unlikely that they are 
confounders of the association between TLR1 polymorphisms and candidemia (data not shown).
Recent studies have demonstrated that TLR2, TLR4, TLR6 and TLR9 are also implicated in recognition 
of components of Candida spp. Polymorphisms in TLR2 have been reported as risk factor for 
candidemia in a small number of patients (21), while we have reported the association of TLR4 
D299G/T399I polymorphisms in a small cohort of patients (20). These data could not be confirmed 
in the present study that investigated by far the largest cohort of patients with candidemia, 
further emphasizing the importance of recruiting cohorts of sufficient size and comparing them to 
controls at similar risk of infection. In contrast to TLR1, no effects of TLR6, TLR9, TIRAP or MYD88 
polymorphisms on susceptibility to Candida bloodstream infections were apparent.
Our study is subject to several limitations. While we had a relatively large sample for a study of 
genetic association of an infectious disease, we had a small sample of African-American patients, 
which limited our ability to detect differences in this segment of the population, except large 
differences in allelic frequency. In addition, the associations we report for TLR1 polymorphisms 
among Caucasians were not significant enough to withstand adjustment for multiple comparisons. 
However, we demonstrated that genetic variants of TLR1 associated with higher susceptibility 
result in a suppressed function of TLR1, as revealed by impaired induction of cytokine responses 
upon activation of innate immune cells through TLR1. Together, these complementary genetic and 
immunologic data support a role of this receptor in antifungal host defense against candidemia.  
In conclusion, the present study demonstrates the association between TLR1 polymorphisms and 
susceptibility to candidemia. We also found that these same TLR1 polymorphisms are associated 
with impaired function of TLR1 and decreased cytokine responses. While this correlation between 
genetic and functional data strengthens the conclusion of the study, further research is warranted 
to elucidate the exact role of TLR1 signaling in host defense against Candida spp. in humans, and 
how knowledge on polymorphisms in TLR1 could be used in risk assessment for strategies of 
prophylactic, empiric or pre-emptive therapies.
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Abstract 
Background: Candida bloodstream infections cause significant morbidity and mortality among 
hospitalized patients. While clinical and microbiological factors affecting prognosis have been 
identified, the impact of genetic variation in the innate immune responses mediated by cytokines 
on outcomes of infection remains to be studied. 
Methods: A cohort of 338 candidemia patients and 351 non-infected controls were genotyped 
for single nucleotide polymorphisms (SNPs) in six cytokine genes (IFNG, IL10, IL12B, IL18, IL1β, 
IL8) and one cytokine receptor gene (IL12RB1). The association of SNPs with both candidemia 
susceptibility and outcome were assessed. Concentrations of pro- and anti-inflammatory cytokines 
were measured in in vitro PBMC stimulation assays and in serum from infected patients. 
Results: None of the cytokine SNPs studied was associated with susceptibility to candidemia. 
Persistent fungemia occurred in 13% of cases. In the multivariable model, persistent candidemia 
was significantly associated with (OR, [95% CI]): total parenteral nutrition (2.79 [1.26-6.17]), 
dialysis dependence (3.76 [1.46-8.64]) and the SNPs IL10 rs1800896 (3.45 [1.33-8.93]) and IL12B 
rs41292470 (5.36 [1.51-19.0]). In vitro production capacity of IL-10 and IFN-g was influenced by 
these polymorphisms, and significantly lower pro-inflammatory cytokine concentrations were 
measured in serum from patients with persistent fungemia. 
Conclusion: Polymorphisms in IL10 and IL12B that result in low production of pro-inflammatory 
cytokines are associated with persistent fungemia in candidemia patients. This provides insights for 
future targeted management strategies for patients with Candida bloodstream infections.
Introduction
Invasive candidiasis is a pervasive nosocomial infection. While some patients may experience 
only transient fungemia, others develop complications including endocarditis, abscesses, and 
chronic disseminated candidiasis. Persistent fungemia is an increasingly recognized complication 
of candidemia, which occurs in 8-15% of candidemia patients. Few studies have provided an 
explanation for these differential outcomes, although immune response to infection, comorbidities, 
and pharmacologic therapy have all been suggested to contribute to patient outcomes (1). 
Both innate and adaptive immune mechanisms are important for host defense against Candida 
spp. infection (2). The innate immune system provides the first line of defense against fungal 
pathogens by phagocytosis and killing of invading pathogens, as well as through activation of 
adaptive immunity through antigen presentation and secretion of pro-inflammatory cytokines 
(3). Adaptive fungal immunity stimulates host responses to pathogens via protective cellular 
T-helper 1 (Th1) cytokines such IFN-g, and humoral Th2 responses that may have maladaptive anti-
inflammatory effects by the release of IL-4 and IL-10. The interplay between Th1 and Th2 responses 
to Candida infection is complex, but critical for the response to this pathogen. Previous studies 
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have demonstrated that vigorous Th1-type responses are essential for eradication of Candida (4;5). 
In contrast, Th2-type responses to Candida may lead to down-regulation of pro-inflammatory 
cytokines, thereby terminating the protective response to infection (6).
Genetic factors are known to have an important impact on susceptibility to infections (7). Although 
much has been learned about the immune mechanisms that determine an effective host defense 
against Candida, very little is known about the role played by single nucleotide polymorphisms 
(SNPs) of genes comprising the cytokine network for susceptibility to systemic candidiasis. This 
study was undertaken to investigate the role of polymorphisms in the main cytokine genes for the 
susceptibility to Candida infection, and assess whether there is any association with the subsequent 
clinical outcome. 
Materials and Methods
Study Design
This was a prospective, observational cohort study conducted at Duke University Medical Center 
(DUMC) and Radboud University Nijmegen Medical Center (RUNMC). Subjects were enrolled after 
informed consent (or waiver as approved by the Institutional Review Boards) at DUMC, Durham, 
North Carolina, USA and RUNMC, Nijmegen, The Netherlands. The study was approved by the 
Institutional Review Boards at each study center, and enrollment took place between January 2003 
and January 2009. The study was performed in accordance with the Declaration of Helsinki.
Subjects
Infected adults ( 18 years of age and older) were identified by report of one or more positive 
blood cultures for Candida spp. in the clinical microbiology laboratory at the participating center. 
Non-infected controls recruited at DUMC must have been hospitalized with no history or evidence 
of candidemia/invasive candidiasis, or any other invasive fungal infection. Non-infected controls 
at DUMC were recruited from the same hospital wards as infected patients so that comorbidities 
and clinical risk factors for infection would be as similar as possible between groups. Non-infected 
controls enrolled at RUNMC were non-hospitalized healthy controls. Subjects were excluded from 
the study if insufficient volume of blood or clinical data were available. Intergroup comparisons 
between the two groups of non-infected subjects and between the two groups of infected subjects 
(at DUMC and RUNMC) were performed regarding similarity in genetic distribution of the studied 
SNPs prior to further statistical analysis of infected versus non-infected subjects.  
Procedures
Plasma, serum, and whole blood specimens were obtained in combination with routine blood 
draws at baseline and during a 12-week follow-up period. Blood cultures were drawn as part of 
routine care until clearance of fungemia was documented or death occurred. For genetic analysis, 
DNA was isolated from whole blood by standard procedures. For in vitro PBMC stimulation assays 
blood was drawn from healthy volunteers recruited at RUNMC, Nijmegen, The Netherlands. 
Outcomes
Presence of invasive candidiasis was determined on the basis of EORTC definitions. All-cause 
mortality was determined based on hospital records and, if necessary for DUMC subjects, the 
Social Security Death Index. Disseminated disease was defined as the presence of Candida spp. 
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at normally sterile sites outside the bloodstream (excluding the urine), and further characterized 
as acute or chronic. Persistent fungemia was defined as five or more days of persistently positive 
blood cultures for the same Candida spp. All infected patients were followed for up to 12 weeks to 
assess for clinical outcome.  
Predictor variables
Within the DUMC infected cohort, numerous baseline clinical and microbiological variables 
were assessed for their relationship to study outcomes. These included age, race, sex, 
immunocompromised host status (see Table 2).     
Genotyping
Mostly SNPs in promoter and 5’-untranslated regions of the analyzed genes were selected based 
on previously established associations with human diseases or known functional effects on protein 
function or gene expression. Single nucleotide polymorphisms in six cytokine genes (IL1β, IL8, IL10, 
IL12B, IL18, IFNG) and one cytokine receptor gene (IL12RB1) were genotyped (Table S1) by using 
a mass-spectrometry genotyping platform (Sequenom, LUMC, Leiden, The Netherlands). Quality 
control was performed by duplicating samples within and across plates and by incorporation of 
positive control samples. 
In vitro PBMC stimulation assays
Isolation and stimulation of peripheral blood mononuclear cells (PBMCs) was performed as 
described previously (8) [8]. In brief, PBMCs obtained from individuals were incubated at 37 °C for 
48 hours with either culture medium, or with C. albicans conidia or hyphae (strain UC820, both 106/
ml). Production of IL-10 and IFN-g was measured in PBMC supernatants by ELISA (R&D Systems, 
MN, USA and Sanquin, The Netherlands).
Cytokine Assays
Cytokine concentrations of IL-6, IL-8, IFN-g, IL-10 and IL-12p40 in plasma and serum samples 
obtained from infected patients from day 0 to 7 after initial positive blood culture were measured 
by Multiplex Fluorescent Bead Immunoassays (xMAP technology, Bio-Rad, The Netherlands) and 
a Bio-plex microbead analyzer (Luminex, TX, USA) according to the manufacturer’s protocol. Day 0 
was defined as the date that the first positive blood culture was drawn.  
Statistical Analysis
For the genetic analysis, statistical tests for single locus association and for deviations from Hardy 
Weinberg Equilibrium (HWE) for all SNPs were calculated using PLINK statistical software (9). 
Statistical significance for deviations from HWE in cases and controls were determined using c2 tests. 
Single locus tests of association were performed with logistic regression using both a dominant and 
a recessive model. Standard summary statistics (Odds Ratio (OR) and 95% confidence interval (CI)) 
were reported for these tests of association. Pairwise linkage disequilibrium (LD), D’ and r2, were 
calculated using Haploview (10). Haplotype blocks were assigned using the D’ confidence interval 
algorithm created by Gabriel et al. (11). Data on susceptibility to infection were analyzed for 
Caucasian descendents separately from African-Americans since allelic frequencies were expected 
to differ among these two populations and controls. 
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Within the infected DUMC cohort, allelic frequencies were further assessed in association with 
three pre-specified clinical outcomes: (1) disseminated disease, (2) persistent fungemia, and (3) 
all-cause mortality at 30 days. This analysis was performed in the entire cohort and race was 
considered as covariate in the analysis. Variables with p-values <0.2 in the univariate analysis or 
thought to be clinically important were further assessed in multivariable logistic regression models. 
Only variables with p-values <0.05 were retained in the final predictive model. Odds ratios and 95% 
Confidence Intervals were reported for variables that remained significant in the final multivariable 
model.
For the analysis of cytokine concentrations in the in vitro PBMC stimulation assays and in serum/
plasma from the infected patients, Mann-Whitney U tests were performed to test for statistical 
differences. All tests were two-sided.  
Results
Baseline Characteristics
338 infected (298 DUMC, 40 RUNMC) and 351 (300 DUMC, 51 RUNMC) non-infected adults were 
included (Table 1). The Caucasian patient group consisted of 237 infected and 263 non-infected 
subjects. Clinical characteristics of infected and non-infected subjects from DUMC were similar 
(Table 2). The following Candida species were commonly identified in the blood of infected subjects: 
C. albicans (42%), C. glabrata (29%), C. parapsilosis (16%), C. tropicalis (13%), C. krusei (4%). 5% of 
subjects had >1 Candida species isolated. Persistent fungemia was found in 13% of individual cases. 
Disseminated disease was observed in 18% of infected cases, and 30-day mortality was 29%. 
Table 1. Demographics for DUMC and RUNMC Adult Study Subjects. 
Infected Cohort (N=338)
% (N)
Non-Infected Controls (N=351)
% (N)
Race
Caucasian
African-American
Other
70% (237)
28% (93)
2% (8)
75% (263)
25% (88)
0% (0)
Sex
Male
Female
59% (199)
41% (139)
52% (184)
48% (167)
Susceptibility to Infection
All infected patients and non-infected controls were successfully genotyped for all variants. All 
variants were in HWE (data not shown). The intergroup comparison between the Dutch RUNMC and 
Caucasian DUMC non-infected controls and between the infected subjects recruited at DUMC and 
RUNMC revealed a similar genetic distribution of the genotyped SNPs, which allowed the groups 
to be merged into one group of non-infected controls and one group of infected subjects (data not 
shown). Allelic frequencies of the cytokine SNPs were not significantly different between infected 
and non-infected Caucasian subjects (Table 3). Similar results were obtained in the European-
American group, when analyzed separately (not shown). Similarly, no association between cytokine 
polymorphisms and susceptibility to bloodstream Candida infections was observed in the African-
American cohort (Table 4). Therefore, none of the cytokine SNPs studied were associated with 
susceptibility to candidemia. 
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Univariate Analysis of Clinical Outcomes
In the DUMC infected cohort, variables that were significantly associated with persistent fungemia 
on univariate analysis included immunocompromised status, receipt of TPN, and C. parapsilosis 
infection. Of the cytokine SNPs tested, polymorphisms in IL10 and IL12B genes were associated 
with persistent fungemia using univariate analysis in a recessive model (Table 5). In contrast, no 
association was observed between polymorphisms in cytokine genes and disseminated disease or 
30-day mortality (data not shown). 
Multivariate Logistic Regression Analysis of Persistent Fungemia
In the multivariable model, the following variables were analyzed within the logistic regression 
model and were significantly associated with persistent candidemia (OR, [95% CI]): TPN (2.79 [1.26-
6.17]), dialysis dependence (3.76 [1.46-8.64]) and the following SNPs: IL10 rs1800896 (GG or GA 
vs. AA, 3.45 [1.33-8.93]) and IL12B rs41292470 (INS/DEL or DEL/DEL vs. INS/INS, 5.36 [1.51-19.0]). 
In vitro cytokine production by PBMCs
Stimulation of PBMCs obtained from healthy individuals bearing different IL10 rs1800896 genotypes 
with either C. albicans conidia or C. albicans hyphae for 48 hours revealed increased production 
of IL-10 upon stimulation with C. albicans conidia in PBMCs from individuals homozygous for 
the IL10 rs1800896 G allele, compared to PBMCs from individuals homozygous for the A allele. 
Individuals heterozygous for this polymorphism exhibited an intermediate production of IL-10. The 
production capacity of PBMCs after stimulation with C. albicans hyphae was very low and revealed 
no differences between genotypes (Figure 1A).
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Table 2. Baseline Patient Characteristics for DUMC Infected Cohort (N=298) and Control Cohort 
(N=300), including Caucasian and African-American Adults.
Variable Infected cohort, % Control cohort, % p value
Median age [IQR] (years) 58.7 [43.0-68.1] 58.7 [45.0-69.6] 0.407
Primary Admitting Service/ Primary Problem
     Medical 50% 54% 0.306
     Surgical 33% 31% 0.640
     Oncology 17% 15% 0.355
Median Length of Hospitalization [IQR] (days) ** 9 [2-18] 6 [4-12] 0.795
Immunocompromised State 59% 42% <0.0001
Hematopoietic stem cell transplantation (HSCT) 1% 0% 0.124
Solid organ transplant 12% 2% <0.0001
Active Malignancy*  
Solid Tumor
Leukemia
Lymphoma
32%
23%
7%
4%
20%
12%
5%
4%
0.002
0.269
0.292
1
Chemotherapy within past 3 months 16% 11% 0.029
Neutropenia (ANC <500 cells/mm3) 10% 4% 0.001
HIV-infected 1% 0.1% 0.061
Surgery within past 30 days 43% 48% 0.246
Receipt of Total Parenteral Nutrition 19% 4% <0.0001
Dialysis dependent 12% 7% 0.019
Acute Renal Failure 34% 22% 0.001
Liver Disease 25% 4% <0.0001
Intensive Care Unit Admission within past 14 days 49% 33% <0.0001
Central Intravascular Catheter 82% 41% <0.001
Peripheral Intravenous Catheter 100% 97% 0.004
Baseline Serum Creatinine, Median [IQR] (mg/dL) 1.3 [0.8-2.3] 1.0 [0.8-1.5] 0.001
Median Baseline WBC count [IQR] (cells/mm3) 10.5 [6.0-17.1] 8.6 [6.4-12.4] 0.036
Candida spp. ***
albicans
glabrata
parapsilosis
tropicalis
krusei
other Candida spp.
42%
29%
16%
13%
4%
3%
-
*subjects could have more than one; ** til index blood culture for cases; ***16 subjects had >1 
species isolated 
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Table 3. The associations of polymorphisms in IFNG, IL10, IL12B, IL18, IL1B, IL8 and IL12RB1 and 
susceptibility to candidemia in adult Caucasians (245 infected, 263 non-infected).
 Polymorphism WT HETEROZY HOMOZY MUTANT P-value
IFNG rs2430561 TT TA AA 0.07
Non-infected 30.8% 46% 23.2%
Infected 23.4% 56.6% 20%
IL10 rs1800872 GG TG TT 0.50
Non-infected 61.1% 32.8% 6.1%
Infected 58.3% 35.3% 6.4%
IL10 rs1800896 AA GA GG 0.98
Non-infected 24.4% 47.7% 27.9%
Infected 27.2% 45.1% 27.6%
IL12B rs41292470 INS INS INS DEL DEL DEL 0.11
Non-infected 23.6% 47.7% 28.7%
Infected 24.8% 52.9% 22.2%
IL12B rs3212227 AA CA CC 0.95
Non-infected 64.8% 32.9% 2.3%
Infected 64.7% 31.0% 4.3%
IL12RB1 rs17882232 CC TC TT 0.34
Non-infected 67.2% 28.2% 4.6%
Infected 62.8% 33.8% 3.4%
IL12RB1 rs17884858 AA GA GG 0.67
Non-infected 48.1% 41.8% 10.2%
Infected 45.9% 43.3% 10.8%
IL18 rs187238 GG GC CC 0.85
Non-infected 53.6% 35.9% 10.5%
Infected 51.9% 41.3% 7.9%
IL18 rs549908 TT TG GG 0.78
Non-infected 48.1% 40.1% 11.8%
Infected 49.2% 41% 9.8%
IL1B rs1143634 GG GA AA 0.85
Non-infected 59.9% 33.6% 6.5%
Infected 60.5% 36.1% 3.4%
IL1B rs16944 AA GA GG 0.42
Non-infected 15.95% 45.5% 38.5%
Infected 11.5% 46.6% 41.9%
IL8 rs4073 AA TA TT 0.86
Non-infected 18% 54% 27.9%
Infected 19.9% 51.1% 29%
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Table 4. The associations of polymorphisms in IFNG, IL10, IL12B, IL18, IL1B, IL8 and IL12RB1 and 
susceptibility to candidemia in adult African Americans (93 infected, 88 non-infected).
 Polymorphism WT Heterozygous
Homozygous 
Mutant
P-value
IFNG rs2430561 TT TA AA 0.12
Non-infected 69.3% 25.0% 5.7%
Infected 56.9% 40.9% 2.15%
IL10 rs1800872 GG TG TT 0.23
Non-infected 41.4% 37.9% 20.7%
Infected 33.3% 47.3% 19.4%
IL10 rs1800896 AA GA GG 0.52
Non-infected 47.1% 42.5% 10.3%
Infected 41.9% 47.3% 10.8%
IL12B rs41292470 INS INS INS DEL DEL DEL 0.45
Non-infected 17.1% 48.9% 34.1%
Infected 12.9% 45.2% 41.9%
IL12B rs3212227 AA CA CC 0.11
Non-infected 37.5% 47.7% 14.8
Infected 50.5% 37.6% 11.8%
IL12RB1 rs17882232 CC TC TT 0.67
Non-infected 68.9% 27.6% 3.5%
Infected 66.7% 29.0% 4.3%
IL12RB1 rs17884858 AA GA GG 0.74
Non-infected 77.7% 22.3% 0%
Infected 75.8% 20.9% 3.3%
IL18 rs187238 GG GC CC 0.11
Non-infected 69.4% 27.1% 3.5%
Infected 59.3% 30.9% 9.9%
IL18 rs549908 TT TG GG 0.39
Non-infected 62.8% 34.9% 2.3%
Infected 66.9% 37.6% 6.5%
IL1B rs1143634 GG GA AA 0.23
Non-infected 73.6% 22.9% 3.5%
Infected 65.6% 31.2% 3.2%
IL1B rs16944 AA GA GG 0.13
Non-infected 22.1% 48.8% 29.1%
Infected 31.8% 38.5% 29.7%
IL8 rs4073 AA TA TT 0.66
Non-infected 56.5% 36.5% 7.1%
Infected 60.2% 32.2% 7.5%
1235
Cytokine gene polymorphisms and outcome of invasive candidiasis
14
Table 5. Univariate Analysis of Clinical, Microbiological and Genetic Factors Associated with 
Persistent Fungemia in DUMC infected adults (N=298)*
Variable
Non-persistent 
(N=259)
Persistent (N=39) P value
Female Gender 42.3% 45% 0.71
Immunocompromised 56.8% 76.9% 0.02
HSCT 0.1% 2.5% 0.31
Solid organ transplant 10.9% 17.5% 0.23
Intensive Care Unit Admission within past 14 days 50.2% 47.5% 0.75
Active Malignancy**
Solid Tumor
Leukemia
Lymphoma
31.8%
22.5%
6.6%
2.7%
27.5%
15%
7.5%
10.0%
0.59
0.28
0.74
0.05
Chemotherapy within past 3 months 15.9% 22.5% 0.29
Neutropenia (ANC <500 cells/mm3) 9.3% 15% 0.26
HIV-infected 1.6% 0% 1.00
Surgery within past 30 days 43.2% 45.0% 0.83
Receipt of Total Parenteral Nutrition 17.0% 32.5% 0.02
Dialysis dependent 10.7% 23.1% 0.02
Acute Renal Failure 34.6% 32.5% 0.79
Liver Failure 24.5% 27.5% 0.69
Bacteremia within 48 hours 24.8% 17.5% 0.31
Candida spp. 
albicans
glabrata
parapsilosis
tropicalis
krusei
       other Candida spp
       > 1 Candida spp
43.0%
29.5%
14.0%
12.4%
3.5%
3.5%
5.1%
35.0%
27.5%
27.5%
15.0%
5%
0%
7.5%
0.34
0.80
0.03
0.65
0.64
0.61
0.46
Bacteremia within 14 days 34.9% 27.5% 0.36
IFNG rs2430561 (AA) 12.2% 12.5% 1.00
IL10 rs1800872 (TT) 10.9% 5.0% 0.39
IL10 rs1800896 (AA) 34.8% 17.5% 0.03
IL12B rs41292470 (INS/INS) 24.3% 7.7% 0.02
IL12B rs3212227 (CC) 7.5% 2.6% 0.49
IL12RB1 rs17882232 (TT) 2.8% 12.5% 0.01
IL12RB1 rs17884858 (GG) 7.6% 12.8% 0.34
IL18 rs187238 (CC) 43.0% 47.4% 0.62
IL18 rs549908 (GG) 7.8% 7.7% 1.00
IL1B rs1143634 (AA) 4.7% 0% 0.38
IL1B rs16944 (AA) 20.6% 12.5% 0.29
IL8 rs4073 (AA) 32.4% 38.5% 0.44
 
*Variables in bold were further assessed in multivariate analysis
** Some patients had >1 active malignancy 
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When PBMCs were stimulated with these same stimuli and were stratified for their IL12B 
rs41292470 genotype, a 3-fold increased production of IFN-g was observed by PBMCs homozygous 
for the insertion allele, compared to PBMCs from individuals homozygous for the IL12B deletion 
allele upon stimulation with C. albicans hyphae but not conidia. Again, PBMCs from heterozygous 
individuals produced intermediate amounts of IFN-g (Figure 1B)
Circulating cytokine concentrations
Lower pro-inflammatory cytokine concentrations (IFN-g, IL-8, IL-6) were apparent in serum/plasma 
from patients with persistent fungemia, compared to patients that cleared Candida rapidly. While 
the differences were statistically significant for IFN-g and IL-8, the differences in circulating IL-6 
concentrations were not statistically significant (Table 6, Mann Whitney U test). 
Table 6. Cytokine concentrations of IFN-g, IL-6 and IL-8 in plasma and serum samples obtained 
from infected patients from day 0 up to day 2 after initial positive blood culture. 
No Persistent Fungemia Persistent Fungemia
N Mean (95% CI) N Mean (95% CI) P-value*
IFN-g (pg/ml)
Day 0-1
Day 0-2 
75
112
359 (103-615)
399 (105-694)
11
16
48 (20-77)
43 (19-66)
0.01
0.01
IL-6 (pg/ml)
Day 0-1
Day 0-2 
75
112
1174 (581-1768)
1296 (498-2094)
11
16
554 (137-970)
523 (25-1021)
0.08
0.09
IL-8 (pg/ml)
Day 0-1
Day 0-2
75
112
1007 (421-1594)
1109 (408-1811)
11
16
299 (72-527)
252 (97-408)
0.02
0.01
 
*Mann Whitney U Test 
Discussion
The interest in genetic susceptibility to systemic fungal infections has increased in recent years, 
being stimulated by the discovery of several polymorphisms in immune genes associated with 
invasive fungal infections such as aspergillosis (12;13). However, much less is known in patients with 
systemic Candida infections, and no systematic study has been dedicated to this most prevalent 
systemic fungal infection. To our knowledge, this is the first large prospective study aimed at 
characterizing the role of SNPs in genes of the cytokine network along with other risk factors for 
susceptibility to invasive Candida infections. 
The first observation made in this study is that SNPs in the cytokine genes, chosen based on in 
vitro and clinical studies suggesting a functional role in infection, do not seem to impact the overall 
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susceptibility to systemic Candida infections. This conclusion is supported by analysis of both 
patients with European and African-American ancestry. In addition, no differences in the Candida 
species were identified between patients with different cytokine polymorphisms, compared to 
those carrying wild-type alleles. It appears therefore that exogenous factors well known to impact 
susceptibility to systemic fungal infections (neutropenia, total parenteral nutrition, dialysis, ICU 
stay) may supersede the impact of cytokine polymorphisms. Alternatively, polymorphisms in other 
important classes of innate immunity genes such as TLR4, TLR2 or TLR1, may play a more important 
role in the susceptibility to acquire the infection (14;15).
In contrast to the conditions influencing susceptibility to infection, a different set of factors is likely 
to determine the progression of the disease. In sepsis patients, one of the major factors impacting 
the outcome of the infection is represented by development of immunoparalysis. Immunoparalysis 
is characterized by counterregulatory anti-inflammatory responses, decreased expression of 
MHC-II and lymphocyte apoptosis. A major factor influencing these processes is represented by 
the capacity of the host to mount a Th1/IFN-g response, known to activate antifungal properties 
of neutrophils and macrophages, increase cell survival and MHC-II expression (16). In contrast, 
Th2 type responses represented by the anti-inflammatory cytokines IL-10 and IL-4 counteract the 
action of IFN-g (17). The importance of the Th1/Th2 balance for the outcome of systemic fungal 
infections has been demonstrated in series of elegant experimental models (18;19).
These data in mouse models of candidiasis are now for the first time supported by our findings 
demonstrating that common polymorphisms in IL12B and IL10 have a significant impact on the 
persistence of systemic Candida infections in humans. IL-12 is a cytokine secreted by activated 
phagocytes and dendritic cells that induces IFN-g production by natural-killer and T lymphocytes. 
IL-12 consists of two subunits, p35 and p40, which are encoded by IL12A and IL12B, respectively. 
In previous studies, the presence of this IL12B SNP in the promoter region of the gene has been 
shown to be accompanied by higher production of IL-12 and IFN-g (20). In the present study we 
demonstrate that an insertion/deletion polymorphism in the promoter region of IL12B influences 
the likelihood of the patients to develop persistent infection with Candida. While the effect of the 
IL12B promoter polymorphism on IL-12 expression is complex and secretion of this cytokine in vivo 
may be influenced by several factors including IL-10, previous studies suggested that dendritic cells 
from individuals bearing the IL12B insertion allele produced the highest amounts of IL-12 upon 
stimulation (21). This IL12B allele proved also to protect against persistent candidemia in our study, 
and this is in line with a beneficial effects of enhanced IL-12/Th1 responses in fungal infections.
In contrast, IL-10 counterbalances the effects of pro-inflammatory cytokines, including IFN-g. 
The IL10 SNP at -1082 (G to A) modifies IL-10 secretion and may influence outcome in several 
disease states (22). The IL10 -1082 G/A SNP lies within a putative ETS-consensus binding site 
and is associated (A allele) with lower IL-10 production (23;24). Hence, the IL10 -1082 SNP may 
modify the response to sepsis caused by a variety of microorganisms (25). The G allele in the 
promoter region of IL10 at position -1082 was also associated with a higher rate of persistence 
of the infection, and in other studies individuals bearing the G allele had higher IL-10 production 
(26). In the present study, this same G allele is also associated with a higher probability of 
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Figure 1. IL10 and IL12B polymorphisms and Candida induced cytokine responses. (A) Cytokine producti on 
capacity of IL-10 of PBMCs from healthy individuals with diff erent IL10 rs1800896 genotypes, unsti mulated 
or sti mulated with either 106/ml C. albicans conidia or 106/ml C. albicans hyphae for 48 hours. Data are mean 
± SEM. (B) Cytokine producti on capacity of IFN-g of PBMCs from healthy individuals with diff erent IL12B 
rs41292470 genotypes, unsti mulated or sti mulated with either 106/ml C. albicans conidia or 106/ml C. albicans 
hyphae for 48 hours. Data are mean ± SEM.
developing persistent fungemia, which implies that high IL-10 producti on is predisposing to 
prolonged candidemia.
The results from the in vitro PBMC sti mulati on assays support the associati ons of the IL10 and 
IL12B polymorphisms with persistent fungemia. The IL10 G allele and the IL12B DEL allele, which 
both increase the risk for persistent fungemia, were demonstrated to modulate cytokine responses 
by PBMCs from healthy volunteers when sti mulated with C. albicans conidia or hyphae; the IL10 
G allele is associated with higher producti on of IL-10 by PBMCs when sti mulated with C. albicans 
conidia, whereas the IL12B DEL allele was shown to downmodulate the producti on of IFN-g 
specifi cally upon sti mulati on with C. albicans hyphae. 
Unfortunately, detectable concentrati ons of IL-10 and IL-12 could not be measured in serum 
from our study pati ents, but our results are further supported by our analysis of other circulati ng 
cytokines, which demonstrate very low cytokine responses (IFN-g and IL-8) in pati ents with 
A B
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persistent fungemia. The concentrations of these circulating cytokines could not be shown to be 
directly related to IL12B and IL10 polymorphisms in our cohort, probably owing to the relatively 
small number of subjects in whom cytokines could be measured. 
The important role that proficient Th1 responses play in severe systemic Candida infections is 
indirectly supported by the earlier observation that counterbalancing Th2/IL-10 responses are 
deleterious in patients with invasive aspergillosis (27). Moreover, there is an accumulating body of 
evidence that treatment of patients with either invasive Candida (28) or Aspergillus (29) infections 
with recombinant pro-inflammatory cytokines such as IFN-g, GM-CSF or G-CSF, has beneficial 
effects on the outcome of systemic fungal infections.
Other genes investigated (IL1β, IL8, IL10, IL18, IFNG, IL12RB1) did not reveal significant effects on 
susceptibility to systemic Candida infections or severity of the disease. In line with this lack of 
effect at the genetic level, cytokine production in in vitro PBMC stimulation assays and circulating 
concentrations of IFN-g, IL-6 and IL-8 were not influenced by the presence of these polymorphisms 
(data not shown).
Apart from the association of IL10 and IL12B polymorphisms, this study also revealed the association 
of persistent fungemia with total parenteral nutrition and dialysis dependence, which is consistent 
with previous studies (30). Persistent fungemia is an increasingly recognized complication of 
Candida infections, and has been reported in 8% to 15% of candidemic patients in randomized 
controlled clinical trials. 
In conclusion, in the present study we demonstrate that polymorphisms in genes modulating 
the Th1/Th2 responses (IL12B and IL10) influence the likelihood of systemic Candida infection 
persistence in a large cohort of patients. This study provides the first genetic markers that may be 
used to predict a prolonged course of disease and which needs to be confirmed in future studies. 
Furthermore, the association of low Th1 responses with unfavorable outcome of infection provide 
additional arguments for adjunctive immunotherapy with recombinant IFN-g in systemic Candida 
infections.
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Supplemental information.
Table S1. Genotyped SNPs in genes encoding cytokines and cytokine receptors.
Gene SNP ID Gene region
IL1b rs1143634 synonymous F105F
IL1b rs16944 5’ end non-coding
IL8 rs4073 5’ end non-coding
IL10 rs1800872 promoter
IL10 rs1800896 promoter
IL12B rs41292470 (INS/DEL) promoter
IL12B rs3212227 promoter
IL18 rs187238 5’ end non-coding
IL18 rs549908 synonymous S35S
IFNG rs2430561 intron 1
IL12RB1 rs17882232 5’ end non-coding
IL12RB1 rs17884858 missense Q214R
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Abstract
Background: Candidemia is an important cause of morbidity and mortality in critically ill patients 
or patients undergoing invasive treatments. Dectin-1 is the main β-glucan receptor, and patients 
with a complete deficiency of either dectin-1 or its adaptor molecule CARD9 display persistent 
mucosal infections with C. albicans. The role of genetic variation of DECTIN-1 and CARD9 genes on 
the susceptibility to candidemia is unknown. 
Methods: We assessed whether genetic variation in the genes encoding dectin-1 and CARD9 
influence the susceptibility to candidemia and/or the clinical course of the infection in a large 
cohort of American and Dutch candidemia patients (N=331) and non-infected matched controls 
(N=351). Furthermore, functional studies have been performed to assess the effect of the DECTIN-1 
and CARD9 genetic variants on cytokine production in vitro and in vivo in the infected patients. 
Results: No significant association between the single nucleotide polymorphisms DECTIN-1 Y238X 
and CARD9 S12N and the prevalence of candidemia was found, despite the association of the 
DECTIN-1 238X allele with impaired in vitro and in vivo cytokine production. 
Conclusions: Whereas the dectin-1/CARD9 signaling pathway is non-redundant in mucosal immunity 
to C. albicans, a partial deficiency of β-glucan recognition has a minor impact on susceptibility to 
candidemia.
Introduction
In developed countries candidemia is one of the most prevalent bloodstream infections in 
hospitalized settings and is associated with significant morbidity and mortality. Candidemia is a 
systemic infection with Candida spp., predominantly C. albicans, that occurs mostly in patients that 
are immunocompromised due to neutropenia, the use of broad spectrum antibiotics or invasive 
surgery, or by total parenteral nutrition (1;2). The first line of defense against fungal infections 
is the innate immune system that initiates recognition and initial elimination of pathogens, and 
subsequently induces the activation of adaptive immunity. Pattern recognition receptors (PRRs) are 
expressed by innate immune cells, and they specifically recognize moieties expressed on the surface 
of the microbial pathogens, designated as PAMPs (Pathogen Associated Molecular Patterns) (3). 
The recognition of PAMPs relies on several families of PRRs, such as Toll-like receptors (TLRs), 
C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-I helicases, all acting in concert 
to activate downstream signaling in innate immune cells, thereby inducing production of pro-
inflammatory cytokines and activation of T-cell responses (4). In case of fungal pathogens, it is 
especially TLRs and CLRs that mediate recognition (3). Among the PRRs recognizing C. albicans, 
the archetypal C-type lectin receptor (CLR) dectin-1 detects β-glucans (5-8), which comprise 40% 
of the total cell wall of C. albicans. Upon β-glucan recognition, intracellular signaling is induced 
involving the adaptor proteins spleen tyrosine kinase (Syk), CARD9 (caspase recruitment domain 
family member 9) as well as Bcl-10 and Malt1, ultimately activating the transcription factor NF-
κB (7;9). The dectin-1 receptor is mainly expressed by cells of the myeloid lineage (monocytes/
macrophages, dendritic cells and neutrophils) (7;10).
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Previously, we described a Dutch family with members suffering from onycomycosis and recurrent 
vulvovaginal candidiasis, in which genetic studies have demonstrated that the presence of an early 
stop mutation in the DECTIN-1 gene led to a partial or total deficiency in b–glucan recognition 
(11). This genetic defect resulted in impaired recognition of C. albicans and decreased cytokine 
production by immune cells, especially for cytokines involved in the Th17 pathway (11). The support 
for the hypothesis of an important role of dectin-1 recognition for mucosal anti-Candida defense 
was provided by the description of another family with a defective CARD9 gene. Interestingly, 
family members with CARD9 deficiency exhibited a similar clinical phenotype with predominantly 
recurrent mucocutaneous Candida infections. Non-functional CARD9 was also associated with 
defects in Th17 responses (12). Of note, patients with non-functional dectin-1 appeared not to be 
predisposed to invasive Candida infection, whereas CARD9 deficient patients were severely prone 
to develop invasive Candida infections, especially in the brain (11;12).
These studies implicate the dectin-1/CARD9 pathway as non-redundant in mucosal host defense 
against C. albicans. However, the role of the dectin-1/CARD9 innate pathway for the host defense 
against systemic Candida infections has not been directly investigated, although it would be 
expected to be less important. In the present study, a cohort of patients with candidemia has 
been studied for the potential association of susceptibility to candidemia with genetic variation 
in the DECTIN-1 and CARD9 gene. The early stop codon mutation in the DECTIN-1 gene that 
was previously characterized in the Dutch family as described above is a polymorphism with a 
general allele frequency of 6 to 8% in Caucasian populations and 4% in African populations. This 
polymorphism, which clearly affects dectin-1 function, could therefore be studied as a population-
wide potential determinant in susceptibility to candidemia. In contrast, the mutation in the CARD9 
gene causing CARD9 deficiency is a very rare mutation, which until now was only found in one 
family (12). Alternatively, a common genetic variation in the coding region of the CARD9 gene 
has been detected with a single nucleotide polymorphism (SNP) at amino acid position 12. This 
non-synonymous SNP leads to an amino acid substitution from a serine to an asparagine residue. 
Because of its potential to influence CARD9 function and high minor allele frequency in both 
Caucasian (53%) and African (25%) populations, this SNP was also selected in this genetic study 
(13). Therefore, the aim of this study was to determine whether these DECTIN-1 and CARD9 SNPs 
influence susceptibility to candidemia. 
Patients, materials and methods
Patients
Patients were enrolled after informed consent (or waiver as approved by the Institutional Review 
Board) at the Duke University Hospital (DUMC, Durham, NC, USA) and Radboud University 
Nijmegen Medical Center (RUNMC, Nijmegen, The Netherlands). The study was approved by the 
Institutional Review Boards at each study center, and enrollment occurred between January 2003 
and January 2009. The clinical characteristics of the patients, both infected and non-infected, are 
presented in Table 1.
To be included in the analysis of susceptibility to infection, infected subjects must have had at least 
one positive blood culture for a Candida species while hospitalized at the participating center. Non-
infected controls must have been hospitalized with no history or evidence of candidemia/invasive 
candidiasis, or any invasive fungal infection. Non-infected controls were recruited from the same 
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hospital wards as infected patients so that comorbidities and clinical risk factors for infection would 
be similar between groups. Intergroup comparisons between the two groups of non-infected 
subjects and between the two groups of infected subjects (at DUMC and RUNMC) were performed 
regarding similarity in genetic distribution of the studied SNPs prior to further statistical analysis of 
infected versus non-infected subjects. Subjects were excluded from the study if insufficient volume 
of blood or clinical data were available to allow for analysis. 
Genetic analysis
Genomic DNA was isolated from whole blood using standard procedures. Genotyping for the 
DECTIN-1 Y238X (c.714T>G, rs16910526) and CARD9 S12N (c.35G>A, rs4077515) polymorphisms 
was performed by using the TaqMan single-nucleotide assay C_33748481_10 and C_25956930_20, 
respectively, on the 7300 ABI Real-Time polymerase chain reaction system (all from Applied 
Biosystems, CA, USA). 
Genetic association with clinical outcomes
Due to the lack of detailed clinical data on the Dutch candidemia patients (N=40) and 
controls (N=51) recruited at RUNMC, the correlations of the genetic data with clinical 
outcome was performed with the North-American patients (N=291) and controls 
(N=300) from DUMC only. Infected subjects at DUMC were followed prospectively 
for up to 12 weeks following diagnosis of candidemia to determine clinical outcome: 
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Table 1. Baseline Patient Characteristics for DUMC Infected Cohort (N=291) and Control Cohort 
(N=300), including Caucasian and African-American Adult patients.
Variable Infected cohort, % Control cohort, % 
Mean age (years) 55.9 57.8
Immunocompromised State 59% 38%
HSCT 1% 0%
Solid organ transplant 12% 2%
Chemotherapy within past 3 months 17% 11%
Active Malignancy*  
Solid Tumor
Leukemia
Lymphoma
32%
23%
7%
4%
20%
12%
5%
4%
Neutropenia (ANC <500 cells/mm3) 10% 4%
HIV-infected 2% 0.1%
Surgery within past 30 days 43% 48%
Receipt of Total Parenteral Nutrition 19% 4%
Dialysis dependent 12% 7%
Acute Renal Failure 34% 22%
Liver Failure 25% 4%
Intensive Care Unit Admission within past 14 days 49% 34%
Bacteremia within past 48 hours 24% 2%
Median Baseline Serum Creatinine (mg/dL) 1.3 1.0
Median Baseline WBC count (cells/mm3) 10.55 8.55
Candida spp. **
albicans
glabrata
parapsilosis
tropicalis
krusei
other Candida spp.
42%
29%
16%
13%
4%
3%
-
*subjects could have more than one; **16 subjects had >1 species isolated
(1) disseminated disease, (2) persistent fungemia, and (3) all-cause mortality at 30 days. 
Disseminated infection was defined as the presence of Candida spp. at normally sterile body sites 
outside the bloodstream (excluding the urine). Persistent fungemia was defined as ≥ 5 days of 
persistently positive blood cultures. This analysis was performed in the entire infected cohort, as 
the progression of the disease once occurring is not expected to differ between European and 
African-American patients, and race was considered as covariate in the analysis. Variables with 
P-value <0.2 were further assessed in a multivariable logistic regression model. Variables with 
P<0.05 were retained in the final predictive model. Odds Ratios and 95% Confidence Intervals were 
reported for variables that remained significant in the final multivariable model.
Cytokine stimulation assays
Peripheral Blood Mononuclear Cells (PBMC) were isolated from healthy volunteers by Ficoll-Paque 
gradient. Subsequently, stimulation with heat-killed Candida albicans was performed for 24 hours, 
1251
Dectin-1/CARD9 recognition pathway and candidemia
15
48 hours or 7 days. The stimulation time varied for each cytokine, being 24 hours for TNFα, IL-1β, 
IL-6, IL-8, 48 hours for IFN-g and 7 days for IL-17 production. For the 7 days culture, the medium 
was supplemented with 10% human serum. After the incubation time, the above cytokines 
were measured in the supernatants by ELISA (purchased from R&D systems, CA, USA or Sanquin 
Research, Amsterdam, The Netherlands). 
Serum cytokine measurements 
Cytokine concentrations of IL-6, IL-8 and IFN-g in plasma and serum samples obtained from infected 
patients from day 1 up to day 5 after initial positive blood culture were measured by Multiplex 
Fluorescent Bead Immunoassays (xMAP technology, Bio-Rad, Veenendaal, The Netherlands) and a 
Bio-plex microbead analyzer (Luminex, Austin, TX, USA) according to the manufacturer’s protocol.
Bioinformatic analysis
In order to predict the effect on the conformation of the CARD9 protein given the S12N amino 
acid change we used HOPE (http://www.cmbi.ru.nl/hope/), a web server that performs automatic 
mutant analysis. No homology model was produced because no template with enough identity 
to the CARD9 sequence exists (14). We used as well the Polyphen software in order to determine 
quantitatively the damage for the protein stability taking into account the amino acid change of 
the CARD9 SNP (15).
Statistical analysis
For the analysis of SNPs, statistical comparisons of frequencies were made between infected versus 
non-infected subjects and of clinical parameters within the infected group using the Chi-square 
test with SPSS. Data were analyzed for Caucasian descendents separately from African-Americans, 
since allelic frequencies were expected to differ between these two populations. For the analysis 
of the in vitro PBMC stimulation and in vivo serum cytokine measurements, a Mann-Whitney U 
test was performed on the DECTIN-1 genotype experiment and a Kruskal-Wallis one way ANOVA 
was performed on the CARD9 genotype experiment with the use of GraphPad Prism version 4.00 
(GraphPad Software, San Diego, CA, USA). 
Results
Genetic analysis
Data from adult patients (N=331, 291 North-American and 40 Dutch) and controls (N=351, 300 
North-American, 51 Dutch) were included in the analysis for genetic association with susceptibility 
to infection. Data from children were excluded from this analysis since the number of children 
enrolled (N=27) was insufficient to analyze this association extensively in a pediatric population, 
where factors relating to susceptibility to candidemia may differ from adults.
The intergroup comparison between the Dutch RUNMC and North-American Caucasian DUMC 
non-infected controls and between the infected subjects recruited at DUMC and RUNMC revealed 
a similar genetic distribution of the genotyped SNPs, which allowed the groups to be merged 
into one group of non-infected controls and one group of infected subjects (data not shown). 
In contrast, the African-American patients from the DUMC cohort displayed a different genetic 
pattern, and they were analyzed separately. Genetic distribution of the DECTIN-1 Y238X and 
CARD9 S12N polymorphisms in the studied patient groups is shown in Table 2 and 3, respectively. 
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The genotyping of candidemia patients and non-infected matched controls for polymorphisms in 
DECTIN-1 and CARD9 revealed no significant association with susceptibility to candidemia. After 
statistical analysis of the Dutch and the North-American cohort separately also no significant 
differences were obtained (data not shown). Similarly, no differences were observed when data 
were analyzed separately in non-neutropenic and neutropenic patients (not shown). A post-hoc 
analysis of power for the dectin-1 polymorphism demonstrated that we had 86.7% power to 
detect a 10% difference in frequency in the Caucasian cohort, with 238 infected and 263 non-
infected subjects, with a two-sided alpha=0.05. For African Americans, a post-hoc analysis of power 
for dectin-1 polymorphism demonstrated that we had 76% power to detect a 10% difference in 
frequency, with 93 infected and 88 non-infected subjects, also with a two-sided alpha=0.05.
In order to study the role of these genetic variants in the clinical outcome of 
candidemia, clinical parameters on dissemination, persistence and 30-day mortality 
of infected patients were correlated with the DECTIN-1 and CARD9 genotype. Since 
these data were only available for the North-American cohort, for these analyses 
Table 2. Frequencies of the genotype of the DECTIN-1 early stop polymorphism Y238X and the 
incidence of candidemia in African American and Caucasian patients.
TT (%) TG (%) GG (%) P-value*
African-American Non-Infected (N=88) 95.5 4.5 0
0.515
Infected (N=93) 97.1 2.9 0
Caucasian
Non-Infected (N=263) 83.4 16.6 0
0.624
Infected (N=238) 83.9 15.7 0.4
* Chi-square
Table 3. Frequencies of the genotype of the CARD9 Ser12Asn polymorphism and the incidence of 
candidemia in African American and Caucasian patients.
GG (%) GA (%) AA (%) P-value*
African-American Non-Infected (N=88) 44.2 50.7   5.2      0.305
Infected (N=93) 49.5 40.8   9.7
Caucasian
Non-Infected (N=263) 34.1 48.3   17.6
     0.413
Infected (N=238) 40.3 43.0   16.7
* Chi-square
the Dutch patients were excluded. No significant associations between DECTIN-1 and CARD9 
polymorphisms and clinical parameters were observed in these analyses (Table 4). Minor differences 
in the clinical characteristics of the control and candidemia groups have been observed. Although 
we cannot completely rule out that these differences might have caused the lack of effect of the 
polymorphisms, from the clinical point of view these differences were not as big as to expect major 
effects.
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Functional analysis of cytokine profiles
In order to assess the functional consequences of the SNPs in DECTIN-1 and CARD9, both in vitro 
and in vivo cytokine measurements were performed. The in vitro evaluation was performed 
by measuring cytokine production upon heat-killed Candida stimulation of peripheral blood 
mononuclear cells (PBMCs) with different DECTIN-1 and CARD9 genotypes, obtained from healthy 
volunteers. The results of these in vitro assays are shown in Figure 1. Significant differences in 
cytokine production were observed between cells obtained from individuals with different 
DECTIN-1 genotypes, including decreased production of TNFα (P = 0.003) and IL-1β (P < 0.0001), 
while differences in the production of IL-6, IL-8, IFN-g (Figure 1) and IL-17 (data not shown) were 
not statistically significant. In contrast, no effect of the CARD9 polymorphism on C. albicans induced 
cytokine production was apparent. 
Serum samples collected from infected patients during the first 5 days after initial positive blood 
culture were measured for concentrations of IL-6, IL-8 and IFN-g. The results are shown in Figure 2. 
In general, the IL-6, IL-8 and IFN-g production decreased over time. Correlation with the genotype 
of the patients revealed that patients heterozygous for the DECTIN-1 polymorphism had lower 
cytokine concentrations at the initiation of infection, which remained low throughout the follow-up 
period. No differences in cytokine circulating concentrations were apparent between individuals 
bearing different CARD9 genotypes. 
Table 4. Univariate analysis of the association between the DECTIN-1 and CARD9 polymorphisms 
with disseminated disease, persistent fungemia, and 30-day mortality in the DUMC infected 
cohort (N=291). Numbers are the percentages of patients with each outcome who were found to 
bear the mutant allele of the particular polymorphism.
Genotype DECTIN-1 Y238X CARD9 S12N
No disseminated disease (N=268) 11.6% 56.9%
Disseminated disease (N=63) 15.0% 61.5%
P-value* 0.46 0.54
No persistent fungemia (N=280) 12.1% 56.6%
Persistent fungemia (N=51) 12.8% 64.3%
P-value* 0.90 0.35
Survivors (N=238) 13.4% 56.8%
Non-survivors (N=93) 9.0% 60.0%
P-value* 0.29 0.61
 
* Chi-square
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Figure 1. Functional analysis on the stimulation of the peripheral blood mononuclear cells (PBMCs) with 
heat-killed C. albicans blasto-conidia. Cytokine production capacity of TNFα, IL-1β, IL-6, IL-8 and IFN-g was 
compared between the cells obtained from healthy volunteers bearing wild-type or variant DECTIN-1 or CARD9 
SNPs. Wt: Wild-type, He: Hetero-zygous. Ho: homozygous. Data are presented as means ± SEM, * p < 0.05 
(Mann-Whitney U test or Kruskal-Wallis one way ANOVA).
Discussion
In the present study, we assessed the influence of genetic polymorphisms in the genes encoding 
Dectin-1 and CARD9 for susceptibility to candidemia. Patients heterozygous for the DECTIN-1 
Y238X polymorphism exhibited moderately lower cytokine responses compared to individuals 
bearing wild-type DECTIN-1 genotypes, whereas no effects of the CARD9 SNP on these responses 
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were observed. Despite these differences, the genetic variation in DECTIN-1 and CARD9 was not 
associated with susceptibility to candidemia.
Polymorphisms in several PRRs have been suggested to be associated with a higher risk to fungal 
infections (16-19). Recent studies have unveiled genetic variants of DECTIN-1 and CARD9 that 
predispose to mucocutaneous fungal infections (11;12). Individuals heterozygous for the DECTIN-1 
Y238X allele have also been shown to display increased colonization with Candida when they 
suffer from hematological malignancies, leading to more frequent prescription of prophylactic 
antifungal therapy (20). However, the role of genetic variability in these genes in susceptibility to 
candidemia was not known. Therefore, we have investigated whether SNPs in DECTIN-1 and CARD9 
are associated with susceptibility to systemic Candida infection.
Dectin-1 is the most important receptor of b–glucans, and it plays an important role for induction 
of cytokines in human monocytes and macrophages (21;22). The DECTIN-1 Y238X polymorphism, 
the best characterized of the two SNPs analyzed in this study, clearly affects dectin-1 function (11), 
as confirmed by the in vitro cytokine data provided here. However, our data indicate that if patients 
are heterozygous for this DECTIN-1 polymorphism, neither susceptibility to Candida bloodstream 
infections, nor clinical parameters such as severity and dissemination of the infection or 30-day 
mortality, are affected. This might be due to the specific involvement of dectin-1 recognition pathway 
in mucosal immunity to C. albicans, reflected by the induction of cytokines that are crucial for Th17 
responses, including IL-6 and IL-17. In contrast, for an effective immune response to prevent Candida 
bloodstream infections, pro-inflammatory cytokines such as TNFα, or Th1 responses releasing IL-18 
and IFN-g may play a more important role. Indeed, the production of pro-inflammatory cytokines 
after stimulation of cells in vitro with C. albicans was only moderately decreased in individuals 
heterozygous for the DECTIN-1 Y238X SNP, and these data are supported by cytokine stimulation 
experiments from individuals with complete dectin-1 deficiency (11). Unexpectedly, serum 
cytokine measurements of IFN-g were found to be lower in patients heterozygous for the DECTIN-1 
Y238X polymorphism, although this genetic variant does not seem to confer an additional risk to 
develop or worsen the outcome of candidemia. Presumably, the relatively high residual circulating 
cytokine concentrations in individuals bearing the DECTIN-1 polymorphism was sufficient to afford 
protection against candidemia. It can be therefore concluded that other PRRs and mechanisms of 
antifungal host defense can compensate for the deficit of dectin-1 function, especially at the tissue 
level where Candida invasion takes place.
Several explanations are possible for why no association of the CARD9 S12N SNP with susceptibility 
to candidemia was observed. Since the consequences of the presence of the CARD9 polymorphism 
for its function have not been studied, one possibility is that this polymorphism only minimally 
affects the protein structure. A bio-informatical approach may assess the putative effect on the 
function of the molecule of the amino acid change from serine to asparagine in CARD9. Since in the 
Protein Data Bank there is no three-dimensional model of the CARD9 protein available, as well as 
no modeling template to build a homology model, the analysis was made by comparing the amino 
acid composition of the protein bearing the mutation with the wild-type protein with the Swift 
Yasara twinset via the HOPE server (14) (Venselaar, te Beek et al. Submited). This analysis generated 
evidence that the amino acid change is important, since the mutation is located on position 12 in 
the CARD domain. These domains occur in a wide range of proteins and are thought to mediate the 
formation of larger protein complexes via direct interactions between individual CARDs. Moreover, 
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as serine and asparagine differ in size and hydrophobicity and the mutated residue is buried in 
the core of the protein, this change may also modify CARD9 function. Nevertheless, the Swift 
Figure 2. Cytokine concentrations of IL-6, IL-8 and IFN-g in plasma and serum samples obtained from infected 
patients from day 1 up to day 5 after initial positive blood culture correlated with the DECTIN-1 or CARD9 
genotype. WT: Wild-type, HET: Heterozygous. HOM: homozygous. Data are presented as means ± SEM, * p < 
0.05 (Mann-Whitney U test or Kruskal-Wallis one way ANOVA).
algorithm predicted that the polymorphism S12N is “allowed” (23), the Polyphen algorithm 
predicts the effect of the serine to asparagine amino acid change as “benign” for protein function, 
taking into account that this residue position is not conserved through evolution (15), and this is 
supported by the lack of differences in cytokine production. 
In conclusion, we demonstrate that genetic variations in SNPs of the dectin-1/CARD9 pathway have 
no major impact on the susceptibility to systemic infections with C. albicans. The dectin-1/CARD9 
recognition pathway seems therefore to be of high importance for mucosal antifungal host defense, 
whereas systemic immunity to Candida largely relies on alternative immune recognition pathways. 
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Summary
Infections with Candida spp. have different manifestations in humans, ranging from mucosal to 
bloodstream and deep-seated disseminated infections. Immunocompromised patients have 
increased susceptibility to these types of infections, due to reduced capacity to elicit effective 
innate or adaptive immunity. In addition, rare and common genetic variants in the human genome 
have been identified that influence susceptibility to Candida infections. Genetic determinants of 
primary immunodeficiencies leading to chronic mucocutaneous candidiasis have been reported, 
and polymorphisms in genes that are known to be involved in anti-Candida host defense are 
associated with increased susceptibility to systemic infection. These findings have greatly increased 
understanding of pathways important for anti-Candida defense in humans, and patterns of 
prevalence of Candida infections. In addition, these pathways may offer novel therapeutic targets 
for treatment. This review provides an overview of the current insights in genetic susceptibility to 
Candida infections and their consequences for the immune response against Candida. 
Introduction
Candida is a dimorphic fungal pathogen that colonizes the mucosal surfaces of approximately 
30% of healthy individuals at any given moment (1). In immunocompetent hosts, the colonization 
by Candida does not cause disease, but during a breach of the anatomical barriers or in 
immunocompromised hosts, important clinical consequences may ensue. The spectrum of clinical 
diseases caused by Candida spp. comprises clinical syndromes ranging from mucocutaneous 
infections of the oral and vaginal mucosae, to candidemia and deep-seated infections that are 
often associated with a septic syndrome (2-4). Although C. albicans is still the most prevalent 
species causing infection, the recent years have witnessed a trend towards an increased prevalence 
of non-albicans species such as C. glabrata and C. krusei (5;6). Furthermore, increasing reports of 
resistance to antifungal azoles have occurred, which may be in part promoted by the frequent use 
of antifungal prophylaxis, pre-emptive therapeutic strategies in high-risk patients, or alteration of 
host status (7;8). Clinical observations have taught us that mucocutaneous candidiasis develops 
when either T-cell immunity is defective (as probably best exemplified in HIV infection), whereas 
invasive infections tend to occur when phagocytic function falls short or innate immunity is 
compromised (such as in neutropenia and neutrophil disorders). In recent years the insight in host 
defense against candidiasis has been greatly augmented and this gain in knowledge has started to 
be applied to clinical medicine.
The first step in mounting a protective immune response is the recognition of the fungal pathogens 
by pattern recognition receptors (PRRs), followed by activation of a protective inflammatory 
reaction. In this early response, neutrophil influx and macrophage activation come into play, 
followed by the initiation of adaptive immunity through Th1 or Th17 responses. The host-Candida 
interaction results either in the elimination of the pathogen in the immunocompetent host, or in 
persistence of infection such as observed in chronic mucocutaneous candidiasis (CMC), candidemia 
and/or persistent disseminated candidiasis in immunocompromised individuals. Here, we describe 
the current understanding of the molecular mechanisms involved in the recognition of Candida 
spp. and activation of host defense by cells of the innate immune system, and we present the 
recent insights in the genetic defects of innate and adaptive immunity that can lead to an increased 
susceptibility to Candida infections.
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Pattern recognition and host defense mechanisms against Candida infections
Host defense against pathogenic microorganisms, fungi in particular, relies on rapid (hours to days) 
activation of an acute inflammatory response after the encounter with the fungal pathogen. This is 
followed by an incremental stimulation of specific immune responses mediated by T-lymphocytes 
(cellular immunity) or B-lymphocytes (humoral immunity), including production of T-cell dependent 
cytokines such as IFN-g and IL-17 (9;10). The first step in the initiation of an immune response is 
the recognition of conserved structures of the pathogen named pathogen-associated molecular 
patterns (PAMPs) by PRRs (11;12). This recognition is followed by induction of intracellular signals 
leading to phagocytosis and killing of the fungus, production of proinflammatory cytokines, and the 
induction of specific adaptive immune responses.
Pattern recognition of Candida
The cell wall of Candida albicans consists of an internal skeleton of chitin and b-glucans that confers 
the necessary rigidity; this layer is covered by a heavily mannosylated layer of mannoproteins at 
the surface. Mannans and mannoproteins are recognized by specific PRRs (13-15), as are b-glucans 
and chitin structures (16;17). These PAMPs are recognized by receptors grouped in three major 
families: the Toll-like receptors (TLRs), the C-type lectin receptors (CLRs), and the nucleotide 
binding domain leucine-rich repeat-containing receptors (NLRs). The fourth major family of PRRs, 
the retinoic acid-inducible gene-I (RIG-I) receptors (RLRs), is believed to mediate especially the 
immune responses to viruses (13). 
 The first suggestion of a fundamental role of TLRs in antifungal host defense was made by Lemaitre 
and colleagues, who observed that Drosophila deficient in the Toll receptor succumbed rapidly 
to A. fumigatus infection (18). Subsequently, mammalian orthologs have been identified that 
have a leucine-rich repeats extracellular domain that recognizes PAMPs, and a cytoplasmic Toll/
IL-1 receptor (TIR) domain responsible for transducing intracellular signals (19). Ligand recognition 
by TLRs and subsequent transduction of intracellular signals by several adaptor proteins such as 
myeloid differentiation factor 88 (MyD88)/Mal and the TRIF/TRAM pathway activates a kinase 
cascade, followed by nuclear translocation of transcription factors such as NF-kB, AP-1 and IRF3, 
and production of chemokines and cytokines (13). 
Several TLRs, including TLR2, TLR4 and TLR9, have been reported to mediate recognition of 
components of Candida (20-23). TLR2 on myeloid cells recognizes the phospholipomannan 
component of the Candida cell wall (21), while a limited role for TLR1 and especially TLR6, two 
receptors known for forming heterodimers with TLR2, has been recently reported to play a role 
in C. albicans recognition in a mouse model of invasive candidiasis (24). TLR4 recognizes mannans 
from S. cerevisiae and C. albicans (25), and a subsequent study found that short linear O-bound 
mannans of C. albicans are recognized by TLR4 and induce proinflammatory cytokines such as TNFα 
(26). Both TLR2 and TLR4 influence susceptibility to murine disseminated candidiasis (20;22;27;28). 
Unmethylated CpG sequences of DNA are the natural ligands for TLR9. Indeed, TLR9 is able to 
recognize fungal DNA from C. albicans, and upon recognition induces stimulation of cytokines in 
dendritic cells (29). Bellochio et al. have reported that TLR9 knockout mice produced less IL-12 
and more IL-4 and IL-10, but this had little effect on the overall mortality of the animals (20;30). 
In conclusion, most of the data available at this time suggest a role for TLR9 for the recognition 
265
Human genetic susceptibility to fungal infections
16
of fungal DNA, but the magnitude of this effect for the overall antifungal defense seems to be 
overshadowed by redundant signals induced by other PRRs.    
Although TLRs are clearly involved in the recognition of Candida spp., the potent residual production 
of cytokines in mice with genetic defects in TLRs or MyD88 clearly demonstrates that a second 
major route of pattern recognition must be involved. CLRs are a large family of PRRs including 
the mannose receptor (MR), dectin-1, dectin-2, DC-SIGN, Mincle, and circulating mannose-binding 
lectin (MBL). These receptors share one or more carbohydrate recognition domains that were 
originally found in MBL (31), and are involved in the recognition of polysaccharide structures 
from both microorganisms and endogenous ligands (32). Importantly, over the recent years these 
receptors have been shown to be central for fungal recognition and induction of the innate immune 
response.
The MR described by Stahl and co-workers (33) has been implicated in the recognition of C. 
albicans by both mouse and human monocyte-derived macrophages (15), and recently the 
role of the MR in the recognition of C. albicans has been strengthened by a study showing that 
it recognizes branched N-bound mannans from C. albicans (26). In line with this, a recent study 
has demonstrated an important role of MR for the induction of protective Th17 responses by C. 
albicans (34). MR was found to be recruited to the phagosome relatively late after ingestion of 
C. albicans; there it mediates intracellular signals leading to cytokine production (35). Additional 
CLRs involved in the recognition of C. albicans mannans are dectin-2, detected on myeloid cells 
and maturing inflammatory monocytes recognizing high-mannose structures (36;37), and DC-SIGN 
and Mincle, primarily expressed on mature DCs, which also recognize mannans (38-40). Finally, 
galectin-3 is a receptor mainly expressed by macrophages, and it has been shown to be involved in 
the recognition of the b–mannosides of C. albicans, in close collaboration with TLR2, especially at 
the level of the intestinal mucosa (41;42). 
In contrast to CLRs that recognize mannan structures, dectin-1 is the main receptor on myeloid cells 
for b-1,3-glucans (43;44). Dectin-1 signals through the kinase Syk and the adaptor molecule CARD9, 
and this pathway has been shown to induce IL-2 and IL-10 in DCs. Moreover, it was demonstrated 
that infection with C. albicans induces protective dectin-1/CARD9-dependent Th17 responses that 
have a role in the antifungal host defense (45). Although dectin-1 signaling alone may be sufficient 
to induce responses upon fungal recognition, several studies have emphasized that dectin-1 
induces stronger proinflammatory responses in collaboration with other PRRs. Two independent 
studies have shown that dectin-1 in collaboration with TLR2 triggers proinflammatory responses 
upon stimulation with C. albicans and zymosan (44;46). Recently, dectin-1 has been found to also 
amplify TLR4-dependent pathways in both murine and human myeloid cells (47;48). 
NLRs and inflammasome activation
In addition to the mainly cell-membrane bound TLRs and CLRs, mammalian host defense has 
developed a second line of recognition receptors located in the cytoplasm; for the recognition of C. 
albicans these are the receptors of the NLR family. The inflammasomes are protein platforms that 
upon recognition of a microbial PAMP or an endogenous danger signal (e.g. ATP or uric acid) induce 
activation of the cysteine protease caspase-1, which in turn processes pro-IL-1b and pro-IL-18 into 
the bioactive cytokines (49). IL-1β proved to be important for neutrophil granulocyte recruitment 
and generation of superoxide (50). Both IL-1α and IL-1b deficient mice show increased mortality 
266
Chapter 16
during disseminated candidiasis (50), and NLRP3 and ASC knockout mice have also been reported 
to be more susceptible to both systemic (51;52) and mucosal (53) Candida infections, although 
conflicting data exist regarding NLRP3 (van de Veerdonk, personal communication). These data 
underscore the role of this pathway for host defense against Candida infections. However, the role 
of the inflammasome components ASC and NLRP3 for antifungal defense in humans is unclear 
yet, although genetic variation in NLRP3 has been associated with increased risk for developing 
recurrent vulvovaginal candidiasis (RVVC) (54). 
Primary immunodeficiencies with an increased susceptibility to fungal infections
The in vitro and the experimental studies described above provide evidence that PRRs and the 
mechanisms induced by these receptors are crucial components of the host defense against fungal 
pathogens. The knowledge regarding the specific roles of PRRs for human antifungal defense has 
increased during the last few years by the discovery of a number of defects within the innate 
immune system, and their specific profiles in terms of increased susceptibility to fungal infections. 
Recently, Casanova and colleagues have identified patients with defects in the TLR-adaptor 
molecules IRAK-4 and MyD88 (55;56). Patients with IRAK-4 or MyD88 deficiency, and thus broad 
defects in TLR and IL-1 signaling, have a phenotype characterized by increased susceptibility to pus-
forming Gram-positive bacteria such as Streptococcus pneumoniae and staphylococci, as well as 
Gram-negative bacteria such as Pseudomonas spp (57). Interestingly, these patients do not seem to 
have an increased susceptibility to fungal infections (either invasive or mucocutaneous), suggesting 
that the MyD88/IRAK-4 pathway may be redundant for human antifungal defense.
The role of CLR-dependent pathways for antifungal host defense is supported by the identification 
of a family bearing mutations in CARD9, an adaptor molecule in the intracellular signaling pathway 
of dectin-1 and dectin-2, and possibly other CLRs. This family exhibited increased susceptibility 
to both mucocutaneous and systemic Candida infections (58). The CARD9-deficient patients 
also displayed almost complete absence of Th17 responses. In addition to CARD9 deficiency, an 
early stop codon polymorphism Y238X in dectin-1 (CLEC7A) has been identified in a family with 
several individuals suffering from recurrent mucocutaneous fungal infections, including RVVC (59). 
Myeloid cells of affected patients showed defective β-glucan recognition and impaired cytokine 
responses (IL-6, TNFα and IL-17). Neutrophils of patients exhibited normal phagocytosis and killing 
of opsonized C. albicans. This underlines the redundant nature of dectin-1 for the phagocytosis and 
killing of yeast pathogens by human myeloid cells, explaining the absence of invasive candidiasis in 
these patients. It is likely that the defective cytokine release of myeloid cells in the patients bearing 
the Y238X dectin-1 polymorphism, and especially the diminished IL-17 responses, is responsible 
for the clinical phenotype. However, this genetic variant is not rare: in the Western world the 
prevalence of heterozygous individuals ranges from 10 to 15%, suggesting that it behaves as a 
susceptibility factor, rather than a true immunodeficiency. Indeed, the role of dectin-1 Y238X as 
a susceptibility polymorphism for mucosal anti-Candida defense has been confirmed in a study 
showing that individuals heterozygous for the dectin-1 stop polymorphism and undergoing stem 
cell transplantation are more likely to be colonized with C. albicans and need more often antifungal 
therapy (60). In a subsequent study that assessed the role of common genetic variants of dectin-1 
(Y238X) and CARD9 (the S12N polymorphism, not the rare mutation leading to immunodeficiency) 
in systemic Candida infection, no association was observed with either susceptibility for or clinical 
outcome of the infection, suggesting that the b-glucan recognition pathway is redundant in 
systemic immunity to C. albicans (61). 
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The crucial role of Th17 responses for the host defense against mucosal Candida infections is 
further supported by the discovery of severe IL-17 defects in patients with two major primary 
immunodeficiencies syndromes, i.e., hyper IgE syndrome (HIES) and chronic mucocutaneous 
candidiasis (CMC). Patients with these conditions suffer from chronic mucocutaneous fungal 
infections (62-64). In case of HIES, this is most frequently due to mutations in Signal Transducer and 
Activator of Transcription (STAT) 3, one of the main signaling molecules of the IL-23 receptor. More 
rarely, HIES is caused by mutations in DOCK8 (dedicator of cytokinesis 8) or TYK2 (Tyrosine Kinase 
2), which also predispose to CMC (65;66). Furthermore, one study has proposed a polymorphism 
in TLR3 to be associated with infectious manifestations caused by C. albicans in CMC patients (67). 
However, it is likely that this TLR3 polymorphism represents a susceptibility risk factor rather than a 
genetic cause of CMC, as this polymorphism is a common variant in the healthy population.  
A subgroup of patients with CMC, those with the clinical syndrome named APECED (autoimmune 
polyendocrinopathy, candidiasis, ectodermal dysplasy) which is due to a defect in the AIRE 
gene (autoimmune regulator), has a propensity for autoimmune phenomena. In these patients, 
neutralizing autoantibodies against IL-17 and IL-22 have been found (68). In addition, approximately 
20% of patients with defects in IL12Rb1, a receptor subunit shared by the IL12 receptor and IL-23 
receptor, present with Candida infections (69). 
CMC is a relatively heterogeneous immunodeficiency disorder in which several investigators have 
found strongly decreased IFN-g and IL-17 production. The availability of next-generation sequencing 
techniques has allowed for the identification of mutations in the coiled-coil domain of STAT1 as 
the genetic cause of the disease in families with autosomal dominant CMC (AD-CMC) (70;71). 
The discovery of STAT1 mutations as cause of AD-CMC was remarkable, as STAT1 deficiency had 
been previously reported to be associated with mycobacterial and viral, but not fungal, infections 
(72;73). The presence of the AD-CMC mutations in the coiled-coil domain of STAT1, rather than in 
the Src homology 2 (SH2) or DNA-binding domains of the protein as in patients with mycobacterial/
viral infections, is believed to explain the difference (70;71). Functional studies revealed that these 
mutations lead to a gain-of-function of STAT1, thereby impairing STAT3 and STAT4 signaling which 
leads to defects in downstream signaling of the IL-12 receptor and the IL-23 receptor. This results 
in diminished production of IFN-g, IL-17 and IL-22, crucial cytokines in mucosal antifungal host 
defense ((70;74) and Smeekens et al., PLoS One 2011, in press). Moreover, in a small number of 
patients with CMC, loss-of-function mutations were detected in the genes encoding IL-17F and IL-17 
receptor A, resulting in defective IL-17 signaling (75). An overview of primary immunodeficiencies 
associated with increased susceptibility to Candida infections is listed in Table 1.
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Table 1. Primary immunodeficiencies associated with increased susceptibility to Candida 
infections.
Affected gene Main symptoms Immune defects References
STAT1
CMC, hypothyroidism, esophageal 
cancer
Diminished production of Candida 
induced IFN-g, IL-17 and IL-22
70;71
STAT3
Serum hyper IgE, Staphylococcus 
and Candida infections
Diminished production of Candida 
induced IFN-g, IL-17 and IL-22
105;106
DOCK8
Serum hyper IgE, Staphylococcus 
and Candida infections
Impaired T-cell activation, diminished 
production of Candida induced IFN-g, 
IL-17 and IL-22
65
TYK2
Serum hyper IgE, Staphylococcus 
and Candida infections
Defective cytokine signaling 66
IL-17RA CMC Loss-of-function of IL-17RA 75
IL-17F CMC Loss-of-function of IL-17F 75
CARD9
Mucosal and disseminated Candida 
infections
Diminished production of Candida 
induced IL-17 
58
IL-12Rb1
Mycobacterial and Salmonella 
infections and candidiasis 
Loss-of-function of IL-12 and IL-23 
receptor, diminished production of 
Candida induced IFN-g and IL-17
69
AIRE
CMC, adrenal insufficiency, 
hypoparathyroidism 
Defective thymic negative selection of 
autoreactive T-cells, autoantibodies 
against IL-17 and IL-22
107;108
Common genetic variation and susceptibility to Candida infections
The prevalence of bloodstream infections with Candida spp. has steadily increased in recent years 
due to the increased use of invasive procedures, treatment of malignancies and autoimmune 
diseases with chemotherapy and immunosuppressive drugs, and prolonged ICU stays; the mortality 
due to this disease remains high at between 30% and 40% (76;77). 
Several epidemiological studies have assessed the role of TLR polymorphisms for the susceptibility 
to disseminated candidiasis. The Asp299Gly TLR4 polymorphism has been proposed to act as a 
susceptibility trait for systemic candidiasis (78) and the Asp753Gln TLR2 polymorphism resulted in 
an altered cytokine profile in patients with Candida sepsis (79). However, these findings could not 
be confirmed in a much larger cohort including patients and matched controls (Plantinga et al, J. 
Infect. Dis 2011, in press), suggesting that in the previous studies the cohorts were too small, leading 
to positive associations likely caused by type I errors. Similarly, no role of TLR4 polymorphisms in 
vaginal colonization with Candida spp. has been observed (80). 
Studies dedicated to identify common genetic variants that predispose to bloodstream infections 
have revealed a significant role for non-synonymous polymorphisms in TLR1, of which three were 
associated with increased risk of developing candidemia as compared to matched control patients 
in a hospitalized setting (Plantinga et al., J. Infect Dis 2011, in press). These TLR1 polymorphisms 
result in loss-of-function of the receptor and consequently decreased cytokine responses induced 
through the TLR1/TLR2 heterodimer. Although no important role for TLR1 was observed in a 
mouse model of invasive candidiasis (24), several mechanisms could account for the role of human 
TLR1 in anti-Candida immune responses. The configuration of other TLRs such as TLR2 and TLR6 
either as homodimer or heterodimer could be deregulated, that in turn could affect intracellular 
signaling. Another mechanism through which TLR1 could exert its effect on antifungal host defense 
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is the recent finding that beta-defensin-3 activates immune cells through TLR1/TLR2, with an 
important lytic activity against C. albicans (81;82). This is complemented by the observation that 
polymorphisms in beta-defensin-1 are associated with RVVC (83), emphasizing the important role 
of beta-defensins in antifungal immunity.
In the same invasive candidiasis cohort, persistence of fungemia was shown to be associated with 
promoter polymorphisms in the cytokine genes IL-12B and IL-10 (Johnson et al, Clinical Infectious 
Diseases, in press). These polymorphisms affect cytokine transcription and thereby influence the 
IL-10 and IL-12 production capacity of innate immune cells (84-88). The persistence of infection 
was demonstrated to correlate with decreased IL-12 and increased IL-10 production induced by 
Candida, that likely results in inhibition of the T helper 1 response, known to be crucial for anti-
Candida systemic immunity (89;90). In line with this, a decreased production of T helper 2 cytokines 
such as IL-4 due to genetic variation in the IL4 gene leads to protective effects (91;92). 
Multiple studies have been dedicated to investigate the role of mannose binding lectin (MBL) 
deficiency in infections with Candida spp., since it was demonstrated that MBL could bind and 
thereby opsonize fungi to facilitate complement activation and phagocytosis (92;93). Indeed, 
genetic associations of MBL deficiency with infection risk were observed in cohorts of patients with 
candidemia, abdominal infections and RVVC (91;94-96). 
Another common Candida infection is oropharyngeal candidiasis (OPC), mucosal colonization 
of the mouth and upper digestive tract that is frequently observed in patients that are 
infected with human immunodeficiency virus (HIV). About 50-95% of patients encounter 
this type of candidiasis at least once during their progression to AIDS (97-99). Hence, 
occurrence of OPC is associated with decreased numbers of CD4+ T-cells. However, also human 
genetic variation in innate immunity may contribute to the susceptibility for OPC. A recent 
study addressed the potential role of genetic variants of pattern recognition receptors in 
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Table 2. Common genetic variants associated with increased susceptibility to Candida infections. 
Affected gene Polymorphism Type of infection Immune defects References
Dectin-1 Y238X
Recurrent vulvovaginal 
infections and oral/
gastrointestinal colonization
Lack of b-glucan 
recognition, lower 
production of Candida 
induced TNFα, IL-6 and 
IL-17 
59;60 
I223S Oropharyngeal candidiasis
Reduced zymosan-binding 
capacity and IFN-g 
production
100
TLR1
R80T
N248S
S602I
Candidemia
Impaired production 
of pro-inflammatory 
cytokines induced through 
TLR1-2 heterodimers
Plantinga et al., 
JID, in press
TLR3 L412F CMC Defective TLR3
signaling
67
IL-12B -2724INS/DEL Persistent candidemia Lower production of IFN-g 
induced by Candida
Johnson et al. CID, 
in press
IL-10 -1082A/G Persistent candidemia Higher production of IL-10 
induced by Candida
Johnson et al. CID, 
in press 
MBL2 Codon 54 and 57
Candidemia, abdominal 
Candida infection, recurrent 
vulvovaginal candidiasis
Lower MBL serum levels 91;94-96
IL-4 -589T/C Recurrent vulvovaginal candidiasis
Increased levels of vaginal 
IL-4 and reduced levels of 
nitric oxide and MBL
109
-1098T/G
-589C/T
-33C/T
Chronic disseminated 
candidiasis Unknown 110
NLRP3 Length 
polymorphism
Recurrent vulvovaginal 
candidiasis
Impaired production of 
IL-1b 54
DEFB1 -44C/G C. albicans carriage Unknown 83
Figure 1. Schematic overview of proteins involved in anti-Candida host defense of which genetic variants 
have been identified to increase susceptibility to either mucosal or systemic Candida infection.
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susceptibility to OPC in West-African HIV patients, which revealed a potential role for another 
genetic variant of dectin-1 specific for African populations, I223S (100). 
In Table 2 a complete overview of common genetic variants associated with fungal infection is 
depicted. Figure 1 illustrates the role and location in antifungal defense of proteins encoded by 
susceptibility genes for both rare congenital disorders and for Candida infections with population-
wide occurrence.
Summary and future directions
Genetic association studies, either on rare monogenic disorders or common fungal infections 
among immunocompromised patients, have provided fundamental insights into the mechanisms 
involved in conferring resistance to the fungal pathogen C. albicans. Especially cytokines that 
are crucial in antifungal host defense have been identified, including IFN-g, IL-17 and IL-22 for 
mucosal infections, and IL-12 and IFN-g for systemic infections. These findings have generated the 
rationale for proposing the treatment with adjuvant immunotherapy in the form of recombinant 
cytokines for the treatment of Candida infections. Indeed, experimental studies (101;102) and 
anecdotal case reports (103;104) have provided the proof-of-concept for the use of IFN-g or colony-
stimulating factors for the treatment of systemic fungal infections. Future research should extend 
the studies recently started to deepen the knowledge of the genetic profile that would predispose 
to candidemia: from assessing an increasing number of candidate genes, to genome wide arrays 
when large enough cohorts will be available. In addition, it has been suggested that only 10 to 15% 
of genetic susceptibility to diseases is to be found in the main effects of the individual common 
polymorphisms and the rest is most likely hidden in rare genetic variants and complex interactions 
between genes and the environment. This warrants more detailed assessment of genetic variation 
by deep-sequencing of candidate genes, pathways and in the future (as assays become more cost-
effective) the entire exomes or even genomes of affected patients.
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The immune system plays a fundamental role in human health and disease, with morbidity and 
mortality associated with immune-related diseases increasing constantly during the past decades. 
This is not only the case for infectious diseases, but also for cancer, allergy, autoimmune diseases, 
diabetes and atherosclerosis. Hence, there is a necessity to delineate the disease-associated 
immune pathways, leading to the better understanding of risk factors and disease pathogenesis, 
and to the development of novel and more effective (prophylactic) treatment strategies.
Important advances have been established when a few years ago it became appreciated that genetic 
variability may determine protection or susceptibility to autoimmune diseases as well as infections, 
and may predict the patients’ response to therapy. After the human genome was first sequenced 
by the Human Genome Project (1), the extent of genetic variation between individuals was also 
revealed within the HapMap project (2). The genetic variation comprises approximately 0.1% of the 
total genome, of which a large part is located within immune genes and could potentially affect the 
expression or function of the encoded proteins.    
In this thesis, studies have been performed to assess the immunological mechanisms that are 
involved in immune-related diseases and to identify and characterize genetic variants that 
predispose to disease susceptibility and clinical outcome. 
Modulation of the inflammatory reaction
In Chapter 2, the process of autophagy has been studied in relation to innate immune responses. 
Autophagy, a bulk degradation machinery to recycle cell constituents but also to process microbes 
for antigen presentation (3), was demonstrated to affect cytokine responses in mice, especially 
interleukin (IL)-1β (4). IL-1b is one of the most potent proinflammatory cytokines with a wide 
array of biological effects. Among these effects are the activation of monocytes, macrophages and 
neutrophils, and the induction of adaptive cellular responses are relevant for the scope of this 
thesis. Our results indicate that these modulatory mechanisms of autophagy on IL-1b production 
also exist in human cells, and we demonstrated this in a system of human primary immune cells 
stimulated with microbial ligands. Interestingly, opposite effects of autophagy were observed on the 
production of two different proinflammatory cytokines, IL-1β and TNFα. Whereas IL-1β production 
was elevated by inhibition of autophagy, TNFα responses were decreased in these conditions. These 
effects were shown during stimulation of cells with both TLR2 or TLR4 ligands. In mice, modulation 
of IL-1β production by autophagy was exerted at the level of caspase-1 activation through the 
inflammasome. However, we demonstrate that in human cells the autophagy machinery affects 
the mRNA transcription of both IL-1β and TNFα, while inflammasome activation was not affected. 
These data underscore that inflammasome activation and regulation differs greatly between 
human peripheral blood mononuclear cells and murine macrophages, as inflammasome activation 
is constitutive in human monocytes, but not in mouse macrophages (5). Although a role for p38 
kinase was observed in the TNFα response, further research is needed to dissect the molecular 
pathways that link autophagy with mRNA transcription of these cytokines. These results have 
important implications for human disease, especially Crohn’s disease (CD), in which genetic variants 
of autophagy genes have been implicated. This has been explored in Chapter 3.
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In this chapter we addressed the question what the functional consequences are of a genetic 
variant in an autophagy gene that increases susceptibility to Crohn’s disease: the ATG16L1 
Thr300Ala polymorphism. Two large genome-wide association studies (GWAS) have identified 
this polymorphism as a susceptibility factor for CD (6;7). Subsequently, important effects on the 
autophagy process have been observed concerning antigen presentation in human dendritic cells 
(8). Our aim of the study was to assess whether this polymorphism influences cytokine responses 
of human peripheral blood mononuclear cells upon microbial triggering. These experiments 
revealed that the Thr300Ala polymorphism affects ATG16L1 protein expression and subsequently 
modulates production of IL-1β and IL-6, but not of TNFα, upon activation of innate immune cells 
specifically through the NOD2 receptor. Cytokines induced through TLR2 and TLR4, however, were 
unchanged. Interestingly, as was observed when autophagy was inhibited by 3-methyl adenine, 
the effect of the ATG16L1 polymorphism on IL-1b production could be ascribed to increased mRNA 
transcription of this cytokine, whereas caspase-1 activation was unaffected. This investigation 
demonstrates that the ATG16L1 genotype is associated with increased IL-1β responses induced 
through NOD2; this indicates a direct link with the CD risk-associated ATG16L1 300Ala allele with 
excessive inflammation which is pathognomonic of CD (Figure 1). A striking observation is that 
also NOD2 mutations are linked to CD. The apparent relationship between NOD2 and ATG16L1 is 
corroborated by the recently described ability of NOD2 and ATG16L1 to form a protein complex 
essential for NOD2-induced autophagy (9). Thus, these findings have important implications for 
our understanding of the pathogenesis of Crohn’s disease. And Crohn’s disease patients bearing 
the risk allele might benefit from anti-inflammatory therapy by specifically antagonising these 
cytokines, especially interleukin 1β.
Figure 1. Schematic overview of the proposed model of NOD2-induced autophagy versus RICK/RIP2 dependent 
IL-1β production. The ATG16L1 300Ala allele affecting ATG16L1 availability for complex formation with NOD2 
could shift the balance of NOD2 downstream signalling towards increased RIP2 signalling and elevated IL-1β 
mRNA expression. TLR2- and TLR4-induced signalling and IL-1β production is not affected since TLRs have no 
physical interaction with ATG16L1. NOD, nucleotide-oligomerization domain; RICK, receptor-interacting protein 
(RIP)-like interacting caspase-like apoptosis regulatory protein (CLARP) kinase; RIP2, receptor-interacting 
protein 2; TLR, Toll-like receptor; MDP, muramyl dipeptide; NF-κB, Nuclear Factor κB.
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Chapter 4 provides an overview of the current concepts of the interaction of autophagy pathways 
with innate immunity. In this review, we describe the crucial role of autophagy in eradication of 
intracellular bacteria, in antigen presentation, and activation of adaptive immunity, and in the 
modulation of proinflammatory cytokine release. Furthermore, we emphasize the consequences 
of these processes in relation to variation in human autophagy genes and their contribution to 
disease pathogenesis. 
CD is a frequent form of chronic inflammatory bowel disease, which causes segmental lesions 
in the gastrointestinal tract (10). The commonly held theory regarding pathogenesis is that the 
disease is precipitated by the combination of ubiquitous commensal bacteria and ‘hyperactive’ 
host mucosal immune responses. Certain bacterial strains have been selected for their ability 
to dampen gut inflammation, which is mediated by activation of anti-inflammatory pathways 
(11) or by termination of pro-inflammatory T-cell responses (12). Such bacterial strains are 
designated as probiotics, defined as live bacteria that confer a health benefit to the host. As 
treatment approach to inflammatory bowel disease, a suitable probiotic strain would ideally be 
one with a low immunogenic potential. However, the knowledge to select the most appropriate 
probiotic strain within this context is largely missing. In Chapter 5, we therefore analyzed three 
potentially probiotic strains of the genera Bifidobacterium and Lactobacillus. We compared their 
potential to activate immune responses and aimed to distinguish which immune pathways were 
involved when exposing them to human primary immune cells in vitro. These studies revealed 
that Bifidobacterium breve induced lower levels of the pro-inflammatory cytokine IFN-g than the 
tested Lactobacillus rhamnosus and Lactobacillus casei strains. This difference could be ascribed 
to activation of the TLR2 pathway specifically by B. breve. Both B. breve and Lactobacilli induced 
cytokines in a TLR9 dependent manner. Furthermore, no induction of IL-17 was observed for any 
of the bacterial strains, a cytokine strongly associated with gut inflammation (13). In conclusion, 
B. breve appears a more suitable candidate than Lactobacilli for treatment of inflammatory bowel 
disease, based on its lower inflammatory potential. These findings could contribute to the decision 
making for choosing a probiotic to use in a given application. Future studies are required to confirm 
these differences in vivo. 
However, probiotics are not alone in the gut. The gastrointestinal tract harbors an extensive array 
of different microorganisms, known as the gut microbiome. Hence, to understand the interaction 
between probiotics and potentially pathogenic microorganisms in the gut is as important as 
knowing the immune pathways activated by probiotics themselves. In order to investigate the 
interplay between probiotics and immune activating stimuli, we have performed experiments 
to mimic the gut microenvironment in vitro, as described in Chapter 6. Both simultaneous and 
consecutive stimulation of human primary immune cells with probiotics, pattern-recognition 
receptor ligands and the fungus Candida albicans were performed. This commensal fungus was 
chosen because of its proven correlation with CD etiology and severity (14;15). C. albicans is a 
potent inducer of TNFα and IL-17 responses, and in our experiments preincubation with either 
Bifidobacterium or Lactobacillus spp. dampened the production of these cytokines. Furthermore, in 
simultaneous stimulation experiments, activation of the TLR2 pathway led to decreased TNFα and 
IFN-g responses induced by Lactobacilli, whereas TLR4 signaling resulted in increased IL-1b release. 
Finally, TLR9 ligation negatively influenced the cross-tolerance effects of the tested probiotic strains. 
Our findings indicate that these probiotic strains are able to modulate cytokine responses induced 
by other stimuli; this implies that these probiotics, by counteracting gut inflammation, might be 
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useful for treatment. Future studies in animal models are required to investigate the potential of 
these probiotic strains to skew immune responses in vivo. 
Dectin-1 is a C-type lectin receptor that facilitates the recognition of b-1,3-glucans, which are 
major components of the fungal cell wall. Upon recognition, signaling pathways are activated and 
cytokine responses ensue (16). Dectin-1 function is affected by a genetic variant of the coding 
gene. This polymorphism results in an early stop codon (Tyr238X), causing the loss of the last 10 
amino acids of the protein. Individuals homozygous for the polymorphism have been characterized 
as dectin-1 deficient, leading to increased susceptibility to mucocutaneous fungal infections (17). 
The evident correlation between C. albicans gut colonization and CD prompted us to hypothesize 
that the dectin-1 polymorphism affects susceptibility to or severity of CD, as reported in Chapter 7. 
At first, immunohistochemical staining for the dectin-1 protein was performed on tissue sections 
obtained from CD patients. These stainings revealed an increased expression of dectin-1 in inflamed 
areas of the gut mucosa. This enhanced expression of dectin-1 was mainly present on infiltrating 
macrophages. Subsequently, a cohort of 778 CD patients was compared with 759 ulcerative colitis 
(UC) patients and 772 healthy controls for the frequency of the dectin-1 polymorphism. However, 
these studies did not reveal any statistically significant differences in the prevalence of the dectin-1 
polymorphism between CD patients, UC patients and healthy controls. Furthermore, statistical 
testing for association of the dectin-1 polymorphism with clinical parameters was also unable to 
find significant effects of this genetic variant. Most carriers of the dectin-1 polymorphism were 
identified as heterozygous, only few homozygous individuals were found. From this study we can 
conclude that dectin-1 is present in increased amounts in inflamed gut mucosa, suggesting a role 
for dectin-1 in gut inflammation. However, since partial deficiency in dectin-1 function was not 
related with CD susceptibility and clinical outcome, one might conclude that dectin-1 is redundant 
here. Interestingly, individuals homozygous for the polymorphism were underrepresented in both 
the CD and UC cohorts, although not to a statistically significant degree. Thus, these genetic studies 
need to be extended to settle their exact role in CD. 
A similar approach was used in Chapter 8 to investigate whether the dectin-1 Tyr238X 
polymorphism is associated with susceptibility to and severity of rheumatoid arthritis (RA), another 
important autoimmune disease. There are obvious indications that dectin-1 might play a role in 
arthritis. First of all, dectin-1 signaling evokes Th17-type adaptive immune responses that have 
been demonstrated to mediate autoimmunity (18); moreover, it was demonstrated that b-glucan-
induced autoimmune arthritis in genetically susceptible SKG mice was shown to be prevented by 
blocking the dectin-1 receptor (19). Evaluation of dectin-1 mRNA expression in synovial biopsies 
revealed increased expression in RA specimens, compared to biopsies from osteoarthritis and 
non-rheumatic patients. Accordingly, dectin-1 protein expression in RA synovial tissue biopsies 
was moderate to high, especially on macrophage-like cells. Cytokine production capacity of 
macrophages bearing the dectin-1 Tyr238X polymorphism was demonstrated to be impaired on 
dectin-1 stimulation. However, in our studies the presence of the dectin-1 Tyr238X polymorphism 
appeared not to be associated with RA susceptibility or disease severity. 
Whether homozygosity for the dectin-1 Tyr238X polymorphism may result in a different susceptibility 
to CD, UC or RA remains to be investigated in studies large enough to identify sufficient numbers of 
the rare homozygous individuals.  
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Genetic variation and anti-Candida host response
Candida albicans is a ubiquitous dimorphic fungal microorganism that often colonizes 
asymptomatically the alimentary and reproductive tracts. In immunocompetent hosts, appropriate 
immune responses control the fungus, thereby preventing it from invading the tissue and reaching 
the bloodstream (20). However, in situations of anatomical barrier injury or in immunocompromised 
hosts, infection may ensue. Infections with the Candida spp. have different manifestations in 
humans, ranging from mucosal, to bloodstream, and to deep-seated disseminated infections. 
One well-established risk factor for mucosal and systemic Candida infection is myeloablative 
conditioning followed by hematopoietic stem cell transplantation (HSCT) as treatment for 
hematologic malignancy. Treated patients may develop severe complications, including mucosal 
barrier injury, prolonged neutropenia, and graft-versus-host disease, all of which contribute to 
fungal and other opportunistic infections (21). Conventional risk factors are predictive for incidence 
of invasive fungal disease in general, but the individual risk is more difficult to determine, although 
this is needed for a more targeted use of antifungal prophylaxis and therapy. In Chapter 9 we 
demonstrate the association of the dectin-1 Tyr238X polymorphism with oral and gastrointestinal 
colonization caused by Candida species in a cohort of 142 HSCT patients. Furthermore, patients 
heterozygous for the dectin-1 polymorphism were more frequently treated with fluconazole 
prophylaxis in order to prevent candidemia. The dectin-1 polymorphism was not associated with 
occurrence of candidemia in these patients at risk. However, this effect might have been diluted 
because of the decreased incidence of candidemia due to the antifungal prophylactic treatment. 
At the functional level, we observed important differences in the cytokine production capacity of 
cells with different dectin-1 genotypes. Cells (partially) deficient in dectin-1 exhibited decreased 
production of IL-1b in response to C. albicans and purified fungal components in vitro, whereas no 
differences in IFN-g and IL-18 were observed. Furthermore, in these same cells dectin-1 expression 
on the cell surface was severely reduced. In conclusion, the dectin-1 polymorphism results in a 
decreased ability of immune cells to recognize and respond to Candida spp. and might be used as 
a genetic determinant to predict the risk for developing Candida infections before, during and after 
HSCT.
One of the primary immunodeficiency syndromes associated with persistent Candida infections 
is chronic mucocutaneous candidiasis (CMC). We have conducted a study to identify the genetic 
cause of the autosomal dominant (AD) inherited form of the disease, AD-CMC, as described in 
Chapter 10. In initial studies we unraveled the underlying functional defect in these patients 
by showing that Candida-induced IFN-g and IL-17 production was strongly diminished. Next, 
experiments designed to identify the defective molecular pathways enabled us to determine that 
the IL-12 receptor and IL-23 receptor pathways were functionally compromised in these patients. 
Finally, with next-generation sequencing we analyzed those genes that code for the proteins shared 
by these two cytokine receptor pathways and those involved in the generation of the IL-17 and 
IFN-g responses. Interestingly, all patients from 5 AD-CMC families from The Netherlands and the 
United Kingdom were carriers of a heterozygous mutation in the CC domain of STAT1, whereas 
no mutations were detected in unaffected family relatives and 636 unrelated healthy controls. 
Three families were positive for the Ala267Val mutation (one Dutch and two British families), and 
two families carried the Arg274Trp mutation (one Dutch and one British family). Strikingly, some 
phenotypic differences between patients with different STAT1 mutations were observed. Only 
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patients with the Ala267Val have developed oral/esophageal carcinoma, whereas autoimmune 
phenomena including autoimmune hepatitis and autoimmune hemolytic anemia were restricted 
to patients bearing the Arg274Trp mutation. These observations indicate that, although the two 
STAT1 mutations are only seven amino acids apart, phenotypical differences are apparent between 
AD-CMC patients with different STAT1 mutations, arguing for differences in functionality of the 
STAT1 protein bearing either one or the other mutation. 
In Chapter 11, we report STAT1 mutations in two other AD-CMC families and we have further 
dissected the molecular mechanisms leading to AD-CMC. We have performed biochemical 
studies that revealed hyperphosphorylation of STAT1 and, concomitantly, increased expression of 
interferon-regulated genes when white blood cells from AD-CMC patients were stimulated with 
IFN-g. Transfection studies with plasmids encoding either wild-type or Arg274Trp mutated STAT1 
demonstrated that mutant STAT1 inhibited IL-12 receptor and IL-23 receptor induced genes, but 
increased IFN-g signaling. These data are in agreement with our findings in the AD-CMC patients 
and confirm the genetic association.
Infection by Candida spp. in the mouth and upper digestive tract, designated as oropharyngeal 
candidiasis (OPC), is a very common mucosal infection in individuals that are infected with HIV. 
OPC is an opportunistic infection, almost entirely caused by C. albicans. Between 50%–95% of HIV-
seropositive patients suffer from OPC at least once during progression to AIDS (22). Due to limited 
access to highly active antiretroviral therapy, OPC remains the most frequent HIV-associated oral 
disease in Sub-Saharan Africa. Although a low CD4+ T-cell count is a major risk factor for developing 
OPC, not all patients with low CD4+ T-cell counts display OPC, whereas others with relatively high 
T-cell counts do develop OPC. Therefore, in Chapter 12 we assessed whether genetic variation in 
innate immunity genes is associated with occurrence of OPC in a cohort of 225 Tanzanian HIV-
patients that were either OPC-positive or OPC-negative. We detected no significant differences 
in the frequency of the tested genetic variants. One polymorphism in dectin-1 specific for African 
populations, Ile223Ser, exhibited decreased IFN-g production in whole blood cultures stimulated 
with C. albicans. Furthermore, we provide evidence that this polymorphism, similar to the Tyr238X 
polymorphism, severely impairs dectin-1 function and membrane expression. Nevertheless, this 
dectin-1 loss-of-function appears to be redundant in resistance to OPC.
The burden of candidemia has been steadily increasing during the last several decades. This is due 
to the increased use of invasive procedures, treatment of malignancies and autoimmune diseases 
with chemotherapy and immunosuppressive drugs, and prolonged ICU stays; the mortality due to 
this infection remains very high at between 30% and 40% (23). Despite its increasing incidence and 
severity, candidemia is still a relatively rare disease, and recruitment of large cohorts of patients 
with candidemia has been notoriously difficult. Genetic association studies performed so far 
to identify genetic variants that predispose to candidemia were relatively small and lacked the 
required statistical power to obtain firm positive associations (24;25). We have performed the first 
study of a large cohort of 338 patients that has investigated genetic susceptibility to candidemia. 
An additional strength of our study is that the control group consists of 351 patients recruited from 
the same hospital wards/services as infected patients, with a balanced distribution of medical, 
surgical, and oncological patients in case and control groups. This enabled us to exclude that any 
significant genetic association potentially found between cases and controls could be attributed to 
the underlying disease. Polymorphisms in TLRs have previously been associated with aspergillosis 
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(26;27), and could potentially also influence susceptibility or clinical outcome of candidemia. In the 
first part of our study, as described in Chapter 13, we genotyped polymorphisms in genes encoding 
TLRs and their adaptor proteins MyD88 and Mal/TIRAP in this cohort of candidemia patients and 
non-infected controls. These analyses identified the TLR1 polymorphism Arg80Thr, Ser248Asn 
and Ile602Ser to be associated with increased susceptibility to candidemia in Caucasian patients, 
but not with clinical outcome of the infection. We also demonstrated that these polymorphisms 
lead to diminished TLR1 function, suggesting that TLR1 is involved in anti-Candida immune 
responses. Although TLR1 knockout mice are not more susceptible to experimental candidemia 
(28), TLR1 is implicated in antifungal defense by cooperating with TLR2 that recognizes fungal 
phospholipomannan (29) and by mediating immune signaling of beta-defensin-3 (30). The fact 
that TLR1 polymorphisms are not associated with clinical outcome of the infection implies that 
TLR1 is mainly involved in the early host response, thereby preventing bloodstream infection with 
Candida, rather than determining the outcome of established candidemia. Of note, the earlier 
studies in mouse models of disseminated candidiasis in TLR1 knockout mice have only addressed 
the latter condition, which may provide an additional explanation for the differences observed in 
the role of TLR1 in candidemia between mice and humans.
Adaptive antifungal immunity stimulates host responses to pathogens via protective cellular 
T-helper 1 (Th1) cytokines such as IFN-g, whereas humoral Th2 responses contribute to resolution 
of inflammation and contribute to repair tissue damage. However, when too early or too strongly 
induced, Th2 responses may have maladaptive anti-inflammatory effects by the release of IL-4 and 
IL-10. The interplay between Th1 and Th2 responses to Candida infection is complex, but critical 
for the appropriate response to this pathogen. This delicate balance is regulated by cytokines 
such as IL-1b, IL-12, IFN-g and IL-10. Variation in the genes encoding these cytokines are identified 
that affect mRNA expression and hence cytokine release from innate immune cells. In Chapter 
14, we have performed genetic analysis of the polymorphisms in cytokine (receptor) genes in our 
candidemia cohort and showed the association of polymorphisms in IL10 and IL12B with persistent 
fungemia. Accordingly, the risk alleles of IL10 and IL12B influence the release of these cytokines 
when we stimulate peripheral blood mononuclear cells with C. albicans conidia or hyphae. 
Interestingly, proinflammatory cytokine concentrations in serum obtained from patients with 
persistent fungemia were significantly lower than in serum from patients that rapidly cleared the 
infection. In conclusion, aberrant production of Candida-induced IL-10 and IL-12p40 predisposes 
to persistent fungemia in candidemia patients. This study is the first to provide genetic markers 
that might be useful to predict a prolonged course of disease. Furthermore, the association of 
low Th1 responses with unfavorable outcomes during infection provides additional arguments for 
adjunctive immunotherapy with recombinant IFN-g in systemic Candida infections.
Two studies in mice dedicated to investigate the role of dectin-1 in experimental disseminated 
candidiasis by comparing wild-type with dectin-1 knock-out mice, reported divergent results. 
Whereas one study concluded that dectin-1 is required for resistance to candidemia (31), the 
other found a redundant role for dectin-1 (32). Human dectin-1 deficiency is not associated with 
candidemia in the initial family described (17), whereas loss-of-function mutations in human 
CARD9, the intracellular adaptor protein of dectin-1, is described to cause disseminated candidiasis 
in affected family members (33). To clarify whether dectin-1 and CARD9 are important players in 
human systemic antifungal defense, genetic variants of dectin-1 (Tyr238X) and CARD9 (Ser12Asn) 
were analyzed for their association with candidemia in our cohort of 338 infected patients and 
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351 non-infected matched controls, as described in Chapter 15. No statistically significant 
associations were observed with either susceptibility to candidemia or with clinical parameters 
including disseminated disease, persistent fungemia and 30-day mortality. This lack of association 
is discordant with the in vitro experiments in peripheral blood mononuclear cells and in vivo serum 
cytokine measurements from infected patients bearing different dectin-1 genotypes, that indicate 
a lower production capacity of TNFα and IL-1b in vitro, and IL-6, IL-8 and IFN-g in vivo, by cells of 
individuals heterozygous for the Tyr238X polymorphism in response to Candida albicans conidia. 
The dectin-1/CARD9 recognition pathway seems therefore to be of high importance for mucosal 
antifungal host defense, as shown in Chapter 9 and as previously reported (17), whereas systemic 
immunity to Candida largely relies on alternative immune recognition pathways such as TLR1 and 
on a robust Th1 response.
In Chapter 16 we review the recent advances in our knowledge on the role of genetic variation in 
immune pathways, comprising both rare and common genetic variants, in susceptibility to either 
mucosal or systemic Candida infections. In addition, we describe the innate and adaptive immune 
mechanisms that protect the immunocompetent host from infection. Disease mechanisms and 
the contributions of the identified susceptibility genes to the pathogenesis of the infection are 
summarized. Important understanding has been obtained regarding cytokines that are crucial 
in antifungal host defense. These include IFN-g, IL-17 and IL-22 for mucosal infections, and IL-
12 and IFN-g for systemic infections. These findings provide the rationale for proposing adjuvant 
immunotherapy in the form of recombinant cytokines for the treatment of Candida infections. 
Furthermore, the identified genetic risk factors will allow patients at risk to be identified at an early 
stage, enabling tailor-made prophylactic and curative treatment.
General discussion
The genomics era has revolutionized the medical and scientific world by providing the knowledge 
and the tools to explore the human genetic variation and its role in health and disease. The studies 
presented in this thesis contribute to the increasing body of evidence that genetic variation 
influences susceptibility to rare and common diseases. Furthermore, the advances in the field have 
greatly augmented the understanding of the biological mechanisms involved. These studies can 
potentially represent the foundation on which new therapies can be developed, patients can be 
screened for the presence of genetic risk factors and tailor-made treatments can be applied. The 
challenge for the future is how to implement this knowledge into direct clinical practice. Should the 
patient’s complete genetic map be deciphered and included in the medical records? In addition, 
important ethical issues will start to accompany the increasingly powerful capacity for routine 
genetic screening, and a balance between the potential benefits and pitfalls of genetic testing will 
have to be found. Nevertheless, the implementation of the enormous opportunities that genetic 
screening offers should be promoted and should guide the public debate.    
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Het immuunsysteem speelt een fundamentele rol in ziekte en gezondheid van de mens. Morbiditeit 
en mortaliteit geassocieerd met ziekten die gerelateerd zijn aan het niet naar behoren functioneren 
van het immuunsysteem, nemen onverminderd toe. Dit geldt niet alleen voor infectieziekten, maar 
ook voor kanker, allergie, auto-immuunziekten, diabetes en arteriosclerose. Om die reden is er een 
dringende noodzaak om de immunologische processen die geassocieerd zijn met ziekte bloot te 
leggen, zodat we risicofactoren kunnen identificeren en de pathogenese beter begrijpen. Daarmee 
kunnen uiteindelijk nieuwe en effectievere behandelingsstrategieën worden ontwikkeld.
Belangrijke stappen zijn gezet toen een aantal jaren geleden werd vastgesteld dat genetische 
variatie de gevoeligheid voor auto-immuunziekten, infectieziekten en de effectiviteit van medicijnen 
kan beïnvloeden. Nadat het humane genoom voor de eerste maal in kaart was gebracht door het 
Humane Genoom Project (1), werd ook de mate van genetische variatie tussen individuen duidelijk 
door uitvoering van het HapMap project (2). Deze genetische variatie omvat ongeveer 0.1% van 
het totale genoom, waarvan een groot deel in immuun genen is gelokaliseerd en wat mogelijk de 
expressie dan wel functie van de gecodeerde eiwitten kan beïnvloeden.
Voor dit proefschrift zijn studies uitgevoerd om de immunologische mechanismen te 
onderzoeken die betrokken zijn bij immuungerelateerde ziekten en om de genetische varianten 
die verantwoordelijk zijn voor het ontstaan dan wel het klinische verloop van deze ziekten te 
identificeren en karakteriseren.
Modulatie van de inflammatoire respons
In Hoofdstuk 2 is het proces van autofagie bestudeerd in relatie tot immuunresponsen van het 
aangeboren immuunsysteem. Autofagie is een cellulaire machinerie die de cel gebruikt voor 
enerzijds de degradatie en daarmee het hergebruik van intracellulaire bestanddelen en anderzijds 
voor het afbreken van microbiële bestanddelen zodat dit kan worden ingezet voor antigen 
presentatie (3). In de muis is aangetoond dat autofagie de productie van cytokines, met name 
interleukine (IL)-1β, beïnvloedt (4). IL-1β is één van de meest potente pro-inflammatoire cytokines 
met een breed scala aan biologische effecten. Voor de inhoud van dit proefschrift zijn de activatie 
van monocyten, macrofagen en neutrofielen, en de inductie van adaptieve cellulaire responsen 
de belangrijkste. Onze onderzoeksresultaten tonen aan dat deze modulatoire mechanismen van 
autofagie op IL-1β productie ook aanwezig zijn in humane cellen, wat we hebben onderzocht 
aan de hand van een model van humane primaire immuuncellen gestimuleerd met microbiële 
liganden. Opvallend was dat in dit model autofagie tegengestelde effecten had op de productie van 
twee verschillende pro-inflammatoire cytokines; IL-1β en TNFα. IL-1β productie werd verhoogd 
door remming van autofagie, terwijl TNFα productie juist werd verlaagd in dezelfde condities. Deze 
effecten waren zichtbaar na stimulatie met zowel TLR2 als TLR4 liganden. In de muis is aangetoond 
dat de modulatie van IL-1β productie door autofagie kan worden toegeschreven aan de mate van 
caspase-1 activatie door het zogenaamde inflammasoom. Echter, wij hebben aangetoond dat in 
humane cellen het effect van autofagie op de productie van beide cytokines tot stand komt door 
een afname dan wel toename van de mRNA transcriptie. Activatie van het inflammasoom was in 
deze context niet verschillend en kan daarom niet verantwoordelijk zijn voor deze effecten. Dit 
onderzoek toont eens te meer aan dat er grote verschillen zijn in de activatie en regulatie van het 
inflammasoom tussen monocyten van de mens en macrofagen van de muis; constitutieve activatie 
van het inflammasoom in humane monocyten tegenover geïnduceerde activatie in macrofagen 
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van de muis (5). Alhoewel een rol voor het p38 kinase kon worden aangetoond voor de TNFα 
respons, is verder onderzoek vereist om de moleculaire mechanismen uit te diepen die autofagie 
en cytokineproductie verbinden. Deze resultaten genereren vergaande inzichten in met name de 
ziekte van Crohn, waarvan bekend is dat genetische varianten van autofagie genen een belangrijke 
rol spelen in de pathogenese. Dit is verder onderzocht in Hoofdstuk 3. 
In dit hoofdstuk hebben we de vraag gesteld wat de functionele consequenties zijn van een genetische 
variant in het autofagie gen dat leidt tot een verhoogde gevoeligheid voor de ziekte van Crohn: het 
ATG16L1 Thr300Ala polymorfisme. Twee grootschalige genetische associatie studies hebben dit 
polymorfisme aangewezen als een susceptibiliteitfactor voor de ziekte van Crohn (6;7). Vervolgens 
zijn duidelijke effecten van deze genetische variant ontdekt voor het vermogen van dendritische 
cellen om antigenen te presenteren (8). Het doel van onze studie was om te onderzoeken of dit zelfde 
polymorfisme de cytokinerespons van humane perifere mononucleaire bloedcellen beïnvloedt als 
deze cellen worden blootgesteld aan microbiële stimuli. Deze experimenten hebben blootgelegd 
dat het Thr300Ala polymorfisme de expressie van het eiwit ATG16L1 beïnvloedt en daardoor de 
monocyte afhankelijke productie van IL-1β en IL-6, maar niet TNFα, verhoogt. Voorwaarde voor 
dit effect was wel dat de cellen geactiveerd waren door middel van het doelgericht activeren van 
de NOD2 receptor. Cytokineproductie geïnduceerd via TLR2 en TLR4 was onveranderd, ongeacht 
het ATG16L1 genotype. In overeenstemming met de effecten van de autofagie remmer 3-methyl 
adenine, werd het verschil in IL-1β productie veroorzaakt door een toegenomen mRNA transcriptie 
van het IL-1β gen, terwijl opnieuw de activatie van caspase-1 door het inflammasoom onveranderd 
was. Deze bevindingen geven aan dat het ATG16L1 genotype geassocieerd is met een toegenomen 
productie van IL-1β dat geïnduceerd wordt door NOD2. Dit suggereert dat er een directe associatie 
bestaat tussen het ATG16L1 300Ala allel, dat de gevoeligheid voor de ziekte van Crohn verhoogt, 
en de buitensporige inflammatie waardoor de ziekte van Crohn wordt gekenmerkt (Figuur 1). Een 
opvallende observatie is dat ook mutaties in NOD2 geassocieerd zijn met de ziekte van Crohn. 
De biologische relatie die er klaarblijkelijk is tussen NOD2 en ATG16L1 wordt ondersteund door 
de recent beschreven complexvorming tussen NOD2 en ATG16L1 dat essentieel is voor autofagie 
geïnduceerd door NOD2 (9). Kortom, deze bevindingen hebben een belangrijke betekenis voor het 
begrijpen van de pathogenese van de ziekte van Crohn. Bovendien zouden vooral Crohn patiënten 
die drager zijn van het risico allel baat hebben bij anti-inflammatoire therapie door het specifiek 
remmen van deze cytokines, met name IL-1β. 
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Figuur 1. Schematisch overzicht van het model van NOD2 geïnduceerde autofagie versus RICK/RIP2 
afhankelijke IL-1β productie. Het ATG16L1 300Ala allel, dat de beschikbaarheid van het ATG16L1 eiwit voor 
complexvorming met NOD2 beïnvloedt, verschuift de balans naar signalering van NOD2 naar een toename 
van RICK/RIP2 activatie en verhoogde IL-1β mRNA expressie. TLR2 en TLR4 geïnduceerde signalering en IL-1β 
productie is onveranderd, omdat TLRs geen fysieke interactie aan kunnen gaan met ATG16L1. NOD, nucleotide-
oligomerization domain; RICK, receptor-interacting protein (RIP)-like interacting caspase-like apoptosis 
regulatory protein (CLARP) kinase; RIP2, receptor-interacting protein 2; TLR, Toll-like receptor; MDP, muramyl 
dipeptide; NF-κB, Nuclear Factor κB. 
Hoofdstuk 4 geeft een overzicht van de huidige kennis over de interactie van autofagie met 
aangeboren immuniteit. In deze samenvatting beschrijven we de cruciale rol van autofagie voor het 
elimineren van intracellulaire bacteriën, voor antigen presentatie en activatie van de verworven 
immuniteit en voor de modulatie van de secretie van pro-inflammatoire cytokines. Bovendien 
wordt de nadruk gelegd op de consequenties voor deze processen in relatie tot variatie in humane 
autofagie genen en hun bijdrage aan de pathogenese van ziekte.
De ziekte van Crohn is een frequente vorm van chronische ontsteking in de darm die lokale laesies 
veroorzaakt in het maag-darmkanaal (10). De huidige theorie over de ontstaanswijze van de ziekte is 
een combinatie van een overvloed aan commensale bacteriën en een hyperactieve immuunrespons 
in de mucosa van de patiënt. Bepaalde bacteriestammen zijn geselecteerd vanwege hun capaciteit 
om ontsteking in de darm tegen te gaan. Deze capaciteit wordt mogelijk gemaakt door de activatie 
van anti-inflammatoire mechanismen (11) of door het beëindigen van pro-inflammatoire T-cel 
responsen (12). Deze bacteriestammen worden omschreven als probiotisch, wat gedefinieerd 
is als levende bacteriën die een gezondheidsvoordeel voor de gastheer bewerkstelligen. Als 
behandelingsmogelijkheid voor patiënten met chronische ontsteking in het maag-darmkanaal zou 
een dergelijke probiotische bacterie idealiter één zijn die weinig immunogeen is. Echter, de kennis 
op basis waarvan een geschikte probiotische bacterie gekozen zou moeten worden, ontbreekt 
grotendeels. In Hoofdstuk 5 hebben we daarom drie potentieel probiotische bacteriestammen 
onderzocht van de genera Bifidobacterium en Lactobacillus. We hebben de mate en de mechanismen 
van activatie van het immuunsysteem door deze drie bacteriestammen vergeleken door middel 
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van het in vitro blootstellen van humane primaire immuuncellen aan deze stammen. Het resultaat 
was dat de Bifidobacterium breve stam minder productie van het pro-inflammatoire cytokine IFN-g 
induceert dan de geteste Lactobacillus rhamnosus en Lactobacillus casei stammen. Dit verschil kon 
worden toegeschreven aan de specifieke activatie van TLR2 door B. breve. Zowel B. breve alsook 
de Lactobacilli stammen induceerden cytokine productie via TLR9. Bovendien werd productie 
van IL-17 niet geïnduceerd door de bacteriestammen, een cytokine dat sterk geassocieerd is met 
chronische ontsteking in het maag-darmkanaal (13). In conclusie, gebaseerd op de lage immuun 
activatie, blijkt B. breve, ten opzichte van de Lactobacilli, de meest geschikte kandidaat om toe 
te passen als behandelingsmethode van chronische darmontsteking. Deze bevindingen kunnen 
bijdragen aan de uiteindelijke beslissing welke probiotische bacteriën toegepast dienen te worden 
in een bepaalde context. In de toekomst zullen vervolgstudies moeten worden uitgevoerd om de 
resultaten te bevestigen in vivo. 
Een belangrijk gegeven is dat probiotische bacteriën niet de enige bewoners zijn van het maag-
darmkanaal, maar dat er een immense verscheidenheid van micro-organismen, bekend als het 
microbioom, in de darm aanwezig is. Om die reden is het vereist om niet alleen te onderzoeken 
welke immuun mechanismen worden geactiveerd door probiotische stammen, maar ook wat 
de gevolgen zijn van de interactie tussen probiotische stammen en potentieel pathogene micro-
organismen in de darm. Om de interactie tussen probiotische stammen en pro-inflammatoire 
stimuli te onderzoeken, hebben we experimenten uitgevoerd die het micromilieu in de darm 
nabootsen, zoals beschreven in Hoofdstuk 6. Zowel gelijktijdige alsook successievelijke stimulaties 
van humane primaire immuuncellen met probiotische stammen, liganden van patroonherkennende 
receptoren en de pathogene fungus Candida albicans zijn uitgevoerd. Candida albicans is 
gekozen, omdat aangetoond is dat de aanwezigheid van deze fungus in de darm gecorreleerd is 
met de ontstaanswijze en met een verergerd verloop van de ziekte van Crohn (14;15). Stimulatie 
van immuuncellen met C. albicans resulteert in een hoge productie van TNFα en IL-17. In onze 
experimenten leidde pre-incubatie met Bifidobacterium of Lactobacillus spp. ertoe dat de 
productie van deze cytokines verlaagd was. Bovendien veroorzaakte een gelijktijdige stimulatie 
van TLR2 tot een afname van TNFα en IFN-g productie door Lactobacilli, terwijl activatie van TLR4 
resulteerde in een toename van IL-1β productie. Daarnaast deed activatie van TLR9 de effecten 
van de probiotische stammen op de kruistolerantie teniet. Deze resultaten geven aan dat deze 
probiotische stammen de capaciteit bezitten om de cytokineresponsen geïnduceerd door andere 
stimuli te moduleren. Daarom worden deze bacteriën als effectief geacht als behandelingsstrategie. 
Verdere in vivo studies zijn vereist om te toetsen of probiotische stammen ook in die context in 
staat zijn om pro-inflammatoire immuunresponsen te dempen.   
Dectin-1 is een C-type lectine receptor die de herkenning van β-1,3-glucanen, een belangrijk 
bestanddeel van de celwand van fungi, mogelijk maakt. Op het moment van herkenning wordt 
een signaleringscascade in gang gezet waarna cytokineproductie volgt (16). De functie van 
het dectin-1 eiwit wordt beïnvloed door een genetische variant van het coderende gen. Dit 
polymorfisme resulteert in een vroege stop tijdens de translatie van het eiwit (Tyr238X), waardoor 
de laatste 10 aminozuren missen. Individuen die homozygoot drager zijn van het polymorfisme 
worden gekarakteriseerd als dectin-1 deficiënt, dat leidt tot een verhoogde susceptibiliteit voor 
mucocutane schimmelinfecties (17). De evidente correlatie tussen enerzijds de kolonisatie van 
de darm door C. albicans en anderzijds de ziekte van Crohn, resulteerde in de hypothese dat 
het dectin-1 polymorfisme de gevoeligheid voor of het ziekteverloop van de ziekte van Crohn 
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beïnvloedt, zoals gerapporteerd in Hoofdstuk 7. Allereerst hebben we immunohistochemische 
kleuringen voor het dectin-1 eiwit uitgevoerd in darmweefsel van Crohn patiënten. Met deze 
kleuringen hebben we aangetoond dat dectin-1 verhoogd tot expressie komt in ontstoken gebieden, 
met name op geïnfiltreerde macrofagen, van het darmweefsel. Vervolgens is een cohort van 778 
Crohn patiënten vergeleken met een groep van 759 ulceratieve colitis patiënten en met een groep 
van 772 gezonde controles aan de hand van de frequentie van het dectin-1 polymorfisme in deze 
afzonderlijke groepen. Echter, geen statistisch significante verschillen in de prevalentie van het 
dectin-1 polymorfisme konden worden aangetoond tussen de drie groepen. Ook geen significante 
verschillen werden aangetoond tussen het dectin-1 polymorfisme en klinische parameters van 
Crohn dan wel ulceratieve colitis patiënten. De meeste individuen die drager waren van het 
dectin-1 polymorfisme waren heterozygoot en alleen enkele waren homozygoot drager. Conclusie 
van deze studie is dat de sterke aanwezigheid van dectin-1 in ontstoken darmweefsel van Crohn 
patiënten suggereert dat dectin-1 een rol speelt in chronische darmontsteking. Partiële deficiëntie 
van dectin-1 functie leidt echter niet tot een toegenomen risico voor het ontwikkelen van de 
ziekte van Crohn. Er was wel een duidelijke trend zichtbaar van minder homozygote individuen in 
zowel de groep van Crohn als van ulceratieve colitis patiënten ten opzichte van de groep gezonde 
controles, wat zeker vervolgonderzoek rechtvaardigt.
Een vergelijkbare benadering is gebruikt in Hoofdstuk 8 om te onderzoeken of het dectin-1 
Tyr238X polymorfisme geassocieerd is met gevoeligheid dan wel klinisch verloop van reumatoïde 
artritis (RA), een andere auto-immuunziekte met hoge prevalentie. Er zijn duidelijke indicaties dat 
dectin-1 een rol zou kunnen spelen in artritis. Ten eerste is dectin-1 betrokken bij het induceren van 
Th17 adaptieve immuunresponsen waarvan is aangetoond dat deze auto-immuniteit in de hand 
werken (18); ten tweede is bewijs geleverd dat experimentele artritis geïnduceerd door β-glucan 
in genetisch gevoelige SKG muizen kan worden voorkomen door het blokkeren van de dectin-1 
receptor (19). Metingen van dectin-1 mRNA expressie in synoviale biopten toonde een hogere 
expressie aan in biopten van RA patiënten ten opzichte van vergelijkbare weefsels van osteoartrose 
en niet-reumatische patiënten. In overeenstemming met deze resultaten was ook eiwitexpressie 
verhoogd, met name op cellen met een morfologie van macrofagen. De capaciteit van macrofagen 
die drager zijn van het dectin-1 Tyr238X polymorfisme om cytokines te produceren via de dectin-1 
receptor was verminderd. Echter, op basis van een genetische associatie studie kon worden 
geconcludeerd dat het dectin-1 Tyr238X polymorfisme niet geassocieerd was met de gevoeligheid 
voor het ontwikkelen dan wel een verergerd klinisch beeld van RA. 
Of homozygoot dragerschap voor het dectin-1 Tyr238X polymorfisme zou kunnen resulteren 
in een veranderde gevoeligheid voor Crohn, ulceratieve colitis of RA dient verder te worden 
onderzocht door middel van studies met grote groepen patiënten om voldoende aantallen van 
deze homozygote individuen te identificeren.
Genetische variatie en anti-Candida respons van de gastheer 
Candida albicans is een alom vertegenwoordigt dimorfe schimmel die veelal asymptomatisch het 
verterings- en reproductiestelsel koloniseert. In immuuncompetente gastheren worden effectieve 
immuunresponsen in gang gezet die de fungus in bedwang houdt, zodat wordt voorkomen dat het 
de weefsels kan infiltreren en de bloedbaan kan bereiken (20). Echter, in situaties van beschadigde 
weefselbarrières of in individuen met een verminderde weerstand, kunnen infecties zich 
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ontwikkelen. Infecties met Candida spp. hebben verschillende verschijningsvormen in de mens, wat 
varieert van mucosale tot systemische en gedissemineerde infecties. Een welbekende risicofactor 
voor mucosale en systemische Candida infecties is myeloablatieve conditionering gevolgd door 
hematopoietische stamceltransplantatie (HSCT) als behandeling voor hematologische maligniteiten. 
Behandelde patiënten kunnen ernstige complicaties ontwikkelen, waaronder schade aan mucosale 
barrières, voortdurende neutropenie en GvHD, die allen kunnen bijdragen aan het ontstaan van 
opportunistische infecties door onder andere schimmels (21). Traditionele risicofactoren zijn in het 
algemeen voorspellend voor de incidentie van invasieve schimmelinfecties. Het individuele risico 
is echter moeilijker te duiden, alhoewel dit vereist is voor een doelmatig gebruik van antischimmel 
profylaxe en therapie. In Hoofdstuk 9 hebben we aangetoond dat er een associatie bestaat 
tussen de aanwezigheid van het dectin-1 Tyr238X polymorfisme met orale en gastro-intestinale 
kolonisatie door Candida spp. in een cohort van 142 HSCT patiënten. Bovendien waren patiënten 
heterozygoot voor het dectin-1 polymorfisme frequenter behandeld met fluconazol profylaxe om 
daarmee candidemie te voorkomen. Het dectin-1 polymorfisme was niet gecorreleerd met het 
ontwikkelen van candidemie in deze patiënten met hoog risico. Echter, dit effect, indien aanwezig, 
zou afgezwakt kunnen zijn doordat de incidentie van candidemie verlaagd is door het toedienen 
van antischimmel profylaxe. Op functioneel niveau hebben we belangrijke verschillen ontdekt in 
de capaciteit van cellen met verschillende dectin-1 genotypes om cytokines te produceren. Cellen 
met een (partiële) deficiëntie voor dectin-1 functie waren niet of minder goed in staat om in vitro 
IL-1β te produceren als reactie op stimulatie met C. albicans of daarvan afgeleide gepurificeerde 
bestanddelen. Echter, geen verschillen waren zichtbaar in productiecapaciteit van IFN-g en IL-18. 
Op het membraan van deze immuuncellen was eveneens de expressie van dectin-1 sterk verlaagd. 
Concluderend resulteert het dectin-1 polymorfisme in een afgenomen capaciteit van immuuncellen 
om Candida spp. te herkennen en erop te reageren. Daarom kan het dectin-1 polymorfisme worden 
gebruikt als genetische determinant voor het voorspellen van het risico op Candida infecties zowel 
voor, tijdens alsook na HSCT.
Eén van de primaire immunodeficiënties die geassocieerd is met persistente Candida infecties 
is chronische mucocutane candidiasis (CMC). We hebben een studie uitgevoerd die erop gericht 
was om de genetische oorzaak van de autosomaal dominant (AD) overervende vorm, AD-CMC, 
te identificeren, zoals beschreven in Hoofdstuk 10. Initiële studies hebben het onderliggende 
functionele defect in deze patiënten blootgelegd, waaruit bleek dat Candida geïnduceerde IFN-g 
en IL-17 productie sterk was verlaagd. Vervolgens hebben we experimenten ontworpen die ons 
ertoe in staat stelden om aan te tonen dat de functionaliteit van de signalering via de IL-12 receptor 
en IL-23 receptor was aangedaan. Uiteindelijk is met een geheel nieuwe methode de DNA code 
ontcijferd van in totaal 100 genen die coderen voor eiwitten die betrokken zijn bij de signalering 
van beide receptoren of bij het genereren van de IFN-g en IL-17 responsen. Alle patiënten van 5 
AD-CMC families uit Nederland en het Verenigd Koninkrijk bleken heterozygote dragers te zijn van 
mutaties in het CC-domein van STAT1, terwijl geen mutaties gevonden zijn in gezonde familieleden 
en 636 ongerelateerde gezonde controles. Drie families hadden de Ala267Val mutatie (één 
Nederlandse en twee Britse families), de twee andere de Arg274Trp mutatie (één Nederlandse 
en één Britse familie). Opvallend was dat er duidelijke fenotypische verschillen waren tussen 
patiënten met verschillende STAT1 mutaties. Alleen de patiënten met de Ala267Val mutatie hebben 
oraal/oesofageaal carcinoom ontwikkeld, terwijl symptomen van auto-immuniteit zoals auto-
immuun hepatitis en auto-immuun hemolytische anemie voorbehouden waren aan patiënten met 
de Arg274Trp mutatie. Deze observaties duiden erop dat, alhoewel de twee STAT1 mutaties slechts 
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zeven aminozuren van elkaar verwijderd zijn, er fenotypische verschillen zijn tussen patiënten met 
verschillende STAT1 mutaties, die pleiten voor een verschil in functionaliteit van het STAT1 eiwit 
afhankelijk van de aanwezigheid van één van de twee mutaties.
In Hoofdstuk 11 beschrijven we de identificatie van STAT1 mutaties in nog twee AD-CMC families 
en hebben we de moleculaire mechanismen uitgediept die verantwoordelijk zijn voor het ontstaan 
van AD-CMC. We hebben biochemische studies uitgevoerd waarmee we hyperfosforylatie van 
STAT1 hebben ontdekt en, als gevolg daarvan, een toename van de expressie van interferon 
gereguleerde genen als witte bloedcellen van AD-CMC patiënten worden gestimuleerd met 
IFN-g. Transfectiestudies met plasmiden die wildtype dan wel Arg274Trp gemuteerd STAT1 
coderen hebben aangetoond dat mutant STAT1 de expressie van IL-12 receptor en IL-23 receptor 
geïnduceerde genen remt, maar de interferon gereguleerde genen juist extra stimuleert. Deze 
gegevens zijn overeenkomstig met onze bevindingen in de AD-CMC patiënten en bevestigen de 
genetische associatie.
Infecties veroorzaakt door Candida spp. in de mond en het bovenste gedeelte van het maag-
darmstelsel, orofaryngeale candidiasis (OFC) genaamd, is een veelvoorkomende mucosale infectie 
in individuen die geïnfecteerd zijn met HIV. OFC is een opportunistische infectie die vrijwel 
uitsluitend wordt veroorzaakt door C. albicans. Van de HIV seropositieve patiënten leidt tussen 
de 50%–95% aan OFC tenminste eens tijdens de progressie naar AIDS (22). Vanwege gelimiteerde 
toegang tot medicatie die de ontwikkeling van AIDS tegengaat, blijft OFC de meest frequente 
HIV geassocieerde orale ziekte in de Sub-Sahara van Afrika. Alhoewel een laag CD4+ T-cel aantal 
een belangrijke risicofactor is voor het ontwikkelen van OFC, hebben niet alle patiënten met een 
laag CD4+ T-cel aantal eveneens OFC. Andersom hebben anderen wel OFC, ondanks een relatief 
hoog CD4+ T-cel aantal. Om die reden hebben we in Hoofdstuk 12 onderzocht of genetische 
variatie in genen van het aangeboren immuunsysteem geassocieerd is met het vóórkomen 
van OFC in een cohort van 225 Tanzaniaanse HIV patiënten die al dan niet leden aan OFC. We 
hebben geen significantie verschillen kunnen aantonen in de frequentie van de onderzochte 
genetische varianten tussen de twee groepen. Een polymorfisme in dectin-1, die alleen voorkomt 
in Afrikaanse populaties, Ile223Ser, leidde tot een afname van de IFN-g productie in bloedkweken 
gestimuleerd met C. albicans. Bovendien hebben we kunnen bewijzen dat dit polymorfisme, gelijk 
aan het Tyr238X polymorfisme, de membraanexpressie en de functie van het dectin-1 eiwit nadelig 
beïnvloedt. Desondanks bleek dat dit verlies van dectin-1 functie geen beslissende rol speelt in 
resistentie tegen OFC.
Tijdens de afgelopen tientallen jaren is de prevalentie van candidemie jaarlijks gestegen door 
de toegenomen toepassing van invasieve chirurgie, behandeling van maligniteiten en auto-
immuunziekten met chemotherapie en immunosuppressiva en langer verblijf op de intensive 
care; de mortaliteit geassocieerd met deze systemische infectie blijft hoog met 30 tot 40% (23). 
Ondanks de toename van de incidentie en een ernstiger wordend ziekteverloop is candidemie 
nog altijd een zeldzame ziekte, waardoor het opbouwen van grote cohorten van candidemie 
patiënten erg moeilijk is. Genetische associatiestudies die tot op heden zijn uitgevoerd om 
genetische varianten te identificeren die predisponeren voor candidemie waren relatief klein van 
omvang en ontbeerden om die reden het onderscheidend vermogen om positieve associaties te 
verkrijgen (24;25). Wij hebben als eerste een studie volbracht die in een groot cohort van 338 
patiënten de genetische gevoeligheid heeft onderzocht. Een ander sterk uitgangspunt van deze 
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studie was dat er naast deze patiëntengroep een controlegroep van 351 patiënten is opgebouwd 
die behandeld zijn op dezelfde ziekenhuisafdelingen als de geïnfecteerde patiënten met een zelfde 
distributie van medische, chirurgische en oncologische patiënten in beide groepen. Deze groep van 
controlepatiënten, die ondanks een hoog risico geen candidemie ontwikkelden, stelde ons ertoe 
in staat om uit te sluiten dat een aangetoonde genetische associatie tussen de beide groepen zou 
kunnen worden toegeschreven aan de onderliggende ziekte. Polymorfismen in TLRs zijn voorheen 
geassocieerd met verhoogde susceptibiliteit voor aspergillose (26;27) en zouden in potentie ook 
de gevoeligheid of klinisch verloop van candidemie kunnen beïnvloeden. In het eerste deel van 
de studie, zoals beschreven in Hoofdstuk 13, hebben we polymorfismen gegenotypeerd in genen 
die coderen voor TLRs en hun adaptereiwitten MyD88 en Mal/TIRAP in dit cohort van candidemie 
patiënten en niet-geïnfecteerde controles. Deze analyses hebben de TLR1 polymorfismen Arg80Thr, 
Ser248Asn en Ile602Ser geïdentificeerd als susceptibiliteitfactoren voor candidemie in patiënten 
van Indo-Europese afkomst, maar niet met het klinische verloop van de infectie. We hebben 
eveneens aan kunnen tonen dat deze polymorfismen leiden tot een afgenomen TLR1 functie, wat 
suggereert dat TLR1 betrokken is bij anti-Candida immuunresponsen. Alhoewel muizen deficiënt 
voor TLR1 niet gevoeliger zijn voor experimentele candidemie (28), is TLR1 wel degelijk belangrijk 
voor de verdediging tegen schimmels door de coöperatie met TLR2 dat het van schimmels 
afgeleide fosfolipomannan herkent (29) en door het doorgeven van de immuunsignalering van 
beta-defensine-3 (30). Het feit dat TLR1 polymorfismen niet geassocieerd zijn met de klinische 
uitkomst van de infectie suggereert dat TLR1 met name betrokken is bij de vroege anti-Candida 
gastheerrespons, waardoor het de systemische infectie met Candida voorkomt, en minder 
beslissend is voor de uitkomst van een al ontwikkelde candidemie. Nota bene, de eerdere studies 
in muismodellen van gedissemineerde candidiasis in muizen deficiënt voor TLR1 hebben slechts 
alleen de tweede toestand onderzocht, wat een extra verklaring kan zijn voor het verschil dat is 
opgetreden in de rol van TLR1 in candidemie tussen muis en mens.
Therapieën die het adaptieve immuunsysteem stimuleren en gericht zijn tegen schimmels 
berusten op de activatie van beschermende cellulaire T-helper 1 (Th1) cytokines zoals IFN-g. 
Daartegenover zijn humorale Th2 responsen verantwoordelijk voor de resolutie van inflammatie 
en dragen bij aan het ongedaan maken van weefselschade. Echter, indien te vroeg en te sterk 
geïnduceerd, kunnen Th2 responsen ongewilde anti-inflammatoire effecten hebben door de 
secretie van IL-4 en IL-10. De interactie tussen Th1 en Th2 responsen in de context van Candida 
infectie is complex maar cruciaal voor een adequate respons tegen deze pathogeen. Deze delicate 
balans wordt gereguleerd door cytokines als IL-1β, IL-12, IFN-g en IL-10. Varianten in de genen die 
coderen voor deze cytokines en die de mRNA expressie en daardoor de productie door cellen van 
het aangeboren immuunsysteem beïnvloeden, zijn geïdentificeerd. In Hoofdstuk 14 hebben we 
genetische analyses uitgevoerd van polymorfismen in cytokine (receptor) genen in ons candidemie 
cohort die de associatie van polymorfismen in IL10 en IL12B met persistente candidemie hebben 
blootgelegd. Overeenkomstig moduleerden de risicovarianten van IL10 en IL12B de secretie van 
deze cytokines als mononucleaire cellen afkomstig van perifeer bloed werden gestimuleerd met C. 
albicans conidiën of hyphen. Bovendien waren concentraties van pro-inflammatoire cytokines in 
serum van patiënten met persistente candidemie significant lager dan in serum van patiënten die 
relatief snel de infectie konden klaren. Concluderend leidt een afwijkende productie van Candida 
geïnduceerde IL-10 en IL-12p40 tot een toegenomen risico voor persistente candidemie. Deze studie 
is de eerste die genetische aangrijpingspunten aandraagt die belangrijke voorspellers zijn voor een 
langere ziekteduur en een toegenomen overlijdenskans. De associatie van een lage Th1 respons 
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met een verslechterde uitkomst van infectie levert extra argumenten aan voor de toepassing van 
adjunctieve immuuntherapie met recombinant IFN-g in systemische Candida infecties.
Tot op heden zijn twee studies in de muis gewijd aan het onderzoeken van de rol van dectin-1 
in experimentele gedissemineerde candidiasis. Over deze studies, waarbij wildtype muizen zijn 
vergeleken met muizen deficiënt voor dectin-1, zijn verschillende resultaten gerapporteerd. De 
ene studie concludeerde dat dectin-1 vereist is voor resistentie tegen candidemie (31), terwijl de 
andere een minder belangrijke rol voor dectin-1 ontdekte (32). Dectin-1 deficiëntie in de mens 
is niet geassocieerd met candidemie in de initieel beschreven familie (17). Echter, mutaties die 
leiden tot een verlies van de functie van CARD9, het intracellulaire adaptereiwit van dectin-1, zijn 
beschreven om gedissemineerde candidiasis in aangedane familieleden te veroorzaken (33). Om 
uit te zoeken of dectin-1 en CARD9 belangrijke spelers zijn in het verdedigingsmechanisme van de 
mens tegen systemische schimmelinfecties, zijn genetische varianten van dectin-1 (Tyr238X) en 
CARD9 (Ser12Asn) geanalyseerd voor de mogelijke correlatie met candidemie in ons cohort van 
338 geïnfecteerde patiënten en 351 niet-geïnfecteerde controles, zoals beschreven in Hoofdstuk 
15. Geen statistisch significante verschillen werden aangetoond met gevoeligheid dan wel klinische 
parameters, inclusief gedissemineerde infectie, persistente candidemie en mortaliteit na 30 dagen. 
De afwezigheid van deze associatie staat in schril contrast met de gegevens verkregen in de in vitro 
experimenten met primaire immuuncellen en met de in vivo cytokinemetingen in het serum van 
geïnfecteerde patiënten. Deze metingen geven aan dat zowel de in vitro productiecapaciteit van 
TNFα en IL-1β als de in vivo concentraties van IL-6, IL-8 en IFN-g lager waren van individuen die 
heterozygoot drager waren voor het Tyr238X polymorfisme. De dectin-1/CARD9 signaleringsroute 
blijkt daarom van groot belang te zijn voor het mucosale verdedigingsmechanisme tegen 
schimmelinfecties, zoals aangetoond in Hoofdstuk 9 en zoals eerder beschreven (17), terwijl 
systemische immuniteit tegen Candida grotendeels afhangt van andere herkennings- en 
signaleringsroutes zoals van TLR1 en van een robuuste Th1 respons. 
In Hoofdstuk 16 vatten we de meest recente inzichten samen in onze kennis van de rol van genetische 
variatie, zowel zeldzame als veelvoorkomende varianten, in de modulatie van het immuunsysteem 
die de gevoeligheid voor mucosale dan wel systemische Candida infecties beïnvloedt. Daarnaast 
beschrijven we de mechanismen van zowel het aangeboren alsook het adaptieve immuunsysteem 
in het beschermen van de immuuncompetente gastheer tegen infectie. Eveneens worden 
de ziektemechanismen en de bijdrage van de geïdentificeerde susceptibiliteitgenen voor de 
pathogenese van de infectie beschreven. Belangrijke stappen zijn gezet in het begrijpen van de 
cruciale betrokkenheid van cytokines in de afweer tegen schimmels. Deze zijn IFN-g, IL-17 en IL-22 
voor mucosale infecties en IL-12 en IFN-g voor systemische infecties. De genoemde bevindingen 
vormen de wetenschappelijke basis voor het toepassen van adjuvante immuuntherapie in de vorm 
van recombinante cytokines voor de behandeling van Candida infecties. Bovendien kunnen de 
geïdentificeerde genetische risicofactoren gebruikt worden om patiënten met hoog risico in een 
vroeg stadium te identificeren, waarmee doelgericht profylactische en curatieve medicatie kan 
worden toegepast.
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Algehele discussie
Het tijdperk van de genetica heeft een revolutie teweeg gebracht in de medische en 
wetenschappelijke wereld door het aanleveren van de kennis en de middelen om de rol van humane 
genetische variatie in gezondheid en ziekte te onderzoeken. De studies die in dit proefschrift zijn 
gepresenteerd dragen bij aan een immer uitbreidend wetenschappelijk bewijs dat genetische 
variatie de gevoeligheid voor zeldzame en veelvoorkomende ziekten beïnvloedt. Daarnaast hebben 
verstrekkende inzichten in het veld tot een toegenomen begrip van de betrokken biologische 
processen geleid. Deze studies kunnen in potentie de basis vormen voor de ontwikkeling van 
nieuwe therapieën, voor het toetsen van de aanwezigheid van genetische risicofactoren en voor 
behandelingen toegespitst op de patiënt. De grote uitdaging voor de toekomst is hoe deze kennis te 
implementeren in de directe klinische praktijk. Zou de complete genetische kaart van elke patiënt 
moeten worden ontcijferd en toegevoegd moeten worden aan het medisch dossier? Belangrijke 
ethische kwesties zullen een rol gaan spelen bij een toenemende capaciteit voor genetisch 
testen op routinebasis. Daarom zal er een balans gevonden moeten worden tussen de voor- en 
nadelen van genetisch testen. Desalniettemin zou mijns inziens de implementatie van de immense 
mogelijkheden die genetisch testen biedt moeten worden bevorderd en het uitgangspunt moeten 
zijn in het publieke debat.
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Dit proefschrift is door onmisbare bijdrages van velen totstandgekomen, waarvoor ik alle 
betrokkenen hartelijk wil bedanken. Een aantal personen wil ik expliciet noemen. 
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door u aangezwengelde discussies tijdens de werkbesprekingen stimuleren om scherp te blijven, 
niets zomaar aan te nemen en geeft daarom altijd stof tot nadenken. Ik ben trots om één van de 
vele promovendi te zijn die u tijdens uw imposante carrière hebt begeleid.     
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stoppen, waarvoor hartelijk dank.  
Dr. Joosten, beste Leo, je bent een ware sidekick vol goede ideeën, humor en relativering in 
situaties die daarom vragen. Dit nodigt altijd uit tot gesprek, al dan niet serieus, waarna vrolijkheid 
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faciliteit weten te creëren waar ik ook als postdoc uitstekend mee uit de voeten kan. Ik hoop nog 
lang met jou te kunnen samenwerken.    
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which I would like to express my greatest appreciation and gratitude. Melissa, it has been a great 
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meeting you in Miami and Nijmegen. Bill, your guidance in the world of statistics was an essential 
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Dana Philpott and Stephen Girardin, many thanks for your willingness to have me in your lab and to 
educate me in the field of autophagy. The knowledge I gained will be of great value for my future 
work.  
Jeroen van Bergenhenegouwen en Bea van ’t Land, de probiotica studies die door jullie mogelijk 
zijn gemaakt zijn een genot om aan te werken. Dank voor de prettige discussies zowel bij ons als 
bij jullie in Wageningen. 
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Cor, Ineke, Johanna, Trees, “good old” Liesbeth, Karin, Helga, Magda, Anneke, Heidi en Zewen, jullie 
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met ongekende mogelijkheden. Jullie belangstelling en goede zorgen voor zowel werk als privé zijn 
hartverwarmend. Hartelijk dank voor alles wat ik van jullie heb mogen leren.
Jelle, Edwin, Frank en Eveline, vanaf de kennismaking aan het begin van Biomedische Wetenschappen 
hebben we elkaar als een hecht team door de studie weten te loodsen. Wat is het goed om deel uit 
te maken van zo’n geweldige groep van “partners in crime”. Ik ben erg trots te constateren dat het 
ons allemaal gelukt is om ook het promotietraject tot een goed einde te brengen, zijn we ineens 
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allemaal Dr.! En alhoewel we allemaal duidelijk verschillende plannen hebben voor de voortzetting 
van onze wetenschappelijke carrières in Nederland en daarbuiten, is onze band onverminderd 
sterk.   
Beste Ullies, vanaf het moment dat ik met jullie meeging naar dansles werd ik onderdeel van het 
zeer hechte geheel. Vanaf die tijd heb ik me door jullie toedoen sociaal kunnen ontwikkelen tot 
wie ik nu ben. Ik ben jullie erg dankbaar daarvoor, jullie als vrienden was en is nog steeds heel 
belangrijk voor me. Ik hoop nog veel met jullie te beleven! 
Niek en Samantha, Silvana en Arjan, Marieke en Pascal, Marijke en Martijn, Miriam en Martijn, 
Karin, Heleen, de feestjes en weekendjes weg met jullie staan altijd bol van plezier en humor. Het 
is fantastisch om met jullie om te gaan.  
Henk en Ada, Wendy en Geert, opa, vanaf het begin zijn jullie een tweede thuis voor mij. Jullie 
gezelschap is als een warme deken. Dank voor de nodige steun, behulpzaamheid en de vele 
gezellige momenten samen. 
Wim en Wilma, zonder jullie goede zorgen, steun en strijdvaardigheid tijdens al die jaren was ik nooit 
zover gekomen en was dit proefschrift er niet geweest. Met jullie hulp heb ik voor mij persoonlijk 
de beste beslissing op één van de belangrijkste momenten in mijn leven kunnen nemen. Arie en 
Miny, ook jullie cruciale rol is onuitwisbaar. Die bewuste nazomerdag, nu ruim 15 jaar geleden, 
staat in mijn geheugen gegrift. Het bleek een nieuw begin dat me vleugels heeft gegeven.  
Meint-Jan, Sjouke en Eelke, ik hoop dat dit proefschrift jullie zuurverdiende belastingcenten waard 
is! Ondanks dat we zo verschillend zijn en we voor een groot deel niet samen zijn opgegroeid, ben 
ik erg blij en dankbaar dat we het contact niet verloren zijn.  Elk bezoek is opnieuw onvergetelijk. 
Heit, ik ben ontzettend blij dat we na lange tijd weer goed contact hebben en we weer als voltallig 
gezin samen kunnen zijn. De wilskracht, de discipline en het doorzettingsvermogen die je mij hebt 
bijgebracht zijn van grote waarde. 
Mem, de jaren die je in mijn leven kon zijn waren intens gelukkig. Ik mis je nog elke dag. In gedachten 
ben je altijd bij me.
Ingrid, mijn allerliefste. Door jouw liefde, steun en enthousiasme heb ik de kracht en de motivatie 
om uit het leven te halen wat er in zit. Ik hou zielsveel van je. De toekomst lacht ons toe!
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